# Mayer_2024_Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis.

Cochrane
Library

Cochrane Database of Systematic Reviews

Cognitive behavioural therapy added to standard care for first-
episode and recent-onset psychosis (Review)

Mayer SF, Corcoran C, Kennedy L, Leucht S, Bighelli I

Mayer SF, Corcoran C, Kennedy L, Leucht S, Bighelli I. 
Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis. 
Cochrane Database of Systematic Reviews 2024, Issue 3. Art. No.: CD015331. 
DOI: 10.1002/14651858.CD015331.pub2.

www.cochranelibrary.com

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

T A B L E   O F   C O N T E N T S

ABSTRACT.....................................................................................................................................................................................................
PLAIN LANGUAGE SUMMARY.......................................................................................................................................................................
SUMMARY OF FINDINGS..............................................................................................................................................................................
BACKGROUND..............................................................................................................................................................................................
OBJECTIVES..................................................................................................................................................................................................
METHODS.....................................................................................................................................................................................................
RESULTS........................................................................................................................................................................................................
Figure 1..................................................................................................................................................................................................
DISCUSSION..................................................................................................................................................................................................
Figure 2..................................................................................................................................................................................................
Figure 3..................................................................................................................................................................................................
Figure 4..................................................................................................................................................................................................
AUTHORS' CONCLUSIONS...........................................................................................................................................................................
ACKNOWLEDGEMENTS................................................................................................................................................................................
REFERENCES................................................................................................................................................................................................
CHARACTERISTICS OF STUDIES..................................................................................................................................................................
RISK OF BIAS................................................................................................................................................................................................
DATA AND ANALYSES....................................................................................................................................................................................
Analysis 1.1. Comparison 1: CBT plus standard care versus control, Outcome 1: Mental state - general: mean endpoint PANSS
total (high = poor).................................................................................................................................................................................
Analysis 1.2. Comparison 1: CBT plus standard care versus control, Outcome 2: Mental state - general: mean change PANSS total
(high = poor)..........................................................................................................................................................................................
Analysis 1.3. Comparison 1: CBT plus standard care versus control, Outcome 3: Mental state - general: mean endpoint PSYRATS
(high = poor)..........................................................................................................................................................................................
Analysis 1.4. Comparison 1: CBT plus standard care versus control, Outcome 4: Mental state - general: mean endpoint BPRS
total (high = poor).................................................................................................................................................................................
Analysis 1.5. Comparison 1: CBT plus standard care versus control, Outcome 5: Mental state - general: mean endpoint overall
symptom scales (high = poor) (combined time points).....................................................................................................................
Analysis 1.6. Comparison 1: CBT plus standard care versus control, Outcome 6: Mental state - general: mean endpoint overall
symptom scales (high = poor) (separated time points).....................................................................................................................
Analysis 1.7. Comparison 1: CBT plus standard care versus control, Outcome 7: Mental state - general: number of participants
with clinically important change in general mental state (combined time points)..........................................................................
Analysis 1.8. Comparison 1: CBT plus standard care versus control, Outcome 8: Mental state - general: number of participants
with clinically important change in general mental state (separated time points)..........................................................................
Analysis 1.9. Comparison 1: CBT plus standard care versus control, Outcome 9: Mental state - specific: number of participants
with clinically important change in positive symptoms (combined time points)............................................................................
Analysis 1.10. Comparison 1: CBT plus standard care versus control, Outcome 10: Mental state - specific: number of participants
with clinically important change in positive symptoms (separated time points).............................................................................
Analysis 1.11. Comparison 1: CBT plus standard care versus control, Outcome 11: Mental state - specific: mean endpoint PANSS
positive (high = poor)...........................................................................................................................................................................
Analysis 1.12. Comparison 1: CBT plus standard care versus control, Outcome 12: Mental state - specific: mean change PANSS
positive (high = poor)...........................................................................................................................................................................
Analysis 1.13. Comparison 1: CBT plus standard care versus control, Outcome 13: Mental state - specific: mean endpoint BPRS
positive (high = poor)...........................................................................................................................................................................
Analysis 1.14. Comparison 1: CBT plus standard care versus control, Outcome 14: Mental state - specific: mean endpoint SAPS
(high = poor)..........................................................................................................................................................................................
Analysis 1.15. Comparison 1: CBT plus standard care versus control, Outcome 15: Mental state - specific: mean endpoint positive
symptoms scales (high = poor) (combined time points)....................................................................................................................
Analysis 1.16. Comparison 1: CBT plus standard care versus control, Outcome 16: Mental state - specific: mean endpoint positive
symptoms scales (high = poor) (separated time points)....................................................................................................................
Analysis 1.17. Comparison 1: CBT plus standard care versus control, Outcome 17: Mental state - specific: mean endpoint PANSS
negative (high = poor)..........................................................................................................................................................................
Analysis 1.18. Comparison 1: CBT plus standard care versus control, Outcome 18: Mental state - specific: mean change PANSS
negative (high = poor)..........................................................................................................................................................................

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1
2
4
6
7
7
14
15
23
24
25
26
27
27
28
47
130
149
164

165

165

166

167

168

169

170

170

171

172

173

173

174

174

175

176

177

i

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.19. Comparison 1: CBT plus standard care versus control, Outcome 19: Mental state - specific: mean endpoint BPRS
negative (high = poor)..........................................................................................................................................................................
Analysis 1.20. Comparison 1: CBT plus standard care versus control, Outcome 20: Mental state - specific: mean endpoint SANS
(high = poor)..........................................................................................................................................................................................
Analysis 1.21. Comparison 1: CBT plus standard care versus control, Outcome 21: Mental state - specific: mean endpoint BNSS
(high = poor)..........................................................................................................................................................................................
Analysis  1.22.  Comparison  1:  CBT  plus  standard  care  versus  control,  Outcome  22:  Mental  state  -  specific:  mean  endpoint
negative symptoms scale (high = poor) (combined time points)......................................................................................................
Analysis  1.23.  Comparison  1:  CBT  plus  standard  care  versus  control,  Outcome  23:  Mental  state  -  specific:  mean  endpoint
negative symptoms scale (high = poor) (separated time points)......................................................................................................
Analysis 1.24. Comparison 1: CBT plus standard care versus control, Outcome 24: Mental state - specific: mean endpoint BDI
short form (high = poor).......................................................................................................................................................................
Analysis 1.25. Comparison 1: CBT plus standard care versus control, Outcome 25: Mental state - specific: mean endpoint BDI-
II (high = poor)......................................................................................................................................................................................
Analysis 1.26. Comparison 1: CBT plus standard care versus control, Outcome 26: Mental state - specific: mean endpoint HADS
Depression (high = poor)......................................................................................................................................................................
Analysis 1.27. Comparison 1: CBT plus standard care versus control, Outcome 27: Mental state - specific: mean endpoint CDS
(high = poor)..........................................................................................................................................................................................
Analysis 1.28. Comparison 1: CBT plus standard care versus control, Outcome 28: Mental state - specific: mean change CDS
(high = poor)..........................................................................................................................................................................................
Analysis 1.29. Comparison 1: CBT plus standard care versus control, Outcome 29: Mental state - specific: mean endpoint MADRS
(high = poor)..........................................................................................................................................................................................
Analysis  1.30.  Comparison  1:  CBT  plus  standard  care  versus  control,  Outcome  30:  Mental  state  -  specific:  mean  endpoint
Hamilton Depression (high = poor).....................................................................................................................................................
Analysis 1.31. Comparison 1: CBT plus standard care versus control, Outcome 31: Mental state - specific: mean endpoint CESD-
R (high = poor)......................................................................................................................................................................................
Analysis  1.32.  Comparison  1:  CBT  plus  standard  care  versus  control,  Outcome  32:  Mental  state  -  specific:  mean  endpoint
depressive symptoms (high = poor) (combined time points)............................................................................................................
Analysis  1.33.  Comparison  1:  CBT  plus  standard  care  versus  control,  Outcome  33:  Mental  state  -  specific:  mean  endpoint
depressive symptoms (high = poor) (separated time points)............................................................................................................
Analysis 1.34. Comparison 1: CBT plus standard care versus control, Outcome 34: Global state - number of participants with
relapse/exacerbations of psychosis (combined time points)............................................................................................................
Analysis 1.35. Comparison 1: CBT plus standard care versus control, Outcome 35: Global state - number of participants with
relapse/exacerbations of psychosis (separated time points).............................................................................................................
Analysis 1.36. Comparison 1: CBT plus standard care versus control, Outcome 36: Global state - number of participants with
remission (combined time points).......................................................................................................................................................
Analysis 1.37. Comparison 1: CBT plus standard care versus control, Outcome 37: Global state - number of participants with
remission (separated time points).......................................................................................................................................................
Analysis 1.38. Comparison 1: CBT plus standard care versus control, Outcome 38: Global state - number of participants with
clinically important change in global state.........................................................................................................................................
Analysis 1.39. Comparison 1: CBT plus standard care versus control, Outcome 39: Global state - mean endpoint CGI (high = poor)
(separated time points)........................................................................................................................................................................
Analysis 1.40. Comparison 1: CBT plus standard care versus control, Outcome 40: Global state - mean endpoint/change CGI-S
(high = poor) (separated time points).................................................................................................................................................
Analysis 1.41. Comparison 1: CBT plus standard care versus control, Outcome 41: Global state - mean endpoint CGI-I (high =
poor) (separated time points)..............................................................................................................................................................
Analysis 1.42. Comparison 1: CBT plus standard care versus control, Outcome 42: Global state - mean endpoint/change global
state scales (high = poor) (combined time points).............................................................................................................................
Analysis 1.43. Comparison 1: CBT plus standard care versus control, Outcome 43: Global state - mean endpoint/change global
state scales (high = poor) (separated time points).............................................................................................................................
Analysis 1.44. Comparison 1: CBT plus standard care versus control, Outcome 44: Service use - admission to hospital (combined
time points)...........................................................................................................................................................................................
Analysis 1.45. Comparison 1: CBT plus standard care versus control, Outcome 45: Service use - admission to hospital (separated
time points)...........................................................................................................................................................................................
Analysis 1.46. Comparison 1: CBT plus standard care versus control, Outcome 46: Service use - number of days in hospital
(combined time points)........................................................................................................................................................................

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

177

178

178

179

180

181

181

182

182

183

183

184

184

185

186

187

188

188

189

189

190

190

191

191

192

192

193

194

ii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.47. Comparison 1: CBT plus standard care versus control, Outcome 47: Service use - number of days in hospital
(separated time points)........................................................................................................................................................................
Analysis 1.48. Comparison 1: CBT plus standard care versus control, Outcome 48: Leaving the study early - for any reason -
overall acceptability (combined time points).....................................................................................................................................
Analysis 1.49. Comparison 1: CBT plus standard care versus control, Outcome 49: Leaving the study early - for any reason -
overall acceptability (separated time points).....................................................................................................................................
Analysis 1.50. Comparison 1: CBT plus standard care versus control, Outcome 50: Functioning - mean endpoint GAF (high =
good)......................................................................................................................................................................................................
Analysis 1.51. Comparison 1: CBT plus standard care versus control, Outcome 51: Functioning - mean change GAF (high = good)...
Analysis 1.52. Comparison 1: CBT plus standard care versus control, Outcome 52: Functioning - mean endpoint SOFAS (high
= good)...................................................................................................................................................................................................
Analysis 1.53. Comparison 1: CBT plus standard care versus control, Outcome 53: Functioning - mean endpoint PSP (high =
good)......................................................................................................................................................................................................
Analysis 1.54. Comparison 1: CBT plus standard care versus control, Outcome 54: Functioning - mean endpoint FAST (high =
poor).......................................................................................................................................................................................................
Analysis 1.55. Comparison 1: CBT plus standard care versus control, Outcome 55: Functioning - mean endpoint FESFS (high =
good)......................................................................................................................................................................................................
Analysis 1.56. Comparison 1: CBT plus standard care versus control, Outcome 56: Functioning - mean endpoint functioning
scale (high = good) (combined time points).......................................................................................................................................
Analysis 1.57. Comparison 1: CBT plus standard care versus control, Outcome 57: Functioning - mean endpoint functioning
scale (high = good) (separated time points).......................................................................................................................................
Analysis 1.58. Comparison 1: CBT plus standard care versus control, Outcome 58: Quality of life - mean endpoint WHO QoL-
bref (high = good).................................................................................................................................................................................
Analysis 1.59. Comparison 1: CBT plus standard care versus control, Outcome 59: Quality of life - mean endpoint EQ5d (WHO)
(high = good).........................................................................................................................................................................................
Analysis 1.60. Comparison 1: CBT plus standard care versus control, Outcome 60: Quality of life - mean endpoint QLS (high =
good)......................................................................................................................................................................................................
Analysis 1.61. Comparison 1: CBT plus standard care versus control, Outcome 61: Quality of life - mean endpoint MSQoL (high
= good)...................................................................................................................................................................................................
Analysis 1.62. Comparison 1: CBT plus standard care versus control, Outcome 62: Quality of life - mean change MSQoL (high
= good)...................................................................................................................................................................................................
Analysis 1.63. Comparison 1: CBT plus standard care versus control, Outcome 63: Quality of life - MANSA (high = good).............
Analysis 1.64. Comparison 1: CBT plus standard care versus control, Outcome 64: Quality of life - mean endpoint quality of life
scale (high = good) (combined time points).......................................................................................................................................
Analysis 1.65. Comparison 1: CBT plus standard care versus control, Outcome 65: Quality of life - mean endpoint quality of life
scale (high = good) (separated time points).......................................................................................................................................
Analysis 1.66. Comparison 1: CBT plus standard care versus control, Outcome 66: Behaviour - occurence of violent incidents.....
Analysis 1.67. Comparison 1: CBT plus standard care versus control, Outcome 67: Behaviour - participants with self-injury.......
Analysis  1.68.  Comparison  1:  CBT  plus  standard  care  versus  control,  Outcome  68:  Behaviour  -  participants  with  suicide
attempts.................................................................................................................................................................................................
Analysis 1.69. Comparison 1: CBT plus standard care versus control, Outcome 69: Adverse events - participants with at least
one adverse event.................................................................................................................................................................................
Analysis 1.70. Comparison 1: CBT plus standard care versus control, Outcome 70: Adverse events - specific: Non Compliance.....
Analysis 1.71. Comparison 1: CBT plus standard care versus control, Outcome 71: Adverse events - specific: Deterioration of
symptoms..............................................................................................................................................................................................
Analysis 1.72. Comparison 1: CBT plus standard care versus control, Outcome 72: Mortality - overall mortality (combined time
points)....................................................................................................................................................................................................
Analysis 1.73. Comparison 1: CBT plus standard care versus control, Outcome 73: Mortality - overall mortality (separated time
points)....................................................................................................................................................................................................
Analysis 1.74. Comparison 1: CBT plus standard care versus control, Outcome 74: Mortality - due to natural causes...................
Analysis 1.75. Comparison 1: CBT plus standard care versus control, Outcome 75: Mortality - due to suicide...............................
Analysis 1.76. Comparison 1: CBT plus standard care versus control, Outcome 76: Sensitivity analysis - Blinding of outcome
assessor..................................................................................................................................................................................................
Analysis 1.77. Comparison 1: CBT plus standard care versus control, Outcome 77: Sensitivity analysis - Assumptions for missing
data........................................................................................................................................................................................................
Analysis 1.78. Comparison 1: CBT plus standard care versus control, Outcome 78: Sensitivity analysis - Risk of Bias...................

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

194

195

196

198

198
199

200

200

201

201

202

203

203

204

204

205

205
206

206

207
207
208

208

209
210

210

211

211
212
213

214

215

iii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.79. Comparison 1: CBT plus standard care versus control, Outcome 79: Sensitivity analysis - Imputed values............
Analysis 1.80. Comparison 1: CBT plus standard care versus control, Outcome 80: Sensitivity analysis - Fixed-effect...................
Analysis 1.81. Comparison 1: CBT plus standard care versus control, Outcome 81: Sensitivity analysis excluding outliers...........
Analysis 1.82. Comparison 1: CBT plus standard care versus control, Outcome 82: Subgroup analysis - Different types of CBT.....
Analysis 1.83. Comparison 1: CBT plus standard care versus control, Outcome 83: Subgroup analysis - Modality of treatment.....
Analysis 1.84. Comparison 1: CBT plus standard care versus control, Outcome 84: Subgroup analysis - Method of delivery........
Analysis 1.85. Comparison 1: CBT plus standard care versus control, Outcome 85: Subgroup analysis - Control group................
HISTORY........................................................................................................................................................................................................
CONTRIBUTIONS OF AUTHORS...................................................................................................................................................................
DECLARATIONS OF INTEREST.....................................................................................................................................................................
SOURCES OF SUPPORT...............................................................................................................................................................................
DIFFERENCES BETWEEN PROTOCOL AND REVIEW....................................................................................................................................
INDEX TERMS...............................................................................................................................................................................................

216
217
218
219
220
221
222
222
222
223
223
223
224

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

iv

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

[Intervention Review]

Cochrane Database of Systematic Reviews

Cognitive behavioural therapy added to standard care for first-episode
and recent-onset psychosis

Susanna Franziska Mayer1, Ciaran Corcoran2, Liam Kennedy3, Stefan Leucht1,4, Irene Bighelli1,4

1Section for Evidence-Based Medicine in Psychiatry and Psychotherapy, TUM School of Medicine and Health, Technical University of
Munich, München, Germany. 2St Loman’s Hospital, Mullingar, Ireland. 3Department of Old Age Psychiatry, Carew House, St Vincent’s
Hospital, Dublin, Ireland. 4German Center for Mental Health (DZPG), Munich, Germany

Contact: Irene Bighelli, irene.bighelli@tum.de.

Editorial group: Cochrane Schizophrenia Group.
Publication status and date: New, published in Issue 3, 2024.

Citation: Mayer SF, Corcoran C, Kennedy L, Leucht S, Bighelli I. Cognitive behavioural therapy added to standard care for
first-episode and recent-onset psychosis. Cochrane Database of Systematic Reviews 2024, Issue 3. Art. No.: CD015331. DOI:
10.1002/14651858.CD015331.pub2.

Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Background

A B S T R A C T

Cognitive behavioural therapy (CBT) can be effective in the general population of people with schizophrenia. It is still unclear whether CBT
can be effectively used in the population of people with a first-episode or recent-onset psychosis.

Objectives

To assess the effects of adding cognitive behavioural therapy to standard care for people with a first-episode or recent-onset psychosis.

Search methods

We conducted a systematic search on 6 March 2022 in the Cochrane Schizophrenia Group's Study-Based Register of Trials, which is based
on CENTRAL, MEDLINE, Embase, CINAHL, PsycINFO, PubMed, ClinicalTrials.gov, ISRCTN, and WHO ICTRP.

Selection criteria

We included randomised controlled trials (RCTs) comparing CBT added to standard care vs standard care in first-episode or recent-onset
psychosis, in patients of any age.

Data collection and analysis

Two review authors (amongst SFM, CC, LK and IB) independently screened references for inclusion, extracted data from eligible studies and
assessed the risk of bias using RoB2. Study authors were contacted for missing data and additional information. Our primary outcome was
general mental state measured on a validated rating scale. Secondary outcomes included other specific measures of mental state, global
state, relapse, admission to hospital, functioning, leaving the study early, cognition, quality of life, satisfaction with care, self-injurious or
aggressive behaviour, adverse events, and mortality.

Main results

We included 28 studies, of which 26 provided data on 2407 participants (average age 24 years). The mean sample size in the included
studies was 92 participants (ranging from 19 to 444) and duration ranged between 26 and 52 weeks.

When looking at the results at combined time points (mainly up to one year after start of the intervention), CBT added to standard care
was associated with a greater reduction in overall symptoms of schizophrenia (standardised mean difference (SMD) -0.27, 95% confidence
interval (CI) -0.47 to -0.08, 20 RCTs, n = 1508, I2 = 68%, substantial heterogeneity, low certainty of the evidence), and also with a greater

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

reduction in positive (SMD -0.22, 95% CI -0.38 to -0.06, 22 RCTs, n = 1565, I2 = 52%, moderate heterogeneity), negative (SMD -0.20, 95%
CI -0.30 to -0.11, 22 RCTs, n = 1651, I2 = 0%) and depressive symptoms (SMD -0.13, 95% CI -0.24 to -0.01, 18 RCTs, n = 1182, I2 = 0%) than
control. CBT added to standard care was also associated with a greater improvement in the global state (SMD -0.34, 95% CI -0.67 to -0.01, 4
RCTs, n = 329, I2 = 47%, moderate heterogeneity) and in functioning (SMD -0.23, 95% CI -0.42 to -0.05, 18 RCTs, n = 1241, I2 = 53%, moderate
heterogeneity, moderate certainty of the evidence) than control.

We did not find a difference between CBT added to standard care and control in terms of number of participants with relapse (relative risk
(RR) 0.82, 95% CI 0.57 to 1.18, 7 RCTs, n = 693, I2 = 48%, low certainty of the evidence), leaving the study early for any reason (RR 0.87, 95%
CI 0.72 to 1.05, 25 RCTs, n = 2242, I2 = 12%, moderate certainty of the evidence), adverse events (RR 1.29, 95% CI 0.85 to 1.97, 1 RCT, n = 43,
very low certainty of the evidence) and the other investigated outcomes.

Authors' conclusions

This review synthesised the latest evidence on CBT added to standard care for people with a first-episode or recent-onset psychosis.

The  evidence  identified  by  this  review  suggests  that  people  with  a  first-episode  or  recent-onset  psychosis  may  benefit  from  CBT
additionally to standard care for multiple outcomes (overall, positive, negative and depressive symptoms of schizophrenia, global state
and functioning).

Future studies should better define this population, for which often heterogeneous definitions are used.

P L A I N   L A N G U A G E   S U M M A R Y

Cognitive behavioural therapy plus standard care for first-episode and recent-onset psychosis

Key messages

Cognitive  behavioural  therapy  (CBT)  is  effective  for  reducing  symptoms  of  schizophrenia  and  improving  functioning  in  people  at  the
beginning of the disorder.

Very little information was available on the potential adverse effects connected with this intervention.

Introduction

Schizophrenia is a severe mental disorder because of the heavy effect of the symptoms on the daily lives of those affected. People with this
illness struggle to differentiate between their own thoughts, beliefs and ideas versus reality. For example, they may be hearing voices in
their head, but it feels like someone is really talking to them. The treatment of the beginning phase of the illness is of critical importance,
in order to prevent or reduce the risk of a chronic course. This phase is usually defined as 'first episode', and the term 'recent onset' is also
used to describe the period of three to five years from the first episode.

A psychological intervention, cognitive behavioural therapy, can be effective for treating the symptoms in people with schizophrenia in
general; it is still not clear if this intervention could be helpful also for people in the initial phases of the illness.

What did we want to find out?

We wanted to find out the effects of cognitive behavioural therapy added to standard care for people with a first episode or recent onset
of schizophrenia.

What did we do?

We searched for studies that examined cognitive behavioural therapy given in addition to standard care (usually drugs) compared with
standard care alone or other psychosocial interventions.

We compared and summarised the results of the studies and rated our confidence in the evidence. For example, some factors in the studies
(such as too few participants or results not showing clear effects) were rated with a lower confidence in the evidence.

What did we find?

We found 28 studies, of which 26 had usable data on 2407 participants with recent-onset or first-episode schizophrenia. The studies had
a duration of between 26 and 52 weeks for the intervention phase and, in 18 studies, participants were contacted again to collect further
data after the end of the treatment. The studies were conducted in the UK, Europe, Australia, Canada, USA and China. They were mainly
funded by public institutions, and a small number also by pharmaceutical companies.

When looking at the results about one year after the start of the intervention, we found that CBT added to standard care:

- is more effective than control conditions in reducing the overall symptoms of schizophrenia

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

- is more effective than control conditions in reducing positive symptoms of schizophrenia (e.g. hearing voices)

- is more effective than control conditions in reducing negative symptoms of schizophrenia (e.g. apathy, loss of interest and motivation,
lack of concentration)

- is more effective than control conditions in reducing depressive symptoms of schizophrenia

- is more effective than control conditions in improving the global state (number of participants with symptoms improvement, number of
participants with symptoms worsening, scores on scales that measure the general level of symptoms of the participants)

- is more effective than control conditions in improving functioning (e.g. participating in social life, taking part in everyday activities).

What are the limitations of the evidence?

The certainty of the evidence is between moderate and very low, meaning that we have moderate to very little confidence in the effect
estimates. This is due to the fact that, for some of the studies, the quality ('risk of bias') was low, and that the results of the various studies
sometimes slightly differed from each other. Moreover, for some outcomes, the results were imprecise, and a limited number of participants
contributed to the data.

How up-to-date is this evidence?

The evidence is up-to-date until March 2022.

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

3

 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
4
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

C
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
u
r
a
l

t
h
e
r
a
p
y
a
d
d
e
d
t
o
s
t
a
n
d
a
r
d
c
a
r
e
f
o
r

f
i
r
s
t
-
e
p
i
s
o
d
e
a
n
d
r
e
c
e
n
t
-
o
n
s
e
t
p
s
y
c
h
o
s
i
s
(
R
e
v
i
e
w

)

4

S U M M A R Y   O F   F I N D I N G S

Summary of findings 1.   Summary of findings table - Cognitive behavioural therapy plus standard care compared to control for first-episode or
recent-onset psychosis

Cognitive behavioural therapy plus standard care compared to control for first-episode or recent-onset psychosis

Patient or population: first-episode or recent-onset psychosis
Setting: 
Intervention: Cognitive behavioural therapy plus standard care
Comparison: control

Outcomes

Anticipated absolute effects* (95% CI)

Risk with con-
trol

Risk with Cognitive be-
havioural therapy plus
standard care

Relative effect
(95% CI)

№ of partici-
pants
(studies)

Certainty of
the evidence
(GRADE)

Comments

Mental state - general: mean endpoint overall
symptom scales (high = poor) (combined time
points)

-

SMD 0.27 SD lower
(0.47 lower to 0.08 lower)

-

1508
(20 RCTs)

Global state - number of participants with re-
lapse/exacerbations of psychosis (combined
time points)

358 per 1000

293 per 1000
(204 to 422)

RR 0.82
(0.57 to 1.18)

693
(7 RCTs)

Leaving the study early - for any reason -
overall acceptability (combined time points)

214 per 1000

186 per 1000
(154 to 225)

RR 0.87
(0.72 to 1.05)

2242
(25 RCTs)

Functioning - mean endpoint functioning
scale (high = good) (combined time points)

-

SMD 0.23 SD lower
(0.42 lower to 0.05 lower)

-

1241
(18 RCTs)

Adverse events - participants with at least one
adverse event - < 12 months

591 per 1000

762 per 1000
(502 to 1000)

RR 1.29
(0.85 to 1.97)

43
(1 RCT)

⊕⊕⊝⊝
Lowa,b

⊕⊕⊝⊝
Lowc

⊕⊕⊕⊝
Moderated

⊕⊕⊕⊝
Moderatee

⊕⊝⊝⊝
Very lowf

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).

CI: confidence interval; RR: risk ratio; SMD: standardised mean difference

GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

See interactive version of this table: https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_439588391841774344.

a Downgraded by one level for risk of bias: 5 out of 20 studies were at overall high risk of bias
b Downgraded by one level for serious inconsistency (I-squared = 68%)
c Downgraded by two levels for imprecision: inadequate information size (< 1000 participants for a dichotomous outcome) and CI includes both better outcome for CBT + TAU
and no difference between CBT + TAU and control
d Downgraded by one level for imprecision: CI includes both better outcome for CBT + TAU and no difference between CBT + TAU and control
e Downgraded by one level for risk of bias: 2 out of 18 studies were at overall high risk of bias
f Downgraded by three levels for imprecision: inadequate information size (< 1000 participants for a dichotomous outcome, N = 43) and CI includes both better outcome for control
and no difference between CBT + TAU and control

C
o
p
y
r
i
g
h
t

©
2
0
2
4
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

C
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
u
r
a
l

t
h
e
r
a
p
y
a
d
d
e
d
t
o
s
t
a
n
d
a
r
d
c
a
r
e
f
o
r

f
i
r
s
t
-
e
p
i
s
o
d
e
a
n
d
r
e
c
e
n
t
-
o
n
s
e
t
p
s
y
c
h
o
s
i
s
(
R
e
v
i
e
w

)

5

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

B A C K G R O U N D

Description of the condition

The estimate of the lifetime prevalence of psychotic illnesses is 7
per  1000  of  the  population;  the  incidence  of  the  first  episode  of
psychosis (FEP) is estimated at 34 new cases per 100,000 persons/
year  (Kirkbride  2012;  Kirkbride  2017).  Psychosis  usually  starts  in
late  adolescence  and  early  adulthood,  with  an  average  age  of
onset  at  the  beginning  of  the  second  decade  of  life  (Kirkbride
2017).  Psychotic  symptoms  fall  into  two  broad  categories:  a)
positive  symptoms,  which  are  abnormal  by  their  presence  (such
as  hallucinations,  delusions,  and  disordered  thinking),  and  b)
negative  symptoms,  which  involve  a  loss  or  reduction  of  normal
functions  that  should  be  normally  present  (social  withdrawal,
flat  or  blunted  affect,  poverty  of  speech,  restricted  range  or
intensity  of  emotional  expressions).  Psychotic  illnesses  include  a
range of different diagnoses, such as schizophrenia, schizoaffective
disorder,  and  delusional  disorder  (WHO  2019).  The  prevalence  of
schizophrenia is similar in men and women, higher in developed
countries compared with the least developed countries, and higher
in migrants compared with native-born individuals (Saha 2005).

There  is  no  consensus  on  the  definition  of  FEP  (Breitborde  2009;
Puntis 2020) and different criteria are used in clinical and research
settings  to  define  this  term.  These  include  duration  criteria  (e.g.
less than three or five years since first onset of symptoms), contact
with mental health services criteria (e.g. first contact with mental
health  services),  or  initiation  of  antipsychotic  medication  criteria
(e.g. no more than six months of antipsychotic prescription (Puntis
2020)). In this review, we will focus on people with a first episode
of psychosis as defined in the included studies. In order to capture
this uncertainty, we will also accept studies including participants
with a recent-onset psychosis, defined with a time criterion of five
years (see Types of participants).

A  study  of  outcomes  of  FEP  found  that  58%  of  patients  with  FEP
met criteria for remission (absent psychotic symptoms for at least
six months) and 38% met criteria for recovery (both symptomatic
and  functional  improvement  -  including  social,  educational  and
occupational domains - for at least two years) over mean follow-
up periods of 5.5 years and 7.2 years, respectively (Lally 2017). In
a review of predictors of treatment resistance in FEP, the following
were  found  to  influence  outcome:  lower  premorbid  functioning;
lower level of education; negative symptoms from first psychotic
episode;  comorbid  substance  use;  younger  age  at  onset;  lack  of
early response; non-adherence to treatment; and longer duration
of  untreated  psychosis  (Bozzatello  2019).  Evidence  regarding
the  longer-term  course  of  clinical  symptomatology,  social  and
occupational  functioning  following  FEP  remains  lacking,  with
significant  heterogeneity  between  studies  limiting  comparability.
A  longitudinal  study  of  an  FEP  cohort  (n  =  326)  in  the  UK
identified four broad trajectories of psychotic symptoms over a ten-
year  follow-up  period;  the  majority  of  patients  were  categorised
as  either  remitting-improving  (58%)  or  persistent  (30.6%),  while
smaller groups displayed late decline (5.6%), and late improvement
(5.4%) (Morgan 2022).

The  impact  on  the  individual  is  usually  significant,  because  the
onset  of  the  illness  typically  occurs  at  an  age  when  the  person
is  engaged  in  many  important  life  tasks,  such  as  completing
their  education,  establishing  oneself  in  the  job  market,  and
forming  significant  relationships.  A  psychotic  illness  has  wide-

Cochrane Database of Systematic Reviews

ranging implications for quality of life, functioning, social inclusion,
education,  and  employment  (Marwaha  2004;  Meltzer  2002).  For
these reasons, the burden of schizophrenia and related psychotic
illnesses  is  dramatic  for  the  person,  his  or  her  relatives,  and
society.  According  to  the  2019  Global  Burden  of  Disease  Report,
schizophrenia  ranks  20th  in  years  lived  with  disability  (YLD  (GBD
2019)). With estimated total costs of more than EUR 29 billion per
year, schizophrenia is also amongst the most expensive illnesses in
the European Union (EU (Gustavsson 2010)). Annual societal costs
per person with schizophrenia vary across countries, and have been
estimated  to  be  USD  5818  in  Thailand,  USD  30,140  in  Germany,
USD  33,851  in  Japan,  and  USD  94,587  in  Norway  (Jin  2017).  The
main  reasons  for  these  costs  are  high  hospitalisation  rates,  high
unemployment, and loss of productivity; 80% to 90% of people with
schizophrenia do not work (Evensen 2016; Marwaha 2004; Marwaha
2007). In addition, there are high rates of physical morbidity, and
lower life expectancy (Hjorthøj 2017).

Improving  the  ability  of  people  with  schizophrenia  to  function
in  society  and,  therefore,  being  active  in  their  educational,
professional, and social life can help reduce the burden connected
with  first-episode  and  recent-onset  psychosis.  Furthermore,
treatment  of  people  with  their  first-episode  and  recent-onset
psychosis  is  of  fundamental  importance,  in  order  to  prevent
an  exacerbation  of  the  symptomatology  (relapse),  and  the
development of chronicity of the illness.

Description of the intervention

for 

first-episode  psychosis 

The  mainstay  of  treatment 
is
antipsychotic  medication,  even  though  about  26%  of  people  in
their  first  episode  continue  to  experience  psychotic  symptoms
(Ceraso 2020), and may experience unwanted and unpleasant side
effects (Schneider-Thoma 2019). Psychotherapy can be additional
interventions, provided in conjunction with medication.

Cognitive  behavioural  therapy  (CBT)  is  a  type  of  psychotherapy,
during  which  people  are  encouraged  to  establish  links  between
their  thoughts,  feelings,  or  actions,  and  their  current  or  past
symptoms or functioning (or both). People are encouraged to re-
evaluate their perceptions, beliefs, and reasoning in relation to the
target  symptoms.  Therapy  promotes  alternative  ways  of  coping
with  the  target  symptom,  with  the  aim  of  reducing  stress  and
improving functioning (NICE 2014).

CBT for psychosis was developed with the primary aim of reducing
symptom severity, and there is evidence that it may be effective in
this regard for the general population of people with schizophrenia
(Bighelli 2018; Jones 2018a; Jones 2018b). There is also evidence
that CBT could be beneficial for improving other outcomes, such
as  insight,  well-being,  and  functioning  in  this  population  (Jones
2018a; Laws 2018).

recommend  offering  CBT 

The  National  Institute  for  Health  and  Care  Excellence  (NICE)
guidelines 
in  conjunction  with
antipsychotic  medication  to  people  with  first-episode  psychosis
for at least 16 sessions (NICE 2014). NICE guidelines for psychosis
and schizophrenia in children and young people also recommend
offering CBT in addition to pharmacotherapy (NICE 2013).

How the intervention might work

CBT  promotes  the  creation  of  links  between  thoughts,  feelings,
actions, and symptoms, with the goal of changing the way in which

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

6

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

the person interprets and evaluates their experiences and reflects
on their meanings.

One  goal  of  CBT  for  psychosis  is  to  reduce  the  occurrence  of
symptoms.  People  with  schizophrenia  are  taught  to  identify  and
monitor  their  thoughts  and  assumptions  in  specific  situations,
and  to  evaluate  and  correct  these  thoughts  and  assumptions  by
considering objective external evidence and actual circumstances.
This  encourages  people  to  challenge  their  delusional  beliefs  and
their perceptions of hallucinations (Hagen 2010).

Other  goals  of  CBT  include  reducing  the  distress  associated  with
symptoms and their interference with the person's well-being and
quality of life, for example, by improving coping skills (Hagen 2010).

Why it is important to do this review

A  prior  Cochrane  Review  of  early  interventions  for  psychosis
found  only  two  eligible  randomised  controlled  trials  on  CBT
(Marshall 2011). Recent Cochrane Reviews on cognitive behavioural
therapy  for  people  with  schizophrenia  identified  nine  studies  on
people with first-episode schizophrenia, but did not analyse them
separately;  so  currently,  there  is  no  reliable  summary  of  the
evidence for CBT in this important population (Jones 2018a; Jones
2018b).

Therefore,  a  high-quality  synthesis  is  needed  and  relevant  for  all
stakeholders, including clinicians, consumers, and funders.

O B J E C T I V E S

To assess the effects of adding cognitive behavioural therapy (CBT)
to  standard  care  for  participants  with  a  first-episode  and  recent-
onset schizophrenia.

M E T H O D S

Criteria for considering studies for this review

Types of studies

We considered all relevant randomised controlled trials (RCTs). We
included RCTs that met our inclusion criteria and reported data that
were usable for either the qualitative or quantitative synthesis. We
considered  both  open-label  and  blind-outcome  assessor  studies.
Given the nature of cognitive behavioural therapy (CBT), it may not
have been possible to blind the participant to the treatment; on the
contrary, the active engagement of the person in the therapy was
required. As a result, we did not expect to find double-blind studies;
if we identified any, we included them. The researcher collecting
outcome  data  could  have  been  unaware  of  the  allocation  of  the
individual participant (blind outcome assessor). We examined the
role of a blind outcome assessor in a Sensitivity analysis, excluding
the studies that had not used blinding for this role.

We  excluded  quasi-randomised  studies,  such  as  those  that
allocated  participants  to  interventions  on  alternate  days  of  the
week.  When  people  were  given  additional  treatments,  such  as
pharmacological treatment with antipsychotics, we only included
data  if  the  adjunct  treatment  was  evenly  distributed  between
groups, and it was only the cognitive behavioural therapy that was
randomised.

Cochrane Database of Systematic Reviews

Types of participants

The  target  of  this  review  were  people  with  a  first-episode  or
recent-onset psychosis. We included studies with participants who
exhibited  symptoms  that  matched  the  criteria  for  an  episode  of
a  psychotic  disorder  (schizophrenia,  however  defined;  or  related
disorders,  including  schizophreniform  disorder,  schizoaffective
disorder, and delusional disorder, however diagnosed).

A first episode of psychosis is defined as the first manifestation of
the disorder that meets the defining diagnostic symptoms and time
criteria  (APA  2013).  Studies  that  explicitly  recruited  participants
with a first episode were included. Studies that use terms such as
"recent-onset psychosis" were also included if it was defined as no
longer than five years from first contact/treatment/diagnosis.

We  also 
included  studies  that  recruited  participants  from
early  intervention  services,  since  these  centres  usually  recruit
participants within three to five years of the illness, so matching our
inclusion criteria.

We included studies independently of the age of the participants
(except those over the age of 65 years), in order to account for the
variability  in  age  of  onset  for  psychosis.  We  excluded  trials  that
reported outcomes from participants with a second or subsequent
episode, deemed to be at risk of developing schizophrenia, trials
that focused on participants with a late-onset psychosis (e.g. first
episode around the age of 65), and trials that focused on people
older than 65 as part of their inclusion criteria.

We also excluded studies specifically focused on participants with a
first episode of mania, psychotic depression, and psychosis related
to  substance  abuse;  studies  in  which  participants  had  organic
psychoses;  or  studies  that  recruited  participants  with  prodromal
symptoms, or at risk mental states.

If a study included participants with other diagnoses, we included
the  study  only  if  participants  with  psychosis  (as  defined  above)
comprised  at  least  50%  of  the  participants,  or  if  we  were  able  to
extract  the  data  on  the  eligible  participants  separately.  If  a  study
included participants with recent-onset psychosis, without further
defining this term, we included the study only if participants with
a first episode of psychosis (as defined above) were at least 75% of
the sample population.

Types of interventions

1. Cognitive behavioural therapy (CBT)

Cognitive  behavioural  therapy  is  used  as  a  broad  label  that
can  include  a  variety  of  interventions,  such  as  manualised  CBT
programmes,  CBT  integrated  with  other  treatments  (for  example
motivational  interviewing),  or  CBT  combined  with  third-wave
components (mindfulness, acceptance, and commitment therapy).
Therefore, it is difficult to provide a single definition of CBT.

For  the  aims  of  this  review,  any  CBT-based  interventions  were
eligible  for  inclusion.  The  role  of  different  subtypes  of  CBT
interventions  was  ascertained  by  analysing  them  separately,  in
a  subgroup  analysis  (see  Subgroup  analysis  and  investigation  of
heterogeneity).

2. Control

We included studies that compared CBT to non-CBT interventions:

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

7

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

• standard  care,  or  treatment-as-usual  (TAU),  defined  as  the
treatment that a person with a first episode of psychosis would
normally  receive  had  they  not  been  involved  in  the  trial.  This
may include antipsychotic medication;

• waiting list;
• inactive treatments (e.g. psychological placebo), defined as any
inactive intervention intended to control for the time spent with
the therapist (e.g. recreational activities) plus standard care; or
• other  psychosocial  interventions,  such  as  family  therapy  or

psychoeducation, plus standard care.

1.2.4  Average  endpoint  or  change  score  on  a  published  scale  or
subscale that addresses negative symptoms (e.g. PANSS negative,
Scale for the Assessment of Negative Symptoms (SANS))

1.2.5  Clinically  important  change  in  depressive  symptoms,  as
defined by individual studies

1.2.6  Average  endpoint  or  change  score  on  a  published  scale  or
subscale that addresses depressive symptoms (e.g. Montgomery-
Asberg  Depression  Rating  Scale  (MADRS),  Beck  Depression
Inventory (BDI))

Types of outcome measures

2. Global state

We divided all outcomes into short-term (up to six months since the
onset of therapy), medium-term (up to 12 months), and long-term
(over  12  months).  This  grouping  reflects  the  recommendations
of  the  National  Institute  for  Health  and  Care  Excellence  (NICE),
according to which, CBT should be delivered for at least 16 sessions
and usually once a week (NICE 2014).

Data  were  presented  both  for  the  above-mentioned  time  points
separately and for the time points combined. When combining time
points,  we  gave  priority  to  medium-term,  then,  if  not  available,
short-term,  then  long-term.  For  outcomes  such  as  relapse  and
adverse  events,  we  gave  priority  to  long-term,  then  medium-
term, then short-term. This priority was determined following the
predefined time points for evaluating Risk of Bias 2 (see Assessment
of risk of bias in included studies).

2.1 Relapse. If more than one measure of relapse is reported, we will
give priority to: 1. relapse defined with operationalised criteria (e.g.
worsening on a symptom scale); 2. clinical judgement.

2.2 Recovery

2.3 Remission

2.4  Clinically  important  change  in  global  state  (e.g.  global
impression of much improved, or more than 50% improvement on
a rating scale, such as the Clinical Global Impression scale (CGI))

2.5 Average endpoint or change score on a global state scale

3. Service use

3.1 Admission to hospital

For outcomes, such as 'clinically important change', 'any change',
and 'relapse', we used the definition used by each of the trials.

3.2 Number of days in hospital

For valid scales, please see Data extraction and management.

Primary outcomes

1. Mental state

1.1 General

1.1.1 Average endpoint or change score on a general mental state
scale  (e.g.  Positive  and  Negative  Syndrome  Scale  (PANSS),  Brief
Psychiatric Rating Scale (BPRS))

Secondary outcomes

1. Mental state

1.1 General

4. Leaving the study early

4.1 For any reason

4.2 Due to inefficacy

4.3 Due to adverse effect(s)

5. Functioning

important  change 

5.1  Clinically 
in  functioning:  number  of
participants  with  a  clinically  important  change  in  functioning,  as
defined in each study

5.2 Average endpoint or change score on a functioning scale. We will
accept any published rating scales, such as the Global Assessment
of Functioning (GAF), or the Psychosocial Performance Scale (PSP).

1.1.1  Clinically  important  change  in  general  mental  state  (study
defined)

6. Cognitive functioning

6.1 Clinically important change in cognitive functioning

1.2 Specific

1.2.1 Clinically important change in positive symptoms (delusions,
hallucinations,  disordered  thinking),  as  defined  by  individual
studies

1.2.2  Average  endpoint  or  change  score  on  a  published  scale  or
subscale  that  addresses  positive  symptoms  (e.g.  PANSS  positive,
Scale for the Assessment of Positive Symptoms (SAPS))

1.2.3 Clinically important change in negative symptoms (avolition,
poor self-care, blunted affect), as defined by individual studies

6.2  Average  endpoint  or  change  score  on  a  cognitive
functioning  scale  assessing  multiple  cognitive  domains.  We
will  accept  any  published  cognitive  functioning  scale  (e.g.  the
MATRICSTM consensus cognitive battery, or the Neuropsychological
Assessment Battery).

7. Quality of life

7.1 Clinically important change in quality of life

7.2  Average  endpoint  or  change  score  on  a  quality  of  life  scale.
We  will  accept  any  published  quality  of  life  scale  (e.g.  Heinrich-
Carpenter quality of life scale).

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

8

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

8. Satisfaction with care

8.1 Recipient

8.1.1 Recipient satisfied with care

8.1.2  Average  endpoint  or  change  score  on  satisfaction  with
care  scale.  We  will  accept  any  published  rating  scale  measuring
satisfaction with care.

8.2 Carers

8.2.1 Carers satisfied with care

8.2.2  Average  endpoint  or  change  score  on  satisfaction  with  care
scale

9. Behaviour

9.1 Occurrence of violent incidents (to self, others, or property)

9.2 Self-injury

9.3 Suicide attempt

10. Adverse events

10.1 At least one adverse event

10.2 Specific adverse events. We will use the classification proposed
by  Linden  and  colleagues  to  record  adverse  events  potentially
connected with CBT (Linden 2014).

11. Mortality

11.1 Overall mortality

11.2 Mortality due to natural causes

11.3 Mortality due to suicide

Search methods for identification of studies

Electronic searches

The  Cochrane  Schizophrenia  Information  Specialist  searched
Cochrane  Schizophrenia's  register,  using  the  following  search
strategy:

*Cognit* in Intervention Field of STUDY

In a study-based register, searching for the major concept retrieved
all the synonyms and relevant studies. This is because the studies
have  already  been  organised,  based  on  their  interventions,  and
linked to the relevant topics (Shokraneh 2017). This allowed rapid
and  accurate  searches  that  reduced  waste  in  the  next  steps  of
systematic reviewing (Shokraneh 2019).

Following  standard  Cochrane  methodology,  the 
information
specialist compiled this register from systematic searches of major
resources  and  their  monthly  updates  (unless  otherwise  specified
(Lefebvre 2020)).

• Cochrane Central Register of Controlled Trials (CENTRAL) in the

Cochrane Library

• MEDLINE
• Embase
• Allied and Complementary Medicine (AMED)

Cochrane Database of Systematic Reviews

• BIOSIS
• Cumulative  Index  to  Nursing  and  Allied  Health  Literature

(CINAHL)
• PsycINFO
• PubMed
• US  National 

Institute  of  Health  Ongoing  Trials  Register

(ClinicalTrials.gov)

• World Health Organization International Clinical Trials Registry

Platform (ICTRP; www.who.int/ictrp)

• ProQuest Dissertations and Theses A & I and its quarterly update

register  also 

The 
included  handsearches  and  conference
proceedings  (see  the  group's  website).  It  did  not  place  any
limitations on language, date, document type or publication status.

Searching other resources

1. Reference searching

We  inspected  the  references  of  all  included  studies  for  further
relevant studies.

2. Personal contact

We contacted the first author of each included study for information
regarding  unpublished  trials  and  additional  data.  We  noted  the
outcome of this contact in the included studies or studies awaiting
classification tables.

Data collection and analysis

Selection of studies

At  least  two  review  authors  (IB,  CC,  or  EA)  have  independently
inspected  citations  from  the  searches  and  identified  relevant
abstracts. When disputes arose, we acquired the full report for more
detailed scrutiny. At least two review authors (IB, CC, or EA) then
obtained and independently inspected full reports of the abstracts
or  reports  that  met,  or  appeared  to  meet,  the  review  criteria.
When  it  was  not  possible  to  resolve  disagreement  by  discussion,
we  discussed  the  issue  with  the  senior  author  of  the  review
team to resolve it. If, following discussion with the senior author,
disagreement still existed, we attempted to contact the authors of
the  study  concerned  for  clarification.  We  further  documented  all
decisions.

Data extraction and management

1. Extraction

At  least  two  review  authors  (amongst  SFM,  CC,  LK  or,  IB)
independently  extracted  data  from  all  included  studies.  Data
presented only in graphs and figures were also extracted with the
same  strategy.  We  discussed  any  disagreement.  When  it  was  not
possible to resolve disagreements by discussion, we discussed the
matter  with  the  senior  author.  We  documented  all  decisions.  If
necessary,  we  attempted  to  contact  authors,  and  used  an  open-
ended  request  to  obtain  missing  information,  or  clarification.  IB
and SL helped clarify issues regarding any remaining problems, and
we documented these final decisions.

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

9

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

2. Management

2.1 Forms

We  extracted  data  onto  simple,  pre-designed  forms,  which  we
specifically designed for this review.

2.2 Scale-derived data

We  included  continuous  data  from  rating  scales  only  if:  (1)  the
psychometric  properties  of  the  measuring  instrument  have  been
described  in  a  peer-reviewed  journal  (Marshall  2000);  (2)  the
measuring  instrument  has  not  been  written  or  modified  by  one
of the trialists for that particular trial; and (3) the instrument is a
global  assessment  of  an  area  of  functioning  and  not  a  subscore,
which is not, in itself, validated or shown to be reliable. However,
we  included  subscores  of  scales  if  they  were  validated,  or  if  they
were predefined on a scale, such as the positive symptom, negative
symptom, and general symptom scores of the PANSS (Kay 1986).

Ideally,  the  measuring  instrument  should  be  either:  (1)  a  self-
report,  or  (2)  completed  by  an  independent  rater  or  relative  (not
the  therapist).  However,  we  realised  that  this  is  often  not  clearly
reported.

2.3 Endpoint versus change data

There are advantages of both endpoint and change data: change
data  can  remove  a  component  of  between-person  variability
from  the  analysis;  however,  calculation  of  change  needs  two
assessments  (baseline  and  endpoint),  which  can  be  difficult  to
obtain  in  unstable  and  difficult-to-measure  conditions,  such  as
schizophrenia. However, we decided to primarily use change data,
and  only  use  endpoint  data  if  the  former  were  not  available.
If  necessary,  we  combined  endpoint  and  change  data  in  the
analysis.  This  procedure  was  possible  when  using  both  mean
differences (MDs), or standardised mean differences (SMDs (Higgins
2020)).  Although  theoretically,  the  combination  of  change  and
endpoint  data  when  SMDs  are  used  can  be  problematic,  meta-
epidemiological  research  has  shown  that,  on  average,  no  major
over- or underestimations can have been expected (da Costa 2013).
We analysed endpoint and change data separately in a Sensitivity
analysis for the primary outcome, mental state.

2.4 Skewed data

Continuous  data  on  clinical  and  social  outcomes  are  often  not
normally  distributed.  To  avoid  the  pitfall  of  applying  parametric
tests  to  non-parametric  data,  we  applied  the  following  checks  to
relevant continuous data before including them.

For  endpoint  data  from  studies 
including  fewer  than  200
participants,  we  calculated  the  observed  mean  minus  the  lowest
possible  value  of  the  scale,  and  divided  this  by  the  standard
deviation (Higgins 2020).

For example, in a scale that has a minimum possible score higher
than  0  (such  as  the  PANSS,  which  can  have  values  from  30  to
210  (Kay  1986)),  we  subtracted  the  minimum  score  (in  this  case,
30)  from  the  observed  mean,  and  then  divided  by  the  standard
deviation (SD). In a scale that has 0 as the minimum possible score,
we divided the observed mean by the standard deviation.

For  this  calculation,  we  checked  the  original  publication  of  the
scales  referenced  in  the  studies,  to  determine  if  they  can  have

Cochrane Database of Systematic Reviews

a  minimum  possible  score  different  from  0,  and  whether  the
adjustment described above is needed or not.

A ratio that is lower than one strongly suggests that the data are
skewed. A ratio that is higher than one but less than two suggests
that the data are skewed; if the ratio is larger than two, it is less likely
that they are skewed (Altman 1996).

Where there was a suggestion of skewness (ratio < 2), we excluded
the relevant studies in a sensitivity analysis, to check if they have
an impact on the results (see Sensitivity analysis).

We reported skewed results in other data tables.

We  entered  all  relevant  data  from  studies  with  more  than  200
participants in the analysis, regardless of the above rules, because
skewed data pose less of a problem in large studies. We also entered
all relevant change data, since it was difficult to tell whether data
were  skewed  or  not  when  continuous  data  were  presented  on  a
scale that includes a possibility of negative values (such as change
data).

2.5 Common measurement

To facilitate comparison between trials, we converted variables that
can be reported in different metrics, such as days in hospital (mean
days per year, per week, or per month) to a common metric (e.g.
mean days per month), where relevant.

2.6 Conversion from continuous to binary

Where  possible,  we  tried  to  convert  outcome  measures  to
dichotomous data. We have done this by identifying cut-off points
on rating scales, and divided participants accordingly into 'clinically
improved' or 'not clinically improved'. It is generally assumed that,
if  there  is  a  50%  reduction  in  a  scale-derived  score,  such  as  the
BPRS (Overall 1962), or the PANSS (Kay 1986), which corresponds to
'much improved' according to the clinical global impressions (CGI)
of raters (Guy 1976), it could be considered a clinically significant
response, especially for people who are acutely ill (Leucht 2005a;
Leucht  2005b).  Since  our  population,  people  with  first-episode
psychosis,  usually  responded  well  to  treatment,  we  planned  to
keep  the  cut-off  of  50%  improvement  to  convert  continuous  to
binary  outcomes.  If  data  based  on  these  thresholds  were  not
available, we would have used the primary cut-off presented by the
original authors, because the exact cut-off was not as important in
a meta-analysis that uses risk ratios or odds ratios as effect sizes
(Furukawa  2010).  Since  many  studies  provided  data  only  for  the
25% cut-off, we took this one also from the other studies, in order
to present consistent results.

2.7 Direction of graphs

When possible, we entered data so that the area to the left of the
line  of  no  effect  indicates  a  favourable  outcome  for  CBT.  When
keeping  to  this  makes  it  impossible  to  avoid  outcome  titles  with
clumsy double-negatives (e.g. not unimproved), we reported data
for  which  the  estimates  left  of  the  line  indicate  an  unfavourable
outcome, and noted this in the relevant graphs.

Assessment of risk of bias in included studies

Review authors SFM, CC, LM and IB worked independently to assess
the  risk  of  bias,  using  the  RoB  2  tool  and  the  criteria  described
in  chapter  8  of  the  Cochrane  Handbook  for  Systematic  Reviews  of
Interventions (Higgins 2020; Sterne 2019).

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

10

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

This  set  of  criteria  was  based  on  the  judgement  of  the  following
domains:

of findings table(s), we calculated the anticipated absolute effects
for the intervention and control, where possible.

1. bias arising from the randomisation process;
2. bias due to deviations from intended interventions;
3. bias due to missing outcome data;
4. bias in measurement of the outcome; and
5. bias in selection of the reported result.

For  each  domain,  we  rated  the  available  signalling  questions
to  reach  a  judgement  (high,  some  concerns,  low)  following  the
algorithms implemented in the RoB 2 Excel tool (available on the
riskofbiasinfo.org website).

RoB 2 generally allows one to address studies from two angles: a)
the effect of assignment to the interventions at baseline, regardless
of  whether  the  interventions  were  received  as  intended,  i.e.  the
intention-to-treat effect; and b) the adherence to the interventions,
i.e. the per-protocol effect, or completer analysis (chapter 8.2.2 in
Higgins 2020). For the purpose of this review, we planned to assess
the intention-to-treat effect, when possible.

We assessed the risk of bias for the following outcomes:

1. Mental  state  (primary  outcome):  average  endpoint  or  change

score on a general mental state scale; medium-term

2. Global state: relapse; long-term
3. Leaving the study early: leaving the study early for any reason;

medium-term

4. Functioning: average endpoint or change score on functioning

scale; medium-term

5. At least one adverse event, measured in the long term

For  cluster-randomised  trials,  we  used  the  specific  version  of
the  RoB  2  tool,  provided  at  sites.google.com/site/riskofbiastool/
welcome/rob-2-0-tool.

Since we only used data from the first phase for cross-over trials,
we used the standard version of RoB 2.

If  there  was  disagreement  amongst  the  review  authors,  we
made  the  final  rating  by  consensus.  When  inadequate  details  of
randomisation and other characteristics of trials were provided, we
attempted to contact the authors of the studies to obtain further
information.

We noted the risk of bias in both the text of the review, the relevant
forest plots, and the summary of findings table(s).

Measures of treatment effect

1. Binary data

For binary outcomes, we calculated a standard estimation of the
risk ratio (RR) and its 95% confidence interval (CI), as it has been
shown that RR is more intuitive than odds ratios (Boissel 1999), and
odds ratios tend to be interpreted as RR by clinicians (Deeks 2000).
Although the number needed to treat for an additional beneficial
outcome (NNTB) and the number needed to treat for an additional
harmful outcome (NNTH), with their CIs, are intuitively attractive to
clinicians, they are problematic to calculate and interpret in meta-
analyses (Hutton 2009). For binary data presented in the summary

2. Continuous data

For continuous outcomes, we estimated the mean difference (MD)
between  groups,  in  particular,  when  natural  units  (such  as  days,
kilograms, etc.) were used. We preferred not to calculate effect size
measures (standardised mean difference (SMD)). However, if trials
use outcome scales of considerable similarity (such as PANSS and
BPRS), we presumed there was a small difference in measurement,
and we calculated the SMD (Higgins 2020).

Unit of analysis issues

1. Cluster-randomised trials

Studies 
(such  as
increasingly  use  cluster-randomisation 
randomisation  by  clinician  or  practice),  but  analysis  and  pooling
of clustered data pose problems. Authors often fail to account for
intra-class  correlation  in  clustered  studies,  leading  to  a  unit-of-
analysis  error,  whereby  P  values  are  spuriously  low,  CIs  unduly
narrow,  and  statistical  significance  overestimated  (Divine  1992).
This causes type I errors (Bland 1997; Gulliford 1999).

Where  clustering  has  been  incorporated  into  the  analysis  of
included  studies,  we  presented  these  data  as  if  they  were  from
a  non-cluster-randomised  study,  and  adjusted  for  the  clustering
effect.

Where clustering was not accounted for in the included studies, we
presented data in a table, with a (*) symbol to indicate the presence
of a probable unit of analysis error. We contacted first authors of
studies to obtain intra-class correlation coefficients (ICC) for their
clustered  data,  and  adjusted  for  this  by  using  accepted  methods
(Gulliford 1999).

We have sought statistical advice, and have been advised that the
binary  data  from  cluster  trials  presented  in  a  report  should  be
divided  by  a  'design  effect'.  This  was  calculated  using  the  mean
number  of  participants  per  cluster  (m)  and  the  ICC:  thus,  design
effect = 1 + (m − 1) * ICC (Donner 2002). If the ICC was not reported,
we assumed it to be 0.1 (Ukoumunne 1999).

If  cluster-randomised  studies  had  been  appropriately  analysed,
and 
intra-class  correlation  coefficients  and  relevant  data
documented in the report had been taken into account, we used the
generic  inverse  variance  technique  to  synthesise  the  results  with
results of other studies.

2. Cross-over trials

A  major  concern  of  cross-over  trials  was  the  carry-over  effect.
This  occurs  if  an  effect  (e.g.  pharmacological,  physiological,  or
psychological)  of  the  treatment  in  the  first  phase  was  carried
over  to  the  second  phase.  As  a  consequence,  participants  can
differ  significantly  from  their  initial  state  at  entry  to  the  second
phase, despite a wash-out phase. For the same reason, cross-over
trials were not appropriate if the condition of interest is unstable
(Elbourne 2002). As both carry-over and unstable conditions were
very likely in severe mental illness, we only used data from the first
phase of cross-over studies.

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

11

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

3. Studies with multiple treatment groups

When  a  study  involved  more  than  two  treatment  arms,  we
presented the additional treatment arms in the same comparisons,
if  relevant.  If  data  were  binary,  we  simply  added  and  combined
them  in  the  two-by-two  table.  If  data  were  continuous,  we
combined data following the formula in the Cochrane Handbook,
which  was  implemented  in  the  Review  Manager  Web  (RevMan
Web) calculator (Higgins 2020; Review Manager Web 2022). When
additional treatment arms were not relevant, we did not use these
data.

Dealing with missing data

1. Overall loss of credibility

Although, at some degree of loss of follow-up, data lose credibility,
we did not exclude studies based on this (Xia 2009).

However, if more than 50% of data were unaccounted for (lost to
follow-up),  we  excluded  these  studies  in  a  Sensitivity  analysis.  If
more than 50% of participants in one arm of a study were lost to
follow-up, but the total loss was less than 50%, we addressed this
in the summary of findings table(s) by downgrading the certainty of
the evidence (and not excluded the study in the sensitivity analysis).
Finally,  we  also  downgraded  the  certainty  of  the  evidence  in  the
summary of findings table(s), should the total loss be 25% to 50%.

2. Binary

We  presented  data  using  an  intention-to-treat  analysis  (ITT).  We
undertook  a  Sensitivity  analysis,  excluding  studies  that  analysed
only the data from participants who remained in the study at the
point of measurement.

3. Continuous

3.1 Standard deviations

If standard deviations (SDs) were not reported, we tried to obtain
the missing values from the authors. If SDs were still not available,
and there were missing measures of variance for continuous data,
but  an  exact  standard  error  (SE)  and  CI  was  available  for  group
means, and either a P value or t value was available for differences
in the mean, we calculated SDs according to the rules described in
the Cochrane Handbook (Higgins 2020).

When  only  the  SE  was  reported,  SDs  were  calculated  with  the
formula SD = SE * √(n). The Cochrane Handbook presents detailed
formulae for estimating SDs from P, t, or F values, CIs, ranges, or
other statistics (Higgins 2020). If these formulae did not apply, we
calculated  the  SDs  according  to  a  validated  imputation  method,
which  was  based  on  the  SDs  of  the  other  included  studies
(Furukawa  2006).  Although  some  of  these  imputation  strategies
could introduce error, the alternative would be to exclude a given
study’s  outcome  and,  thus,  lose  information.  Nevertheless,  we
examined  the  validity  of  the  imputations  in  a  sensitivity  analysis
that excluded trials that imputed values.

3.2 Assumptions about participants who left the trials early or were
lost to follow-up

Various methods were available to account for participants who left
the trials early, or were lost to follow-up. Some trials just presented
the  results  of  participants  who  completed  the  study;  others
used the method of last-observation-carried-forward (LOCF). More
recently,  methods,  such  as  multiple  imputation  or  mixed-effects

Cochrane Database of Systematic Reviews

models for repeated measurements (MMRM), have become more of
a  standard.  While  the  latter  methods  seemed  to  be  more  precise
than LOCF, we decided that the core problems in randomised trials
of  schizophrenia  were  often  the  high  percentage  of  participants
who  left  the  studies  early,  and  the  differences  between  groups
in  their  reasons  for  doing  so  (Leon  2006).  Therefore,  we  did  not
exclude studies based on the statistical approach used. However,
by  preference,  we  used  the  more  sophisticated  approaches;  i.e.
we used MMRM or multiple imputation before LOCF, and we only
presented  completer  analyses  if  ITT  data  were  not  available.  We
also addressed this issue in the 'Missing outcome data' domain of
RoB 2.

Assessment of heterogeneity

1. Clinical heterogeneity

Initially, we considered all the included studies, without seeing the
comparison data, to judge clinical heterogeneity. We inspected all
studies for participants or settings that were clearly different to the
participants or settings in the other included studies, and discussed
such differences or participant groups.

2. Methodological heterogeneity

Initially,  we  considered  all  the  included  studies,  without  seeing
comparison  data,  to  judge  methodological  heterogeneity.  We
inspected all studies for clearly outlying methods, which we had not
predicted would arise, and discussed them.

3. Statistical heterogeneity

3.1 Visual inspection

We  inspected  graphs  visually  to  investigate  the  possibility  of
statistical heterogeneity (e.g. observing the overlap of confidence
intervals).

3.2 Using the I2 statistic

We investigated heterogeneity between studies by considering the
I2  statistic  alongside  the  Chi2  P  value.  The  I2  statistic  provides  an
estimate of the percentage of inconsistency thought to be due to
chance (Higgins 2003). The importance of the observed value of I2
depends on the magnitude and direction of effects, as well as the
strength of evidence for heterogeneity (e.g. P value from Chi2 test,
or  a  confidence  interval  for  I2).  We  interpreted  the  I2  estimate  as
follows (chapter 10; Cochrane Handbook (Higgins 2020)):

1. 0% to 40%: might not be important;
2. 30% to 60%: may represent moderate heterogeneity;
3. 50% to 90%: may represent substantial heterogeneity;
4. 75% to 100%: may represent considerable heterogeneity.

When  we  found  substantial  levels  of  heterogeneity  (>  50%)  for
the  primary  outcome,  we  explored  reasons  for  heterogeneity
(Subgroup analysis and investigation of heterogeneity).

Assessment of reporting biases

Reporting biases arise when the dissemination of research findings
is  influenced  by  the  nature  and  direction  of  results  (Egger  1997).
These  are  described  in  Chapter  13  of  the  Cochrane  Handbook
(Higgins 2020).

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

12

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

1. Protocol versus full study

We  tried  to  locate  protocols  of  the  included  randomised  trials.  If
the protocol was available, we compared outcomes in the protocol
and  in  the  published  report.  If  the  protocol  was  not  available,
we compared outcomes listed in the Methods section of the trial
reported with the actual reported results.

2. Funnel plot

Funnel plots may be useful in investigating reporting biases, but are
of limited power to detect small-study effects. We did not use funnel
plots  for  outcomes  for  which  there  were  fewer  than  ten  studies,
or  when  all  studies  were  of  similar  size.  When  funnel  plots  were
possible,  we  sought  statistical  advice  on  their  interpretation.  We
applied the Egger's test for funnel plot asymmetry to support the
visual  inspection  of  the  forest  plot  with  a  statistical  test,  using  R
software (R).

Data synthesis

as treatment-as-usual, waiting list, psychological placebo, or other
psychological treatments.

1.5 Therapist experience

We planned to investigate the role of the experience of the therapist
providing the CBT intervention, by separately analysing trials that
used only expert therapists, and trials that also included therapists
in training.

Sensitivity analysis

Where possible, we undertook sensitivity analyses for the primary
outcome – mental state – to explore the influence of the following
factors  on  effect  size.  If  there  were  substantial  differences  in  the
direction  or  precision  of  effect  estimates  in  any  of  the  sensitivity
analyses listed below, we discussed them in the discussion section.

1. Blinding of outcome assessor

We excluded trials that did not blind the outcome assessor.

We undertook a meta-analysis only if we judged that participants,
interventions, comparisons, and outcomes were sufficiently similar
to ensure an answer that was clinically meaningful.

2. Assumptions for missing data

We excluded studies that used completer analyses only.

We used a random-effects model for analyses. The random-effects
method  incorporated  an  assumption  that  the  different  studies
were  estimating  different,  yet  related,  intervention  effects.  This
often  seemed  to  be  true  to  us,  and  the  random-effects  model
took  into  account  differences  between  studies,  even  if  there  was
no statistically significant heterogeneity. The disadvantage of this
model was that it puts added weight onto small studies.

To check the effect of the decision to use the random-effects model,
we  applied  the  fixed-effect  model  in  a  sensitivity  analysis  of  the
primary outcome.

Subgroup analysis and investigation of heterogeneity

1. Subgroup analyses

When  we  found  substantial  levels  of  heterogeneity  (>  50%)  for
the  primary  outcome,  we  explored  reasons  for  heterogeneity  by
conducting the following subgroup analyses.

1.1 Different types of CBT

We  analysed  different  kinds  of  CBT  as  different  subgroups,
such  as  manualised  CBT  programmes,  CBT  integrated  with  other
treatments (for example, motivational interviewing), or combined
with  third  wave  components  (mindfulness,  acceptance,  and
commitment therapy).

1.2 Modality of treatment

We  analysed  CBT  administered  in  individual  or  group  sessions
separately.

3. Loss to follow-up

We planned to exclude studies in which the overall loss of data was
greater than 50%, but this was never the case.

4. Risk of bias

We analysed the effects of excluding trials that were at overall high
risk of bias.

5. Imputed values

We  excluded  trials  in  which  we  used  imputed  values  for  ICC  to
calculate the design effect in cluster-randomised trials, or in which
we imputed SDs.

6. Fixed-effect

We re-synthesised data using a fixed-effect model.

7. Separating endpoint and change data

We  planned  to  analyse  studies  that  provided  data  as  endpoint
scores and change scores separately.

8. Skewed data

We planned to exclude studies for which there was a suggestion of
skewness (mean/SD ratio lower than 2). If the results were different
from  the  main  analysis  (from  superiority  of  the  intervention  to
superiority of the control, or vice-versa), we would have excluded
these studies from the main analysis, and presented their data in
other data tables.

1.3 Method of delivery

9. Outliers

We analysed CBT delivered face-to-face or with other methods of
delivery (online, telephone) separately.

We performed an additional post hoc sensitivity analysis excluding
an outlier study (Palma-Sevillano 2019).

1.4 Control group

In  order  to  investigate  the  role  of  the  comparator,  we  analysed
CBT  compared  with  different  control  conditions  separately,  such

Summary of findings and assessment of the certainty of the
evidence

We used the GRADE approach to interpret findings, and GRADEpro
GDT  software  to  export  data  from  our  RevMan  Web  file  to

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

13

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

create a summary of findings table (GRADEpro GDT; Higgins 2020;
Review Manager Web 2022). A summary of findings table provided
outcome-specific  information  concerning  the  overall  certainty
of  evidence  from  the  included  studies  in  the  comparison,  the
magnitude of effect of the interventions examined, and the sum of
available data on all outcomes we rated as important to healthcare
and decision-making. We used the overall RoB 2 judgements to feed
into the GRADE assessment.

4. Functioning: average endpoint or change score on functioning

scale (medium-term)

5. At least one adverse event (long-term)

If  data  were  not  available  for  these  prespecified  outcomes,  but
were available for ones that are similar, we presented the closest
outcome to the prespecified one in the summary of findings table,
but took this into account when grading the evidence.

We  created  a  summary  of  findings  table  for  the  comparison,
cognitive behavioural therapy plus standard care versus control.

R E S U L T S

We included results for these outcomes in the summary of findings
table.

1. Mental  state:  average  endpoint  or  change  score  on  a  general

mental state scale (medium-term)

2. Global state: relapse (long-term)
3. Leaving the study early: leaving the study early for any reason

(medium-term)

Description of studies

For  details,  see  Characteristics  of 
Characteristics of excluded studies.

included  studies  and

Results of the search

Our  search  of  the  Cochrane  Schizophrenia  Group's  Study-Based
Register  of  Trials  identified  260  articles  for  full-text  screening
(corresponding to 74 studies) (Figure 1).We included a total of 28
studies in the review and 26 studies in the quantitative synthesis.

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

14

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 1.

Cochrane Database of Systematic Reviews

2418 records 
identified through 
database searching

32 records 
identified through 
other sources

2447 records after 
duplicates removed

2447 records 
screened 
(title/abstract)

2187 records 
excluded

260 full-text 
articles assessed 
for eligibility

80 full-text articles 
corresponding to 
30 studies 
excluded, with 
reasons: 

- 5 studies wrong 
study design

- 15 studies wrong 
population 

- 9 studies wrong 
intervention 

- 1 study has been 
cancelled 

10 full-text articles 
awaiting 
classification, 
corresponding to 7 
studies 

9 full-text articles 
ongoing, 
corresponding to 8 
studies

28 studies included 
in qualitative 
synthesis, 
corresponding to 
160 full-text articles

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

15

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 1.   (Continued)

Cochrane Database of Systematic Reviews

28 studies included 
in qualitative 
synthesis, 
corresponding to 
160 full-text articles

26 studies included 
in quantitative 
synthesis 
(meta-analysis), 
corresponding to 
160 full-text articles

Included studies

We included 28 studies (2498 participants) in the review, of which
26 studies (2407 participants) contributed to the meta-analyses and
are described below.

1. Design and duration

All  included  studies  were  RCTs.  Of  the  studies  contributing  data
to  the  meta-analyses,  18  studies  had  a  duration  of  treatment  of
up  to  26  weeks  (Bucci  2018  (Actissist);  Edwards  2006;  Edwards
2011;  Gleeson  2009  (EPISODE  II);  Haddock  1999;  Hjorthoj  2013
(CapOpus);  Jackson  2008  (ACE);  Jackson  2009;  Lecomte  2008;
Lepage 2022; Liu 2019; Madigan 2013; Morrison 2020 (MAPS); Pos
2019;  Lewis  2002  (SOCRATES);  Puig-Navarro  2020;  Sönmez  2020;
Uzenoff  2008);  seven  studies  lasted  between  27  and  52  weeks
(Barrowclough 2014; GetUp; Gonzalez-Ortega 2021; Morrison 2018
(COMPARE); Müller 2020; Palma-Sevillano 2019; Supereden3); and
no studies lasted more than 52 weeks. Eighteen studies provided
data at a longer follow-up after the end of treatment. For one study,
the  assessment  took  place  at  six  months  but  the  study  duration
remained unclear (Jolley 2003).

2. Participants

Of  all  the  studies  which  contributed  data  to  the  meta-analyses,
four studies did not provide further information on the diagnostic
criteria  (did  not  refer  to  a  diagnostic  manual)  (Bucci  2018
(Actissist); Lecomte 2008; Lepage 2022; Supereden3). In 12 studies,
participants  could  be  diagnosed  according  to  the  Diagnostic  and
Statistical  Manual  of  Mental  Disorders,  Fourth  Edition  (DSM-IV)
criteria (Barrowclough 2014; Edwards 2006; Edwards 2011; Gleeson
2009 (EPISODE II); Haddock 1999; Liu 2019; Madigan 2013; Müller
2020; Palma-Sevillano 2019; Lewis 2002 (SOCRATES); Sönmez 2020;
Uzenoff 2008). In three studies, the researchers used Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition, Text Revision
(DSM-IV-TR)  diagnostic  criteria  (Gonzalez-Ortega  2021;  Jackson
2008  (ACE);  Pos  2019).  In  one  study,  participants  were  diagnosed
according to DSM-V (Puig-Navarro 2020). In six studies, the authors
used  the  ICD-10  (GetUp;  Hjorthoj  2013  (CapOpus);  Jackson  2009;
Jolley 2003; Morrison 2018 (COMPARE); Morrison 2020 (MAPS)). The

average  age  of  participants  in  the  studies  contributing  to  meta-
analyses was about 24.39 years old.

3. Size

The  mean  number  of  participants  in  the  included  studies  was
92. Furthermore, the smallest study included only 19 participants
(Uzenoff  2008),  whereas  the 
largest  study  randomised  444
participants (GetUp).

4. Setting

In only one study (Haddock 1999), the participants were recruited in
an inpatient setting; in eight studies (Bucci 2018 (Actissist); Edwards
2006;  GetUp;  Gleeson  2009  (EPISODE  II);  Lecomte  2008;  Lepage
2022; Liu 2019; Puig-Navarro 2020) in an outpatient setting; and in
eleven studies in both in- and outpatient settings (Edwards 2011;
Gonzalez-Ortega  2021;  Jackson  2008  (ACE);  Jolley  2003;  Madigan
2013;  Morrison  2018  (COMPARE);  Müller  2020;  Palma-Sevillano
2019;  Pos  2019;  Lewis  2002  (SOCRATES);  Uzenoff  2008).  For  six
studies  (Barrowclough  2014;  Hjorthoj  2013  (CapOpus);  Jackson
2009;  Morrison  2020  (MAPS);  Sönmez  2020;  Supereden3)  this
information was not available. Most of the studies were conducted
in  the  UK  (Barrowclough  2014;  Bucci  2018  (Actissist);  Haddock
1999;  Jackson  2009;  Jolley  2003;  Morrison  2018  (COMPARE);
Morrison 2020 (MAPS); Lewis 2002 (SOCRATES); Supereden3). Four
studies were conducted in Australia (Edwards 2006; Edwards 2011;
Gleeson 2009 (EPISODE II); Jackson 2008 (ACE)); two studies were
conducted  in  Canada  (Lecomte  2008;  Lepage  2022);  one  in  the
USA  (Uzenoff  2008);  and  one  in  China  (Liu  2019).  The  remaining
nine studies were all conducted in Europe (GetUp; Gonzalez-Ortega
2021; Hjorthoj 2013 (CapOpus); Madigan 2013; Müller 2020; Palma-
Sevillano 2019; Pos 2019; Puig-Navarro 2020; Sönmez 2020).

5. Interventions

In all included studies, cognitive behavioural therapy plus standard
care was compared with a control group.

Nevertheless,  different  types  of  CBT  can  be  distinguished:
four  studies  (Bucci  2018  (Actissist);  GetUp;  Palma-Sevillano

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

16

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

2019;  Supereden3)  comprised  an  integrated  form  of  CBT  (CBT
integrated  in  an  app,  CBT  combined  with  family  intervention
and  case  management,  CBT  combined  with  psychoeducation
and  family  intervention,  CBT  combined  with  social  recovery
therapy).  Moreover,  four  studies  (Barrowclough  2014;  Edwards
2006; Hjorthoj 2013 (CapOpus); Madigan 2013) specifically focused
on  a  special  form  of  CBT  and  Motivational  Interviewing  (MI)
for  cannabis  cessation.  Additionally,  three  studies  (Gleeson  2009
(EPISODE  II);  Jackson  2009;  Uzenoff  2008)  used  special  types  of
CBT such as Relapse Prevention Therapy (RPT), Cognitive Recovery
Intervention  (CRI)  and  Adherence-Coping-Education  (ACE).  The
remaining studies provided a form of CBT that could be considered
standard  (Edwards  2011;  Gonzalez-Ortega  2021;  Haddock  1999;
Jackson 2008 (ACE); Jolley 2003; Lecomte 2008; Lepage 2022; Liu
2019;  Morrison  2018  (COMPARE);  Morrison  2020  (MAPS);  Müller
2020; Pos 2019; Puig-Navarro 2020; Santos 2008; Sönmez 2020).

Most  of  the  studies  (17:  Barrowclough  2014;  Edwards  2011;
GetUp; Gleeson 2009 (EPISODE II); Gonzalez-Ortega 2021; Hjorthoj
2013  (CapOpus);  Jackson  2009;  Jolley  2003;  Liu  2019;  Madigan
2013;  Morrison  2018  (COMPARE);  Morrison  2020  (MAPS);  Müller
2020; Palma-Sevillano 2019; Pos 2019; Sönmez 2020; Supereden3)
compared CBT plus standard care with treatment as usual (TAU).
Additionally, seven studies compared CBT plus standard care with
active control (Bucci 2018 (Actissist); Edwards 2006; Haddock 1999;
Jackson  2008  (ACE);  Lepage  2022;  Puig-Navarro  2020;  Uzenoff
2008).  Two  studies  compared  CBT  plus  standard  care  both  with
active control and TAU (Lecomte 2008; Lewis 2002 (SOCRATES)).

Except for one study (Bucci 2018 (Actissist)), all studies took place
within  a  face-to-face  setting.  Moreover,  three  studies  (Lecomte
2008;  Lepage  2022;  Madigan  2013)  took  place  in  a  group  setting
whereas,  in  20  studies,  CBT  was  delivered  individually.  Three
studies (Pos 2019; Puig-Navarro 2020; Supereden3) had both group
and individual elements.

These aspects of the intervention were investigated in the subgroup
analyses (Analysis 1.82; Analysis 1.83; Analysis 1.84; Analysis 1.85).

Standard  care  usually  comprised  antipsychotic  medication,  but
details on dose and type of antipsychotic were rarely provided in
the  studies.  The  percentage  of  participants  taking  antipsychotic
medication, where available, is reported in Included studies.

6. Outcomes

Different  studies  used  various  scales  to  measure  the  following
outcomes. As study reporting has often been incomplete, authors
were contacted for missing outcome data as well as clarifications
via email. Some study authors provided additional information and
data (see Notes in Characteristics of included studies).

6.1. Outcome scales

6.1.1 Mental state

Positive and Negative Symptom Scale (PANSS) (Kay 1986)

PANSS  is  a  clinician-rated  scale  containing  30  items,  where  each
item is scored on a 7-point Likert scale ranging from 1 'absent' to 7
'extreme'. PANSS originally consisted of three subscales assessing
both positive, negative, and general psychopathological symptoms
of schizophrenia. By summing the scores of all items, a total score
can be calculated which represents a measure of overall symptoms
of  schizophrenia  (ranging  from  30  to  210,  with  a  higher  score

Cochrane Database of Systematic Reviews

corresponding  to  higher  severity  of  symptoms).  Fifteen  studies
used  PANSS  (Barrowclough  2014;  Bucci  2018  (Actissist);  GetUp;
Gonzalez-Ortega 2021; Hjorthoj 2013 (CapOpus); Liu 2019; Morrison
2018  (COMPARE);  Morrison  2020  (MAPS);  Müller  2020;  Palma-
Sevillano  2019;  Pos  2019;  Lewis  2002  (SOCRATES);  Supereden3;
Sönmez 2020; Uzenoff 2008), but Sönmez 2020 only had data for
PANSS  positive  and  negative.  There  are  also  different  versions  of
PANSS, but none of the included studies used them.

The Psychotic Symptom Rating Scales (PSYRATS) (Haddock 1999)

PSYRATS consists of 11 items evaluating the severity of psychotic
symptoms  over  different  dimensions.  Only  one  study  (Liu  2019)
used PSYRATS for assessing psychotic symptoms.

Brief Psychiatric Rating Scale (BPRS) (Overall 1962)

BPRS is a scale that measures the severity of psychiatric symptoms,
including psychotic symptoms. It is rated by the clinician, and the
most frequently used version of the scale is composed of 18 items,
including positive, negative, and affective symptoms. Each item is
scored on a 7-point Likert scale from 1 'not present' to 7 'extremely
severe'. It is possible to calculate a total score by adding the scores
of  all  items  as  a  measure  of  overall  symptoms  of  schizophrenia
(ranging  from  18  to  126,  where  higher  scores  mean  more  severe
symptoms). Four studies used BPRS (Edwards 2006; Gleeson 2009
(EPISODE II); Haddock 1999; Lecomte 2008). Two studies assessed
only BPRS positive (Edwards 2011; Jackson 2008 (ACE)).

Scale for the Assessment of Positive Symptoms (SAPS) (Andreasen
1984a)

Positive symptoms of schizophrenia can be assessed on the SAPS
rating  scale.  The  scale  can  be  divided  into  the  following  four
domains: hallucinations, delusions, bizarre behaviour, and positive
formal thought disorder. All the items are rated from 0 (none) to 5
(severe). Two studies used SAPS (Lepage 2022; Madigan 2013).

Scale for the Assessment of Negative Symptoms (SANS) (Andreasen
1984b)

SANS  is  a  clinician-rated  scale  consisting  of  25  items  to  assess
negative  symptoms  of  patients  with  schizophrenia.  The  scale
comprises  five  domains  (affective  flattening  or  blunting,  alogia,
avolition/apathy, anhedonia/associality, attention), and each item
is rated on a scale from 0 (none) to 5 (severe). Six studies used SANS
(Edwards 2006; Edwards 2011; Gleeson 2009 (EPISODE II); Jackson
2008 (ACE); Lepage 2022; Supereden3).

Brief Negative Symptom Scale (BNSS) (Kirkpatrick 2011)

BNSS  is  composed  of  13  items  measuring  the  five  domains  of
blunted  affect,  alogia,  associality,  anhedonia,  and  avolition.  The
items can be rated from 0 to 6, with higher scores meaning more
severe symptoms. One study used BNSS (Pos 2019).

Beck Depression Inventory-Short Form (BDI-SF) (Beck 1972)

The  BDI-SF  is  a  short  form  of  the  BDI,  and  comprises  13  items
which are rated from 0 to 3, with higher scores corresponding to
more severe depression. Two studies used BDI-SF (Edwards 2006;
Edwards 2011).

Beck Depression Inventory (BDI-II) (Beck 1996a, Beck 1996b)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

17

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

BDI-II  consists  of  21  symptom-attitude  categories,  that  describe
specific  behavioural  manifestations  of  depression.  Each  category
consists of four to five self-evaluative statements, to be evaluated
with a score from 0 to 3, with higher scores indicating more severe
depression. Two studies used BDI-II (Sönmez 2020; Supereden3).

Hospital Anxiety and Depression Scale (HADS-D) (Zigmond 1983)

A lower score means lower severity of illness, more improvement
or  less  deterioration,  respectively.  A  CGI-I  score  of  1  'very  much
improved'  or  2  'much  improved'  corresponds  to  a  clinically
important  improvement.  One  study  used  CGI  (Palma-Sevillano
2019).  Three  studies  used  CGI-S  (Edwards  2011;  Gonzalez-Ortega
2021; Morrison 2018 (COMPARE)). Two studies used CGI-I (Gonzalez-
Ortega 2021; Morrison 2018 (COMPARE)).

HADS  is  a  self-assessment  scale  that  measures  anxiety  and
depression. The fourteen-item HADS includes the Anxiety subscale
(HADS-A)  and  the  Depression  subscale  (HADS-D),  with  each  one
composed of seven items. Each item can be rated from 0 to 3. By
adding the subscale scores, a total of 0 to 21 points can be obtained
for each of the depression and anxiety subscales. It is stated that a
total of 0 to 7 points for each subscale are in the normal range, 8 to
10 points suggest the presence of a mood disorder, and a score of
11 and above indicates possible mood disorder. Two studies used
HADS-D (Morrison 2018 (COMPARE); Morrison 2020 (MAPS)).

Calgary  Depression  Scale  for  Schizophrenia  (CDSS)  (Addington
1993)

CDSS  is  a  clinician-rated  scale  measuring  depressive  symptoms
in  people  with  schizophrenia.  It  includes  9  items  (8  structured
questions  and  one  observation  item)  considering  depressive
symptoms  that  can  be  scored  on  a  4-point  Likert  scale  from  0
'absent' to 3 'severe'. By summing the score of all items, a total score
can be computed which ranges from 0 to 27, with a higher score
corresponding to a higher severity of symptoms. Nine studies used
CDSS  (Barrowclough  2014;  Bucci  2018  (Actissist);  Jackson  2009;
Jolley 2003; Lepage 2022; Madigan 2013; Müller 2020; Sönmez 2020;
Uzenoff 2008).

Montgomery–Åsberg  Depression 
(Montgomery 1979)

Rating 

Scale 

(MADRS)

MADRS consists of ten items measuring depressive symptoms such
as  reduced  sleep,  reduced  appetite,  apparent  sadness,  reported
sadness and suicidal thoughts. The items are rated on a score from
0 to 6, where 6 represents the highest severity of symptoms. One
study used MADRS (Gleeson 2009 (EPISODE II)).

Hamilton Depression Rating Scale (HDRS) (Hamilton 1960)

HDRS  consists  of  17  variables  plus  four  additional  variables.  The
variables/items can be rated either on a 3-point rating scale (from
0 to 2) or on a 5-point rating scale (from 0 to 4), with higher scores
meaning more severe symptoms. Two studies used HDRS (GetUp;
Gonzalez-Ortega 2021).

Centre for Epidemiologic Studies Depression scale - Revised (CESD-
R) (Eaton 2001)

CESD-R can be used to screen for depression as well as depressive
disorders.  It  was  initially  developed  by  Laurie  Radloff  in  1977
(Radloff  1977)  and  revised  by  Eaton  in  2001.Only  one  study  used
CESD-R (Jackson 2008 (ACE)).

6.1.2 Global state

Clinical Global Impression (CGI) (Guy 1976)

CGI  scales  are  7-point  clinician-rated  scales,  composed  of  two
scales  measuring  global  severity  of  illness  (CGI-Severity,  or  CGI-
S)  and  global  clinical  improvement  (CGI-Improvement,  or  CGI-I).

6.1.3 Functioning

Global Assessment of Functioning (GAF)(APA 1987, Lehman 1983)

GAF is a clinician-rated scale measuring the impact of a patient's
severity  of  illness  on  their  daily  life.  It  is  brief  and  easily
administered,  using  a  numeric  scale  from  0  to  100,  broken  into
10 intervals, with a higher score indicating better functioning.Ten
studies used GAF (Barrowclough 2014; Bucci 2018 (Actissist); GetUp;
Gonzalez-Ortega  2021;  Hjorthoj  2013  (CapOpus);  Madigan  2013;
Müller 2020; Palma-Sevillano 2019; Pos 2019; Sönmez 2020).

Social  and  Occupational  Functioning  Assessment  Scale  (SOFAS)
(APA 1994, Goldman 1992)

SOFAS  was  developed  to  measure  the  level  of  social  and
occupational  functioning,  taking  into  account  the  impact  on  a
person's  general  health.  The  scale,  which  is  found  in  DSM-IV,  is
especially  used  to  determine  5th  axis  features  and  to  measure
functionality. It can be rated from 0 to 100 points, with higher scores
indicating  good  functioning.  Five  studies  used  SOFAS  (Edwards
2006;  Edwards  2011;  Gleeson  2009  (EPISODE  II);  Jackson  2008
(ACE); Lepage 2022).

Personal and Social Performance Scale (PSP) (Morosini 2000)

PSP  is  a  clinician-rated  scale  that  measures  personal  and  social
functioning.  It  is  rated  on  a  single-item,  from  1  to  100  and
divided  into  10  equal  intervals,  with  a  higher  score  meaning
better  functioning.  The  total  score  is  calculated  considering  four
indicators rated on a 6-point scale from 1 'absent' to 6 'very severe'
difficulties: 1) socially useful activities, including work and study,
2) personal and social relationships, 3) self-care, and 4) disturbing
and  aggressive  behaviours.Three  studies  used  PSP  (Bucci  2018
(Actissist); Liu 2019; Morrison 2018 (COMPARE)).

Functioning Assessment Short test (FAST) (Rosa 2007)

The interviewer-administered scale is composed of 24 items that
assess  impairment  and  disability  in  six  areas  of  functioning:
functioning,
autonomy,  occupational 
financial issues, interpersonal relationships, and leisure time. The
items are rated on a 4-point scale, with 0 meaning no difficulty and
3 meaning severe difficulty. One study used FAST (Gonzalez-Ortega
2021).

functioning,  cognitive 

First-Episode Social Functioning Scale (FESFS) (Lecomte 2014)

FESFS  assesses  nine  functional  domains:  'Life  skills',  'Interaction
with  people',  'Friends  and  activities',  'Intimacy',  'Family',  'Work
relationships  and  social  activities',  'Work  skills',  'Interpersonal
relationships  and  social  activities  at  school',  and  'Educational
skills'.  Each  domain  or  area  of  functioning  is  rated  by  the
participant on a scale from 1 to 4 (e.g. 'strongly agree' to 'strongly
disagree' or 'strongly disagree' to 'always agree'), considering their
perceived  competencies  and  frequency  of  involvement.  Higher

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

18

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

scores indicate better functioning. One study used FESFS (Morrison
2020 (MAPS)).

6.1.4 Quality of life

World  Health  Organization  Quality  of  Life  abbreviated  form
(WHOQoL-BREF) (O'Carroll 2000)

WHOQoL-BREF  is  a  self-rated  scale  measuring  quality  of  life.  It
is  composed  of  26  questions  regarding  satisfaction  with  health,
psychological functioning, social relationships, and environmental
opportunities within the last 2 weeks. The participant is asked to
rate  each  question  on  a  5-point  Likert  scale  from  1  to  5.  A  total
score  can  be  calculated  by  adding  the  scores  of  all  items,  with
higher scores indicating a better quality of life.Three studies used
WHOQoL-BREF (Gleeson 2009 (EPISODE II); Madigan 2013; Morrison
2018 (COMPARE)).

EuroQol-5 Dimensions three-level version (EQ-5D-3L) (The EuroQol
Group 1990)

EQ-5D-3L  is  a  self-rated  scale  used  to  measure  health-related
quality of life. It is composed of two parts: 1) a descriptive system
with five questions about mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression, each rated from 1 'no problem'
to 3 'extreme problems'; and 2) a visual analogue scale rated from
0 'worst imaginable' to 100 'best imaginable' health.The scores of
the first part can be converted to a single summary index of health-
related quality of life (EQ-5D-HRQoL) according to the preferences
of the general population of a region/country, and can range from
less than 0 (worse than death) to 1 (perfect health). Three studies
used  EQ-5D-3L  (Bucci  2018  (Actissist);  Morrison  2020  (MAPS);  Pos
2019).

Heinrich-Carpenter Quality of Life Scale (QLS) (Heinrichs 1984)

QLS  is  a  clinician-rated  scale  administered  as  a  semi-structured
interview.  It  is  composed  of  21  items  in  four  domains:  1)
interpersonal  relations,  2)  instrumental  role,  3)  intrapsychic
foundations,  and  4)  common  objects  and  activities.  Each  item  is
rated regarding the last four weeks on a 7-point Likert scale from
0 to 6, with a higher score indicating less impairment. A total score
can  be  calculated  by  adding  the  scores  of  all  items.  Two  studies
used QLS (Edwards 2011; Uzenoff 2008).

Modular System for Quality of Life (MSQoL) (Pukrop 2003)

The self-report scale consists of 46 items in seven domains, and a
total score can also be calculated. The items are rated from 1 to 7,
with higher scores indicating a higher quality of life. One study used
MSQoL (Müller 2020).

Manchester  Short  Assessment  of  Quality  of  Life  (MANSA)(Priebe
1999)

MANSA  is  a  clinician-rated  scale  representing  a  shortened  and
slightly  adapted  version  of  the  Lancashire  Quality  of  Life  Profile
(LQLP) consisting of 16 items. Four items can be answered with 'yes/
no', and 12 items are rated on a scale ranging from 1 to 7, with higher
scores meaning better quality of life. Only one study used MANSA
(Hjorthoj 2013 (CapOpus)).

Cochrane Database of Systematic Reviews

7. Funding sources

One study was sponsored by a private foundation (Sönmez 2020);
17  studies  reported  public  funding;  three  studies  were  jointly
funded by public institutions and pharmaceutical companies; and
five studies did not provide clear information on funding.

Excluded studies

We excluded 30 studies based on full-text assessment. The reasons
for exclusion were:

• ineligible  design:  not  randomised  (Browning  2013;  Edwards

2008; Jackson 2005; Lally 2019; Newton 2005);

• ineligible  population:  (Drury  1996;  Fowler  2002;  Fowler  2009
(Isrep); Gumley 2003; Haddock 2018; Kemp 2007; Lecomte 2020;
Lysaker  2007;  McGorry  1998;  McGorry  2000;  Morrison  2016;
Morrison 2018 (FOCUS); Tarrier 2014; Van der Gaag 2011; Wölwer
2022);

• ineligible intervention: no CBT plus standard care (Amann 2005;
Gaebel 2005; Gleeson 2012; Griffiths 2019; Kidd 2020; Morrison
2014 (ACTION); Ostergaard Christensen 2014; Vohs 2018; Weller
2018 (EBIRT));

• other reasons: cancelled (NCT00722163).

Ongoing studies

We  identified  eight  ongoing  studies  that  matched  our  inclusion
criteria  (Barrowclough  2001;  Haddock  2000;  ISRCTN60855021;
ISRCTN65536352;  NCT00161408;  NCT03491852;  NCT04180709;
NCT04916626).

Studies awaiting classification

There  are  seven  studies  awaiting  classification  (Gonzalez-Ortega
2022; Lewis 2000; NCT02653729; NCT04889911; Renton 2004; Suri
2001; Wood 2022).

Risk of bias in included studies

The risk of bias assessment for each of the predefined outcomes
is  located  in  the  risk  of  bias  section  (see  Characteristics  of
included studies), including all domain judgements and support for
judgements, and at the side of the relevant forest plots. Detailed
risk of bias assessments are available upon request.

In general, the assessment of risk of bias ranged from low to high
across studies and outcomes.

For  the  primary  outcome,  the  risk  of  bias  across  all  studies  was
predominantly assessed as having some concerns. In most of the
studies, the allocation of participants was described as randomised
and  details  were  given  on  how  the  randomisation  sequence  was
generated. However, in one study, the randomisation process could
be criticised (GetUp). Furthermore, baseline differences could only
be detected in two studies (Lecomte 2008; Uzenoff 2008) indicating
potential problems with the randomisation process.

In  all  studies  examining  the  primary  outcome,  participants  and
personnel  were  aware  of  the  intervention,  but  there  were  no
apparent deviations because the trial context could be identified.
In  14  out  of  20  studies,  an  appropriate  analysis  was  used.  In
six studies (Bucci 2018 (Actissist); Gonzalez-Ortega 2021; Haddock
1999;  Jackson  2008  (ACE);  Jolley  2003;  Palma-Sevillano  2019),  it
was either unclear or no appropriate analysis was used.

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

19

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Referring to missing data, there were only four studies (Jolley 2003;
Lecomte 2008; Morrison 2020 (MAPS); Supereden3) for which data
on the primary outcome were not available for more than 20% of
the participants and which had high risk of bias in this domain.

Except for one study (GetUp), in all studies, the primary outcome
was  measured  on  a  validated  rating  scale  by  blind  outcome
assessors.

In  eleven  out  of  20  studies  the  primary  outcome  was  mentioned
in  the  prespecified  plan  of  the  study,  whereas  in  nine  studies
(Barrowclough  2014;  Edwards  2006;  Gleeson  2009  (EPISODE  II);
Haddock  1999;  Jackson  2008  (ACE);  Jolley  2003;  Müller  2020;
Palma-Sevillano  2019;  Uzenoff  2008),  the  primary  outcome  was
either  not  mentioned  in  a  prespecified  plan  or  there  was  no
prespecified plan available.

For  the  outcome,  relapse,  risk  of  bias  across  the  studies  ranged
from overall low (Lewis 2002 (SOCRATES); Liu 2019; Morrison 2018
(COMPARE)), having some concerns (Barrowclough 2014; Gleeson
2009 (EPISODE II); Haddock 1999) to high (Morrison 2020 (MAPS)).

For all studies except one (GetUp), the risk of bias for the outcome,
leaving the study early for any reason, was judged as being overall
low or having some concerns.

For  the  outcome,  functioning,  the  risk  of  bias  in  all  studies  was
judged as being either low overall or having some concerns overall,
except for two studies (GetUp; Morrison 2020 (MAPS)) that had an
overall high risk of bias.

Cochrane Database of Systematic Reviews

(SMD  -0.28,  95%  CI  -0.50  to  -0.06,  19  RCTs,  n  =  1229,  I2  =  69%,
substantial heterogeneity) (Analysis 1.76).

1.1.3 Sensitivity analysis - Assumptions for missing data

After excluding five studies (Bucci 2018 (Actissist); Gonzalez-Ortega
2021;  Haddock  1999;  Jackson  2008  (ACE);  Jolley  2003)  that  used
completer analyses only, results did not essentially change from the
main analysis (SMD -0.29, 95% CI -0.52 to -0.05, 15 RCTs, n = 1215, I2
= 73%, substantial heterogeneity) (Analysis 1.77).

1.1.4 Sensitivity analysis - Loss to follow-up

None of the studies had more than a 50% dropout (loss to follow-
up) rate and, therefore, no sensitivity analysis was conducted.

1.1.5 Sensitivity analysis - Risk of bias

After removing five studies with an overall high risk of bias (GetUp;
Jolley 2003; Lecomte 2008; Morrison 2020 (MAPS); Supereden3), the
results did not essentially change (SMD -0.29, 95% CI -0.56 to -0.01,
15  RCTs,  n  =  1006,  I2  =  76%,  substantial  heterogeneity)  (Analysis
1.78).

1.1.6 Sensitivity analysis - Imputed values

After excluding two trials in which we used imputed values for ICC to
calculate the design effect in cluster-randomised trials, or in which
we imputed SDs (GetUp; Jolley 2003), the results remained similar
to the main analysis (SMD -0.28, 95% CI -0.50 to -0.05, 18 RCTs, n =
1214, I2 = 71%, substantial heterogeneity) (Analysis 1.79).

Finally, for the outcome of adverse events, the only study (Morrison
2020 (MAPS)) providing data was judged as having some concerns.

1.1.7 Sensitivity analysis - Fixed-effect

Effects of interventions

See: Summary of findings 1 Summary of findings table - Cognitive
behavioural  therapy  plus  standard  care  compared  to  control  for
first-episode or recent-onset psychosis

See Summary of findings 1 and forest plots for detailed results.

Comparison 1: CBT plus TAU versus TAU

When  re-synthesising  data  using  a  fixed-effect  model,  results
remained  similar  to  the  main  analysis  (SMD  -0.25,  95%  CI  -0.35
to  -0.14,  20  RCTs,  n  =  1508,  I2  =  68%,  substantial  heterogeneity)
(Analysis 1.80).

1.1.8 Sensitivity analysis - Separating endpoint and change data

No study provided only change data; therefore, this analysis was
not conducted.

Primary outcomes

1. Mental state

1.1. General

1.1.9 Sensitivity analysis - Skewed data

No evidence of skewness (mean/SD ratio lower than 2) was found
for any of the studies, so this analysis was not conducted.

1.1.1 Average endpoint or change score on a general mental state
scale

1.1.10 Sensitivity analysis without outliers

Twenty  studies  provided  data  on  this  outcome.  CBT  +  TAU
was  associated  with  a  greater  reduction  in  overall  symptoms  of
schizophrenia  (SMD  -0.27,  95%  CI  -0.47  to  -0.08,  20  RCTs,  n  =
1508,  I2  =  68%,  substantial  heterogeneity,  low  certainty  of  the
evidence) (Analysis 1.5). No differences emerged between separate
time points (P = 0.96) (Analysis 1.6).

SENSITIVITY ANALYSES

1.1.2 Sensitivity analysis - Blinding of outcome assessor

After  excluding  one  trial  (GetUp)  that  did  not  employ  a  blind
outcome assessor, the results remained similar to the main analysis

Given  the  substantial  heterogeneity  in  the  primary  outcome  (I2
=  68%),  we  performed  a  post  hoc  additional  sensitivity  analysis
excluding an outlier study (Palma-Sevillano 2019). Results did not
substantially change (SMD -0.19, 95% CI -0.30 to -0.09, 19 RCTs, n =
1446) and heterogeneity was reduced (I2 = 0%) (Analysis 1.81).

SUBGROUP ANALYSES

1.1.11 Subgroup analysis - Different types of CBT

Eleven studies investigated CBT (SMD -0.19, 95% CI -0.35 to -0.04, 11
RCTs, n = 775, I2 = 9%), four studies investigated CBT integrated with
other psychosocial interventions (SMD -0.87, 95% CI -1.73 to -0.01,
4 RCTs, n = 494, I2 = 93%, considerable heterogeneity), three studies

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

20

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

investigated  CBT  and  motivational  Interviewing  for  cannabis  use
cessation (SMD -0.04, 95% CI -0.38 to 0.30, 3 RCTs, n = 139, I2 = 0%),
and two studies used a special type of CBT (SMD -0.26, 95% CI -0.82
to 0.31, 2 RCTs, n = 100, I2 = 32%) (Analysis 1.82). Both CBT and CBT
integrated with other psychosocial interventions were associated
with greater reduction in symptoms compared to control, while for
the subgroups CBT and motivational interviewing for cannabis use
cessation and special types of CBT, the confidence interval included
the possibility of no difference. The test for subgroup differences
did not show a difference between different types of CBT (P = 0.37).

1.1.12 Subgroup analysis - Modality of treatment

17  studies  investigated  individual  CBT  (SMD  -0.29,  95%  CI  -0.53
to  -0.05,  17  RCTs,  n  =  1246,  I2  =  73%,  substantial  heterogeneity),
whereas only three studies (Lecomte 2008; Pos 2019; Supereden3)
investigated group CBT (SMD -0.18, 95% CI -0.42 to 0.07, 3 RCTs, n =
262, I2 = 0%) (Analysis 1.83).

= 301, I2 = 38%) (Analysis 1.7). No differences were found between
separate time points (P = 0.72) (Analysis 1.8).

1.2 Specific

1.2.1 Clinically important change in positive symptoms (delusions,
hallucinations,  disordered  thinking),  as  defined  by  individual
studies

Based on two studies, there was a trend in the direction of more
participants  reaching  a  clinically  important  change  in  positive
symptoms with CBT + TAU, but the confidence interval included the
possibility  of  no  difference  (RR  1.38,  95%  CI  0.98  to  1.93,  2  RCTs,
n = 99, I2 = 0%) (Analysis 1.9). Subgroup analysis did not reveal a
difference between separate time points (P = 0.52) (Analysis 1.10).

1.2.2  Average  endpoint  or  change  scores  on  a  published  scale  or
subscale  that  addresses  positive  symptoms  (e.g.  PANSS  positive,
Scale for the Assessment of Positive Symptoms (SAPS))

CBT offered in an individual setting was associated with a reduction
in overall symptoms; however, for CBT applied in a group setting,
the confidence interval includes the possibility of no difference. The
test  for  subgroup  differences  did  not  show  a  difference  between
different types of CBT (P = 0.52).

Twenty-two  studies  provided  data  on  this  outcome.  Positive
symptoms  were  reduced  in  the  CBT  +  TAU  group  compared  to
control (SMD -0.22, 95% CI -0.38 to -0.06, 22 RCTs, n = 1565, I2 = 52%,
moderate heterogeneity) (Analysis 1.15). Analysis of separate time
points revealed no differences (P = 0.64) (Analysis 1.16).

1.1.13 Subgroup analysis - Method of delivery

Except  one  study  which  used  a  smartphone  app  (Bucci  2018
(Actissist)) (SMD -0.60, 95% CI -1.39 to 0.20, 1 RCT, n = 30), all studies
took place in a face-to-face setting (SMD -0.26, 95% CI -0.47 to -0.06,
19  RCTs,  n  =  1478,  I2  =  69%,  substantial  heterogeneity)  (Analysis
1.84). The test for subgroup differences did not show a difference
between the two methods of delivery (P = 0.43).

1.1.14 Subgroup analysis - Control group

Fifteen studies compared CBT to TAU, and seven studies compared
CBT  to  another  psychological  intervention  (Analysis  1.85).  CBT  +
TAU was still more effective in reducing symptoms of schizophrena
when  compared  to  TAU  (SMD  -0.34,  95%  CI  -0.59  to  -0.09,  15
RCTs, n = 1211, I2 = 73%, substantial heterogeneity), but not when
compared to other psychological interventions (SMD -0.08, 95% CI
-0.32 to 0.17, 7 RCTs, n = 297, I2 = 6%). However, no differences were
found between subgroups (test for subgroups differences P = 0.14)
(Analysis 1.85).

1.1.15 Subgroup analysis - Therapist experience

CBT  in  all  studies  that  provided  data  on  the  therapist  was
conducted  by  expert  therapists.  No  study  included  therapists  in
training to deliver the intervention.

Secondary outcomes

1. Mental state

1.1 General

1.1.1  Clinically  important  change  in  general  mental  state  (study
defined)

Four  studies  reported  on  this  outcome.  There  was  a  trend  in
the direction of more participants reaching a clinically important
change with CBT + TAU, but the confidence interval included the
possibility of no difference (RR 1.50, 95% CI 0.95 to 2.39, 4 RCTs, n

1.2.3  Average  endpoint  or  change  score  on  a  published  scale  or
subscale that addresses negative symptoms (e.g. PANSS negative,
Scale for the Assessment of Negative Symptoms (SANS))

Based  on  twenty-two  studies,  CBT  +  TAU  was  associated  with
greater reduction in negative symptoms than control (SMD -0.20,
95%  CI  -0.30  to  -0.11,  22  RCTs,  n  =  1651,  I2  =  0%)  (Analysis  1.22).
No differences were found between separate time points (P = 0.22)
(Analysis 1.23).

1.2.4  Average  endpoint  or  change  score  on  a  published  scale  or
subscale that addresses depressive symptoms (e.g. Montgomery-
Asberg  Depression  Rating  Scale  (MADRS),  Beck  Depression
Inventory (BDI))

Eighteen  studies  provided  data  for  this  outcome.  CBT  +  TAU  was
associated  with  greater  reduction  in  depressive  symptoms  than
control  (SMD  -0.13,  95%  CI  -0.24  to  -0.01,  18  RCTs,  n  =  1182,  I2  =
0%) (Analysis 1.32). Testing for subgroup differences did not reveal
a difference between time points (P = 0.16) (Analysis 1.33).

2. Global state

2.1 Relapse

Based on seven studies, there was no evidence of a difference in
relapse rates between CBT + TAU and the control group (RR 0.82,
95%  CI  0.57  to  1.18,  7  RCTs,  n  =  693,  I2  =  48%,  low  certainty  of
the evidence) (Analysis 1.34). No differences were found between
separate time points in subgroup analysis (P = 0.47) (Analysis 1.35).

2.2 Remission

Two  studies  reported  on  remission,  with  no  difference  found
between CBT + TAU and control (RR 1.16, 95% CI 0.70 to 1.91, 2 RCTs,
n = 73, I2 = 0%) (Analysis 1.36). No differences were found across
separate time points (P = 0.74) (Analysis 1.37).

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

21

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

2.3 Clinically important change in global state (e.g. global impression
of much improved, or more than 50% improvement on a rating scale,
such as the Clinical Global Impression scale (CGI))

Based on one study, results showed no difference in this outcome
between intervention and control groups at six months (RR 1.58,
95% CI 0.82 to 3.01, 1 RCT, n = 99) or twelve months (RR 1.53, 95%
CI 0.83 to 2.83, 1 RCT, n = 99) (Analysis 1.38).

2.4 Average endpoint or change score on a global state scale

Four studies reported on this outcome. CBT + TAU was associated
with  a  greater  reduction  in  global  state  scales  than  control  (SMD
-0.34,  95%  CI  -0.67  to  -0.01,  4  RCTs,  n  =  329,  I2  =  47%,  moderate
heterogeneity)  (Analysis  1.42).  No  differences  were  found  for
separate time points (P = 0.22) (Analysis 1.43).

3. Service Use

3.1 Admission to hospital

Based on ten studies, there was no difference in hospital admission
rates between CBT + TAU and control (RR 1.00, 95% CI 0.80 to 1.25,
10 RCTs, n = 1121, I2 = 0%) (Analysis 1.44). No differences were found
for subgroup analysis of separate time points (P = 0.81) (Analysis
1.45).

3.2 Number of days in hospital

Based on seven studies, there was no evidence of a difference in
number of days in hospital between groups (MD -8.18, 95% CI -24.74
to 8.38, 7 RCTs, n = 571, I2 = 94%) (Analysis 1.46). No differences were
found for separate time points (P = 0.32) (Analysis 1.47).

4. Leaving the study early

4.1 For any reason

Twenty-five studies provided data on leaving the study early for any
reason, with no difference between groups (RR 0.87, 95% CI 0.72 to
1.05, 25 RCTs, n = 2242, I2 = 12%, moderate certainty of the evidence)
(Analysis  1.48).  No  difference  was  found  between  separate  time
points (P = 0.87) (Analysis 1.49).

5. Functioning

Eighteen  studies  reported  on  functioning.  CBT  +  TAU  was
associated with better functioning than control (SMD -0.23, 95% CI
-0.42 to -0.05, 18 RCTs, n = 1241, I2 = 53%, moderate heterogeneity,
moderate certainty of the evidence) (Analysis 1.56). There was no
evidence of a difference between the separate time points (test for
subgroup differences: P = 0.69) (Analysis 1.57).

6. Quality of life

Nine studies reported on quality of life. There was no evidence of a
difference between CBT + TAU and control (SMD -0.13, 95% CI -0.33
to 0.07, 9 RCTs, n = 386, I2 = 0%) (Analysis 1.64).

No differences were found between the separate time-points (P =
0.82) (Analysis 1.65).

7. Behaviour

7.1 Occurrence of violent incidents (to self, others, or property)

Two studies provided data on this outcome. There was no evidence
of a difference between CBT + TAU and control at < 12 months (RR
0.96, 95% CI 0.15 to 6.20, 2 RCTs, n = 92, I2 = 0%) (Analysis 1.66).

Cochrane Database of Systematic Reviews

7.2 Self-injury

Two  studies  provided  data  on  participants  with  self-injury.  There
was no evidence of a difference between CBT + TAU and control at
< 12 months (RR 1.89, 95% CI 0.95 to 3.80, 2 RCTs, n = 92, I2 = 0%)
(Analysis 1.67).

7.3 Suicide attempts

Two  studies  provided  data  on  suicide  attempts.  There  was  no
evidence of a difference in the number of events between CBT + TAU
and control at < 12 months (RR 0.97, 95% CI 0.10 to 9.41, 2 RCTs, n
= 68, I2 = 5%). However, at > 1 year, one study provided data on this
outcome (RR 0.31, 95% CI 0.01 to 6.94, 1 RCT, n = 25); the confidence
interval includes the possibility of no difference between CBT + TAU
and control. No difference was found between separate time points
(test for subgroup differences P = 0.56) (Analysis 1.68).

8. Adverse events

8.1 At least one adverse event

One study provided data on this outcome. There was no evidence of
a difference in terms of participants with at least one adverse event
between CBT + TAU and control (RR 1.29, 95% CI 0.85 to 1.97, 1 RCT,
n = 43, very low certainty of the evidence) (Analysis 1.69).

8.2 Specific adverse events: Non-compliance

Two  studies  provided  data  on  this  outcome.  No  differences  were
found at < 6 months (RR 1.06, 95% CI 0.47 to 2.37, 2 RCTs, n = 190,
I2 = 0%), at < 12 months (RR 0.33, 95% CI 0.04 to 3.07, 1 RCT, n = 80)
and at more than one year (RR 0.33, 95% CI 0.04 to 3.07, 1 RCT, n =
80). No difference was found between separate time points (test for
subgroup differences P = 0.44) (Analysis 1.70).

8.3 Specific adverse events: Deterioration in symptoms

Four studies provided data on this outcome. There was no evidence
of a difference at < 6 months (RR 1.08, 95% CI 0.17 to 7.03, 2 RCTs, n
= 92, I2 = 0%), at < 12 months (RR 0.58, 95% CI 0.12 to 2.79, 3 RCTs,
n = 117, I2 = 0%) and at more than one year (RR 0.53, 95% CI 0.27 to
1.02, 2 RCTs, n = 87). The test for subgroup difference did not reveal
a difference between time points (P = 0.78) (Analysis 1.71).

9. Mortality

9.1 Overall mortality

Four studies provided data on this outcome. There was no evidence
of a difference between CBT + TAU and control (RR 1.22, 95% CI 0.41
to 3.66, 4 RCTs, n = 900, I2 = 6%) (Analysis 1.72). Also, no differences
were found between the separate time points (P = 0.79) (Analysis
1.73).

9.2 Mortality due to natural causes

Two studies provided data on this outcome. There was no evidence
of  a  difference  between  CBT  +  TAU  and  control  (RR  2.00,  95%  CI
0.22 to 17.99, 2 RCTs, n = 635, I2 = 30%) (Analysis 1.74). The test for
subgroup differences did not show a difference between the time
points (P = 0.09).

9.3 Mortality due to suicide

Based on the data of two studies, results did not show a difference
between CBT + TAU and control in terms of mortality due to suicide
(RR 1.08, 95% CI 0.05 to 24.00, 2 RCTs, n = 388, I2 = 50%, moderate

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

22

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

heterogeneity) (Analysis 1.75). The test for subgroup differences did
not show a difference between the time points (P = 0.16).

10. Outcomes without available data

The  following  outcomes  were  pre-planned  in  the  protocol;
however, it was not possible to derive usable data from the included
studies:

- Global state - recovery

- Cognitive functioning

- Satisfaction with care

D I S C U S S I O N

Summary of main results

We identified 28 studies eligible for inclusion in the review, of which
26 (2407 participants) provided data for the meta-analysis.

For our primary outcome, general mental state, our results show
that CBT + TAU was associated with a reduction in overall symptoms
of schizophrenia in comparison with control, with low certainty of
the evidence (Analysis 1.5).

When  excluding  studies  not  using  a  blind  outcome  assessor
(Analysis  1.76),  studies  that  used  completer  analyses  (Analysis
1.77), studies with high overall risk of bias (Analysis 1.78), studies
with  imputed  values  (Analysis  1.79),  analysing  the  data  with  a
fixed-effect model (Analysis 1.80) and excluding one outlier study
(Analysis 1.81), results did not substantially change from the main
analysis.

When  looking  at  different  types  of  CBT,  the  confidence  intervals
excluded  the  possibility  of  no  difference  in  comparison  with  TAU
for all, except for 'CBT and motivational interviewing for cannabis
use cessation' and 'special types of CBT'. However, it must be noted
that  only  a  few  studies  contributed  to  these  categories  (Analysis
1.82). Moreover, testing for subgroup differences did not reveal a
difference  within  the  investigated  subgroups  -  types  of  CBT  (P  =
0.37).

CBT offered in an individual setting was associated with a greater
reduction in overall symptoms of schizophrenia than control, while
for group CBT the confidence interval did not exclude the possibility
of  no  difference  to  control.  However,  also  here  it  must  be  noted
that only three studies investigated group CBT (Analysis 1.83), and
testing for subgroup differences did not reveal a difference between
the two treatment modalities (P = 0.52).

We  found  that  CBT  was  efficacious  when  delivered  in  a  face-to-
face setting, while when using a smartphone app, the confidence
interval did not exclude the possibility of no difference, with only
one  study  investigating  this  (Analysis  1.84).  A  test  for  subgroup
difference did not show a difference between these two methods of
delivery (P = 0.43).

CBT  +  TAU  was  associated  with  a  greater  symptom  reduction
when  compared  to  TAU,  but  not  when  compared  to  other
psychosocial  interventions  (Analysis  1.85).  However,  testing  for
subgroup differences did not reveal a difference due to the control
group (P = 0.14).

Cochrane Database of Systematic Reviews

CBT + TAU was also associated with a greater reduction in positive
(Analysis  1.15),  negative  (Analysis  1.22)  and  depressive  (Analysis
1.32)  symptoms  of  schizophrenia,  and  a  greater  improvement  in
global state (Analysis 1.42) and in functioning (moderate certainty
of the evidence) than control (Analysis 1.56).

We  did  not  find  a  difference  between  CBT  +  TAU  and  control  in
terms of number of participants with relapse (low certainty of the
evidence)  (Analysis  1.34),  leaving  the  study  early  for  any  reason
(moderate certainty of the evidence) (Analysis 1.48), adverse events
(very  low  certainty  of  the  evidence)  (Analysis  1.69)  and  the  other
investigated outcomes.

Overall completeness and applicability of evidence

In  spite  of  the  multiple  systematic  reviews  and  meta  analyses
investigating CBT for schizophrenia, we could not identify a recent
systematic review and meta-analysis on CBT specifically offered to
the special population of participants with a recent-onset or first-
episode schizophrenia.

The present review synthesises the available evidence on CBT + TAU
for  people  in  the  early  stage  of  the  disorder,  with  a  recent-onset
or first-episode schizophrenia. The presented results are therefore
applicable  to  people  in  the  early  stage  of  the  disorder,  meaning
within three to five years from first treatment/first diagnosis/first
contact with services, with no age limits.

in  the 

is  advised 

Caution 
interpretation  of  results  due  to
the  different  definitions  for  this  particular  population  being
used  in  different  studies,  locations  and  countries.  For  example,
Early  Intervention  Psychosis  (EIP)  services  providing  specialist
assertive  multidisciplinary  input,  including  pharmacological  and
interventions  for  first-episode  psychosis,  were
psychosocial 
introduced  in  England  in  1999  (Department  of  Health  and  Social
Care 1999). In 2016, it was recommended that there be no upper
age limit and that there be rapid assessment. In contrast, national
early psychosis services in Australia are run through primary care
youth mental health services, generally catering for a specific age
range  of  15  to  25  years.  Generally,  EIP  services  aim  to  treat  the
disorder early to reduce DUP (duration of untreated psychosis) and
improve outcomes by providing a comprehensive range of services
including  CBT,  family  interventions  and  employment  support.
Similar  services  to  England  are  provided  in  Wales,  Scotland  and
Northern  Ireland.  This  is  particularly  relevant,  since  most  of  the
included  studies  were  conducted  in  the  UK  (N  =  9)  (Included
studies).

We  did  our  best  to  operationalise  the  definition  of  the  target
population as described above and in Types of participants, and we
contacted the study authors whenever clarification was needed.

The results are not applicable to the elderly population which was
specifically excluded from this review (even if we found no study on
recent-onset psychosis focusing on this population).

Concerning  the  CBT  treatment,  it  must  be  noted  that,  on
average,  the  participants  in  the  CBT  +  TAU  arms  of  the  included
studies  received  about  15.6  sessions.  This  is  in  line  with  the
recommendations  of  the  National  Institute  for  Health  and  Care
Excellence (NICE), according to which CBT should be delivered for
at least 16 sessions (NICE 2014).

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

23

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

It must be noted that very scarce information was available in the
included studies about adverse events potentially connected with
CBT, even if this is also an important outcome to be investigated for
psychological interventions (Linden 2014).

Lastly, the last update of the search was conducted in March 2022.
However, we are not aware of potentially eligible studies published
after that date.

interval included both appreciable benefit with CBT + TAU and no
difference  between  CBT  +  TAU  and  control,  and  the  number  of
participants providing data for this outcome was low.

We  evaluated  the  certainty  of  the  evidence  as  moderate  for
the  outcome,  leaving  the  study  early,  due  to  imprecision;  the
confidence interval included both appreciable benefit for CBT + TAU
and no difference between CBT + TAU and control.

Quality of the evidence

Using  the  GRADE  approach,  we  assessed  the  certainty  of  the
evidence  as  ranging  from  very  low  for  the  outcome,  adverse
events, to moderate for the outcomes, leaving the study early and
functioning (see Summary of findings 1).

We evaluated the certainty of the evidence as low for the outcome,
mental state - general: mean endpoint overall symptoms scale, as
some of the studies were at overall high risk of bias and there was
moderate heterogeneity.

We evaluated the certainty of the evidence as low for the outcome,
global  state  -  relapse,  because  of  imprecision;  the  confidence

We  evaluated  the  certainty  of  the  evidence  as  moderate  for  the
outcome  functioning,  because  some  of  the  studies  contributing
data were at high overall risk of bias.

We  evaluated  the  certainty  of  the  evidence  as  very  low  for  the
outcome adverse events, because the confidence interval included
both appreciable harm with CBT + TAU and no difference between
CBT  +  TAU  and  control;  moreover,  the  number  of  participants
providing data for this outcome was extremely low.

We did not detect potential publication bias for any of the outcomes
investigated with funnel plots. Visual inspection of the funnel plots
suggested no asymmetry, and this was confirmed by Egger's test
(mental  state:  P  =  0.6320  (Figure  2),  leaving  the  study  early  P  =
0.4223 (Figure 3), functioning P = 0.8043 (Figure 4)).

Figure 2.   Egger's test for funnel plot asymmetry did not reveal asymmetry in the funnel plot (P = 0.6320).

0

SE(SMD)

0.2

0.4

0.6

0.8

1

-4

-2

0

2

SMD

4

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

24

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 3.   Egger's test for funnel plot asymmetry did not reveal asymmetry in the funnel plot (P = 0.4223).

0

SE(log[RR])

0.5

1

1.5

2
0.01

0.1

1

10

RR

100

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

25

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 4.   Egger's test for funnel plot asymmetry did not reveal asymmetry in the funnel plot (P = 0.8043).

0

SE(SMD)

0.5

1

1.5

2

-2

-1

0

1

2

SMD

Potential biases in the review process

We have documented and justified modifications to our published
protocol in the Differences between protocol and review section.

The current review has some limitations.

Firstly,  the  definition  of  the  population  of  participants  with  a
first-episode  or  recent-onset  psychosis  is  very  heterogeneously
described  in  the  included  studies.  In  recognition  of  this  lack  of
agreement  in  the  definitions  used,  there  have  been  attempts
to  operationalise  the  terms,  but  these  are  still  inconsistently
used  (Breitborde  2009).  Different  decisions  could  be  taken  when
investigating this population; for example, concerning the number
of  years  after  the  first  manifestation  of  the  illness,  including  or
excluding second episodes, and so on. We reported our criteria and
decisions transparently, so that our approach can be replicated.

Furthermore,  it  was  not  possible  to  conduct  some  of  the  pre-
planned  sensitivity  and  subgroup  analyses,  because  no  studies
presented the necessary characteristics (exclusion of studies with
more than 50% dropout, exclusion of studies providing only change
data,  exclusion  of  studies  with  skewed  data,  subgroup  analysis
of  different  levels  of  therapists'  experience),  therefore,  it  is  not
possible  to  say  anything  on  these  potential  effect  moderators.
On  the  other  hand,  we  conducted  a  post  hoc  sensitivity  analysis
excluding a study that had strong outlier results in the direction of
a benefit with CBT + TAU (Palma-Sevillano 2019). Results remained
consistent with the ones of the main analysis.

It must be noted, that the number of sessions provided when CBT
was conducted in the different studies varied, and this might have
contributed to some degree of heterogeneity.

Moreover,  the  reader  should  consider  that  some  standard
deviations  of  the  continuous  outcomes  were  imputed  (and
consequently  excluded  in  the  relevant  sensitivity  analysis).  It
should also be noted that, for binary outcomes, the denominator
we  used 
in  the  analyses  was  the  number  of  randomised
participants.  This  would  imply  that  all  missing  participants  were
considered not to experience the outcomes.

Agreements and disagreements with other studies or
reviews

This review is of special interest, as a timely and effective treatment
of  patients  with  their  first-episode  or  recent-onset  psychosis  is
of  particular  importance  in  order  to  prevent  a  chronification  of
the disease and furthermore reduce the enormous socioeconomic
burden (Evensen 2016; Marwaha 2004).

A meta-analysis published in 2010 investigating early intervention
services,  CBT  and  family  interventions  for  people  with  early
psychosis included only four studies on CBT (Bird 2010). Similar to
our results, they found a higher reduction in positive and negative
symptoms  of  schizophrenia  with  CBT,  and  no  difference  with
control in terms of relapse or hospital admissions. In this review,
early  psychosis  was  defined  as  "a  clinical  diagnosis  of  psychosis
within  5  years  of  the  first  psychotic  episode  or  presentation  to

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

26

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

mental health services", so overlapping with the definition used in
the present review.

with this intervention, unfortunately not adequately covered in the
studies found for this review, also need to be taken in consideration.

In  2021,  Frawley  and  colleagues  published  a  meta-analysis  on
psychosocial interventions for social and occupational functioning
in  early  stage  psychosis,  but  they  included  in  this  definition  also
the high-risk stage (Frawley 2021). Six studies investigated CBT, of
which five assessed participants in the high-risk stage of the disease
and only one assessed those in the first-episode stage, which was
the focus of the present review (Jackson 2008 (ACE)).

As a result, it can be said that no reliable summary of evidence on
CBT for this important population has been identified to date.

Related to the general population of patients with schizophrenia,
it has already been shown in previous meta-analyses and network
meta-analyses  that  CBT  +  TAU  can  be  an  effective  therapy  in
comparison to TAU for treating positive symptoms (Bighelli 2018),
for  reducing  overall  symptoms  of  schizophrenia  (McGlanaghy
2021),  for  preventing  relapses  (Bighelli  2021)  and  for  improving
functioning  (Bighelli  2023).  A  recent  Cochrane  Review  comparing
cognitive  behavioural  therapy  to  treatment-as-usual  for  people
with  schizophrenia  only  identified  nine  studies  on  people  with  a
first  episode,  but  did  not  analyse  them  separately  (Jones  2018a;
Jones 2018b).

A Cochrane Review is currently in development, investigating the
role of CBT when provided without concomitant medication with
antipsychotics  (Bighelli  2022a).  The  included  studies  are  mainly
recruiting  people  in  the  early  phase  of  the  disorder,  so  that  the
results could be relevant also for the population addressed by the
present review.

A U T H O R S '   C O N C L U S I O N S

Implications for practice

The  evidence  identified  by  this  review  suggests  that  people  with
a  first-episode  or  recent-onset  psychosis  may  benefit  from  CBT
additionally  to  standard  care  for  multiple  outcomes  (overall,
positive,  negative  and  depressive  symptoms  of  schizophrenia,
global state and functioning).

CBT is already recommended by clinical guidelines for participants
with  schizophrenia,  including  the  first-episode  and  recent-onset
phase,  in  both  the  adult  and  young  population  (NICE  2013;  NICE
2014). The present results confirm the benefits that can be achieved
by  the  population  of  people  with  a  first-episode  or  recent-onset
psychosis  with  CBT.  Policymakers  may  consider  CBT  for  this
population.

The  present  data  could  help  patients  and  clinicians  in  a  shared
decision-making  process  about  the  benefits  for  individuals  of
starting therapy with CBT. The potential adverse effects connected

Implications for research

At  best,  common  terms  and  clinically  based  criteria  should  be
developed  and  consistently  applied  in  research  on  people  in  the
early stage of the disorder.

In  the  meantime,  given  the  heterogeneous  descriptions  used
for  this  population,  future  studies  should  describe  in  detail
the  included  sample  in  terms  of  first-episode  and  recent-onset
psychosis,  providing  not  only  clear  inclusion  criteria,  but  also
percentages  of  participants  with  a  first  episode.  Furthermore,
services  for  the  early  stages  of  psychosis,  on  which  recruitment
for  clinical  trials  often  relies,  are  organised  differently  in  various
countries. Therefore, a detailed description of the recruited sample
is of crucial importance in the studies in order to allow meaningful
comparisons.

Future  studies  should  also  report  adverse  events  potentially
connected to the treatment of CBT.

Finally,  a  network  meta-analysis  could  investigate  the  active
comparisons of CBT with other psychological interventions used in
this population, such as family interventions.

A C K N O W L E D G E M E N T S

The Cochrane Schizophrenia Editorial Base is situated across the
University of Melbourne, Australia; Technical University of Munich,
Germany;  and  University  of  Nottingham,  UK,  and  produces  and
maintains  standard  text  for  use  in  the  Methods  section  of  their
reviews. We used this text as the basis of what appears here, and
adapted it as required.

The  following  people  conducted  the  editorial  process  for  this
review:

• Sign-off  Editor  (final  editorial  decision):  Mahesh  Jayaram,

University of Melbourne

• Managing  Editor  (selected  peer  reviewers,  collated  peer-
reviewer  comments,  provided  editorial  guidance  to  authors,
edited the article): Hui Wu, Technical University of Munich
• Contact Editor: Yikang Zhu, Shanghai Mental Health Center
• Copy  Editor  (copy-editing  and  production):  Anne  Lethaby,

Cochrane Central Production Service

• Information  Specialists 

(search  strategy):  Gail  Higgins,
University of Melbourne; Anne Parkhill, University of Melbourne
• Peer-reviewers  (provided  comments  and  recommended  an
editorial decision): Alessandro Rodolico, University of Catania;
Anna  Ceraso,  University  of  Brescia;  Jiangling  Jiang,  Shanghai
Jiao Tong University School of Medicine

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

27

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

R E F E R E N C E S

References to studies included in this review

Barrowclough 2014 {published data only}

(Actissist): study protocol for a randomised controlled trial.
Trials 2015;16(1):404. [DOI: 10.1186/s13063-015-0943-3]

Barrowclough C, Lobbanl F, Warburton J, Choudhry I, Gregg L,
Wood H, et al. Helper ReCAP: rethinking choices after psychosis
- a phase-specific psychological therapy for people with
problematic cannabis use following a first episode of psychosis.
Early Intervention in Psychiatry 2010;4:161.

Haddock G, Bucci S, Barrowclough C, Ainsworth J, Morris R,
Berry K, et al. Active Assistance for psychological therapy
(ACTISSIST): a cognitive behavioural therapy informed
smartphone intervention for early psychosis. Early Intervention
in Psychiatry 2016;10:113.

*  Barrowclough C, Marshall M, Gregg L, Fitzsimmons M,
Tomenson B, Warburton J, et al. A phase-specific psychological
therapy for people with problematic cannabis use following
a first episode of psychosis: a randomized controlled trial.
Psychological Medicine 2014;44(13):2749-61. [DOI: 10.1017/
S0033291714000208]

Berry K, Gregg L, Lobban F, Barrowclough C. Therapeutic
alliance in psychological therapy for people with recent
onset psychosis who use cannabis. Comprehensive Psychiatry
2016;67:73-80. [DOI: 10.1016/j.comppsych.2016.02.014]

Berry K, Palmer T, Gregg L, Barrowclough C, Lobban F.
Attachment and therapeutic alliance in psychological therapy
for people with recent onset psychosis who use cannabis.
Clinical Psychology & Psychotherapy 2018;25(3):440-5. [DOI:
10.1002/cpp.2178]

ISRCTN88275061. HELPER programme (substance misuse)
- a phase-specific psychological therapy for people with
problematic cannabis use following a first episode of psychosis
(ReCAP). http://www.isrctn.com/ Submission date 23/08/2012.
[DOI: 10.1186/ISRCTN88275061]

Marshall M, Barrowclough C, Drake R, Husain N, Lobban F,
Lovell K, et al. The HELPER programme: healthy living and
prevention of early relapse - three exploratory randomised
controlled trials of phase-specific interventions in first-
episode psychosis. Programme Grants for Applied Research
2015;3(2):1-240. [DOI: 10.3310/pgfar03020]

Worrell L. Helper programme (substance misuse)- a phase-
specific psychological therapy for people with problematic
cannabis use following a first episode of psychosis (ReCAP).
http://www.isrctn.com/ Submission date 23/08/2012. [DOI:
10.1186/ISRCTN88275061]

Bucci 2018 (Actissist) {published data only}

Berry N, Machin M, Ainsworth J, Berry K, Edge D, Haddock G,
et al. Developing a theory-informed smartphone app for
early psychosis: learning points from a multidisciplinary
collaboration. Frontiers in Psychiatry 2020;11:602861. [DOI:
10.3389/fpsyt.2020.602861]

*  Bucci S, Barrowclough C, Ainsworth J, Machin M, Morris R,
Berry K, et al. Actissist: proof-of-concept trial of a theory-
driven digital intervention for psychosis. Schizophrenia Bulletin
2018;44(5):1070-1080. [DOI: 10.1093/schbul/sby032]

Bucci S, Barrowclough C, Ainsworth J, Morris R, Berry K,
Machin M, et al. Using mobile technology to deliver a cognitive
behaviour therapy-informed intervention in early psychosis

ISRCTN34966555. Active assistance for psychological
therapy (Actissist): using mobile technology to deliver
cognitive behaviour therapy for psychosis - RCT. http://
www.isrctn.com/ Date of registration: 12/06/2014. [DOI:
10.1186/ISRCTN34966555]

Edwards 2006 {published data only}

*  Edwards J, Elkins K, Hinton M, Harrigan SM, Donovan K,
Athanasopoulos O, et al. Randomized controlled trial of
a cannabis-focused intervention for young people with
first-episode psychosis. Acta Psychiatrica Scandinavica
2006;114(2):109-17. [DOI: 10.1111/j.1600-0447.2006.00783.x]

Edwards J, Elkins KS, Hinton MF, Harrigan SM, Donovan KD,
Athanasopoulos O. Randomized controlled trial of a cannabis-
focused intervention versus psychoeducation for young people
continuing to use cannabis in the 12 months following entry to
treatment for first-episode psychosis. Schizophrenia Research
2004;70:61.

Stovall J. Implementing early intervention in psychosis: a
guide to establishing early psychosis services. Prim Care
Companion Journal of Clinical Psychiatry 2003;5(4):187. [PMCID:
PMC419392]

Edwards 2011 {published data only}

*  Edwards J, Cocks J, Burnett P, Maud D, Wong L, Yuen HP, et
al. Randomized controlled trial of clozapine and CBT for first-
episode psychosis with enduring positive symptoms: a pilot
study. Schizophrenia Research and Treatment 2011;NA:394896.
[DOI: 10.1155/2011/394896]

Edwards J, Maude D, McGorry P, Cocks J, Burnett P, Davern M,
et al. Treatment of enduring positive symptoms in first-episode
psychosis: a randomised controlled trial of cbt and clozapine.
Schizophrenia Research 1999;1:278.

Edwards J, Wong L, Burnett P, Harrigan SM, McGorry PD,
Wade D, et al. Enduring positive symptoms in first episode
psychosis: a randomised controlled trial of clozapine and CBT.
Schizophrenia Research 2003;60:321.

GetUp {published data only}

Lasalvia A, Bonetto C, Lenzi J, Rucci P, Iozzino L, Cellini M,
et al. Predictors and moderators of treatment outcome in
patients receiving multi-element psychosocial intervention
for early psychosis: results from the GET UP pragmatic cluster
randomised controlled trial. British Journal of Psychiatry
2017;210(5):342-49. [DOI: 10.1192/bjp.bp.116.190058]

Lenzi J, Iozzino L, De Girolamo G, Rucci P, Tosato S, Lasalvia A,
et al. Predictors of 9-month hospitalization in patients with

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

28

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

first-episode affective and non-affective psychosis. Results
from the GET UP pragmatic cluster randomized controlled trial.
Schizophrenia Research 2017;190:187-8.

NCT01436331. A large pragmatic cluster randomized controlled
trial of a multi-element psychosocial intervention for early
psychosis. https://ClinicalTrials.gov/ First posted: 19/09/2011.

Onwumere J, Kuipers E, Bebbington P, Bonetto C, Cristofalo D,
Cremonese C, et al. Identifying moderators and predictors of
treatment outcome in caregivers. Results from the GET UP
PIANO pragmatic cluster randomized controlled trial. Early
Intervention in Psychiatry 2016;10:26.

Ruggeri M, Birchwood M, Preti A. Feasibility, effectiveness,
predictors and moderators of outcome of a multi-element
psychosocial intervention for first-episode psychosis in "Real
World" community care. Results from the cluster randomized
controlled GET UP PIANO trial in a catchment area of 10 million
inhabitants. Early Intervention in Psychiatry 2016;10:3.

Ruggeri M, Birchwood M. The long journey from biological
markers, environment adversities and treatment effectiveness
of early interventions on psychosis - data from the GET UP
project in community services serving a 10 million inhabitant
catchment area. Early Intervention in Psychiatry 2016;10:24.

Ruggeri M, Bonetto C, Lasalvia A, De Girolamo G, Fioritti A,
Rucci P, et al. A multi-element psychosocial intervention for
early psychosis (GET UP PIANO trial) conducted in a catchment
area of 10 million inhabitants: study protocol for a pragmatic
cluster randomized controlled trial. Trials 2012;13(1):73. [DOI:
10.1186/1745-6215-13-73]

*  Ruggeri M, Bonetto C, Lasalvia A, Fioritti A, de Girolamo G,
Santonastaso P, et al. Feasibility and effectiveness of a multi-
element psychosocial intervention for first-episode psychosis:
results from the cluster-randomized controlled GET UP
PIANO trial in a catchment area of 10 million inhabitants.
Schizophrenia Bulletin 2015;41(5):1192-203. [DOI: 10.1093/
schbul/sbv058]

Ruggeri M, Lasalvia A, Santonastaso P, Pileggi F, Leuci E,
Miceli M, et al. Family burden, emotional distress and service
satisfaction in first episode psychosis. Data from the GET
UP trial. Frontiers in Psychology 2017;8:721. [DOI: 10.3389/
fpsyg.2017.00721]

Tonna M, Ossola P, Marchesi C, Bettini E, Lasalvia A, Bonetto C,
et al. Dimensional structure of first episode psychosis. Early
Intervention in Psychiatry 2019;13(6):1431-8. [DOI: 10.1111/
eip.12789]

Torresani S, Tosato S, Bonetto C, Furlato K, Doimo S,
Cristofalo D, et al. Five-year follow-up of psychopathology and
functioning in FEP patients receiving a multidimensional multi-
element psychosocial Intervention. A pilot study on Bolzano
and Verona catchment areas from the GET UP PIANO trial. Early
Intervention in Psychiatry 2016;10:196.

Gleeson 2009 (EPISODE II) {published data only}

ACTRN12605000514606. EPISODE II: prevention of relapse
following early psychosis. https://www.anzctr.org.au/Trial/

Cochrane Database of Systematic Reviews

Registration/TrialReview.aspx?id=770 Date submitted:
20/09/2005.

Alvarez-Jimenez M, Gee D, McGorry PD, Álvarez-Jiménez M,
Gleeson JF. Preventing the second episode: a randomized
controlled trial of relapse prevention therapy versus specialized
treatment for remitted first-episode psychosis patients.
European Archives of Psychiatry and Clinical Neuroscience
2009;259(Suppl 1):9.

Alvarez-Jimenez M, Gleeson J, Cotton S, Wade D, Gee D,
Pearce T, et al. Duration of untreated psychosis, insight and
adherence with cognitive-behavioural therapy in first-episode
psychosis. Early Intervention in Psychiatry 2008;2:A101.

Alvarez-Jimenez M, Gleeson JF, Cotton S, Wade D,
Gee D, Pearce T, et al. Predictors of adherence to
cognitive-behavioural therapy in first-episode psychosis.
Canadian Journal of Psychiatry 2009;54(10):710-8. [DOI:
10.1177/070674370905401008]

Gleeson J, Alvarez-Jimenez M, Killackey E, McGorry P. Two
year outcomes from the episode II trial. Early Intervention in
Psychiatry 2010;4:24.

Gleeson J, Cotton S, Alvarez-Jimenez M, Wade D, Gee D, Crisp K,
et al. An RCT of relapse prevention therapy for first-episode
psychosis patients. Early Intervention in Psychiatry 2008;2:A20.

Gleeson J, Wade D, Castle D, Gee D, Crisp K, Pearce T, et
al. The EPISODE II trial of cognitive and family therapy for
relapse prevention in early psychosis: rationale and sample
characteristics. Journal of Mental Health 2008;17(1):19-32.

Gleeson J, Wade D, McGorry P, Albiston D, Castle D, Gilbert M, et
al. Episode II: prevention of relapse following early psychosis.
Schizophrenia Research 2004;70(1):61-2.

Gleeson JFM, Cotton SM, Alvarez-Jimenez M, Wade D, Crisp K,
Newman B, et al. Family outcomes from a randomized control
trial of relapse prevention therapy in first-episode psychosis.
Journal of Clinical Psychiatry 2010;71(4):475-83. [DOI: 10.4088/
JCP.08m04672yel]

*  Gleeson JFM, Cotton SM, Alvarez-Jimenez M, Wade D,
Gee D, Crisp K, et al. A randomized controlled trial of relapse
prevention therapy for first-episode psychosis patients. The
Journal of Clinical Psychiatry 2009;70(4):477-486. [DOI: 10.4088/
jcp.08m04407]

Gleeson JFM, Cotton SM, Alvarez-Jimenez M, Wade D,
Gee D, Crisp K, et al. A randomized controlled trial of relapse
prevention therapy for first-episode psychosis patients:
outcome at 30-month follow-up. Schizophrenia Bulletin
2013;39(2):436-448. [DOI: 10.1093/schbul/sbr165]

Gonzalez-Ortega 2021 {published data only}

Barbeito S, Vega P, Ruiz de Azua S, Balanza- Martinez V,
Colom F, Lorente E, et al. Integrated treatment of first episode
psychosis with online training (e-learning): study protocol
for a randomised controlled trial. Trials 2014;15:416. [DOI:
10.1186/1745-6215-15-416]

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

29

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

*  Gonzalez-Ortega I, Vega P, Fernandez-Sevillano J, Gonzalez-
Pinto A, Echeburua E, Alberich S, et al. A multicentre,
randomised, controlled trial of a combined clinical treatment
for first-episode psychosis. International Journal of
Environmental Research and Public Health 2021;18(14):7239.
[DOI: 10.3390/ijerph18147239]

Hjorthoj CR, Fohlmann A, Larsen AM, Madsen MTR, Vesterager L,
Gluud C, et al. Interim analysis of the CapOpus trial: a
randomized, parallel-group, observer-blinded clinical trial
of specialized addiction treatment versus treatment as
usual for young patients with cannabis abuse and psychosis.
Schizophrenia Research 2010;117(2):190.

NCT01783457. eLearning & development of an evidence based
psychoeducational programme for first episode psychosis.
https://clinicaltrials.gov/ Date submitted: 01/02/2013.

Hjorthoj CR, Nordentoft M. Handbook of Cannabis and Related
Pathologies: Biology, Pharmacology, Diagnosis, and Treatment.
Elsevier Inc., 2017. [DOI: 10.1016/B978-0-12-800756-3.00131-9]

Haddock 1999 {published data only}

Haddock G, Hopkins R, Tarrier N, Morrison T, Lewis S. Intensive
cognitive-behavioural therapy for recent onset schizophrenia: a
pilot study. Schizophrenia Research 1997;24(1):223.

*  Haddock G, Tarrier N, Morrison AP, Hopkins R, Drake R,
Lewis S. A pilot study evaluating the effectiveness of individual
inpatient cognitive-behavioural therapy in early psychosis.
Social Psychiatry and Psychiatric Epidemiology 1999;34:254-8.

Hjorthoj 2013 (CapOpus) {published data only}

Fohlmann AH, Hjorthoej C, Larsen A, Nordentoft M.
CapOpus poster. Randomized clinical trial: specialized
addiction treatment (MI & CBT) versus treatment as usual
for young patients with cannabis abuse and psychosis. Early
intervention in Psychiatry 2010;4:159-60. [DOI: 10.1111/
j.1751-7893.2010.00230.x]

Fohlmann AH, Hjorthoej C, Larsen A, Nordentoft M. CapOpus.
Randomized clinical trial: specialized addiction treatment (MI
and CBT) versus treatment as usual for young patients with
cannabis abuse and psychosis. Early Intervention in Psychiatry
2010;4:160.

Hjorthaj CR. Validity of self-reported cannabis use as measured
by the timeline follow-back instrument in a trial randomizing
people with comorbid cannabis use disorder and schizophrenia
spectrum disorder. Early Intervention in Psychiatry 2010;4(Suppl
1):160.

Hjorthoj C, Fohlmann A, Larsen AM, Gluud C, Arendt M,
Nordentoft M. CapOpus-intervention study for cannabis use
disorder in psychosis. Early intervention in Psychiatry 2012;6:28.

Hjorthoj C, Fohlmann A, Larsen AM, Madsen MTR, Vesterager L,
Gluud C, et al. Design paper: the CapOpus trial: a randomized,
parallel-group, observer-blinded clinical trial of specialized
addiction treatment versus treatment as usual for young
patients with cannabis abuse and psychosis. Trials 2008;9:42.

Hjorthoj CR, Fohlmann A, Larsen AM, Gluud C, Arendt M,
Nordentoft M. Specialized addiction treatment versus treatment
as usual for patientswith cannabis use disorder and psychosis-
results from the CapOpus randomized, parallel-group, observer-
blinded clinical trial. Schizophrenia Research 2012;136:S78.

*  Hjorthoj CR, Fohlmann A, Larsen AM, Gluud C, Arendt M,
Nordentoft M. Specialized psychosocial treatment plus
treatment as usual (TAU) versus TAU for patients with cannabis
use disorder and psychosis: the CapOpus randomized trial.
Psychological Medicine 2013;43(7):1499-510. [DOI: 10.1017/
S0033291712002255]

Hjorthoj CR, Orlovska S, Fohlmann A, Nordentoft M. Psychiatric
treatment following participation in the CapOpus randomized
trial for patients with comorbid cannabis use disorder and
psychosis. Schizophrenia Research 2013;151(1):191-6. [DOI:
10.1016/j.schres.2013.10.014]

Hjorthoj CR, Vesterager L, Nordentoft M. Test-retest reliability
of the danish adult reading test in patients with comorbid
psychosis and cannabis-use disorder. Nordic Journal of
Psychiatry 2013;67(3):159-63.

Hjorthøj CR, Fohlmann A, Larsen AM, Arendt M,
Nordentoft M. Correlations and agreement between delta-9-
tetrahydrocannabinol (THC) in blood plasma and timeline
follow-back (TLFB)-assisted self-reported use of cannabis
of patients with cannabis use disorder and psychotic illness
attending the CapOpus randomized clinical trial. Addiction
2012;107(6):1123-31. [DOI: 10.1111/j.1360-0443.2011.03757.x]

NCT00484302. Cannabis and psychosis randomized clinical
trial: specialized addiction treatment versus treatment as usual
for young patients with cannabis abuse and psychosis. https://
ClinicalTrials.gov/ First posted: 08/06/2007.

Nordentoft M, Hjorthoj C, Fohlmann A. Capopus trial: an
observer-blinded RCT of specialized addiction treatment
versus standard treatment for young patients with cannabis.
Proceedings of the 17th European Psychiatric Association, EPA
Congress 2009;24:S1178.

Toftdahl NG, Nordentoft M, Hjorthoj C. The effect of changes
in cannabis exposure on psychotic symptoms in patients with
comorbid cannabis use disorder. Journal of Dual Diagnosis
2016;12:129-36.

Jackson 2008 (ACE) {published data only}

Allott K, Alvarez-Jimenez M, Killackey EJ, Bendall S,
McGorry PD, Jackson HJ. Patient predictors of symptom and
functional outcome following cognitive behaviour therapy or
befriending in first-episode psychosis. Schizophrenia Research
2011;132(2):125-30. [DOI: 10.1016/j.schres.2011.08.011]

Allott KA, Alvarez-Jimenez M, Bendall S, Killackey EJ,
McGorry PD, Jackson HJ. Predictors of functional outcome
following cbt in first-episode psychosis. Schizophrenia Bulletin
2011;37:258.

Bendall S, Allott K, Jovev M, Marois MJ, Killackey EJ, Gleeson JF,
et al. Therapy contamination as a measure of therapist
treatment adherence in a trial of cognitive behaviour
therapy versus befriending for psychosis. Behavioural and
Cognitive Psychotherapy 2015;43(3):314-27. [DOI: 10.1017/
S1352465813000921]

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

30

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bendall S, Jackson HJ, Killackey E, Allott K, Johnson T,
Harrigan S, et al. The credibility and acceptability of befriending
as a control therapy in a randomized controlled trial of cognitive
behaviour therapy for acute first episode psychosis. Behavioural
and Cognitive Psychotherapy 2006;34(3):277-91. [DOI: 10.1017/
S1352465806002815]

Bendall S. A comparison of the nonspecific effects of a control
treatment with cognitive behavioural therapy in first episode
psychosis. Schizophrenia Research 2004;70(1):57.

Jackson HJ, Killackey E, Bendall S, Allott K, Dudgeon P,
Harrigan S, et al. A randomised controlled trial of CBT for early
psychosis with 1 year follow-up. Australian and New Zealand
Journal of Psychiatry 2005;39:A42.

*  Jackson HJ, McGorry PD, Killackey E, Bendall S, Allott K,
Dudgeon P, et al. Acute-phase and 1-year follow-up results of
a randomized controlled trial of CBT versus befriending for
first-episode psychosis: the ACE project. Psychological Medicine
2008;38(5):725-35. [DOI: 10.1017/S0033291707002061]

Killackey E, Jackson H, Bendall S, Allott K, Harrigan S, Gleeson J,
et al. An exploration of the relationship between dose and type
of therapy and outcome in the ACE trial of CBT for first episode
psychosis. Schizophrenia Research 2004;70(1):57.

Killackey E, Jackson H, Bendall S, Allott K, McGorry P. The active
cognitive therapy for early psychosis (ACE) trial: a randomised
controlled trial of CBT for early psychosis with 1-year follow-up.
Acta Psychiatrica Scandinavica 2006;114(Suppl 431):78.

Killackey E, Jackson H, McGorry P, Bendall S, Allott K,
Johnson T, et al. The ACE project: a randomised controlled trial
of CBT versus befriending for acute first episode psychosis:
acute phase results. Schizophrenia Bulletin 2005;31:526-7.

Jackson 2009 {published data only}

ISRCTN43585723. Promoting personal recovery from psychosis:
a randomised controlled trial in first episode schizophrenia.
http://www.isrctn.com/ Registration date: 23/01/2004. [DOI:
10.1186/ISRCTN43585723]

Jackson C, Smith J, Birchwood M, Trower P, Reid I, Townend M,
et al. Preventing the traumatic sequelae of first episode
psychosis: a randomised controlled trial. Schizophrenia
Research 2004;70(1):45-6.

Jackson C, Trower P, Reid I, Smith J, Birchwood M, Hall M, et al.
Improving psychological adjustment following a first episode
of psychosis: a randomised controlled trial of cognitive therapy
to reduce post-psychotic trauma symptoms. Schizophrenia
Research 2006;86:S39.

*  Jackson C, Trower P, Reid I, Smith J, Hall M, Townend M,
et al. Improving psychological adjustment following a first
episode of psychosis: a randomised controlled trial of cognitive
therapy to reduce post psychotic trauma symptoms. Behaviour
Research and Therapy 2009;47(6):454-62. [DOI: 10.1016/
j.brat.2009.02.009]

Jackson C. Promoting personal recovery from psychosis: a
randomised control trial in first episode schizophrenia. National
Research Register Registration date: 23/01/2004.

Cochrane Database of Systematic Reviews

Jackson C. Promoting personal recovery from psychosis: a
randomised control trial in first episode schizophrenia. National
Research Register Start date: 09/01/2001.

Jolley 2003 {published data only}

Garety P. Pilot RCT of cognitive behavioural therapy for early
psychosis. National Research Register 2000.

*  Jolley S, Garety P, Craig T, Dunn G, White J, Aitken M. Cognitive
therapy in early psychosis: a pilot randomized controlled trial.
Behavioural and Cognitive Psychotherapy 2003;31(4):473-8.
[DOI: 10.1017/S1352465803004107]

Lecomte 2008 {published data only}

Beauchamp MC, Lecomte T, Lecomte C, Leclerc C, Corbiare M.
Do personality traits matter when choosing a group
therapy for early psychosis. Psychology and Psychotherapy
2013;86(1):19-32. [DOI: 10.1111/j.2044-8341.2011.02052.x]

Beauchamp MC, Lecomte T, Lecomte C, Leclerc C, Corbiere M.
Personality traits in early psychosis: relationship with symptom
and coping treatment outcomes. Early Intervention in Psychiatry
2011;5(1):33-40. [DOI: 10.1111/j.1751-7893.2010.00198.x]

Beauchamp MC. Etude des resultats des traitements
psychosociaux aupres de jeunes adultes presentant un premier
episode psychotique: Influence des traits de personnalite.
https://papyrus.bib.umontreal.ca/xmlui/handle/1866/4438
2010 - Accessed 04/02/2023.

Leclerc C, Gauvin D, Lecomte T. CBT group to maintain and
improve relationships and intimacy abilities of young adults
with a first psychotic episode - a pilot study. Schizophrenia
Research 2006;86(Suppl 1):138-9.

Leclerc C, Lecomte T. CBT for first episode of psychosis: why
does group therapy offer better results? Journal de Therapie
Comportementale et Cognitive 2012;22(3):104-10. [DOI: 10.1016/
j.jtcc.2012.07.006]

*  Lecomte T, Leclerc C, Corbiere M, Wykes T, Wallace CJ,
Spidel A. Group cognitive behavior therapy or social skills
training for individuals with a recent onset of psychosis?
Results of a randomized controlled trial. Journal of Nervous
and Mental Disease 2008;196:866-875. [DOI: 10.1097/
NMD.0b013e31818ee231]

Lecomte T, Leclerc C, Wykes T, Spidel A. Group CBT for early
psychosis - are there still benefits 1 year later? Early Intervention
in Psychiatry 2010;4:150.

Lecomte T, Leclerc C, Wykes T, Wallace CJ, Spidel A, Corbiere M.
Group CBT vs skills training for first episodes of psychosis -
results of a RCT. Schizophrenia Research 2006;86:45-46.

Lecomte T, Leclerc C, Wykes T, Wallace CJ, Spidel A, Greaves C.
Effectiveness of group cognitive-behaviour therapy for first
episode psychosis - results of a randomized controlled trial.
Schizophrenia Bulletin 2007;33(2):440.

Lecomte T, Leclerc C, Wykes T, Wallace CJ. Group CBT versus
group symptom management for treating psychotic symptoms
of young individuals presenting a first episode of schizophrenia:

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

31

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

preliminary results. In: Proceedings of the 3rd International
Conference on Early Psychosis. 2002.

Lecomte T, Leclerc C, Wykes T, Wallace CJ. Group CBT versus
group symptom management for treating psychotic symptoms
of young individuals presenting with a first episode of
schizophrenia - preliminary results. Schizophrenia Research
2003;60(1):324-5. [DOI: 10.1016/S0920-9964(03)80289-X]

Lecomte T, Leclerc C, Wykes T. Group CBT for early psychosis
- are there still benefits one year later? International Journal
of Group Psychotherapy 2012;62(2):309-21. [DOI: 10.1521/
ijgp.2012.62.2.309]

NCT00358709. Treating psychotic symptoms of young
individuals presenting a first episode of schizophrenia:
comparison of cognitive-behavioral therapy and skills training
symptom management on measures of symptoms and on other
indices of well-being. https://ClinicalTrials.gov/ First Posted:
01/08/2006.

Lepage 2022 {published data only}

*  Lepage M, Bowie CR, Montreuil T, Baer L, Percie du Sert O,
Lecomte T, et al. Manualized group cognitive behavioral therapy
for social anxiety in first-episode psychosis: a randomized
controlled trial. Psychological Medicine 2022:1-10. [DOI:
10.1017/S0033291721005328]

NCT02294409. Manualized group cognitive-behavioral
therapy for social anxiety in first episode psychosis. https://
clinicaltrials.gov/ First Posted: 19/11/2014.

Lewis 2002 (SOCRATES) {published data only}

Bentall R. A multi-centre randomised controlled trial of
cognitive behaviour therapy in early schizophrenia; the
SOCRATES trial. http://www.nrr.nhs.uk/ViewDocument.asp?
ID=N0156011338 Accessed 28/01/2023.

Goldsmith LP, Lewis SW, Dunn G, Bentall RP. Psychological
treatments for early psychosis can be beneficial or harmful,
depending on the therapeutic alliance: an instrumental variable
analysis. Psychological Medicine 2015;45(11):2365-73. [DOI:
10.1017/S003329171500032X]

Goldsmith LP, Lewis SW, Dunn G, Bentall RP. Psychological
treatments for early psychosis can be beneficial or harmful,
depending on the therapeutic alliance: an instrumental variable
analysis. Psychological Medicine 2015;45(11):2365–73.

Haddock G, Lewis S, Bentall R, Dunn G, Drake R, Tarrier N.
Influence of age on outcome of psychological treatments
in first-episode psychosis. British Journal of Psychiatry
2006;188(3):250-4. [DOI: 10.1192/bjp.188.3.250]

Haley C. Health beliefs of patients with schizophrenia and their
relationships to medication compliance. http://www.nrr.nhs.uk/
ViewDocument.asp?ID=N0237001837 Accessed 30/01/2023.

Kingdon D. SOCRATES - a multicentre, randomized controlled
trial of cognitive behavioural therapy in early schizophrenia.
http://www.nrr.nhs.uk/ViewDocument.asp?ID=N0172004444
Accessed 29/01/2023.

Cochrane Database of Systematic Reviews

Lewis S, Tarrier N, Haddock G, Bentall R, Kinderman P,
Kingdon D, et al. A randomised, controlled trial of cognitive-
behaviour therapy in acute, early schizophrenia: the SOCRATES
trial; summary. In: Proceedings of the 2nd International
Conference on Early Psychosis. 2000.

*  Lewis S, Tarrier N, Haddock G, Bentall R, Kinderman P,
Kingdon D, et al. Randomised controlled trial of cognitive-
behavioural therapy in early schizophrenia: acute-phase
outcomes. British Journal of Psychiatry 2002;181(43):91-7. [DOI:
10.1192/bjp.181.43.s91]

Lewis S. Study of cognitive realignment therapy in early
schizophrenia. http://www.isrctn.com/ Date applied
23/10/2000.

Lewis S. The SOCRATES study: cognitive therapy in early
schizophrenia. http://www.nrr.nhs.uk/ViewDocument.asp?
ID=N0226031757 Accessed 29/01/2023.

Lewis SW, Tarrier N, Haddock G, Bentall R, Kinderman P,
Kingdon D, et al. A randomised controlled trial of cognitive
behaviour therapy in early schizophrenia. Schizophrenia
Research 2001;49(1):263-4.

Lewis SW, Tarrier N, Haddock G, Bentall R, Kinderman P,
Kingdon D, et al. Cognitive therapy improves 18-month
outcomes but not time to relapse in first episode schizophrenia.
Schizophrenia Research 2002;53(3):14.

Lewis SW, Tarrier N, Haddock G, Bentall R, Kinderman P,
Kingdon D. A multicentre, randomized controlled trial of
cognitive-behaviour therapy in first-and second-episode
schizophrenia: the Socrates trial. Schizophrenia Research
1999;36(1):329.

Lewis SW, Tarrier N, Haddock R, Bentall R, Kinderman P,
Kingdon D, et al. The Socrates trial: a multicentre, randomised,
controlled trial of cognitive behaviour therapy in early
schizophrenia. Schizophrenia Research 2000;41(1):9.

Lewis SW, Tarrier N, Hadock G, Bentall R, Kinderman P,
Kingdon D. Cognitive therapy improves outcomes in first
episode psychosis. In: Proceedings of the 12th World Congress
of Psychiatry. 2002.

Lewis SW. SOCRATES: study of cognitive realignment therapy
in early schizophrenia. http://www.isrctn.com/ Date applied
23/10/2000.

Lewis SW. Study of cognitive realignment therapy in early
schizophrenia. http://www.isrctn.com/ Date applied
23/10/2000.

Mandelson M. A multi-centre, randomised, controlled trial
of cognitive behavioural therapy in early schizophrenia
(SOCRATES). http://www.nrr.nhs.uk/ViewDocument.asp?
ID=N0237001825 Accessed 28/01/2023.

Mitchell A. CBT for psychosis. The British Journal of Psychiatry
2004;185(5):438. [DOI: 10.1192/bjp.185.5.438]

Palmier-Claus J, Shryane N, Taylor P, Lewis S, Drake R. Mood
variability predicts the course of suicidal ideation in individuals

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

32

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

with first and second episode psychosis. Psychiatry Research
2013;206(2):240-5. [DOI: 10.1016/j.psychres.2012.11.014]

baseline data of the COMPARE trial. Psychosis: Psychological,
Social and Integrative Approaches 2017;9(3):193-204.

Tarrier N, Haddock G, Lewis S, Drake R, Gregg L. Suicide
behaviour over 18 months in recent onset schizophrenic
patients: the effects of CBT. Schizophrenia Research
2006;83(1):15-27. [DOI: 10.1016/j.schres.2005.12.846]

Tarrier N, Lewis S, Haddock G, Bentall R, Drake R, Kinderman P,
et al. Cognitive-behavioural therapy in first-episode and early
schizophrenia: 18-month follow-up of a randomised controlled
trial. British Journal of Psychiatry 2004;184:231-9. [DOI: 10.1192/
bjp.184.3.231]

Tarrier N, Lewis S, Haddock G, Bentall R, Drake R, Kinderman P,
et al. Cognitive-behavioural therapy in first-episode and early
schizophrenia: 18-month follow-up of a randomised controlled
trial. British Journal of Psychiatry 2004;184:231-9.

Liu 2019 {published data only}

ChiCTR-TRC -13003929. A study of the cognitive behavior
therapy for first-episode schizophrenia. http://apps.who.int/
trialsearch/ Date of registration: 12/07/2013.

*  Liu Y, Yang X, Gillespie A, Guo Z, Ma Y, Chen R, et al. Targeting
relapse prevention and positive symptom in first-episode
schizophrenia using brief cognitive behavioral therapy:
a pilot randomized controlled study. Psychiatry Research
2018;272:275-83. [DOI: 10.1016/j.psychres.2018.12.130]

Madigan 2013 {published data only}

Lawlor E, Madigan K, Russell V, O'Connor JJ, Turner N,
Clarke M, et al. Engagement with a group-based psychological
intervention for those with early phase psychosis and
concurrent use of cannabis. Early Intervention in Psychiatry
2012;6:28.

Madigan K, Brennan D, Lawlor E, Turner N, Kinsella A,
O'Connor JJ, et al. A multi-center, randomized controlled
trial of a group psychological intervention for psychosis with
comorbid cannabis dependence over the early course of illness.
Schizophrenia Research 2013;143(1):138-42.

Madigan K, Lawlor E, Brennan D, Turner N, Kinsella A,
O'Connor J, et al. A multi-centre, randomised controlled
trial of a group psychological intervention for psychosiswith
comorbid cannabis dependence over the early course of illness.
Schizophrenia Research 2012;136:S371.

Morrison 2018 (COMPARE) {published data only}

ISRCTN06022197. A trial of antipsychotic medication in
comparison to cognitive behaviour therapy or a combination
of both in adults with psychosis. https://www.isrctn.com/ Date
applied: 20/03/2014. [DOI: 10.1186/ISRCTN06022197]

Jauhar S. Cognitive behavioural therapy - a valid alternative
to antipsychotics for psychosis? The Lancet Psychiatry
2018;5(5):381-83. [DOI: 10.1016/ S2215-0366(18)30123-8]

Law H, Carter L, Sellers R, Emsley R, Byrne R, Davies L, et al.
A pilot randomised controlled trial comparing antipsychotic
medication, to cognitive behavioural therapy to a combination
of both in people with psychosis: Rationale, study design and

Morrison A. Psychological interventions for promoting recovery.
In: European Archives of Psychiatry and Clinical Neuroscience.
Conference: 6th European Conference on Schizophrenia
Research: Advancing Research - Promoting Recovery. Germany.
Vol. 267. 2017:8.

*  Morrison AP, Law H, Carter L, Sellers R, Emsley R, Pyle M,
et al. Antipsychotic drugs versus cognitive behavioural
therapy versus a combination of both in people with
psychosis: a randomised controlled pilot and feasibility
study. Lancet Psychiatry 2018;5(5):411-23. [DOI: 10.1016/
S2215-0366(18)30096-8]

Morrison 2020 (MAPS) {published data only}

Byrne RE, Bird JC, Reeve S, Jones W, Shiers D, Morrison AP, et al.
Understanding young peoples' and family members' views of
treatment for first episode psychosis in a randomised controlled
trial (MAPS). EClinicalMedicine 2020;24:100417. [DOI: 10.1016/
j.eclinm.2020.100417]

Byrne RE, Reeve S, Bird JC, Jones W, Shiers D, Morrison AP,
et al. Clinicians' views of treatment types for first episode
psychosis delivered in a randomised controlled trial
(MAPS). EClinicalMedicine 2020;24:100421. [DOI: 10.1016/
j.eclinm.2020.100421]

ISRCTN80567433. Managing adolescent first episode psychosis:
a feasibility study. https://www.isrctn.com/ Submission date:
27/02/2017. [DOI: 10.1186/ISRCTN80567433]

Jauhar S. Psychosocial interventions versus antipsychotics
forearly-onset psychosis: can we fill the evidence
gap? Lancet Psychiatry 2020;7(9):726-8. [DOI: 10.1016/
S2215-0366(20)30296-0]

Langman-Levy A, Johns L, Palmier-Claus J, Sacadura C, Steele,
A, Larkin, A, et al. Adapting cognitive behavioural therapy
for adolescents with psychosis: insights from the managing
adolescent first episode in psychosis study (MAPS). Psychosis
2022;NA:NA. [DOI: 10.1080/17522439.2021.2001561]

Morrison AP, Pyle M, Byrne R, Broome M, Freeman D, Johns L,
et al. Psychological intervention, antipsychotic medication
or a combined treatment for adolescents with a first episode
of psychosis: the MAPS feasibility three-arm RCT. Health
Technology Assessment 2021;25(4):1-124. [DOI: 10.3310/
hta25040]

*  Morrison AP, Pyle M, Maughan D, Johns L, Freeman D,
Broome MR, et al. Antipsychotic medication versus
psychological intervention versus a combination of both in
adolescents with first-episode psychosis (MAPS): a multicentre,
three-arm, randomised controlled pilot and feasibility
study. Lancet Psychiatry 2020;7(9):788-800. [DOI: 10.1016/
S2215-0366(20)30248-0]

Pyle M, Broome MR, Joyce E, MacLennan G, Norrie J, Freeman,
D, et al. Study protocol for a randomised controlled trial of
CBT vs antipsychotics vs both in 14-18-year-olds: managing
adolescent first episode psychosis: a feasibility study (MAPS).
Trials 2019;20(1):395. [DOI: 10.1186/s13063-019-3506-1]

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

33

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Müller 2020 {published data only}

Puig-Navarro 2020 {published data only}

Bechdolf A, Tecic T, Lehmkuhl G, Walger P, Mueller K,
Wiedemann, et al. Cognitive behavior therapy in adolescents
with persistent psychotic symptoms: results of randomised
controlled trial. European Archives of Psychiatry and Clinical
Neuroscience 2011;261:S14.

*  Mueller H, Kommescher M, Guttgemanns J, Wessels H,
Walger P, Lehmkuhl G, et al. Cognitive behavioral therapy
in adolescents with early-onset psychosis: a randomized
controlled pilot study. European Child & Adolescent Psychiatry
2020;29:1011-1022. [DOI: 10.1007/s00787-019-01415-4]

NCT00465920. Development and pilot evaluation of modified
cognitive behavioural therapy for adolescents with early onset
psychosis. https://clinicaltrials.gov First Posted: 27/04/2007.

Tecic T, Guttgemanns J, Lehmkuhl G, Mueller K, Stoesser D,
Wiedemann G, et al. Modified cognitive behavioral therapy
in adolescents with persistent psychotic symptoms-results
of a randomized controlled trial. Schizophrenia Research
2012;136:302.

Palma-Sevillano 2019 {published data only}

Palma C, Cañete J, Farriols N, Fernández M, Julià J, Soler F, et
al. Cognitive therapy for the initial phase of schizophrenia: a
randomized controlled trial. In: Proceedings of the 8th World
Congress of Psychiatry. 2005.

Palma C, Farriolsa N, Frías, Cañete J, Gomis O, Fernández M,
et al. Randomized controlled trial of cognitive-motivational
therapy program (PIPE) for the initial phase of schizophrenia:
maintenance of efficacy at 5-year follow up. Psychiatry Research
2019;273:586-594. [DOI: 10.1016/j.psychres.2019.01.084]

*  Palma-Sevillano C, CaneTe-Crespillo J, Farriols-Hernando N,
Cebria-Andreu J, Michael M, Alonso-Fernandez I, et al.
Randomised controlled trial of cognitive-motivational therapy
program for the initial phase of schizophrenia: a 6-month
assessment. European Journal of Psychiatry 2011;25(2):86-80.

Pos 2019 {published data only}

NCT03217955. Cognitive Behavioural Therapy- Social
Functioning In Adolescence With RecentOnset Schizophrenia
(Social). https://clinicaltrials.gov/ First Posted: 14/07/2017.

*  Pos K, Franke N, Smit F, Wijnen BFM, Staring ABP, van
der Gaag Mark, et al. Cognitive behavioral therapy for
social activation in recent-onset psychosis: randomized
controlled trial. Journal of Consulting and Clinical Psychology
2019;87(2):151-160. [DOI: 10.1037/ccp0000362]

Velthorst E, Pos K, Franke N, Smit F, Wijnen BFM, Van Der
Gaag M, et al. Cognitive behavioral therapy for social activation
in recent-onset psychosis: randomized controlled trial.
Schizophrenia Bulletin 2019;45:93-94.

Wijnen BFM, Pos K, Velthorst E, Schirmbeck F, Chan HY,
de Haan L, et al. Economic evaluation of brief cognitive
behavioural therapy for social activation inrecent-onset
psychosis. PLoS ONE 2018;13(11):e0206236. [DOI: 10.1371/
journal.pone.0206236]

NCT03261557. Cognitive behavioral social skills training in early
onset psychosis. https://ClinicalTrials.gov/show/NCT03261557
First Posted: 25/08/2017.

*  Puig-Navarro O, Badia F, Baeza I, Varela E, Sugranyes G,
Garcia-Rizo C, et al. Efficacy of cognitive-behavioral social
skills training improving symptoms and functioning in patients
with early-onset psychosis: a randomized controlled trial.
Schizophrenia Bulletin 2020;46:39.

Santos 2008 {published data only}

Santos L, Gago J, Levy P, Mateus P, Robalo P, Ferreira R, et
al. Cognitive-behavioural case management in first-episode
schizophrenia and related psychotic disorders - the Portuguese
experience. Early Intervention in Psychiatry 2008;2:A21.

Sönmez 2020 {published data only}

NCT01511406. Cognitive behavioral therapy for patients with
an early psychosis. https://clinicaltrials.gov/ First Posted:
18/01/2012.

*  Sönmez N, Romm KL, Ostefjells T, Grande M, Jensen LH,
Hummelen B, et al. Cognitive behavior therapy in early
psychosis with a focus on depression and low self-esteem:
a randomized controlled trial. Comprehensive Psychiatry
2020;97:152157. [DOI: 10.1016/j.comppsych.2019.152157]

Supereden3 {published data only}

Fowler D, Addington J, Meneghelli A. New approaches to
detection and intervention for social recovery in early psychosis
and at risk mental states. Early Intervention in Psychiatry
2016;10:4.

*  Fowler D, Hodgekins J, French P, Marshall M, Freemantle N,
McCrone P, et al. Social recovery therapy in combination with
early intervention services for enhancement of social recovery
in patients with first-episode psychosis (SUPEREDEN3): a
single-blind, randomised controlled trial. Lancet Psychiatry
2018;5(1):41-50. [DOI: 10.1016/S2215-0366(17)30476-5]

Griffiths S, Wood S, Reniers R, Birchwood M. The relationship
between cognition and functional improvement in the context
of a psychosocial intervention targeting social disability in first
episode psychosis. Schizophrenia Bulletin 2018;44:S98.

Griffiths SL, Wood SJ, Fowler D, Freemantle N, Hodgekins J,
Jones PB, et al. Improved social functioning following
social recovery therapy in first episode psychosis: Do social
cognition and neurocognition change following therapy, and
do they predict treatment response? Schizophrenia Research
2021;228:249-55. [DOI: 10.1016/j.schres.2020.12.023]

ISRCTN61621571. Sustaining positive engagement and
recovery (SUPEREDEN) - the next step after early intervention
for psychosis. Study 3: improving social recovery in young
people with emerging severe social disability: a proof of
principle randomised controlled trial. http://www.isrctn.com/
Submission date: 26/06/2012. [DOI: 10.1186/ISRCTN61621571]

Lowen C, Hodgekins J, Pugh K, Berry C, Fitzsimmons M,
French P, et al. Measuring adherence in social recovery therapy
with people with first episode psychosis. Behavioural and

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

34

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Cognitive Psychotherapy 2020;48(1):82-90. [DOI: 10.1017/
S1352465819000432]

first-episode psychosis patients in seven European sites. Early
Intervention in Psychiatry 2008;2(Suppl 1):A25.

Uzenoff 2008 {published data only}

Fowler 2002 {published data only}

Perkins D. Modified cognitive behavior therapy for first-episode
schizophrenia. Stanley Foundation Research Programs, http://
www.stanleyresearch.org/ 2000 - accessed February 2001.

*  Uzenoff SR, Perkins DO, Hamer RM, Wiesen CA, Penn DL. A
preliminary trial of adherence-coping education (ACE) therapy
for early psychosis. The Journal of Nervous and Mental Disease
2008;196(7):572-5. [DOI: 10.1097/NMD.0b013e31817d01a5]

Uzenoff SR. A preliminary trial of adherence-coping-education
(ACE) therapy for first-episode schizophrenia [Master thesis].
University of North Carolina, 2007. [DOI: 10.17615/r3ex-6r60]

*  Fowler D. Psychosocial prevention of relapse in psychosis: a
multi-centre randomised controlled trial of cognitive behavioral
therapy and family intervention. In: National Research Register.
Vol. 1. 2002.

Fowler 2009 (Isrep) {published data only}

Barton GR, Hodgekins J, Mugford M, Jones PB, Croudace T,
Fowler D. Cognitive behaviour therapy for improving
social recovery in psychosis: cost-effectiveness analysis.
Schizophrenia Research 2009;112(1-3):158-63. [DOI: 10.1016/
j.schres.2009.03.041]

Weiden 2019 {published data only}

*  Weiden P, Turkington D, Beaumont J, Mihailovic M. Can CBT-
based interventions address medication adherence in early
phases of schizophrenia? Results from a pilot RCT comparing
a CBT-based vs. psychoeducation-based intervention.
Schizophrenia Bulletin 2019;45:343-4. [DOI: 10.1093/schbul/
sbz020.643]

References to studies excluded from this review

Amann 2005 {published data only}

*  Amann S, Krummler P, Schaub A, Wolf B, Gauck L, Klingberg S,
et al. Individual cognitive behavioural therapeutic interventions
in the relapse prophylaxis in patients with a first schizophrenic
illness. Verhaltenstherapie 2005;15(Suppl 1):4.

Browning 2013 {published data only}

*  Browning S, Corrigall R, Garety P, Emsley R, Jolley S.
Psychological interventions for adolescent psychosis: a
pilot controlled trial in routine care. European Psychiatry
2013;28(7):423-426. [DOI: 10.1016/j.eurpsy.2013.05.008]

Drury 1996 {published data only}

*  Drury V, Birchwood M, Cochrane R, Macmillan F. Cognitive
therapy and recovery from acute psychosis: a controlled trial.
I. Impact on psychotic symptoms. British Journal of Psychiatry
1996;169(5):593-601.

Drury V, Birchwood M, Cochrane R, Macmillan F. Cognitive
therapy and recovery from acute psychosis: a controlled
trial. II. Impact on recovery time. British Journal of Psychiatry
1996;169(5):602-607.

Drury V, Birchwood M, Cochrane R. Cognitive therapy and
recovery from acute psychosis: a controlled trial. 3. Five-year
follow-up. British Journal of Psychiatry 2000;177:8-14.

Drury V. A Thesis submitted to the Faculty of Science of the
University of Birmingham [PhD dissertation]. University of
Birmingham, 1999.

Edwards 2008 {published data only}

Edwards J, Harris M, Harrigan S, Merritt A, Amminger G, Santos
Md L, et al. A clinical audit of the first six months of care of

Fowler D, Hodgekins J, French P. Social recovery therapy in
improving activity and social outcomes in early psychosis:
current evidence and longer term outcomes. Schizophrenia
Research 2019;203:99-104. [DOI: 10.1016/j.schres.2017.10.006]

Fowler D, Hodgekins J, Painter M, Reilly T, Crane C, Macmillan I,
et al. Cognitive behaviour therapy for improving social recovery
in early psychosis: a report from the ISREP MRC trial platform
study. Early Intervention in Psychiatry 2008;2:A10.

*  Fowler D, Hodgekins J, Painter M, Reilly T, Crane C,
Macmillan I, et al. Cognitive behaviour therapy for improving
social recovery in psychosis: a report from the ISREP MRC trial
platform study (improving social recovery in early psychosis).
Psychological Medicine 2009;39(10):1627-36. [DOI: 10.1017/
S0033291709005467]

Fowler D. Improving social recovery in early affective and non-
affective psychosis: a randomised controlled trial of social
recovery oriented cognitive behavioural therapy (SRCBT). In:
National Research Register. Vol. 4. 2004.

Hodgekins J, Fowler D, Bradford S, Macmillan I, Jones P.
Psychological and neuropsychological predictors of time use
and social recovery in early psychosis. Schizophrenia Research
2006;86(1):S28.

Hodgekins J, Fowler D. CBT and recovery from psychosis in the
ISREP trial: mediating effects of hope and positive beliefs on
activity. Psychiatric Services 2010;61(3):321-4. [DOI: 10.1176/
appi.ps.61.3.321]

Jones PB. Improving social recovery in early affective and non-
affective psychosis: a randomised controlled trial of Social
Recovery orientated Cognitive behaviour (SRCBT). National
Research Register 2005;3.

Michael A. Improving social recovery in early affective and non-
affective psychosis: a randomised controlled trial of Social
Recovery oriented Cognitive Behaviour Therapy (ISREP).
National Research Register 2005;4.

Reilly T, Wymbs P, Painter M, Fowler D. From psychological
understanding to psychological therapy for social anxiety
and paranoia in early psychosis: addressing psychological
issues while improving social recovery. Schizophrenia Research
2006;86:S139. [DOI: 10.1016/S0920-9964(06)70415-7]

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

35

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gaebel 2005 {published data only}

Gaebel W, Riesbeck M, von Wilmsdorff M, Zielasek J.
Pharmacological long - term treatment strategies in first
episode schizophrenia: preliminary results of an ongoing
randomised clinical trial within the German research network
on schizophrenia. Schizophrenia Bulletin 2005;31:483.

Gleeson 2012 {published data only}

ACTRN12605000594628. A pilot study of psychotherapeutic
intervention for complex presentations of first-episode
psychosis. Orygen Research Centre and Orygen Youth Health
Date submitted: 20/09/2005.

*  Gleeson JF, Chanen A, Cotton SM, Pearce T, Newman B,
McCutcheon L. Treating co-occurring first-episode psychosis
and borderline personality: a pilot randomized controlled trial.
Early Intervention in Psychiatry 2012;6(1):21-29.

Griffiths 2019 {published data only}

Griffiths R, Mansell W, Carey TA, Edge D, Emsley R, Tai SJ.
Method of levels therapy for first-episode psychosis: rationale,
design and baseline data for the feasibility randomised
controlled next level study. British Journal of Psychiatry Open
2018;4(5):339-45. [DOI: 10.1192/bjo.2018.44]

Griffiths R, Mansell W, Carey TA, Edge D, Emsley R, Tai SJ.
Method of levels therapy for first-episode psychosis: the
feasibility randomized controlled next level trial. Journal
of Clinical Psychology 2019;75(10):1756-69. [DOI: 10.1002/
jclp.22820]

Griffiths R, Mansell W, Edge D, Carey TA, Peel H, Tai SJ.
'It was me answering my own questions': experiences of
method of levels therapy amongst people with first-episode
psychosis. International Journal of Mental Health Nursing
2019;28(3):721-34. [DOI: 10.1111/inm.12576]

Griffiths R. Evaluating the feasibility and acceptability of
method of levels therapy for people experiencing first-episode
psychosis [PhD Thesis]. University of Manchester, 2019.

ISRCTN13359355. Next level: method of levels for psychosis.
http://www.isrctn.com/ Submission date: 12/09/2016. [DOI:
10.1186/ISRCTN13359355]

Gumley 2003 {published data only}

Durham RC, Chambers JA, Power KG, Sharp DM, Macdonald RR,
Major KA, et al. Long-term outcome of cognitive behaviour
therapy clinical trials in central Scotland. Health Technology
Assessment 2005;42(9):1-174.

Gumley A, Karatzias A, Power K, Reilly J, McNay L, O'Grady M.
Early intervention for relapse in schizophrenia: impact of
cognitive behavioural therapy on negative beliefs about
psychosis and self-esteem. British Journal of Clinical Psychology
2006;45(2):247-60.

*  Gumley A, O'Grady M, McNay L, Reilly J, Power K, Norrie J.
Early intervention for relapse in schizophrenia: results of a 12-
month randomized controlled trial of cognitive behavioural
therapy. Psychological Medicine 2003;33(3):419-31.

Cochrane Database of Systematic Reviews

Gumley A, Wilson A, Power K. Randomised controlled
comparison of neuroleptic maintenance treatment alone v
neuroleptic maintenance in combination with individualised
psychoeducation in the prevention of relapse in schizophrenia.
Health Bulletin 1997;55(3):199.

N0396126314. A pilot study of cognitive therapy during the
acute phase of psychosis: impact on adjustment to and
recovery from psychosis. National Research Register Date
accessed: 28/01/2023.

N0470080246. A randomised controlled comparison
of neuroleptic maintenance treatment alone versus
neuroleptic maintenance in combination with individualised
psychoeducation in the prevention of relapse schizophrenia.
National Research Register Date accessed: 28/01/2023.

Haddock 2018 {published data only}

*  Haddock G, Berry K, Davies G, Dunn G, Harris K,
Hartley S, et al. Delivery of cognitive-behaviour therapy for
psychosis. Journal of Mental Health 2017;27(4):336-44. [DOI:
10.1080/09638237.2017.1417549]

Jackson 2005 {published data only}

Jackson H, McGorry P, Edwards J, Hulbert C, Henry L, Francey S,
et al. Cognitively-oriented psychotherapy for early psychosis
(COPE). Preliminary results. British Journal of Psychiatry
1998;172(33):93-100. [PMID: 9764134]

*  Jackson H, McGorry P, Edwards J, Hulbert C, Henry L,
Harrigan S, et al. A controlled trial of cognitively oriented
psychotherapy for early psychosis (COPE) with four-
year follow-up readmission data. Psychological Medicine
2005;35(9):1295-306. [DOI: 10.1017/S0033291705004927]

Jackson H, McGorry P, Edwards J, Hulbert C, Henry L,
Harrigan S, et al. A randomised controlled trial of cognitively-
orientated psychotherapy for early psychosis (COPE) with 5-year
follow-up relapse data. Schizophrenia Research 2004;70(1):61.

Kemp 2007 {published data only}

*  Kemp R, Harris A, Vurel E, Sitharthan T. Stop using
stuff: trial of a drug and alcohol intervention for young
people with comorbid mental illness and drug and alcohol
problems. Australasian Psychiatry 2007;15(6):490-3. [DOI:
10.1080/10398560701439665]

Kidd 2020 {published data only}

*  Kidd SA, Herman Y, Virdee G, Bowie CR, Velligan D,
Plagiannakos C, et al. A comparison of compensatory
and restorative cognitive interventions in early psychosis.
Schizophrenia Research: Cognition 2020;19:100157. [DOI:
10.1016/j.scog.2019.100157]

NCT02430935. A study of the effectiveness of cognitive
adaptation training in early intervention for psychosis. https://
clinicaltrials.gov/ First Posted: 30/04/2015.

Williams RS, Virdee GK, Bowie CR, Velligan DI, Maples NJ,
Herman Y, et al. Development and feasibility exploration
of a combined compensatory and restorative approach to
addressing cognitive challenges in early intervention psychosis.

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

36

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cognitive and Behavioral Practice 2020;27(4):454–469. [DOI:
10.1016/j.cbpra.2020.02.004]

Lally 2019 {published data only}

*  Lally J, Spaducci G, Gardner-Sood P, Atakan Z, Greenwood K,
Di Forti M, et al. Tobacco smoking and nicotine dependence
in first episode and established psychosis. Asian Journal of
Psychiatry 2019;43:125-131. [DOI: 10.1016/j.ajp.2019.05.002]

Lecomte 2020 {published data only}

*  Lecomte T, Corbiere M, Giguere CE, Titone D, Lysaker P. Group
cognitive behaviour therapy for supported employment -
results of a randomized controlled cohort trial. Schizophrenia
Research 2020;215:126-33. [DOI: 10.1016/j.schres.2019.10.063]

Lysaker 2007 {published data only}

Lysaker P, Davis LW. Associations of multiple domains of
metacognition with neurocogntion with schizophrenia.
Schizophrenia Bulletin 2007;33(2):530-1.

McGorry 1998 {published data only}

McGorry PD, Yung AR, Phillips L, Adlard S, Hallgren M, Patton G,
et al. Pre-psychotic intervention in schizophrenia: a stitch in
time? Schizophrenia Research 1998.

McGorry 2000 {published data only}

McGorry PD, Phillips LJ, Yung AR, Francey S, Germano D,
Bravin J. A randomised controlled trial of interventions in the
pre-psychotic phase of psychotic disorders. Schizophrenia
Research 2000;41(1):9. [DOI: 10.1016/S0920-9964(00)90325-6]

Morrison 2014 (ACTION) {published data only}

Howes O. Cognitive therapy: at last an alternative to
antipsychotics? The Lancet 2014;383(9926):1364-6. [DOI:
10.1016/S0140-6736(13)62569-6]

Hutton P, Di Rienzo F, Turkington D, Spencer H, Taylor P. Suicidal
Ideation in people with psychosis not taking antipsychotic
medication: do negative appraisals and negative metacognitive
beliefs mediate the effect of symptoms? Schizophrenia Bulletin
2019;45(1):37-47. [DOI: 10.1093/schbul/sby153]

ISRCTN29607432. Cbt for people with psychosis not taking
antipsychotic medication: A randomised controlled trial. http://
www.isrctn.com/ Submission date: 21/10/2010.

ISRCTN29607432. Cognitive behavioural therapy (CBT) for
people with psychosis not taking antipsychotic medication:
a randomised controlled trial. https://www.isrctn.com/
Submission date: 21/10/2010.

Morrison A. Cognitive therapy for people with a diagnosis of
schizophrenia spectrum disorder not taking antipsychotic
medication: a single-blind randomised controlled trial. In: Early
Intervention in Psychiatry. Vol. 10. 2016.

Morrison A. Psychological interventions for promoting recovery.
In: European Archives of Psychiatry and Clinical Neuroscience.
Conference: 6th European Conference on Schizophrenia
Research: advancing research - promoting recovery. Vol. 267.
2017:8.

Cochrane Database of Systematic Reviews

*  Morrison AP, Turkington D, Pyle M, Spencer H, Brabban A,
Dunn G, et al. Cognitive therapy for people with schizophrenia
spectrum disorders not taking antipsychotic drugs: a single-
blind randomised controlled trial. Lancet 2014;383:1395-403.
[DOI: 10.1016/ S0140-6736(13)62246-1]

Morrison AP, Turkington D, Pyle M, Spencer H, Brabban A,
Dunn G, et al. Cognitive therapy for people with schizophrenia
spectrum disorders not taking antipsychotic medication:
a randomised controlled trial. Schizophrenia Research
2014;153:75.

Morrison AP, Wardle M, Hutton P, Davies L, Dunn G,
Brabban A, et al. Assessing cognitive therapy instead of
neuroleptics: rationale, study design and sample characteristics
of the ACTION trial. Psychosis 2013;5(1):82-92. [DOI:
10.1080/17522439.2012.756539]

Shryane N, Drake R, Morrison AP, Palmier-Claus J. Is cognitive
behavioural therapy effective for individuals experiencing
thought disorder? Psychiatry Research 2020;285:112806. [DOI:
10.1016/j.psychres.2020.112806]

Spencer HM, McMenamin M, Emsley R, Turkington D,
Dunn G, Morrison AP, et al. Cognitive behavioral therapy for
antipsychotic-free schizophrenia spectrum disorders: does
therapy dose influence outcome? Schizophrenia Research
2018;202:385-386. [DOI: 10.1016/j.schres.2018.07.016]

Torjesen I. CBT could benefit patients with schizophrenia who
do not take medication, research says. BMJ 2014;348:1417.
[DOI: 10.1136/bmj.g1417]

Morrison 2016 {published data only}

*  Morrison AP, Burke E, Murphy E, Pyle M, Bowe S, Varese F,
et al. Cognitive therapy for internalised stigma in people
experiencing psychosis: a pilot randomised controlled
trial. Psychiatry Research 2016;240:96-102. [DOI: 10.1016/
j.psychres.2016.04.024]

Morrison AP. A pilot randomised controlled trial of cognitive
therapy for internalised stigma in people experiencing
psychosis. Early Intervention in Psychiatry 2016;10(Suppl 1):94.

Morrison 2018 (FOCUS) {published data only}

ISRCTN99672552. Focusing on clozapine unresponsive
symptoms trial. https://www.isrctn.com Submission date:
28/11/2012.

*  Morrison A, Pyle M, Gumley A, Schwannauer M,
Turkington D, MacLennan G, et al. Cognitive behavioural
therapy in clozapine-resistant schizophrenia (FOCUS):
an assessor-blinded, randomised controlled trial. The
Lancet Psychiatry 2018;5(8):633-643. [DOI: 10.1016/
S2215-0366%2818%2930184-6]

Morrison A. Cognitive behaviour therapy for people with
psychosis. Schizophrenia Bulletin 2019;45:S89.

Morrison AP, Pyle M, Gumley A, Schwannauer M, Turkington D,
MacLennan G, et al. Cognitive-behavioural therapy for
clozapine-resistant schizophrenia: the FOCUS RCT. Health

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

37

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Technology Assessment 2019;23(7):1-172. [DOI: 10.3310/
hta23070]

Pyle M, Norrie J, Schwannauer M, Kingdon D, Gumley A,
Turkington D, et al. Design and protocol for the focusing on
clozapine unresponsive symptoms (FOCUS) trial: a randomised
controlled trial. BMC Psychiatry 2016;16:280. [DOI: 10.1186/
s12888-016-0983-6]

Schooler NR. Cognitive behavioural therapy for clozapine non-
responders. The Lancet Psychiatry 2018;5(8):607-608. [DOI:
10.1016/S2215-0366%2818%2930256-6]

NCT00722163 {published data only}

NCT00722163. A randomized controlled trial of individual
therapy for first episode psychosis. https://ClinicalTrials.gov/
First Posted: 25/07/2008.

Newton 2005 {published data only}

*  Newton E, Landau S, Smith P, Monks P, Shergill S, Wykes T, et
al. Early psychological intervention for auditory hallucinations:
an exploratory study of young people's voices groups. Journal
of Nervous & Mental Disease 2005;193(1):58-61.

Ostergaard Christensen 2014 {published data only}

Ostergaard Christensen T, Vesterager L, Krarup G, Olsen BB,
Melau M, Gluud C, et al. Cognitive remediation combined with
an early intervention service in first episode psychosis. Acta
Psychiatrica Scandinavica 2014;130(4):300-310. [DOI: 10.1111/
acps.12287]

Tarrier 2014 {published data only}

Morrison AP, Law H, Barrowclough C, Bentall RP, Haddock G,
Jones SH, et al. Psychological approaches to understanding and
promoting recovery in psychosis and bipolar disorder: a mixed-
methods approach. Programme Grants for Applied Research
2016;4(5):1-304. [DOI: 10.3310/pgfar04050]

Van der Gaag 2011 {published data only}

ISRCTN57292778. Cost effectiveness of cognitive behaviour
therapy of cognitive behaviour therapy for recent onset
schizophrenia patients with persistent and recurrent psychosis.
https://www.isrctn.com Submission date: 20/12/2005. [DOI:
10.1186/ISRCTN57292778]

*  Van der Gaag M, Stant AD, Wolters KJ, Buskens E, Wiersma D.
Cognitive-behavioural therapy for persistent and recurrent
psychosis in people with schizophrenia-spectrum disorder:
cost-effectiveness analysis. British Journal of Psychiatry
2011;198:59-65. [DOI: 10.1192/bjp.bp.109.071522]

Van der Gaag M. CBT in persistent psychotic symptoms affects
functioning and suffering. European Archives of Psychiatry and
Clinical Neuroscience 2011;261(Suppl 1):S-26-004.

Vohs 2018 {published data only}

*  Vohs JL, Leonhardt BL, James AV, Francis MM, Breier A,
Mehdiyoun N, et al. Metacognitive reflection and insight therapy
for early psychosis: a preliminary study of a novel integrative
psychotherapy. Schizophrenia Research 2018;195:428-433. [DOI:
10.1016/j.schres.2017.10.041]

Cochrane Database of Systematic Reviews

Weller 2018 (EBIRT) {published data only}

ACTRN12617000870358. Does antipsychotic dose reduction in
combination with evidence-based intensive recovery treatment
(EBIRT) lead to better functional recovery in first episode
psychosis: a randomised controlled trial. http://apps.who.int/
trialsearch/ Date submitted: 05/05/2017.

Weller A, Gleeson J, Alvarez-Jimenez M, McGorry P, Nelson B,
Allott K, et al. Can antipsychotic dose reduction lead to
better functional recovery in first-episode psychosis? A
randomized controlled-trial of antipsychotic dose reduction.
The reduce trial: study protocol. Early Intervention in Psychiatry
2019;13(6):1345-56.

Weller A, Killackey E, Gleeson J, Allott K, Alvarez-Jimenez M,
Bendall S, et al. Less is more? An Australian RCT comparing
dose reduction of anti-psychotic medication to maintenance
treatment. Early Intervention in Psychiatry 2018;12:207. [DOI:
10.1111/eip.12724]

Wölwer 2022 {published data only}

DRKS00010033. Efficacy of "integrated social cognitive and
behavioral skills therapy" (ISST) in schizophrenia. https://
drks.de Date registrered: 10/03/2016.

NCT02678858. Efficacy of ISST in Schizophrenia. https://
clinicaltrials.gov/ct2/show/NCT02678858 First posted:
10/02/2016.

Wölwer W, Frommann N, Lowe A, Kamp D, Weide K, Bechdolf A,
et al. Efficacy of integrated social cognitive remediation vs.
neurocognitive remediation in improving functional outcome in
schizophrenia: concept and design of a multicenter, single-blind
RCT (the ISST Study). Frontiers in Psychiatry 2022;13:909370.
[DOI: 10.3389/fpsyt.2022.909370]

Wölwer W, Gaebel W, Maier W, Klosterkotter J, Fallgatter A,
Klingberg S. Efficacy of "integrated social cognitive and
behavioral skills therapy (ISST)" in improving functional
outcome in schizophrenia. Early Intervention in Psychiatry
2014;8:21.

References to studies awaiting assessment

Gonzalez-Ortega 2022 {published data only}

Gonzalez-Ortega I, Echeburua E, Garcia-Alocen A, Vega P,
Gonzalez-Pinto A. Cognitive behavioral therapy program for
cannabis use cessation in first-episode psychosis patients: study
protocol for a randomized controlled trial. Trials 2016;17:372.
[DOI: 10.1186/s13063-016-1507-x]

*  González-Ortega I, Echeburúa E, Alberich S, Bernardo M,
Vieta E, de Pablo GS, et al. Cognitive behavioral therapy
program for cannabis use cessation in first-episode psychosis
patients: a 1-year randomized controlled trial. International
Journal of Environmental Research and Public Health
2022;19(12):7325. [DOI: 10.3390/ijerph19127325]

NCT02319746. Cognitive behavioral therapy program to first-
episode psychosis patients and cannabis abuse. https://
ClinicalTrials.gov/ 2014.

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

38

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Lewis 2000 {published data only}

N0226078661. Evaluation of family support and cognitive
behavioural treatment service for recent onset schizophrenia
sufferers with substance misuse problems. National Research
Register Date accessed: 28/01/2023.

NCT02653729 {published data only}

NCT02653729. CBT for psychosis and affect on psychosis
symptoms. https://ClinicalTrials.gov/ First Posted: 12/01/2016.

NCT04889911 {published data only}

NCT04889911. Pilot RCT of self-stigma treatment for first
episode psychosis. https://clinicaltrials.gov/ First Posted:
17/05/2021.

psychosis. http://www.isrctn.com/ Submission date:
21/10/2010.

ISRCTN65536352 {published data only}

ISRCTN65536352. Cognitive behavioural case management
(CBCM) in first-episode schizophrenia and related psychotic
disorders - a pilot study. http://www.isrctn.com/ Submission
date: 29/09/2006.

NCT00161408 {published data only}

NCT00161408. Psychological Intervention for Relapse
Prevention in First Episode Schizophrenia. https://
ClinicalTrials.gov/show/NCT00161408 First submitted:
08/09/2005.

Renton 2004 {published data only}

NCT03491852 {published data only}

Renton J, Morrison AP. Effectiveness of cognitive therapy for
psychosis and implications for early intervention. Schizophrenia
Research 2004;70(1):142.

NCT03491852. A novel treatment approach for self-stigma in
first episode psychosis (BOOST). https://clinicaltrials.gov/ First
submitted: 02/04/2018.

Suri 2001 {published data only}

N0025088646. Cognitive behavioural therapy in early
schizophrenia. http://www.nrr.nhs.uk/ViewDocument.asp?
ID=N0025088646 Date accessed 27/01/2023.

Wood 2022 {published data only}

ISRCTN59055607. Cognitive behavioural therapy for psychosis
(CBTp) in acute mental health inpatient settings. http://
isrctn.com/ISRCTN59055607 Submission date: 18/02/2021.

*  Wood L, Williams C, Pinfold, V, Nolan, F, Morrison AP,
Morant N, et al. Crisis‑focused cognitive behavioural
therapyfor psychosis (CBTp) in acute mental health inpatient
settings (the CRISIS study): protocol for a pilot randomised
controlled trial. Pilot and Feasibility Studies 2022;8:205. [DOI:
10.1186/s40814-022-01160-7]

References to ongoing studies

Barrowclough 2001 {published data only}

N0248081346. An evaluation of the effectiveness of group
cognitive therapy for people with recent onset schizophrenia.
http://www.nrr.nhs.uk/ViewDocument.asp?ID=N0248081346
Accessed 28/01/2023;1.

Haddock 2000 {published data only}

N0244032344. Dual diagnosis project: evaluation of family
support and cognitive behaviour therapy for recent onset
schizophrenia sufferers with substance misuse problems.
http://www.nrr.nhs.uk/ViewDocument.asp?ID=N0244032344
Accessed 28/01/2023.

N0500001590. Evaluation of a family support and cognitive-
behavioural treatment service for recent onset schizophrenia
sufferers with substance misuse problems. http://
www.nrr.nhs.uk/ViewDocument.asp?ID=N0500001590.

ISRCTN60855021 {published data only}

ISRCTN60855021. Social anxiety research clinic: an exploratory
randomised controlled trial of standard versus enhanced
cognitive behavioural therapy for social anxiety in early

NCT04180709 {published data only}

NCT04180709. CBT to reduce insomnia and improve social
recovery in early psychosis (CRISP). https://clinicaltrials.gov/
First submitted: 28/10/2019.

NCT04916626 {published data only}

*  NCT04916626. The OPUS YOUNG trial. Early intervention
versus treatment as usual for adolescents with first-episode
psychosis. https://ClinicalTrials.gov/show/NCT04916626 First
submitted: 06/05/2021.

Additional references

Addington 1993

Addington D, Addington J, Maticka-Tyndale E. Assessing
depression in schizophrenia: the Calgary Depression scale.
British Journal of Psychiatry Supplement 1993;22:39-44.

Altman 1996

Altman DG, Bland JM. Detecting skewness from summary
information. BMJ 1996;313(7066):1200. [DOI: 10.1136/
bmj.313.7066.1200]

Andreasen 1984a

Andreasen NC. Scale for the assessment of positive symptoms
(SAPS). Iowa City: The University of Iowa, 1984.

Andreasen 1984b

Andreasen NC. Modified scale for the assessment of negative
symptoms (SANS). Iowa City: University of Iowa, 1984.

APA 1987

American Psychiatric Association (APA). Diagnostic and
statistical manual of mental disorders (DSM-III-R). Washington,
DC: American Psychiatric Press, 1987.

APA 1994

American Psychiatric Association (APA). Diagnostic and
statistical manual of mental disorders (DSM-IV). Washington DC:
APA, 1994.

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

39

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

APA 2000

American Psychiatric Association (APA). Diagnostic and
statistical manual of mental disorders (DSM IV-TR). 4th edition.
Washington, DC: American Psychiatric Press, 2000.

APA 2013

American Psychiatric Association (APA). Diagnostic and
statistical manual of mental disorders (DSM-V). 5th edition.
Arlington, VA: American Psychiatric Association, 2013.

in schizophrenia: a systematic review and network meta-
analysis. Lancet Psychiatry 2021;8(11):969-80. [DOI: 10.1016/
S2215-0366(21)00243]

Bighelli 2022a

Bighelli I, Çıray O, Leucht S. Cognitive behavioural therapy
without medication for schizophrenia. Cochrane Database
of Systematic Reviews 2022, Issue 7. Art. No: CD015332. [DOI:
10.1002/14651858.CD015332]

Barrowclough 2010

Bighelli 2023

Barrowclough C, Haddock G, Wykes T, Beardmore R, Conrod P,
Craig T, et al. Integrated motivational interviewing and
cognitive behavioural therapy for people with psychosis and
comorbid substance misuse: randomised controlled trial. BMJ
2010;341:c6325. [DOI: 10.1136/bmj.c6325]

Beck 1972

Beck AT, Beck RW. Screening depressed patients in family
practice. A rapid technique. Postgraduate Medicine
1972;52(6):81-5. [DOI: 10.1080/00325481.1972.11713319]

Beck 1996a

Beck AT, Steer RA, Brown GK. BDI-II manual. San Antonio, TX:
The Psychological Corporation, 1996.

Beck 1996b

Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck
depression Inventories -IA and -II in psychiatric outpatients.
Journal of Personality Assessment 1996;67(3):588-97. [DOI:
10.1207/s15327752jpa6703_13]

Becker 1975

Becker MH, Maiman LA. Sociobehavioral determinants
of compliance with health and medical care
recommendations. Medical Care 1975;13:10 –24. [DOI:
10.1097/00005650-197501000-00002]

Bendall 2003

Bendall S, Killackey E, Jackson H, Gleeson J. Befriending
manual. Melbourne: ORYGEN Research Centre andDepartment
of Psychology, University of Melbourne, 2003.

Bendall 2005

Bendall S, Killackey E, Marois MJ, Jackson H. ACE manual
(active cognitive therapy for early psychosis). Melbourne:
ORYGEN Research Centre and Department of Psychology,
University of Melbourne, 2005.

Bighelli 2018

Bighelli I, Salanti G, Huhn M, Schneider-Thoma J, Krause M,
Reitmeir C, et al. Psychological interventions to reduce positive
symptoms in schizophrenia: systematic review and network
meta-analysis. World Psychiatry 2018;17(3):316-29. [DOI:
10.1002/wps.20577]

Bighelli 2021

Bighelli I, Rodolico A, García-Mieres H, Pitschel-Walz G,
Hansen WP, Schneider-Thoma J, Siafis S, Wu H, Wang D,
Salanti G, Furukawa TA, Barbui C, Leucht S. Psychosocial
and psychological interventions for relapse prevention

Bighelli I, Wallis S, Reitmeir C, Schwermann F, Salahuddin NH,
Leucht S. Effects of psychological treatments on functioning
in people with Schizophrenia: a systematic review and
meta‑analysis of randomized controlled trials.
European Archives of Psychiatry and Clinical Neuroscience
2023;273(4):779-810. [DOI: 10.1007/s00406-022-01526-1]

Birchwood 1989

Birchwood M, Smith J, Macmillan F, Hogg B, Prasad R, Harvey C,
et al. Predicting relapse in schizophrenia: the development of
an early signs monitoring system using patients and families as
observers, a preliminary investigation. Psychological Medicine
1989;19:649–656. [DOI: 10.1017/s0033291700024247]

Birchwood 1995

Birchwood M, Tarrier N. El tratamiento psicol ́ogico en la
esquizofrenia. Barcelona: Ariel, 1995.

Birchwood 2014

Birchwood M, Lester H, McCarthy L, Jones P, Fowler D, Amos T,
et al. The UK national evaluation of the development and
impact of early intervention services (the National EDEN
studies): study rationale, design and baseline characteristics.
Early Intervention in Psychiatry 2014;8:59–67. [DOI: 10.1111/
eip.12007]

Bird 2010

Bird V, Premkumar P, Kendall T, Whittington C, Mitchell J,
Kuipers E. Early intervention services, cognitive–behavioural
therapy and family intervention in early psychosis: systematic
review. The British Journal of Psychiatry 2010;197:350-6. [DOI:
10.1192/bjp.bp.109.074526]

Blackburn 2001

Blackburn IM, James I, Milne D, Baker CA, Standart S, Garland A,
et al. The revised cognitive therapy scale (CTSR): psychometric
properties. Behavioural and Cognitive Psychotherapy
2001;29:431–46. [DOI: 10.1017/S1352465801004040]

Bland 1997

Bland JM. Statistics notes. Trials randomised in clusters. BMJ
1997;315(7108):600. [DOI: 10.1136/bmj.315.7108.600]

Boissel 1999

Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F,
Buyse M, et al. The problem of therapeutic efficacy indices.
3: Comparison of the indices and their use [Aperçu sur la
problématique des indices d'efficacité thérapeutique, 3:
comparaison des indices et utilisation. Groupe d'Etude des

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

40

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Indices D'efficacite]. Therapie 1999;54(4):405-11. [PMID:
10667106]

Bowie 2012

Bowie CR, McGurk SR, Mausbach B, Patterson TL, Harvey PD.
Combined cognitive remediation and functional skills training
for schizophrenia: effects on cognition, functional competence,
and real-world behavior. American Journal of Psychiatry
2012;169:710–718. [DOI: 10.1176/ appi.ajp.2012.11091337]

Bozzatello 2019

Bozzatello P, Bellino S, Rocca P. Predictive factors of treatment
resistance in first episode of psychosis: a systematic
review. Frontiers in Psychiatry 2019;10:67. [DOI: 10.3389/
fpsyt.2019.00067]

Breitborde 2009

Breitborde JK, Srihari VH, Woods SW. Review of the
operational definition for first-episode psychosis. Early
Intervention in Psychiatry 2009;3(4):259-65. [DOI: 10.1111/
j.1751-7893.2009.00148.x.]

Burns 2002

Burns T, Firn M. Assertive outreach in mental health. A manual
for practitioners. Oxford: Oxford University Press, 2002.

Ceraso 2020

Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M,
Komossa K, et al. Maintenance treatment with antipsychotic
drugs for schizophrenia. Cochrane Database of
Systematic Reviews 2020, Issue 8. Art. No: CD008016. [DOI:
10.1002/14651858.CD008016.pub3]

Chadwick 1996

Chadwick PJ, Birchwood M, Trower P. Cognitive therapy for
delusions, voices and paranoia. Chichester, UK: Wiley, 1996.

Connor 2000

Connor KM, Davidson JR, Churchill LE, Sherwood A, Foa E,
Weisler RH. Psychometric properties of the Social Phobia
Inventory (SPIN). New self-rating scale. British Journal of
Psychiatry 2000;176:379–386. [DOI: 10.1192/bjp.176.4.379]

Da Costa 2013

Da Costa BR, Nüesch E, Rutjes AW, Johnston BC, Reichenbach S,
Trelle S, et al. Combining follow-up and change data is
valid in meta-analyses of continuous outcomes: a meta-
epidemiological study. Journal of Clinical Epidemiology
2013;66(8):847-55. [DOI: 10.1016/j.jclinepi.2013.03.009]

Davidson 1991

Davidson JR, Potts NL, Richichi EA, Ford SM, Krishnan KR,
Smith RD, et al. The brief social phobia scale. Journal of Clinical
Psychiatry 1991;52:48–51. [DOI: doi: 10.1037/t07672-000]

Deeks 2000

Deeks J. Issues in the selection for meta-analyses of binary
data. In: 8th International Cochrane Colloquium; 2000 Oct
25-28; Cape Town. Cape Town: The Cochrane Collaboration,
2000.

Cochrane Database of Systematic Reviews

Department of Health 2001

Department of Health. Mental health policy implementation
guide. Department of Health: London 2001.

Department of Health and Social Care 1999

Department of Health and Social Care. National service
framework for mental health. https://www.gov.uk 1999.

Divine 1992

Divine GW, Brown JT, Frazier LM. The unit of analysis error
in studies about physicians' patient care behavior. Journal
of General Internal Medicine 1992;7(6):623-9. [DOI: 10.1007/
BF02599201]

Donner 2002

Donner A, Klar N. Issues in the meta-analysis of cluster
randomized trials. Statistics in Medicine 2002;21(19):2971-80.
[DOI: 10.1002/sim.1301]

Eaton 2001

Eaton WW. Centre for epidemiologic studies depression scale
- revised (CESDR). In: VandeCreek L, Jackson T, editors(s).
Innovations in clinical practice: A source book. Vol. 19. Sarasota,
FL, US: Professional Resource Exchange, 2001:295-7.

Edwards 2001

Edwards J, Elkins K, Hinton M, Pitman K, Harrigan S,
Athanosopoulos O. Cannabis use following initial treatment of
first-episode psychosis. Schizophrenia Research 2001;49:12-13.

Edwards 2002

Edwards J, McGorry PD. Implementing early intervention in
psychosis: a guide to establishing early psychosis services.
London: Martin Dunitz, 2002.

Edwards 2003

Edwards J, Hinton M, Elkins K, Athanasopoulos O. Cannabis
abuse and first-episode psychosis. In: Graham HL, Copello
A, Birchwood MJ, Mueser KT, editors(s). Substance Misuse in
Psychosis: Approaches to Treatment and Service Delivery.
Chichester: Wiley, 2003.

Egger 1997

Egger M, Davey Smith G, Schneider M, Minder C. Bias in
meta-analysis detected by a simple, graphical test. BMJ
1997;315(7109):629-34. [DOI: 10.1136/bmj.315.7109.629]

Elbourne 2002

Elbourne D, Altman DG, Higgins JP, Curtina F, Worthingtond HV,
Vaile A. Meta-analyses involving cross-over trials:
methodological issues. International Journal of Epidemiology
2002;31(1):140-9. [DOI: 10.1093/ije/31.1.140]

EPPIC 2001

Early Psychosis Prevention and Intervention Centre. Case
management in early psychosis: a handbook. Parkville, Victoria:
EPPIC, 2001.

Evensen 2016

Evensen S, Wisløff T, Ullevoldsæter Lystad J, Bull H, Ueland T,
Falkum E. Prevalence, employment rate, and cost of

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

41

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

schizophrenia in a high-income welfare society: a population-
based study using comprehensive health and welfare registers.
Schizophrenia Bulletin 2016;42(2):476-83. [DOI: 10.1093/schbul/
sbv141]

Fadden 2004

Fadden GBM, Jackson C, Barton K. Psychological
therapies:implementation in early intervention service.
Chichester: John Wiley & Sons, 2004.

of response in schizophrenia trials. Schizophrenia Research
2011;126(1-3):212-9. [DOI: 10.1016/j.schres.2010.10.016]

GBD 2019

GBD 2019 Diseases and Injuries Collaborators. Global burden of
369 diseases and injuries in 204 countries and territories, 1990–
2019: a systematic analysis for the Global Burden of Disease
Study 2019. The Lancet 2020;386(10258):1204-22. [DOI: 10.1016/
S0140-6736(20)30925-9]

Falloon 1988

Gilbert 2003a

Falloon IR. Handbook of behavioral family therapy. New York:
Guilford Press, 1988.

Fennell 2007

Fennell M. Overcoming low self-esteem. A self-help guide using
cognitive be-havioural techniques. Overcoming books. Reading
Well: Edition, 2007.

First 1995

First M, Spitzer R, Williams J, Gibbon M. Structured clinical
interview for DSM-IV (SCID-I) research version. Biometrics
Research, New York Psychiatric Institute. 1995.

First 2002

First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical
interview for DSM–IV–TR Axis I disorders, research version,
patient edition (SCID-I/P). New York: Biometrics Research, New
York State Psychiatric Institute, 2002.

Fowler 1995

Fowler D, garety P, Kuipers E. Cognitive behaviour therapy for
people with psychosis. East Sussex: Wiley, 1995.

Fowler 1997

Fowler D, Garety P, Kuipers E. Cognitive behaviour therapy for
psychosis: theory and practice. Chichester, UK: Wiley, 1997.

Gilbert M, Miller K, Berk L, Ho V, Castle D. Scope for psychosocial
treatments in psychosis: an overview of collaborative therapy.
Australasian Psychiatry 2003;11:220-224. [DOI: 10.1046/
j.1039-8562.2003.00555.x]

Gilbert 2003b

Gilbert P. Evolution, social roles, and the differences in shame
and guilt. Social Research 2003;70:401–426.. [DOI: 10.1353/
sor.2003.0013]

Goldman 1992

Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-
IV: a review of measures of social functioning. The American
Journal of Psychiatry 1992;149(9):1148–56. [DOI: 10.1176/
ajp.149.9.1148]

GRADEpro GDT [Computer program]

GRADEpro GDT. Hamilton (ON): McMaster University (developed
by Evidence Prime), 2021. Available at gradepro.org.

Gulliford 1999

Gulliford MC. Components of variance and intraclass
correlations for the design of community-based surveys and
intervention studies: data from the Health Survey for England
1994. American Journal of Epidemiology 1999;149(9):876-83.
[DOI: 10.1093/oxfordjournals.aje.a009904]

Fowler 2013

Gustavsson 2010

Fowler D, French P, Hodgekins J, Lower R, Turner R, Burton S,
et al. CBT to address and prevent social disability in early
and emerging psychosis. In: Steel C, editors(s). CBT for
Schizophrenia: Evidence Based Interventions and Future
Directions. Oxford: John Wiley & Sons, 2013:143-67.

Frawley 2021

Frawley E, Cowman M, Lepage M, Donohoe G. Social and
occupational recovery in earlypsychosis: a systematic review
and meta-analysis of psychosocial interventions. Psychological
Medicine 2021;NA:1-12. [DOI: 10.1017/S003329172100341X]

Furukawa 2006

Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N.
Imputing missing standard deviations in meta-analyses can
provide accurate results. Journal of Clinical Epidemiology
2006;59(1):7-10. [DOI: 10.1016/j.jclinepi.2005.06.006]

Furukawa 2010

Furukawa TA, Akechi T, Wagenpfeil S, Leucht S. Relative indices
of treatment effect may be constant across different definitions

Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J,
Beghi E, et al. Cost of disorders of the brain in Europe 2010.
European Neuropsychopharmacology 2011;21(10):718-79. [DOI:
10.1016/j.euroneuro.2011.08.008]

Guy 1976

Guy U. ECDEU assessment manual for psychopharmacology.
Revised edition. Rockville, Maryland, USA: National Institute of
Mental Health, 1976.

Haddock 1999

Haddock G, McCarron J, Tarrier N, Faragher E. Scales to measure
dimensions of hallucinations and delusions: the psychotic
symptom rating scales (PSYRATS). Psychological Medicine
1999;29(4):879-89. [DOI: 10.1017/s0033291799008661]

Haddock 2001

Haddock G, Devane S, Bradshaw T, McGovern J, Tarrier N,
Kinderman P, et al. An investigation into the psychometric
properties of the cognitive therapy scale for psychoses (CTS-
Psy). Behavioural Cognitive Psychotherapy 2001;29:221-233.
[DOI: 10.1017/S1352465801002089]

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

42

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hagen 2010

Hodgekins 2015

Hagen R, Turkington D. Introduction: CBT for psychosis – a
symptom-based approach. In: Hagen R, Turkington D, Berge
T, Gråwe RW, editors(s). CBT for Psychosis: A Symptom-based
Approach. 1st edition. East Sussex: Routledge, 2010:3-11. [ISBN:
0415549477]

Hodgekins J, French P, Birchwood M, Mugford M, Christopher R,
Marshall M, et al. Comparing time use as a measure of social
functioning in individuals at different stages of psychosis and
in a non-clinical comparison group. Schizophrenia Research
2015;161:188–93. [DOI: 10.1016/j.schres.2014.12.011]

Hamilton 1960

Hutton 2009

Hamilton M. A rating scale for depression. Journal of Neurology,
Neurosurgery and Psychiatry 1960;23(1):56-62. [DOI: 10.1136/
jnnp.23.1.56]

Heinrichs 1984

Heinrichs DW, Hanlon TE, Carpenter WT Jr. The quality of
life scale: an instrument for rating the schizophrenic deficit
syndrome. Schizophrenia Bulletin 1984;10(3):388-98. [DOI:
10.1093/schbul/10.3.388]

Henry 2002

Henry L, Edwards J, Jackson H, Hulbert C, McGorry P.
Cognitively oriented psychotherapy for early psychosis (COPE) :
a practitioner’s manual. Melbourne: EPPIC, 2002.

Hermann-Doig 2003

Hermann-Doig T, Maude D, Edwards J. Systematic treatment
of persistent psychosis (STOPP): a psychological approach
to facilitating recovery in young people with first-episode
psychosis. London: Martin Dunitz, 2003.

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring
inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
[DOI: 10.1136/bmj.327.7414.557]

Higgins 2020

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,
et al, editor(s). Cochrane Handbook for Systematic Reviews of
Interventions. Version 6.1 (updated September 2020) edition.
Cochrane, 2020.

Hinton 2002

Hinton M, Elkins K, Edwards J, Donovan K. Cannabis and
psychosis treatment manual. Early Psychosis Prevention and
Intervention Centre 2002.

Hjorthøj 2008

Hjorthøj C, Fohlmann A, Larsen AM, Madsen MT, Vesterager L,
Gluud C, et al. Design paper: the CapOpus trial: a randomized,
parallel-group, observer-blinded clinical trial of specialized
addiction treatment versus treatment as usual for young
patients with cannabis abuse and psychosis. Trials 2008;9:42.
[DOI: 10.1186/1745-6215-9-42]

Hjorthøj 2017

Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of
potential life lost and life expectancy in schizophrenia: a
systematic review and meta-analysis. Lancet Psychiatry
2017;4:295-301. [DOI: 10.1016/S2215-0366(17)30078-0]

Hutton JL. Number needed to treat and number needed to
harm are not the best way to report and assess the results
of randomised clinical trials. British Journal of Haematology
2009;146(1):27-30. [DOI: 10.1111/j.1365-2141.2009.07707.x]

Jablensky 1992

Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A,
Cooper JE et al. Schizophrenia: manifestations, incidence and
course in different cultures. A World Health Organization ten-
country study. Psychological Medicine Monograph Supplement
1992;20:1-97. [DOI: 10.1017/s0264180100000904]

Jackson 1996

Jackson C, Birchwood M. Early intervention in psychosis:
opportunities for secondary prevention. British Journal
of Clinical Psychology 1996;35:487–503. [DOI: 10.1111/
j.2044-8260.1996.tb01206.x]

Jackson 2000

Jackson C, Iqbal Z. Psychological adjustment to early psychosis.
In: Birchwood M, Fowler D, Jackson C, editors(s). Early
Intervention in Psychosis. London: Wiley, 2000.

Jackson 2001

Jackson H, McGorry P, Henry L, Edwards J, Hulbert C,
Harrigan S, et al. Cognitively oriented psychotherapy for early
psychosis (COPE): a 1-year follow-up. British Journal of Clinical
Psychology 2001;40:57–70. [DOI: 10.1348/014466501163481]

Jin 2017

Jin H, Mosweu I. The societal cost of schizophrenia: a systematic
review. PharmacoEconomics 2017;35(1):25-42. [DOI: 10.1007/
s40273-016-0444-6]

Jones 2018a

Jones C, Hacker D, Xia J, Meaden A, Irving CB, Zhao S, et al.
Cognitive behavioural therapy plus standard care versus
standard care for people with schizophrenia. Cochrane
Database of Systematic Reviews 2018, Issue 12. Art. No:
CD007964. [DOI: 10.1002/14651858.CD007964.pub2]

Jones 2018b

Jones C, Hacker D, Meaden A, Cormac I, Irving CB, Xia J,
et al. Cognitive behavioural therapy plus standard care
versus standard care plus other psychosocial treatments
for people with schizophrenia. Cochrane Database of
Systematic Reviews 2018, Issue 11. Art. No: CD008712. [DOI:
10.1002/14651858.CD008712.pub3]

Kay 1986

Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome
scale (PANSS) manual. North Tonawanda, NY: Multi-Health
Systems, 1986.

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

43

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kay 1987

Lally 2017

Kay SR, Fiszbein A, Opler LA. The positive and negative
syndrome scale (PANSS) for schizophrenia. Schizophrenia
Bulletin 1987;13(2):261-276. [DOI: 10.1093/schbul/13.2.261]

Kay 1988

Kay SR, Opler LA, Lindenmayer J-P. Reliability and validity of
the positive and negative syndrome scale for schizophrenics.
Psychiatry Research 1988;23:99-110. [DOI: 10.1016/0165-1781
(88)90038-8]

Kay 1989

Kay SR, Opler LA, Lindenmayer, J-P. The positive and negative
syndrome scale (PANSS): rationale and standardisation.
British Journal of Psychiatry 1989;155:59-65. [DOI: 10.1192/
S0007125000291514]

Kingdon 1994

Lally J, Ajnakina O, Stubbs B, Cullinane M, Murphy K, Gaughran
F et al. Remission and recovery from first-episode psychosis
in adults: systematic review and meta-analysis of long-
term outcome studies.. The British Journal of Psychiatry
2017;211(6):350-58. [DOI: 10.1192/bjp.bp.117.201475]

Laws 2018

Laws KR, Darlington N, Kondel TK, McKenna PJ, Jauhar S.
Cognitive behavioural therapy for schizophrenia – outcomes for
functioning, distress and quality of life: a meta-analysis. BMC
Psychology 2018;6(1):32. [DOI: 10.1186/s40359-018-0243-2]

Lecomte 2003

Lecomte T, Leclerc C, Wykes T, Lecomte J. Group CBT
for clients with a first episode of psychosis. Journal of
Cognitive Psychotherapy 2003;17:375–384. [DOI: 10.1891/
jcop.17.4.375.52538]

Kingdon D, Turkington D. Cognitive-behavioral therapy of
schizophrenia. New York: Guilford Press, 1993.

Lecomte 2014

Kingdon 2005

Kingdon DG, Turkington D. Cognitive therapy of schizophrenia.
Guilford Press, 2005.

Kirkbride 2012

Kirkbride JB, Errazuriz A, Croudace TJ, Morgan C, Jackson D,
Boydell J, et al. Incidence of schizophrenia and other psychoses
in England, 1950-2009: a systematic review and meta-analyses.
PLOS One 2012;7(3):1-21. [DOI: 10.1371/journal.pone.0031660]

Kirkbride 2017

Kirkbride JB, Hameed Y, Ankireddypalli G, Ioannidis K,
Crane CM, Nasir M, et al. The epidemiology of first-episode
psychosis in early intervention in psychosis services: findings
from the social epidemiology of psychoses in east anglia
(SEPEA) study. American Journal of Psychiatry 2017;174:143-53.
[DOI: 10.1176/appi.ajp.2016.16010103]

Kirkpatrick 2011

Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG,
Cienfuegos A, et al. The brief negative symptom scale:
psychometric properties. Schizophrenia Bulletin
2011;37(2):300-5. [DOI: 10.1093/schbul/sbq059]

Kokkevi 1995

Kokkevi A, Hartgers C. EuropASI: european adaptation of a
multidimensional assessment instrument for drug and alcohol
dependence. European Addiction Research 1995;1:208-210. [DOI:
10.1159/000259089]

Kopelowicz 2006

Kopelowicz A, Liberman RP, Zarate R. Recent advances in
social skills training for schizophrenia. Schizophrenia Bulletin
2006;32:s12–s23. [DOI: 10.1093/schbul/sbl023]

Kuipers 2002

Kuipers E, Leff J, Lam D. Family work for schizophrenia: a
practical guide. London: Gaskell, 2002.

Lecomte T, Corbière M, Ehmann T, Addington J, Abdel-Baki A,
MacEwan B. Development and preliminary validation of the
first episode social functioning scale for early psychosis.
Psychiatry Research 2014;216(3):412-17. [DOI: doi.org/10.1016/
j.psychres.2014.01.044]

Lefebvre 2020

Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C,
Metzendorf M-I, et al. Chapter 4: searching for and selecting
studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li
T, Page MJ, et al, editors(s). Cochrane Handbook for Systematic
Reviews of Interventions. Version 6.1 (updated September 2020)
edition. Cochrane, 2020.

Leff 1985

Leff J, Kuipers L, Berkowitz R, Sturgeon D. A controlled trial of
social intervention in the families of schizophrenic patients: two
year follow-up. British Journal of Psychiatry 1985;146:594–600.
[DOI: 10.1192/bjp.146.6.594]

Lehman 1983

Lehman AF. The effects of psychiatric symptoms on
quality of life assessments among the chronic mentally ill.
Evaluation and Program Planning 1983;6(2):143–51. [DOI:
10.1016/0149-7189(83)90028-9]

Leon 2006

Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG,
Archer GE, Chartier K. Attrition in randomized controlled
clinical trials: methodological issues in psychopharmacology.
Biological Psychiatry 2006;59(11):1001-5. [DOI: 10.1016/
j.biopsych.2005.10.020]

Leucht 2005a

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R.
Clinical implications of brief psychiatric rating scale scores.
British Journal of Psychiatry 2005;187:366-71. [DOI: 10.1192/
bjp.187.4.366]

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

44

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Leucht 2005b

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR.
What does the PANSS mean? Schizophrenia Research
2005;79(2-3):231-8. [DOI: 10.1016/j.schres.2005.04.008]

Liberman 1988

Liberman RP, Wallace CJ, Eckman T, Wirshing W. Symptom
management module–UCLA social and independent living
skills. Camarillo (CA): Psychiatric Rehabilitation Consultants,
1988.

Linden 2014

Linden M, Schermuly-Haupt ML. Definition, assessment
and rate of psychotherapy side effects. World Psychiatry
2014;13(3):306-9. [DOI: 10.1002/wps.20153]

Linszen 1996

Linszen DH, Dingemans P, Van Der Does JW, Nugter A, Scholte P,
Lenior R, et al. Treatment, expressed emotion, and relapse in
recent onset schizophrenic disorders. Psychological Medicine
1996;26:333–342. [DOI: 10.1017/s0033291700034723]

Lukoff 1986

Lukoff D, Liberman RP, Nuechterlein KH. Symptom monitoring
in the rehabilitation of schizophrenic patients. Schizophrenia
Bulletin 1986;12:578–593. [DOI: 10.1093/schbul/12.4.578]

Marshall 2000

Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M.
Unpublished rating scales: a major source of bias in randomised
controlled trials of treatments for schizophrenia. British Journal
of Psychiatry 2000;176:249-52. [DOI: 10.1192/bjp.176.3.249]

Marshall 2011

Marshall M, Rathbone J. Early intervention for psychosis.
Cochrane Database of Systematic Reviews 2011, Issue 6. Art. No:
CD004718. [DOI: 10.1002/14651858.CD004718.pub3]

Marwaha 2004

Marwaha S, Johnson S. Schizophrenia and employment
– a review. Social Psychiatry and Psychiatric Epidemiology
2004;39(5):337-49. [DOI: 10.1007/s00127-004-0762-4]

Marwaha 2007

Marwaha S, Johnson S, Bebbington P, Stafford M,
Angermeyer MC, Brugha T, et al. Rates and correlates of
employment in people with schizophrenia in the UK, France
and Germany. The British Journal of Psychiatry 2007;191(1):30-7.
[DOI: 10.1192/bjp.bp.105.020982]

Mattick 1998

Mattick RP, Clarke JC. Development and validation of measures
of social phobia scrutiny fear and social interaction anxiety.
Behavior Research and Therapy 1998;36:455–470. [DOI:
S0005-7967(97)10031-6]

McGlanaghy 2021

McGlanaghy E, Turner D, Davis GA, Sharpea H, Dougall N,
Morris P, Prentice W, Hutton P. A network meta-analysis of
psychological interventions for schizophrenia and psychosis:

Cochrane Database of Systematic Reviews

Impact on symptoms. Schizophrenia Research 2021;228:447-59.
[DOI: 10.1016/j.schres.2020.12.036]

McGorry 1996

McGorry PD, Edwards J, Mihalopoulos C, Harrigan SM,
Jackson HJ. EPPIC: an evolving system of early detection
and optimal management. Schizophrenia Bulletin
1996;22(2):305-326. [DOI: 10.1093/schbul/22.2.305]

Meltzer 2002

Meltzer H, Singleton N, Lee A, Bebbington PE, Brugha T,
Jenkins R. The social and economic circumstances of adults
with mental disorders. London, UK: Stationery Office, 2002.

Miller 1991

Miller WR, Rollnick S. Motivational interviewing: preparing
people to change addictive behavior. The Guilford Press, 1991.

Miller 2002

Miller WR, Rollnick S. Motivational interviewing: preparing
people to change addictive behaviour. New York: The Guilford
Press, 2002.

Montgomery 1979

Montgomery SM, Asberg M. A new depression scale designed
to be sensitive to change.. The British Journal of Psychiatry
1979;134:382–9. [DOI: 10.1192/bjp.134.4.382]

Montreuil 2016

Montreuil TC, Malla A, Joober R, B ́elanger C, Myhr G, Lepage M.
Manualized group cognitive-behavioral therapy for social
anxiety in at-risk mental state and first-episode psychosis: a
pilot study of feasibility and outcomes. International Journal of
Group Psychotherapy 2016;66:225–245.

Morgan 2022

Morgan C, Dazzan P, Lappin J, Heslin M, Donoghue K, Fearon P
et al. Rethinking the course of psychotic disorders: modelling
long-term symptom trajectories. Psychological Medicine
2022;52(13):2641-50. [DOI: 10.1017/S0033291720004705]

Morosini 2000

Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R.
Development, reliability and acceptability of a new version of
the DSM-IV social and occupational functioning assessment
scale (SOFAS) to assess routine social functioning. Acta
Psychiatrica Scandinavica 2000;101(4):323-9.

Morrison 2001

Morrison AP. The interpretation of intrusions in psychosis:an
integrative cognitive approach to hallucinations and delusions.
Behavioural and Cognitive Psychotherapy 2001;29:257–76. [DOI:
10.1017/S1352465801003010]

Morrison 2017

Morrison AP. A manualised treatment protocol to guide delivery
of evidence-based cognitive therapy for people with distressing
psychosis: learning from clinical trials. Psychosis 2017;9:271–81.
[DOI: 10.1080/17522439.2017.1295098]

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

45

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Mueser 1999

Mueser KT, Glynn SM. Behavioral family therapy for psychiatric
disorders. 2nd edition. Oakland, Calif: New Harbinger, 1999.

NICE 2013

National Institute for Clinical Excellence (NICE). Psychosis and
schizophrenia in children and young people: recognition and
management. Clinical guideline (CG155). www.nice.org.uk/
guidance/cg155/chapter/Recommendations#first-episode-
psychosis (accessed October 2021).

NICE 2014

National Institute for Clinical Excellence (NICE). Psychosisand
schizophrenia in adults: prevention and management. Clinical
guideline (CG178). www.nice.org.uk/guidance/cg178/chapter/1-
Recommendations (accessed October 2021).

Nordentoft 1996

Nordentoft M, Knudsen HC, Jessen-Petersen B, Krasnik A,
Sælan H, Treufeldt P, et al. CCPP – copenhagen community
psychiatric project. Implementation of community mental
health centres in Copenhagen: effects of service utilization,
social integration, quality of life and positive and negative
symptoms. Social Psychiatry and Psychiatric Epidemiology
1996;31:336-344. [DOI: 10.1007/BF00783422]

O'Carroll 2000

O'Carroll RE, Smith K, Couston M, Cossar JA, Hayes PC.
A comparison of the WHOQOL-100 and the WHOQOL-
BREF in detecting change in quality of life following liver
transplantation. Quality of Life Research 2000;9(1):121-24. [DOI:
10.1023/A:1008901320492]

Overall 1962

Overall JE, Gorham DR. The brief psychiatric rating scale.
Psychological Reports 1962;10:799-812.

Palma 2005

Palma C, Cebri ̀a J, Farriols N, Ca ̃nete J, Mu ̃noz E. La entrevista
motivacional con el paciente esquizofr ́enico. Psiquis
2005;26:109–120.

Palma 2015

Cochrane Database of Systematic Reviews

first episode of psychotic illness. British Medical Journal
2005;331:602. [DOI: 10.1136/bmj.38565.415000.E01]

Plaistow 1996

Plaistow J, Birchwood M. Back in the saddle: a guide to
relapse prevention. Unpublished manual. Birmingham Early
Intervention Service.

Priebe 1999

Priebe S, Huxley P, Knight S, Evans S. Application and results of
the manchester short assessment of quality of life (MANSA). The
International Journal of Social Psychiatry 1999;45(1):7-12. [DOI:
10.1177/002076409904500102]

Prochaska 1992

Prochaska JO, DiClemente CC. Stages of change in the
modification of problem behaviors. Progress in Behavior
Modification 1992;28:183-218.

Pukrop 2003

Pukrop R, Schlaak V, Möller-Leimkühler AM, Albus M, Czernik A,
Klosterkötter J, Möller HJ. Reliability and validity of quality
of life assessed by the short-form 36 and the modular system
for quality of life in patients with schizophrenia and patients
with depression. Psychiatry Research 2003;119(1):63-79. [DOI:
10.1016/S0165-1781(03)00110-0]

Puntis 2020

Puntis S, Minichino A, De Crescenzo F, Harrison R, Cipriani A,
Lennox B. Specialised early intervention teams for recent-onset
psychosis. Cochrane Database of Systematic Reviews 2020, Issue
11. Art. No: CD013288. [DOI: 10.1002/14651858.CD013288.pub2]

R [Computer program]

R: a language and environment for statistical computing.
Version 4.1.2. Vienna, Austria: R Foundation for Statistical
Computing, 2022. Available at www.R-project.org.

Radloff 1977

Radloff LS. The CES-D scale: a self report depression scale
for research in the general population. Applied Psychological
Measurement 1977;1:385-401.

Palma C. Intervenci ́on psicoterap ́eutica en
la fase inicial de la esquizofrenia. https://
www.tdx.cat/bitstream/handle/10803/9250/
PalmaSevillano.pdf;jsessionid=1B7719767D06AE7B78F5912F2A2B5D45?
sequence=1 Accessed Januar 2022.

Rooke 1998

Review Manager Web 2022 [Computer program]

Review Manager Web (RevMan Web). Version 4.1.0.
The Cochrane Collaboration, 2022. Available at
revman.cochrane.org.

Palmier-Claus 2012

Palmier-Claus JE, Ainsworth J, Machin M, Barrowclough C,
Dunn G, Barkus E, et al. The feasibility and validity of
ambulatory self-report of psychotic symptoms using a
smartphone software application. BMC Psychiatry 2012;12:172.
[DOI: 10.1186/1471-244X-12-172]

Petersen 2005

Petersen L, Jeppesen P, Thorup A, Abel MB, Ohlenschlaeger J,
Christensen TO, et al. A randomised multicentre trial of
integrated versus standard treatment for patients with a

Rooke O, Birchwood M. Loss, humiliation and entrapment
as appraisals of schizophrenic illness: a prospective study
of depressed and non-depressed patients. British Journal
of Clinical Psychology 1998;37:259–268. [DOI: 10.1111/
j.2044-8260.1998.tb01384.x]

Rosa 2007

Rosa AR, Sánchez-Moreno J, Martínez-Aran A, Salamero M,
Torrent C, Reinares M, et al. Validity and reliability of
the functioning assessment short test (FAST) in bipolar
disorder. Clinical Practice and Epidemiology in Mental Health
2007;3(5):NA. [DOI: 10.1186/1745-0179-3-5]

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

46

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ryle 2002

Ryle A, Kerr IB. Introducing cognitive analytic therapy:
principles and practice. Chichester: Wiley, 2002.

Saha 2005

Saha S, Chant D, Welham J, McGrath J. A systematic review of
the prevalence of schizophrenia. PLoS Medicine 2005;2(5):e141.
[DOI: 10.1371/journal.pmed.0020141]

Schneider-Thoma 2019

Schneider-Thoma J, Efthimiou O, Bighelli I, Dörries C, Huhn M,
Krause M, et al. Second-generation antipsychotic drugs and
short-term somatic serious adverse events: a systematic review
and meta-analysis. Lancet Psychiatry 2019;6(9):753-65. [DOI:
10.1016/S2215-0366(19)30223-8]

Sensky 2000

Sensky T, Turkington D, Kingdon D, Scott JL, Scott J, Siddle R,
et al. A randomized controlled trial of cognitive-behavioral
therapy for persistent symptoms in schizophrenia resistant to
medication. Archives of General Psychiatry 2000;57:165–172.
[DOI: 10.1001/archpsyc.57.2.165]

Shokraneh 2017

Shokraneh F, Adams CE. Study-based registers of randomized
controlled trials: starting a systematic review with data
extraction or meta-analysis. BioImpacts (BI) 2017;7(4):209-17.
[DOI: 10.15171/bi.2017.25]

intervention in health and health care: a systematic review.
Health Technology Assessment 1999;3(5):iii-92.

Vendsborg 1999

Vendsborg P, Nordentoft M, Hvenegaard A, Søgaard J. Assertive
community treatment [in Danish]. Copenhagen: Institut for
Sundhedsvæsen, 1999.

Ventura 1993

Ventura J, Green MF, Shaner A, Libersman RP. Training and
quality assurance with the Brief Psychiatric Rating Scale: the
’drift busters’. International Journal of Methods in Psychiatric
Research 1993;3:221-244.

WHO 2019

World Health Organization (WHO). International statistical
classification of diseases and related health problems: eleventh
revision (ICD-11). Geneva: World Health Organization, 2019.

Xia 2009

Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H,
et al. Loss to outcomes stakeholder survey: the LOSS study.
Psychiatric Bulletin 2009;33(7):254-7.

Zigmond 1983

Zigmond AS, Snaith RP. The hospital anxiety and depression
scale. Acta Psychiatrica Scandinavica 1983;67:361-70. [DOI:
10.1111/j.1600-0447.1983.tb09716.x]

Shokraneh 2019

Zubin 1977

Shokraneh F, Adams CE. Study-based registers reduce waste in
systematic reviewing: discussion and case report. Systematic
Reviews 2019;8:129. [DOI: 10.1186/s13643-019-1035-3]

Zubin J, Spring B. Vulnerability—a new view of schizophrenia.
Journal of Abnormal Psychology 1977;86:103-26. [DOI:
10.1037/0021-843X.86.2.103]

References to other published versions of this review

Bighelli 2022b

Bighelli I, Corcoran C, Umama-Agada E, Leucht S. Cognitive
behavioural therapy plus standard care for first episode
psychosis. Cochrane Database of Systematic Reviews 2022, Issue
5. Art. No: CD015331. [DOI: 10.1002/14651858.CD015331]

* Indicates the major publication for the study

Sterne 2019

Sterne JAC, Savović J, Page MJ, Elbers RGE, Blencowe NS,
Boutron I, et al. RoB 2: a revised tool for assessing risk of bias
in randomised trials. BMJ 2019;366:I4898. [DOI: 10.1136/
bmj.l4898]

The EuroQol Group 1990

EuroQol Group. EuroQol - a new facility for the measurement of
health-related quality of life. Health Policy 1990;16(3):199-208.

Ukoumunne 1999

Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ.
Methods for evaluating area-wide and organisation-based

C H A R A C T E R I S T I C S   O F   S T U D I E S

Characteristics of included studies [ordered by study ID]

Barrowclough 2014 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

47

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Barrowclough 2014  (Continued)

Duration in weeks: 39 weeks maximum treatment, 78 weeks maximum follow-up

Number of study arms: 3

Type of blinding: rater blind

Type of data analysis for overall efficacy: ITT

Number of sites: 5

Number of countries: 1

Country: England

Sponsorship source: public

Trial registration ID: ISRCTN88275061

Publication year: 2014

Researcher's allegiance: The authors developed the manual for the intervention group.

Participants

Diagnosis: non-affective psychotic disorder, cannabis dependence or abuse; diagnostic criteria:
DSM-IV

Current clinical state: NA

Definition of stability: NA

Inclusion criteria: "Participants were recruited from Early Intervention Services in ﬁve mental
health trusts in the North West of England. Inclusion criteria were: aged 16–35 years; meeting Diag-
nostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria for non-affective
psychotic disorder; DSM-IV diagnosis of cannabis dependence or abuse; cannabis use of at least 1
day per week in at least half the weeks in the 3 months prior to assessment; having stable accom-
modation; sufﬁcient English to complete the assessments; no signiﬁcant history of organic factors
implicated in the aetiology of psychotic symptoms; and able to give informed consent."

Exclusion criteria: NA

Setting: NA

Special subgroup: drug abuse

N: 110

Gender: 98 men, 12 women

Age: mean 24.2 years

CBT plus standard care arm (brief): participants total: 38, participants male: 34, participants fe-
male: 4, age: mean 24.9 years (SD = 5.6), age range NA years, duration of illness: median 13.4 years,
% taking antipsychotics: NA, % diagnosis of schizophrenia: 52.6, % diagnosis of schizoaffective dis-
order: 13.2, % sub-induced disorder: 5.3, baseline PANSS total M = 66.1, SD = 9.2, N = 38

CBT plus standard care arm (long): participants total: 37, participants male: 34, participants fe-
male: 3, age: mean 24.1 years (SD = 5.4), age range NA years, duration of illness: median 17.5 years,
% taking antipsychotics: NA, % diagnosis of schizophrenia: 43.2, % diagnosis of schizoaffective dis-
order: 13.5, % sub-induced disorder: 2.7, baseline PANSS total M = 61.6, SD = 9.9, N = 37

Control arm: participants total: 35, participants male: 30, participants female: 5, age: mean 23.4
years (SD = 3.8), age range NA years, duration of illness: median 17.2 years, % taking antipsychotics:
NA, % diagnosis of schizophrenia: 51.4, % diagnosis of schizoaffective disorder: 8.6, % sub-induced
disorder: 8.6, baseline PANSS total M = 61.7, SD = 6.8, N = 35

Interventions

1.a Integrated MI-CBT (brief) plus standard care. N = 38

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

48

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Barrowclough 2014  (Continued)

Cochrane Database of Systematic Reviews

Description of treatment: "Phase 1 of the intervention – ‘motivation building’ – concerned engag-
ing the patient, eliciting and understanding their perspective in relation to life goals, and explor-
ing and resolving ambivalence so as to facilitate motivation for change. Information and feedback
from assessments were incorporated into this process, utilising a motivational style, to support the
formulation of a shared understanding in relation to each person’s concerns, their cannabis use
and mental health difﬁculties. Adaptations from the 2010 intervention included youth-friendly and
cannabis-focused information materials in the form of purpose-made DVDs and a cannabis infor-
mation booklet produced by lifeline.org.uk (http://www.exchangesupplies.org/shopdisp_A37.ph-
p). In phase 2 of the intervention, a plan for change was developed. Where the person was open
to change in cannabis use, CBT techniques from both the psychosis and substance use evidence
base were used to help the patient implement and maintain changes. For those not identifying sub-
stances as problematic, the intervention was sufﬁciently ﬂexible to allow therapists to work with
other patient-led problems. In such cases, the therapist would continue to assist the patient to link
substance use to their concerns using MI techniques. Both interventions attempted to progress
through both phases. However, the long intervention was designed to allow more time in phase 2
to develop the change plan and particularly the use of CBT within the plan. Progress was commu-
nicated to the participants’ care co-ordinator at two liaison meetings attended by both the thera-
pist and the participant. Standard care from the Early Intervention Services involved in the study is
compliant with the Mental Health Policy Implementation Guide (Department of Health 2001) and
included intensive case management and crisis response."

Number of sessions: 12 planned, 10.25 delivered (median)

Sessions frequency and duration: 4 per month

Therapist: NA

Therapist experience: experts

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: yes - manual by Barrowclough

1.b Integrated MI-CBT (long) plus standard care. N = 37

Description of treatment: "Phase 1 of the intervention – ‘motivation building’ – concerned engag-
ing the patient, eliciting and understanding their perspective in relation to life goals, and explor-
ing and resolving ambivalence so as to facilitate motivation for change. Information and feedback
from assessments were incorporated into this process, utilising a motivational style, to support the
formulation of a shared understanding in relation to each person’s concerns, their cannabis use
and mental health difficulties. Adaptations from the 2010 intervention included youth-friendly and
cannabis-focused information materials in the form of purpose-made DVDs and a cannabis infor-
mation booklet produced by lifeline.org.uk (http://www.exchangesupplies.org/shopdisp_A37.ph-
p). In phase 2 of the intervention, a plan for change was developed. Where the person was open
to change in cannabis use, CBT techniques from both the psychosis and substance-use evidence
base were used to help the patient implement and maintain changes. For those not identifying sub-
stances as problematic, the intervention was sufﬁciently ﬂexible to allow therapists to work with
other patient-led problems. In such cases, the therapist would continue to assist the patient to link
substance use to their concerns using MI techniques. Both interventions attempted to progress
through both phases. However, the long intervention was designed to allow more time in phase 2
to develop the change plan and particularly the use of CBT within the plan. Progress was commu-
nicated to the participants’ care co-ordinator at two liaison meetings attended by both the thera-
pist and the participant. Standard care from the Early Intervention Services involved in the study is
compliant with the Mental Health Policy Implementation Guide (Department of Health 2001) and
included intensive case management and crisis response."

Number of sessions: 24 planned, 11 delivered (median)

Sessions frequency and duration: 3 per month

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

49

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Barrowclough 2014  (Continued)

Therapist: NA

Therapist experience: experts

Supervision: yes

Modality: individual

Delivery: face-to-face

Cochrane Database of Systematic Reviews

Treatment manualised: yes - manual by Barrowclough

2. Control (Treatment as usual). N = 35

Description of treatment: intensive case management and crisis response

Number of sessions: NA

Sessions frequency and duration: NA

Therapist: NA

Therapist experience: NA

Supervision: NA

Modality: NA

Delivery: NA

Treatment manualised: NA

Outcomes

Mental state - general - PANNS total endpoint (< 6 months, < 12 months, > 1 year)

Mental state - specific - PANNS positive endpoint (< 6 months, < 12 months, > 1 year)

Mental state - specific - PANNS negative endpoint (< 6 months, < 12 months, > 1 year)

Mental state - specific - Calgary Depression Scale endpoint (< 6 months, < 12 months, > 1 year)

Global state - Number of participants that relapsed (< 12 months, > 1 year)

Service use - Admission to hospital (< 12 months, > 1 year)

Leaving the study early - for any reason (dropout) (< 6 months, < 12 months, > 1 year)

Functioning - GAF endpoint (< 6 months, < 12 months, > 1 year)

Adverse events - Non compliance (< 6 months)

Mortality - Overall mortality (> 1 year)

Notes

We contacted the authors but received no reply.

Bucci 2018 (Actissist) 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

50

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bucci 2018 (Actissist)  (Continued)

Duration in weeks: 12 weeks treatment phase, 22 weeks follow-up

Number of study arms: 2

Type of blinding: rater blind

Type of data analysis for overall efficacy: probably completers

Number of sites: NA

Number of countries: 1

Country: UK

Sponsorship source: public

Trial registration ID: ISRCTN34966555

Publication year: 2018

Researcher's allegiance: The authors developed the app for both intervention and control.

Participants

Diagnosis: initial episode of psychosis; diagnostic criteria: NA

Current clinical state: NA

Definition of stability: NA

Inclusion criteria: "Eligibility criteria were: (1) in current contact with an EIS in the North West of
England; (2) capacity to provide informed consent; and (3) English language proficient. EIS are mul-
tidisciplinary community mental health services that provide psychosocial and pharmacological
treatment and support to people in their first 3 years of their initial episode of psychosis."

Exclusion criteria: "Exclusion criteria were: (1) aged less than 16 years at point of recruitment; (2)
not capable of giving informed consent; (3) non-English proficient; and (4) inpatient at point of re-
cruitment."

Setting: outpatient

Special subgroup: first-episode patients

N: 36

Gender: 18 men, 18 women

Age: NA

CBT plus standard care arm: 24 participants, 15 male (16.25%), age: mean NA years, age range > 16
years, duration of illness: NA, duration of untreated psychosis: NA, % taking antipsychotics: NA, %
diagnosis schizophrenia: NA, baseline PANSS total M = 65.9, SD = 12.9, N = 24

Control arm: 12 participants, 3 male (25%), age: mean NA years, age range > 16 years, duration of
illness: NA, duration of untreated psychosis: NA, % taking antipsychotics: NA, % diagnosis schizo-
phrenia: NA, baseline PANSS total M = 64.6, SD = 11.1, N = 12

Interventions

1. CBT plus standard care. N = 24

Description of treatment: "Actissist is a DHI that the user can engage with spontaneously or in re-
sponse to being prompted. It then collects responses from the user and wirelessly uploads user re-
sponses to a server. Actissist is divided in 2 parts, although presented as a single app. Firstly, at 3
pseudo-randomised time points per day, 6 days a week between 10.00 and 22.00, an auditory alert
followed by a visual prompt is emitted from the app inviting participants to access the app. The no-
tifications persist on the handset (i.e. no time out) until such point as they are accepted, dismissed,
“snoozed” (up to 15 min), or another notification is received. The notifications serve merely as a re-
minder; the app also allows self-initiated use at any point. If a user accepts a notification or initi-

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

51

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bucci 2018 (Actissist)  (Continued)

Cochrane Database of Systematic Reviews

ates use, they are invited to select an intervention domain(s) and then complete a series of self-as-
sessment questions structured as question-answer exchanges that focus on cognitive appraisals,
belief conviction, emotions and associated behaviours. Depending on the appraisal selected, the
exchange is followed by normalising messages and cognitive or behavioural strategies aimed at
suggesting ways of coping with distressing experiences. Multiple messages and images associated
with each exchange minimise boredom and repetition within the app. Alternatively, participants
can report that they have had “no problems like this” since their last notification or (self-initiat-
ed) interaction. Part 2 includes a menu of multimedia options that act in a stand-alone fashion de-
signed to complement and support the feedback from the intervention domains. This supplemen-
tary content contains information and activities including relaxation and mindfulness exercises, re-
covery stories (videos), a range of fact sheets (e.g. low mood, anxiety, self-esteem), external links to
web-related content (e.g. TED talks), daily diary, and emergency contact resources. Furthermore, a
graphical summary of data points entered over the previous 7 days allows users to track distressing
experiences to support active self-management of symptoms and shared decision-making about
treatment with clinicians. Users can customise the aesthetics of the Actissist interface; for example,
personally meaningful images from the smartphone’ s local storage can be set as wallpaper to fa-
cilitate positive mood induction." "TAU involved regular clinician meetings, medication, risk mon-
itoring, and psychosocial interventions. Actissist and ClinTouch are standalone apps that do not
link with services."

Number of sessions: 3 prompts per day, 6 days per week, for 12 weeks

Sessions frequency and duration: NA

Therapist: NA

Therapist experience: NA

Supervision: no

Modality: individual

Delivery: smartphone app

Treatment manualised: yes

2. Control (Clintouch). N = 12

Description of treatment: "The ClinTouch app is a symptom-monitoring app that triggers, collects,
and wirelessly uploads symptom data to a server. As in the treatment condition, the app emits an
alarm prompting participants to access the app at 3 pseudo-randomised time points per day, 6
days a week between 10.00 and 22.00 for 12 weeks alongside usual treatment. The ClinTouch pro-
tocol is outlined in detail in Palmier-Claus 2012; although, the number of prompts was altered for
parity with Actissist alerts, such that participants submit one-and-a-half data points daily with 10
branching items covering positive psychotic symptoms, anxiety, and mood. As each full data point
was collected over 2 separate alerts, this equates to having received 3 alerts every day. The alert in-
vites participants to use a touchscreen slider to rate the severity of 12 individual symptoms on a 1–
7 scale. This takes an average of 70 s and the data are wirelessly uploaded to a secure server. Symp-
tom items have been validated against corresponding items on the PANSS (Kay 1987). The aesthet-
ics and interface mirror the Actissist interface. However, unlike the Actissist app, ClinTouch does
not facilitate self-initiated access; data entries must be in response to a notification. The notifica-
tions time out 30 mins after receipt, whereby the notification is no longer visible and the ClinTouch
items are no longer accessible." "TAU involved regular clinician meetings, medication, risk mon-
itoring, and psychosocial interventions. Actissist and ClinTouch are standalone apps that do not
link with services."

Number of sessions: 3 prompts per day, 6 days per week, for 12 weeks

Sessions frequency and duration: NA

Therapist: NA

Therapist experience: NA

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

52

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Bucci 2018 (Actissist)  (Continued)

Supervision: no

Modality: individual

Delivery: smartphone app

Treatment manualised: yes

Outcomes

Mental state - general - PANSS total endpoint (< 6 months)

Cochrane Database of Systematic Reviews

Mental state - specific - PANSS positive endpoint (< 6 months)

Mental state - specific - PANSS negative endpoint (< 6 months)

Mental state - specific - Calgary Depression Scale endpoint (< 6 months)

Leaving the study early - for any reason (dropout) (< 6 months)

Functioning - GAF endpoint (< 6 months)

Functioning - PSP endpoint (< 6 months)

Quality of Life - EQ-5D (WHO) endpoint (< 6 months)

Notes

We contacted the authors and obtained additional information.

Edwards 2006 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: 39 (13 intervention + 26 follow-up)

Number of study arms: 2

Type of blinding: rater blind

Type of data analysis for overall efficacy: ITT

Number of sites: 1 (no information on number of academic sites)

Number of countries: 1

Country: Australia

Sponsorship source: NA

Trial registration ID: NA

Publication year: 2006

Researcher's allegiance: The authors developed the manual for the intervention group.

Participants

Diagnosis: psychotic disorder; diagnostic criteria: DSM-IV

Current clinical state: first episode, clinically stabilised

Definition of stability: NA

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

53

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Edwards 2006  (Continued)

Cochrane Database of Systematic Reviews

Inclusion criteria: "Study inclusion criteria were a DSM-IV (APA 1994) diagnosis of a psychotic dis-
order (i.e. schizophrenia, schizophreniform, schizoaffective, delusional disorder, bipolar disorder,
major depressive disorder with psychotic features, psychosis not otherwise stated, and brief reac-
tive psychosis), informed consent for research participation and adequate English language com-
prehension. As approximately 50% of young people using cannabis at admission to early interven-
tion services such as EPPIC can be expected to voluntarily cease use within the ﬁrst 6–10 weeks
(Edwards 2001), only patients who were continuing to use cannabis at 10 weeks post-initial clinical
stabilization were eligible for study inclusion."

Exclusion criteria: "No additional exclusion criteria were applied."

Setting: NA

Special subgroup: drug abuse (cannabis)

N: 47

Gender: 34 men, 13 women

Age: mean 21.1 years

CBT plus standard care arm: participants total: 23, participants male: NA, participants female: NA,
age: mean 20.9 years (SD = 3.5), age range: 15-29 years, duration of illness: NA, duration of untreat-
ed psychosis: NA, % taking antipsychotics: NA, % diagnosis schizophrenia: NA, baseline BPRS total
M = 49.9, SD = 16.3, N = 23

Control arm: participants total: 24, age: mean 21.3 years (SD = 3.4), age range: 15-29 years, duration
of illness: NA, duration of untreated psychosis: NA, % taking antipsychotics: NA, % diagnosis schiz-
ophrenia: NA, baseline BPRS total M = 48.8, SD = 17, N = 24

Interventions

1. CBT plus standard care. N = 23

Description of treatment: "Cannabis and psychosis therapy is an individually delivered cogni-
tive-behavioral harm minimization approach to cannabis use in individuals with FEP. Young people
are often traumatized by psychosis and its implications, and the desire to avoid further episodes
can encourage reconsideration of cannabis use, providing a window of opportunity to inﬂuence be-
havior change (). The intervention is delivered over 3 months, ideally involving 10 weekly sessions
(20–60 min in duration). A booster telephone call 3 months after end of treatment is designed as
a generalized relapse prevention, and serves to emphasize gains made in treatment and reinforce
strategies to manage potential relapse. CAP commences with a detailed assessment and attention
to engagement, followed by education about cannabis and psychosis and building motivation to
change (Miller 2002). The focus of therapy is then determined by phase of commitment to change
(Prochaska 1992) and may include further education about cannabis and psychosis, motivational
interviewing, goal setting, goal achievement strategies, and discussion about relapse prevention.
Feedback was sought from ﬁve international experts on an early CAP outline and their comments
were incorporated within the ﬁnal treatment manual (Hinton 2002)." In addition to the randomized
condition, each participant received standard EPPIC care which includes case management, reg-
ular psychiatric review and medication; access to mobile assessment and treatment, family work,
group programs, and a prolonged recovery clinic (McGorry 1996)."

Number of sessions: 10 planned, 7.6 received

Sessions frequency and duration: 4, 20-60 minutes each

Therapist: four clinical psychologists trained in cognitive-behaviour therapy and experienced in the
treatment of FEP

Therapist experience: experts

Supervision: yes

Modality: individual

Delivery: face-to-face

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

54

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Edwards 2006  (Continued)

Treatment manualised: yes

2. Control (Psychoeducation); N = 24

Cochrane Database of Systematic Reviews

Description of treatment: "The 10 individual PE sessions were guided by standardized powerpoint
slides (in electronic or
printed form) which covered the nature of psychosis, medication and other treatments, and re-
lapse prevention and stigma, but avoided explicit discussion of cannabis." "In addition to the ran-
domized condition, each participant received standard EPPIC care which includes case manage-
ment, regular psychiatric review and medication; access to mobile assessment and treatment,
family work, group programs, and a prolonged recovery clinic (McGorry 1996)."

Number of sessions: 10 planned, 8.4 received

Sessions frequency and duration: NA

Therapist: four clinical psychologists trained in cognitive-behaviour therapy and experienced in the
treatment of FEP

Therapist experience: experts

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: NA

Outcomes

Mental state - general - BPRS-E total endpoint (< 6 months, < 12 months)

Mental state - specific - BPRS-PS endpoint (< 6 months, < 12 months)

Mental state - specific - SANS endpoint (< 6 months, < 12 months)

Mental state - specific - BDI short form endpoint (< 6 months, < 12 months)

Leaving the study early - for any reason (dropout) (< 6 months, < 12 months)

Functioning - SOFAS endpoint (< 6 months, < 12 months)

Notes

We contacted the authors but received no reply.

Edwards 2011 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: 12 treatment phase, 12-week follow-up phase

Number of study arms: 4

Type of blinding: rater blind

Type of data analysis for overall efficacy: ITT

Number of sites: 1

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

55

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Edwards 2011  (Continued)

Number of countries: 1

Country: Australia

Cochrane Database of Systematic Reviews

Sponsorship source: Victorian Government's Health Promotion Foundation and NOVARTIS

Trial registration ID: NA

Publication year: 2011

Researcher's allegiance: The authors developed the manual for the intervention group.

Participants

Diagnosis: schizophrenia, schizophreniform disorder, delusional disorder, psychotic disorder not
otherwise specified; diagnostic criteria: DSM-IV

Current clinical state: acute/experiencing positive symptoms

Definition of stability: NA

Inclusion criteria: "experiencing a ﬁrst treated episode of a psychotic disorder that fulﬁlled the
DSM-IV criteria for a diagnosis of schizophrenia, schizophreniform disorder, delusional disorder,
or psychotic disorder not otherwise speciﬁed; being registered with EPPIC for 12 to 26 weeks; and
continuing to experience moderate to severe positive symptoms, deﬁned as a score ≥ 4 on at least
one of the hallucinations, unusual thought content, and conceptual disorganisation items of the
expanded version of the brief psychiatric rating scale (BPRS) (Ventura 1993), with a score of not less
than 3 on these items for a period of 14 consecutive days or more during the preceding 12 weeks.
All participants had been treated with at least one atypical antipsychotic (usually risperidone,
olanzapine or quetiapine) at doses up to 500 mg chlorpromazine equivalence (if tolerated), with
demonstrated medication compliance for at least the past 4 weeks."

Exclusion criteria: "an organic mental disorder, pregnancy or lactation, requiring antidepressant
medication, a mood stabiliser or ECT, and a history of drug-induced granulocytopenia."

Setting: both inpatient and outpatient

Special subgroup: treatment-resistant patients

N: 48

Gender: 36 men, 14 women

Age: mean 21.4 years

CBT plus standard care arm 1 (CBT + CLZ): participants total: 11, participants male: 10, participants
female: 1, age: mean 20.8 years (SD = 2.8), age range: 15-29 years, duration of untreated psychosis:
13.75 months (SD = 29.2), % taking antipsychotics: 100, % diagnosis schizophrenia: 81.8, % diagno-
sis schizophreniform disorder: 18.2

CBT plus standard care arm 2 (CBT + TDZ): participants total: 12, participants male: 7, participants
female: 5, age: mean 22 years (SD = 4.1), age range: 15-29 years, duration of untreated psychosis:
15.55 months (SD = 15), % taking antipsychotics: 100, % diagnosis schizophrenia: 75, % diagnosis
schizophreniform disorder: 16.7, % delusional disorder: 8.3

Control arm 1 (CLZ): participants total: 14, participants male: 9, participants female: 5, age: mean
20.5 years (SD = 3.5), age range: 15-29 years, duration of untreated psychosis: 14.65 months (SD =
14.2), % taking antipsychotics: 100, % diagnosis schizophrenia: 78.6, % diagnosis schizophreniform
disorder: 14.3

Control arm 2 (TDZ): participants total: 11, participants male: 8, participants female: 3, age: mean
22.5 years (SD = 3.4), age range: 15-29 years, duration of untreated psychosis: 14.95 months (SD =
15.9), % taking antipsychotics: 100, % diagnosis schizophrenia: 90.9, % diagnosis schizophreniform
disorder: 9.1

Interventions

1. CBT plus standard care. N = 23

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

56

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Edwards 2011  (Continued)

Cochrane Database of Systematic Reviews

Description of treatment: "Participants commenced treatment at a dose of 12.5 mg/day which was
titrated upwards in 25 mg/day increments up to a maximum dose of 300 mg/day, depending on
clinical response. During Week 4 of the study, patients who still showed an inadequate response
had their medication increased to a maximum of 400 mg/day, which could be further increased to
a maximum of 600 mg/daily if necessary during Week 5, after which all patients were maintained
on their current medication dose." "A manualized CBT program, the systematic treatment of persis-
tent psychosis (STOPP, Hermann-Doig 2003) was devised to target enduring positive symptoms and
related patient needs." "In addition, all participants received routine clinical care, which included
access to a 24-hour mobile assessment and treatment team, inpatient service, case management,
and psychiatric review. Patients were seen weekly by a psychiatrist/psychiatry registrar for the du-
ration of the trial, (...)".

Number of sessions: 24 planned (CBT + CLZ: 15.25 done; CBT + TDZ: 13.45 done)

Sessions frequency and duration: 8

Therapist: psychiatrist, psychiatry registrar (TAU)

Therapist experience: NA

Supervision: NA

Modality: individual

Delivery: face-to-face

Treatment manualised: yes

2. Control (Treatment as usual). N = 25

Description of treatment: "Participants commenced treatment at a dose of 12.5 mg/day which was
titrated upwards in 25 mg/day increments up to a maximum dose of 300 mg/day, depending on
clinical response. During Week 4 of the study, patients who still showed an inadequate response
had their medication increased to a maximum of 400 mg/day, which could be further increased to a
maximum of 600 mg/daily if necessary during Week 5, after which all patients were maintained on
their current medication dose." "In addition, all participants received routine clinical care, which
included access to a 24-hour mobile assessment and treatment team, inpatient service, case man-
agement, and psychiatric review. Patients were seen weekly by a psychiatrist/psychiatry registrar
for the duration of the trial, and all participants not receiving CBT attended weekly case manage-
ment sessions."

Number of sessions: NA

Sessions frequency and duration: NA

Therapist: psychiatrist, psychiatry registrar (TAU)

Therapist experience: NA

Supervision: NA

Modality: NA

Delivery: NA

Treatment manualised: yes

Outcomes

Mental state - general - BPRS-P endpoint (< 6 months)

Mental state - specific - SANS endpoint (< 6 months)

Mental state - specific - BDI endpoint (< 6 months)

Global state - Remission (< 6 months)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

57

 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Edwards 2011  (Continued)

Global state - CGI-S endpoint (< 6 months)

Functioning - SOFAS endpoint (< 6 months)

Quality of Life - QLS endpoint (< 6 months)

Notes

We contacted the authors but received no reply.

GetUp 

Study characteristics

Methods

Study design: cluster-randomised controlled trial

Study grouping: parallel

Antipsychotic medication allowed: yes

Duration in weeks: 9-month follow-up (39.1 weeks)

Number of study arms: 2

Type of blinding: open-label

Type of data analysis for overall efficacy: ITT

Number of sites: 117

Number of countries: 1

Country: Italy

Sponsorship source: public

Trial registration ID: NCT01436331

Publication year: 2015

Researcher's allegiance: NA

Participants

Diagnosis: specific ICD-10 codes for psychosis (F1x.4; F1x.5; F1x.7; F20–29; F30.2, F31.2, F31.5, F31.6,
F32.3, F33.3); diagnostic criteria: ICD-10

Current clinical state: clinically stable

Definition of stability: Patients capable of collaborating in at least a brief clinical examination

Inclusion criteria: "age 18–54 years, residence in catchment areas of CMHCs, presence of at least
one of the following: hallucinations, delusions, qualitative speech disorder, qualitative psychomo-
tor disorder, bizarre, or grossly inappropriate behavior, or two of the following: loss of interest,
initiative, and drive; social withdrawal; episodic severe excitement; purposeless destructive-
ness; overwhelming fear; or marked self-neglect, per the WHO Screening Schedule for Psychosis
(Jablensky 1992), first lifetime contact with CMHCs, prompted by these symptoms."

Exclusion criteria: "(1) antipsychotic medication (> 3 months) prescribed for an identical or similar
mental disorder; (2) mental disorders due to general medical condition; (3) moderate-severe men-
tal retardation per a clinical functional assessment; and (4) psychiatric diagnosis other than Inter-
national Classification of Diseases (ICD)-10 for psychosis."

Setting: outpatient

Special subgroup: first-episode patients

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

58

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

GetUp  (Continued)

N: 444

Gender: 260 men, 184 women

Age: mean 30.2 years

Cochrane Database of Systematic Reviews

CBT plus standard care arm: 272 participants, 166 male, 106 female, mean age 29.3 years (SD = 9.8),
age range 18-54 years, duration of illness: NA, duration of untreated psychosis: NA, % taking an-
tipsychotics: NA, % diagnosis nonaffective psychosis: 78.7, % diagnosis affective psychosis: 21.3,
baseline PANSS total M = 2.37, SD = 0.67, N = 271

Control arm: 172 participants, 94 male, 78 female, mean age 31.5 years (SD = 9.2), age range 18-54
years, duration of illness: NA, duration of untreated psychosis: NA, % taking antipsychotics: NA, %
diagnosis nonaffective psychosis: 76.7, % diagnosis affective psychosis: 23.3, baseline PANSS total
M = 2.32, SD = 0.68, N = 172

Interventions

1. CBT plus standard care. N = 272

Description of treatment: "The experimental treatment package was provided by routine public
Community Mental Health Centers (CMHCs) which operate within the Italian National Health Ser-
vice and consisted of standard care (treatment as usual, TAU) plus evidence-based additional treat-
ment. Specifically, the multi-element psychosocial intervention, adjunctive to TAU, comprised:
(i) Cognitive Behavioral Treatment for psychosis (CBTp) to patients; (ii) psychosis-focused Family
Intervention (FIp) to individual families; and (iii) Case Management (CM) to both parties. FIp was
based on the model proposed by Leff 1985 and further developed by Kuipers 2002. It included an
optimal number of 10–15 sessions over 9 months, with each individual family: 6 sessions in the
first 3 months, and at least 1 session/month in the 6 months afterwards. Every patient/family had a
dedicated CM, who coordinated all planned interventions (Burns 2002)"

Number of sessions: 10-15 sessions over 9 months; Number of CBT sessions: mean (SD): 17,8 (10,3);
number of FI sessions: mean (SD): 9,3 (7,0); number of CM contacts: mean (SD): 21,7 (24,4)

Sessions frequency and duration: 1-2 sessions per month; "weekly sessions in the first 3 months,
and at least 1 session/month in the 6 months afterwards"

Therapist: psychiatrist/ psychologist, nurse/educator

Therapist experience: experts (received CBTp and Fip training)

Supervision: yes ("The intervention was provided by CMHC staff, trained in the previous 6 months
and supervised by experts.")

Modality: individual

Delivery: face-to-face

Treatment manualised: yes

2. Control (Treatment as usual). N = 172

Description of treatment: "Treatment as usual (TAU) was also provided by routine public Commu-
nity Mental Health Centers (CMHCs) involved in the Trial. In Italy standard care for FEP patients typ-
ically consisted of personalized outpatient psychopharmacological treatment, combined with non-
specific supportive clinical management and non-specific informal support/educational sessions
for families."

Number of sessions: NA

Sessions frequency and duration: NA

Therapist: NA

Therapist experience: NA

Supervision: NA

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

59

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

GetUp  (Continued)

Modality: individual

Delivery: face-to-face

Treatment manualised: NA

Outcomes

Mental state - general - PANSS total endpoint (< 12 months)

Cochrane Database of Systematic Reviews

Mental state - specific - PANSS positive endpoint (< 12 months)

Mental state - specific - PANSS negative endpoint (< 12 months)

Mental state - specific - Hamilton Depression endpoint (< 12 months)

Service use - admission to hospital (< 12 months)

Service use - number of days in hospital (< 12 months)

Leaving the study early - for any reason (dropout) (< 12 months)

Functioning - GAF endpoint (< 12 months)

Mortality - overall mortality (< 12 months)

Mortality - mortality due to natural causes (< 12 months)

Mortality - mortality due to suicide (< 12 months)

Notes

We contacted the authors and obtained additional data.

Gleeson 2009 (EPISODE II) 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: relapse prevention intervention (of approximately 6-month duration according
to trial registration) - "The study included a total of 6 assessment time points spanning a 2.5-year
follow-up period."

Number of study arms: 2

Type of blinding: rater blind

Type of data analysis for overall efficacy: ITT

Number of sites: 2

Number of countries: 1

Country: Australia

Sponsorship source: public and pharmaceutical

Trial registration ID: ACTRN12605000514606

Publication year: 2009

Researcher's allegiance: The authors developed the manual for the intervention group.

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

60

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gleeson 2009 (EPISODE II)  (Continued)

Cochrane Database of Systematic Reviews

Participants

Diagnosis: diagnosis of a first episode of a DSM-IV psychotic disorder, less than 6 months of prior
treatment with antipsychotic medications; diagnostic criteria: DSM-IV

Current clinical state: remission

Definition of stability: "Remission was defined as 4 weeks or more of scores of 3 (mild) or below on
the subscale items hallucinations, unusual thought disorder, conceptual disorganization, and sus-
piciousness on the expanded version of the Brief Psychiatric Rating Scale (BPRS)". (Lukoff 1986,
Overall 1962)

Inclusion criteria: "The study inclusion criteria were a diagnosis of a first episode of a DSM-IV (APA
1994) psychotic disorder, less than 6 months of prior treatment with antipsychotic medications,
age 15 to 25 years inclusive, and remission on positive symptoms of psychosis. Remission was de-
fined as 4 weeks or more of scores of 3 (mild) or below on the subscale items hallucinations, unusu-
al thought disorder, conceptual disorganization, and suspiciousness on the expanded version of
the Brief Psychiatric Rating Scale (BPRS)."

Exclusion criteria: "Exclusion criteria were ongoing active positive symptoms of psychosis, severe
intellectual disability, inability to converse in or read English, and participation in previous CBT tri-
als."

Setting: outpatient ("outpatient case manager")

Special subgroup: first episode, stable

N: 81

Gender: 51 men, 30 women

Age: mean 20.1 years (SD = 3.1)

CBT plus standard care arm: participants total: 41, participants male: 27, participants female: 14,
age: mean 20.1 years (SD = 2.9), age range: 15-25 years, duration of untreated psychosis: 401.1 days
(SD = 529.1), % taking antipsychotics: 94.6, % diagnosis schizophrenia: 34.1, % diagnosis schizo-
phreniform disorder: 7.3, % diagnosis schizoaffective disorder: 7.3, % diagnosis bipolar disorder:
7.3, % MDE with psychotic features: 2.4, % psychotic disorder NOS: 34.1, baseline BPRS total M =
35.4, SD = 6.9, N = 41

Control arm: participants total: 40, participants male: 24, participants female: 16, age: mean 20.1
years (SD = 3.2), age range: 15-29 years, duration of untreated psychosis: 368.6 days (SD = 611.9),
% taking antipsychotics: 100, % diagnosis schizophrenia: 32.5, % diagnosis schizophreniform dis-
order: 15, % diagnosis schizoaffective disorder: 2.5, % diagnosis bipolar disorder: 2.5, % MDE with
psychotic features: 10, % psychotic disorder NOS: 25, baseline BPRS total M = 34.3, SD = 8, N = 40

Interventions

1. CBT plus standard care (Relapse prevention therapy (RPT)). N = 41

Description of treatment: "Patients randomly assigned to RPT were introduced to their individual
research therapist, who additionally adopted the role of outpatient case manager for the duration
of their treatment at EPPIC. All patients randomly assigned to RPT continued their follow-up treat-
ment with their outpatient psychiatrist and had access to home-based treatment and group inter-
ventions as indicated. The research therapists functioned as fully integrated members of the EP-
PIC treatment team and as visiting therapists to Barwon Health, which allowed the effectiveness
of RPT to be evaluated within existing “real-world” clinical roles. Key differences between TAU and
RPT included (1) the shared, written individualized formulation regarding relapse risk; (2) the sys-
tematic and phased approach to relapse prevention via a range of cognitive behavioral interven-
tions; (3) the parallel individual and family sessions focused on relapse prevention; and (4) super-
vision specifically focused on relapse prevention. The manualized individual therapy intervention
comprises 5 phases of therapy underpinned by a CBT framework and informed by previous psy-
chotherapy trials conducted at EPPIC (Edwards 2003, Jackson 2001) and by the collaborative ther-
apy framework developed at the Mental Health Research Institute, Melbourne, Australia (Gilbert
2003a). The aim of the first phase of the individual therapy was to engage the patient and assess
their extent of recovery and individual risk for relapse (e.g. substance use, medication noncompli-
ance, stressful life events, and comorbid anxiety and depression). In the second phase, the formu-

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

61

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gleeson 2009 (EPISODE II)  (Continued)

Cochrane Database of Systematic Reviews

lation and agenda for therapy were agreed on with the patient and summarized in a letter, which
was read out to the patient – a technique informed by cognitive analytic therapy (Ryle 2002). The
therapeutic agenda was intended to address those risk factors that were identified in the initial
assessment. The third phase focused on increasing awareness for the risk of setbacks and how to
minimize them, and in the fourth phase, the potential early warning signs of relapse were identi-
fied and a relapse plan formulated (Birchwood 1989). The fifth phase included optional modules
that addressed issues of nonadherence to treatment, substance abuse, coping with stress, and co-
morbid anxiety and depression. Selection of the intervention modules to be undertaken during this
therapy phase was based on the collaborative formulation and therapy agenda accomplished after
initial assessment. The final phase included a review and termination, and a booster session. The
individual therapy phases were provided within a 7-month therapy window, approximately fort-
nightly in order to match the recommended frequency of sessions in TAU (EPPIC 2001). The family
intervention, also manualized and provided by a trained family therapist, was informed by cogni-
tive behavioral family therapy for schizophrenia (Falloon 1988, Mueser 1999) and family interven-
tions for FEP (Linszen 1996). The phases of family therapy were assessment and engagement, as-
sessment of family communication, burden and coping, psychoeducation regarding relapse risk,
and a review of early warning signs and documentation of a relapse prevention plan. Intensive
communication skills training and problem solving were undertaken when indicated. Treatment
manuals are available on request."

Number of sessions: Participants randomly assigned to RPT completed a mean of 8.51 sessions;
therapy completers (25 out of 41: 61%): mean of 11.84 sessions; family intervention: mean of 10,2
sessions; family completers (15 out of 24 completed: 62%): mean of 13.1 sessions

Sessions frequency and duration: 2 per month

Therapist: research therapist

Therapist experience: experts

Supervision: yes

Modality: individual and family based

Delivery: face-to-face

Treatment manualised: yes

2. Control (Treatment as usual). N = 40

Description of treatment: "Patients randomly assigned to TAU continued with their routine treat-
ment, via the EPPIC program or Barwon Health, which was coordinated via an outpatient case
manager and outpatient consultant psychiatrist, with access to home-based treatment and a range
of psychosocial interventions (EPPIC 2001). During the course of the trial, the caseload of a full-
time case manager was approximately 35. A case management manual provided detailed guide-
lines for TAU (EPPIC 2001). All case managers were orientated to early psychosis treatment guide-
lines and were provided with a range of additional therapy manuals and standardized psychoed-
ucation materials. Fidelity was managed via approximately fortnightly one-to-one supervision for
all case managers with a senior clinician and via weekly multi-disciplinary case review meetings,
which all outpatient staff were required to attend. At entry into the service, all families were rou-
tinely offered access to a brief family psychoeducation group, and EPPIC families had access to a
family peer support service."

Number of sessions: unknown

Sessions frequency and duration: 2 per month

Therapist: NA

Therapist experience: NA

Supervision: yes

Modality: individual and family psychoeducation group

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

62

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gleeson 2009 (EPISODE II)  (Continued)

Delivery: face-to-face

Treatment manualised: yes

Cochrane Database of Systematic Reviews

Outcomes

Mental state - general - BPRS total endpoint (< 12 months, > 1 year)

Mental state - specific - BPRS positive endpoint (> 1 year)

Mental state - specific - SANS endpoint (< 12 months)

Mental state - specific - MADRS endpoint (< 12 months, > 1year)

Global state - Number of participants that relapsed (< 12 months, > 1 year)

Service use - Number of days in hospital (< 12 months, > 1 year)

Leaving the study early - for any reason (dropout) (< 12 months, > 1 year)

Functioning - SOFAS endpoint (< 12 months, > 1 year)

Quality of life - WHOQoL-BREF endpoint (< 12 months)

Notes

We contacted the authors but received no reply.

Gonzalez-Ortega 2021 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: 28 planned, 28 to 32 weeks actually

Number of study arms: 2

Type of blinding: rater blind

Type of data analysis for overall efficacy: completers

Number of sites: 5

Number of countries: 1

Country: Spain

Sponsorship source: public

Trial registration ID: NCT01783457

Publication year: 2021

Researcher's allegiance: NA

Participants

Diagnosis: first episode psychosis; diagnostic criteria: DSM-IV-TR

Current clinical state: first episode - psychopathologically stable

Definition of stability: NA

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

63

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gonzalez-Ortega 2021  (Continued)

Cochrane Database of Systematic Reviews

Inclusion criteria: "The patients needed to be between 18–45 years old and to have received a di-
agnosis of FEP, according to the 4th edition text-revised of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV-TR) (APA 2000), within the previous ﬁve years, which could include either
schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, delusional disorder,
non-speciﬁed psychotic disorder, bipolar disorder with psychotic symptoms, or major depressive
disorder with psychotic symptoms."

Exclusion criteria: "The exclusion criteria were intellectual disability, organic brain disorders or the
presence of comorbidities that could hinder communication, and substance use disorder as the
primary diagnosis."

Setting: both inpatient and outpatient

Special subgroup: first episode, stable

N: 184 randomised, final sample: 177

Gender: 105 men, 72 women

Age: mean 28.5 years (SD = 8.97)

CBT plus standard care arm: participants total: 92, participants male: 47, participants female: 39,
age: mean 27.74 years (SD = 7.66), age range: 18-45 years, duration of untreated psychosis: NA, %
taking antipsychotics: 98.8, % diagnosis nonspecified psychotic disorder: 67.4, % diagnosis schiz-
ophreniform disorder: 7, % diagnosis bipolar disorder: 15.1, % diagnosis affective psychosis: 1.2,
baseline PANSS total M = 58.29, SD = 14.29, N = 86

Control arm: participants total: 92, participants male: 58, participants female: 33, age: mean 29.27
years (SD = 10.03), age range: 18-45 years, duration of untreated psychosis: NA, % taking antipsy-
chotics: 95.6, % diagnosis nonspecified psychotic disorder: 65.9, % diagnosis schizophreniform dis-
order: 12.1, % diagnosis bipolar disorder: 11, % diagnosis affective psychosis: 2.2, baseline PANSS
total M = 57.61, SD = 12.3, N = 91

Interventions

1. CBT plus standard care. N = 92

Description of treatment: "The combined clinical treatment involved TAU plus an adjuvant individ-
ual CBT intervention. The intervention programme was implemented in all participating centres,
addressing the same content and following the same structure. It was composed of 14 one-hour
sessions fortnightly (±3 days) for a period of 6.5–7.5 months. The ﬁrst part of the program (sessions
1–9) was composed of psychoeducational sessions aimed at improving patients’ insight into their
illness, treatment adherence, prodromal identiﬁcation, early intervention to prevent relapses, and
a healthy lifestyle. The second part of the intervention (sessions 10–14) included cognitive behav-
ioural techniques for symptom and thought management (anxiety management techniques and
social and problem-solving skills). The patients were offered the possibility of using a telephone
helpline between sessions if they had any questions related to the content of the sessions or their
status. The program included the following sessions:
1. What is a ﬁrst episode of psychosis?
2. Challenge and importance of insight into vulnerability.
3. Symptom recognition.
4. Prevention of relapses: protective and risk factors.
5. Detection of prodromes.
6. What can I do if I perceive that the symptoms are emerging again?
7. Treatment adherence.
8. Healthy lifestyles: sleep and sexuality. 
9. Healthy lifestyles: substance use.
10. Anxiety management techniques (I).
11. Anxiety management techniques (II).
12. Social skills: assertiveness techniques.
13. Problem-solving techniques.
14. Final doubts and farewell."

Number of sessions: 14

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

64

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Gonzalez-Ortega 2021  (Continued)

Sessions frequency and duration: 2 per month, 60 minutes

Therapist: NA

Therapist experience: experts

Supervision: NA (only during the training)

Modality: individual

Delivery: face-to-face

Treatment manualised: NA

2. Control (Treatment as usual). N = 92

Description of treatment: "TAU refers to the standard treatment provided to FEP patients. This in-
cludes pharmacological treatment and regular sessions with the assigned psychiatrist and a mul-
ti-disciplinary team in each centre. TAU includes physical care, career counselling, and the provi-
sion of unstructured information to families about disease symptoms, treatment, and prognosis."

Number of sessions: NA

Sessions frequency and duration: NA

Therapist: NA

Therapist experience: NA

Supervision: NA

Modality: NA

Delivery: NA

Treatment manualised: NA

Outcomes

Mental state - general - PANSS total endpoint (< 6 months)

Mental state - specific - PANSS positive endpoint (< 6 months)

Mental state - specific - PANSS negative endpoint (< 6 months)

Mental state - specific - Hamilton Depression endpoint (< 6 months)

Global state - CGI-S endpoint (< 6 months)

Global state - CGI-I endpoint (< 6 months)

Leaving the study early - for any reason (dropout) (< 6 months)

Funcitoning - GAF endpoint (< 6 months)

Functioning - FAST endpoint (< 6 months)

Notes

We contacted the authors but received no reply.

Haddock 1999 

Study characteristics

Methods

Study design: randomised controlled trial

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

65

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Haddock 1999  (Continued)

Cochrane Database of Systematic Reviews

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: 5 weeks + booster sessions at 1, 2, 3 and 4 months following discharge

Number of study arms: 2

Type of blinding: rater blind

Type of data analysis for overall efficacy: completers

Number of sites: NA

Number of countries: 1

Country: UK

Sponsorship source: NA

Trial registration ID: NA

Publication year: 1999

Researcher's allegiance: The authors developed the manual for both intervention and control.

Participants

Diagnosis: schizophrenia or schizoaffective disorder; diagnostic criteria: DSM-IV

Current clinical state: currently admitted to an acute general psychiatric ward for onset or relapse
of psychotic symptoms

Definition of stability: NA

Inclusion criteria: "The study inclusion criteria were:
1. DSM-IV (APA 1994) diagnosis of schizophrenia or schizo-affective disorder conﬁrmed by an inde-
pendent psychiatrist attached to the project
2. First treatment for psychosis less than 5 years ago
3. Currently admitted to an acute general psychiatric ward for
onset or relapse of psychotic symptoms"

Exclusion criteria: NA

Setting: inpatient

Special subgroup: acute (currently admitted to an acute general psychiatric ward for onset or re-
lapse of psychotic symptoms)

N: 21

Gender: 19 men, 2 women

Age: mean 29.1 years

CBT plus standard care arm: participants total: 10, participants male: 10, participants female: 0,
age: mean 28.1 years (SD = 7.24), age range: NA, duration of untreated psychosis: NA, % taking an-
tipsychotics: 100, baseline BPRS total M = 53, SD = 7, N = 8

Control arm: participants total: 11, participants male: 9, participants female: 2, age: mean 30 years
(SD = 7.9), age range: NA, duration of untreated psychosis: NA, % taking antipsychotics: 100, base-
line BPRS total M = 53.2, SD = 8.2, N = 10

Interventions

1. CBT plus standard care. N = 10

Description of treatment: "The cognitive-behavioural treatment followed a detailed treatment
manual designed by the authors and used in earlier CBT for psychosis research studies. It was pri-
marily focused on the treatment of auditory hallucinations and delusions, associated symptoms

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

66

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Haddock 1999  (Continued)

Cochrane Database of Systematic Reviews

and problems (for example, anxiety, depression, self-esteem) and relapse prevention. For some pa-
tients, psychotic symptoms rapidly remitted during the ﬁrst few days of their admission. In these
cases the cognitive-behavioural intervention was focused on relapse prevention, treatment of as-
sociated problems and enhancing medication adherence. Treatment was designed to follow a cog-
nitive-behavioural approach shown to be effective with chronic psychotic patients, and involved
the following elements:
1. Assessment and engagement
2. Formulation of key problems
3. Intervention directed at reducing the severity or occurrence of
key problems
4. Relapse prevention/keeping well
The following speciﬁc CBT strategies were used: formulation, guided discovery, symptom moni-
toring, exposure/focusing strategies for managing voices, hypothesis/reality testing, re-framing
attributions, rational responding, coping strategy enhancement, distraction techniques, anxiety
management, depression/self-esteem work, medication compliance/motivational interviewing,
schema work, relapse prevention and keeping well strategies. The booster
sessions involved review and consolidation of strategies used during inpatient sessions, with par-
ticular emphasis on keeping well strategies."

Number of sessions: 10.2 + 1.76 booster sessions

Sessions frequency and duration: twice monthly during inpatient stay, then monthly

Therapist: clinical psychologists

Therapist experience: experts

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: yes

2. Control (supportive counseling/psychoeducation treatment). N = 11

Description of treatment: "This treatment was also carried out according to a treatment manual
designed by the authors and was matched in terms of therapy time and therapist to the CBT treat-
ment. It aimed to control for non-speciﬁc aspects of therapy by delivering basic assessment, psy-
choeducation and counselling in a supportive, warm, genuine, empathic and unstructured style.
Speciﬁc techniques used involved: reﬂection, paraphrasing, summarising, feedback, avoidance of
criticism, information about schizophrenia, medication and side effects."

Number of sessions: 9.1 + 0.91 booster sessions

Sessions frequency and duration: twice monthly during inpatient stay, then monthly

Therapist: clinical psychologists

Therapist experience: NA

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: yes

Outcomes

Mental state - general - BPRS total endpoint (< 6 months)

Global state - number of participants that relapsed (> 1 year )

Service use - number of days in hospital (< 6 months, > 1 year)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

67

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Haddock 1999  (Continued)

Leaving the study early - for any reason (dropout) (< 6 months)

Notes

We contacted the authors but received no reply.

Hjorthoj 2013 (CapOpus) 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel

Antipsychotic medication allowed: yes

Duration in weeks: 26 weeks

Number of study arms: 2

Type of blinding: rater blind

Type of data analysis for overall efficacy: ITT

Number of sites: NA

Number of countries: 1

Country: Denmark

Sponsorship source: "supported by the Lundbeck Foundation, the Municipality of Copenhagen, the
Egmont Foundation, the Health Insurance Foundation, the Ministry of Social Welfare, Aase and Ej-
nar Danielsen’s Foundation and the Wørzner Foundation"

Trial registration ID: NCT 00484302

Publication year: 2013

Researcher's allegiance: no

Participants

Diagnosis: psychosis and cannabis use disorder; diagnostic criteria: ICD-10

Current clinical state: psychosis and cannabis use disorder

Definition of stability: psychosis and cannabis use disorder

Inclusion criteria: "ICD-10 schizophrenia spectrum psychosis (F2) ; cannabis use disorder (F12); age
18–35 years (chosen so as to yield more homogeneous groups for the planned group sessions; a
combination of slow influx of patients and interested participants just outside the inclusion age
range led us to modify this after 5 months of inclusion and include patients aged 17–42 years); resi-
dence in the Copenhagen area; not requiring an interpreter; and the ability and willingness to give
informed consent." We received data about participants with first episode from the authors.

Exclusion criteria: NA

Setting: both inpatient and outpatient

Special subgroup: cannabis use disorder

N: 36

Interventions

1. CBT plus standard care. With first episode: N = 18

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

68

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Hjorthoj 2013 (CapOpus)  (Continued)

Cochrane Database of Systematic Reviews

Description of treatment: "CapOpus was an add-on intervention to TAU, which all patients re-
ceived. Full details are given in the design paper (Hjorthøj 2008) and full protocol (www.capopus.d-
k). The intervention was based on the EPPIC manual, and was similar to the Midas trial (Hinton
2002; Barrowclough 2010)."

Number of sessions: Twenty-four sessions were planned and, on average, 16 were achieved

Sessions frequency and duration: 2 in first month, then 1 per month for 5 months

Therapist: "Addiction consultants were trained and experienced in motivational interviewing and
CBT. One consultant was a psychologist (handling 71% of participants), one a master student of
psychology, and one an occupational therapist."

Therapist experience: experts

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: yes

2. Control (Treatment as usual). With first episode: N = 18

Description of treatment: "TAU consisted of the treatment available to patients had they not par-
ticipated in the trial, provided by staff not employed by CapOpus. TAU was carried out in Opus,
CMHCs or ACT teams (Nordentoft 1996; Vendsborg 1999; Petersen 2005). No explicit manual exists
regarding co-occurring cannabis use disorder in TAU. Instead, these facilities primarily target the
psychotic disorder using both antipsychotic medication and methods such as CBT (but generally
not targeted at substance use)."

Number of sessions: NA

Sessions frequency and duration: NA

Therapist: NA

Therapist experience: NA

Supervision: NA

Modality: individual

Delivery: face-to-face

Treatment manualised: no

Outcomes

Mental state - general - PANSS total endpoint (< 6 months, < 12 months)

Mental state - specific - PANSS positive endpoint (< 6 months, < 12 months)

Mental state - specific - PANSS negative endpoint (< 6 months, < 12 months)

Quality of fife - MANSA (< 6 months, < 12 months)

Functioning - GAF endpoint (< 6 months, < 12 months)

Notes

We contacted the authors and obtained additional data.

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

69

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Jackson 2008 (ACE) 

Study characteristics

Methods

Study design: randomised controlled trial

Cochrane Database of Systematic Reviews

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: 14 weeks; assessment period: 15 months

Number of study arms: 2

Type of blinding: rater blind

Type of data analysis for overall efficacy: ITT

Number of sites: 1

Number of countries: 1

Country: Australia

Sponsorship source: public

Trial registration ID: NA

Publication year: 2008

Researcher's allegiance: The authors developed the manual for both intervention and control.

Participants

Diagnosis: primary psychotic diagnoses or first-episode psychosis; diagnostic criteria: Structured
Clinical Interview for DSM-IV-TR Axis 1 Disorders-Patient Edition (SCID)

Current clinical state: first episode of psychosis

Definition of stability: consecutive patients admitted to OYH within 4 weeks of their registration
with the service

Inclusion criteria: "EPPIC is a comprehensive treatment service for 15–25-year-old people experi-
encing a first episode of psychosis. It includes a 16-bed in-patient unit, an out-patient case man-
agement system, family work, accommodation, prolonged recovery programmes and tailored
group programmes (Edwards 2002)."

Exclusion criteria: "Patients were excluded (before randomisation) if any of the following criteria
were met: inability to speak English; intellectual disability (IQ < 70); psychosis due to a medical con-
dition; change to a non-psychotic diagnosis ; left the EPPIC catchment area; treatment from a pri-
vate psychiatrist/psychologist ; participating in a first-episode mania trial ; exhibiting violent be-
haviour; or being incarcerated (n = 111)."

Setting: both inpatient and outpatient (16-bed in-patient unit, an outpatient case management
system)

Special subgroup: first episode

N: 62

Gender: 45 men, 17 women

Age: mean 22.3 years

CBT plus standard care arm: participants total: 31, participants male: 19, participants female: 12,
age at start of treatment: mean 22.13 years (SD = 3.30), age at onset of psychosis: mean 21.58 years
(SD = 3.49), age range: 15-25 years, duration of illness: 0.55 years, duration of untreated psychosis:
83 days, % taking antipsychotics: NA, % diagnosis schizophrenia: 12.90, % diagnosis schizophreni-

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

70

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Jackson 2008 (ACE)  (Continued)

Cochrane Database of Systematic Reviews

form disorder: 41.94, % diagnosis schizoaffective disorder: 12.90, % diagnosis affective disorder:
19.35, % delusional/psychotic (NOS): 12.90, baseline BPRS total M = 47.74, SD = 10.84, N = 31

Control arm: participants total: 31, participants male: 26, participants female: 5, age at start of
treatment: mean 22.45 years (SD = 3.82), age at onset of psychosis: mean 21.67 years (SD = 4.20),
age range: 15-25 years, duration of illness: 0.78 years, duration of untreated psychosis: 107 days, %
taking antipsychotics: NA, % diagnosis schizophrenia: 12.90, % diagnosis schizophreniform disor-
der: 38.71, % diagnosis schizoaffective disorder: 9.68, % diagnosis affective disorder: 22.58, % delu-
sional/psychotic (NOS): 16.13, baseline BPRS total M = 50.19, SD = 10.82, N = 31

Interventions

1. CBT plus standard care. N = 31

Description of treatment: "ACE therapy involved an assessment of the presenting psychotic and
non-psychotic complaints followed by a formulation of the relationship between these complaints
and the participant’s life history. Problems were prioritized according to a flowchart that directed
the ACE therapy. Any issues of risk were considered a priority. Positive psychotic symptoms, if they
were present and distressing, were the next priority, followed by co-morbidities, negative symp-
toms, issues of identity and relapse prevention. Each area of difficulty was treated from a broad-
ly cognitive behavioural perspective. Ongoing engagement was essential throughout the therapy
process. This involved a flexible approach to the timing, location and content of therapy. For ex-
ample, therapy might have included going for a bike ride, or being conducted at the participant’s
home. The therapy was adapted from the work of Kingdon 1994, Chadwick 1996 and Fowler 1997.
It also drew on other cognitive work conducted at EPPIC that aimed to assist the adaptation of the
individual to psychosis (e.g. COPE; Henry 2002). A comprehensive description of ACE can be found
in the ACE manual (Bendall 2005)."

Number of sessions: 9 (SD = 4.93)

Sessions frequency and duration: up to 6 sessions (up to 20 sessions over 14 weeks) 45 minutes
each session (median time in therapy: 354 min)

Therapist: clinical psychologist

Therapist experience: experts (received 3 months of training in the treatments)

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: yes (ACE manual, Bendall 2005)

2. Control (Befriending). N = 31

Description of treatment: "Befriending aimed to control for time in therapy, participant expecta-
tions and positive experiences of therapy. Based on the Befriending therapy used by Sensky 2000,
Befriending consisted of talking about neutral topics that interested the participant, such as music,
sport, books, cooking and pets. If the participant found verbal interaction difficult, the participant
and therapist engaged in activities such as board games, walking, or playing sport, with a view to
using the activity as a tool to engage the participant in further neutral conversation during and af-
ter the activity. The therapist’s primary goals were to keep the participant engaged for the full du-
ration of therapy and to keep the conversation or activity as close to a neutral ‘pleasant chat’ as
possible. When emotionally loaded topics arose, such as symptoms or interpersonal problems, the
therapist gently redirected the participant to more neutral topics. Befriending was used in this trial
because it was directive; thus, therapists could control the conversation and redirect acutely psy-
chotic participants from unstructured discussion of their psychotic symptoms, which may have
been detrimental to them."

Number of sessions: 7.21 (SD = 5.17) up to 6 sessions (up to 20 sessions over 14 weeks)

Sessions frequency and duration: up to 6 sessions per month (up to 20 sessions over 14 weeks) 45
minutes each session (median time in therapy: 174 min)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

71

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Jackson 2008 (ACE)  (Continued)

Therapist: clinical psychologist

Therapist experience: experts (received 3 months of training in the treatments)

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: yes (Befriending manual, Bendall 2003)

Outcomes

Mental state - general - BPRS total endpoint (< 6 months)

Mental state - specific - BPRS positive endpoint (< 6 months, > 1 year)

Mental state - SANS endpoint (< 6 months, > 1 year)

Mental state - CESD-R endpoint (< 6 months)

Service use - admission to hospital (> 1 year)

Service use - number of days in hospital (> 1 year)

Leaving the study early - for any reason (dropout) (< 6 months, > 1 year)

Functioning - SOFAS endpoint (< 6 months, > 1 year)

Mortality - Mortality due to suicide (> 1 year)

Notes

We contacted the authors and obtained additional data.

Jackson 2009 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: 26 treatment phase, 52 w follow-up

Number of study arms: 2

Type of blinding: rater blind

Type of data analysis for overall efficacy: ITT

Number of sites: 4

Number of countries: 1

Country: UK

Sponsorship source: public

Trial registration ID: ISRCTN43585723

Publication year: 2009

Researcher's allegiance: The authors developed the manual for the intervention group.

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

72

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Jackson 2009  (Continued)

Cochrane Database of Systematic Reviews

Participants

Diagnosis: first episode of non-affective psychosis; diagnostic criteria: ICD-10

Current clinical state: NA

Definition of stability: NA

Inclusion criteria: "Patients with a ﬁrst episode of non-affective psychosis conforming to ICD-10 cri-
teria (F20, F22, F23, F25) as veriﬁed by experienced Consultant Psychiatrists were recruited from
four Mental Health Services throughout the West Midlands in the UK. The four sites served a to-
tal catchment area of approximately 1.5 million. All candidates for inclusion to the study were re-
quired to have experienced a ﬁrst episode of psychosis within the previous 6–18 months and were
aged between 16 and 35 years old."

Exclusion criteria: "Patients were not admitted to the study if they could not speak English or were
unable to give informed consent."

Setting: NA

Special subgroup: NA

N: 66

Gender: 49 men, 17 women

Age: mean 23.3 years (SD = 4.6)

CBT plus standard care arm: participants total: 36, participants male: 31, participants female: 5,
age: mean 24.1 years (SD = 4.7), age range: 16-38 years, duration of untreated psychosis: 17.4 weeks
(SD = 25.9), % taking antipsychotics: 86, baseline PANSS total M = 56.6, SD = 9.07, N = 36

Control arm: participants total: 30, participants male: 18, participants female: 12, age: mean 22.3
years (SD = 4.4), age range: 16-31 years, duration of untreated psychosis: 23.7 weeks (SD = 58.4), %
taking antipsychotics: 96.6, baseline PANSS total M = 55.6, SD = 10.18, N = 30

Interventions

1. CBT (cognitive therapy based recovery intervention (CRI)) plus standard care. N = 36

Description of treatment: "The cognitive therapy based recovery intervention (CRI) was designed
to be delivered on a weekly basis over a 6 month period (i.e. it was limited to a maximum of 26 ses-
sions) and followed a protocol based modular approach. In essence, the intervention arose from
an individual formulation, which was translated, into an ‘‘individual recovery plan’’. This approach
has been described previously in more detail in Jackson 2000. There were three key components:
(a) engagement and formulation; (b) trauma processing; and (c) appraisals of psychotic illness
(shame, loss and entrapment). The intervention, therefore, is not just designed for those who could
be described as ‘traumatised’ by their experiences of psychosis. It is intended to be helpful for all
ﬁrst episode patients adjusting to and recovering from a ﬁrst episode of psychosis. All participants
completed the core component (engagement and formulation) and those pertinent to their prob-
lem list and goals (i.e. trauma processing and/or addressing appraisals of shame, loss and/or en-
trapment). Trauma processing evolved from the exploration of the primary appraisals of the ﬁrst
episode of psychosis including their symptoms (voices, paranoia), their management (hospital ad-
mission) and the social context in which they occurred (interpersonal reactions of others). A re-
lapse prevention framework; ‘back in the saddle’ (Plaistow 1996) was used to aid this process. Ap-
praisals of psychotic illness and its consequences were explored within the context of social rank
theory as giving rise to shame (emotional reaction to perceived reduction of status or social rank;
Gilbert 2003b), loss (of a valued role or goal) and/or entrapment (‘blocked escape’ or an inability to
reafﬁrm an identity or sense of belonging; Rooke 1998)." "Standard cognitive therapy techniques
(Socratic questioning, guided discovery, identifying and targeting beliefs and behaviours, develop-
ing alternative beliefs and reinforcing through behavioural change etc) were utilised in order to af-
fect change in these appraisals."

Number of sessions: 26 planned, 13 actually done (median)

Sessions frequency and duration: 4 per month

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

73

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Jackson 2009  (Continued)

Therapist: four clinical psychologists and a cognitive behavioural psychotherapist

Therapist experience: experts

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: yes

2. Control (Treatment as usual). N = 30

Description of treatment: NA

Number of sessions: NA

Sessions frequency and duration: NA

Therapist: NA

Therapist experience: NA

Supervision: NA

Modality: NA

Delivery: NA

Treatment manualised: NA

Outcomes

Mental state - specific - CDS endpoint (< 6 months, < 12 months)

Leaving the study early - for any reason (dropout) (< 6 months, < 12 months)

Notes

We attempted to contact the authors but it was not possible to retrieve a valid contact.

Jolley 2003 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: unclear duration of treatment, assessment at 6 months

Number of study arms: 2

Type of blinding: rater blind

Type of data analysis for overall efficacy: completers

Number of sites: NA

Number of countries: 1

Country: UK

Sponsorship source: other

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

74

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Jolley 2003  (Continued)

Trial registration ID: NA

Publication year: 2003

Researcher's allegiance: NA

Cochrane Database of Systematic Reviews

Participants

Diagnosis: schizophrenia spectrum disorder; diagnostic criteria: ICD-10

Current clinical state: NA

Definition of stability: NA

Inclusion criteria: "an ICD-10 schizophrenia spectrum disorder diagnosed < 5 years ago; 1st or 2nd
episode (neither episode longer than 9 months duration); symptoms present within the previous 3
months, but not necessarily at entry."

Exclusion criteria: "known organic aetiology; and alcohol or substance misuse as a primary diagno-
sis."

Setting: both inpatient and outpatient

Special subgroup: NA

N: 21

Gender: 13 men, 8 women

Age: mean 28.1 years (SD = 7.38 years)

CBT plus standard care arm: participants total: 12, participants male: 8, participants female: 4, age:
mean 25.1 years (SD = 6.2), age range: 16-65 years, % diagnosis schizophrenia: 33.3, % diagnosis
schizoaffective disorder: 8.3, % diagnosis unspecified non-organic: 25.0, % diagnosis non-organic:
8.3, % diagnosis persistent delusional disorder: 25.0, baseline PANSS total M = NA, SD = NA, N = NA

Control arm: participants total: 9, participants male: 5, participants female: 4, age: mean 32.0 years
(SD = 7.23), age range: 16-65 years, % diagnosis schizophrenia: 22.2, % diagnosis schizoaffective
disorder: 0, % diagnosis unspecified non-organic: 44.4, % diagnosis non-organic: 33.3, % diagnosis
persistent delusional disorder: 0, baseline PANSS total M = NA, SD = NA, N = NA

Interventions

1. CBT plus standard care. N = 12

Description of treatment: "The CT comprised 18 sessions over 6 months and was adapted to place
more emphasis on areas identified in pre-pilot clinical work as important in early psychosis. These
were i) processing the experiences of psychosis, and often of admission to hospital or other contact
with services; Jackson 1996 work identifies a high prevalence of post-traumatic stress symptoma-
tology following the initial psychotic episode; ii) making sense of these experiences in the context
of a personal formulation, with emphasis on developing as non-stigmatizing as possible a view of
the person’s difficulties; iii) coming to terms with the impact of psychosis on the person’s life – the
losses and changes and the impact on the sense of self, the future, and relationships. Generating
optimistic but realistic plans for the future, and discussing the possible course of the illness, and
what this may mean in terms of future contact with services and care of self, but with an empha-
sis on recovery; iv) emphasis on the preservation, to the greatest extent possible, of social, occupa-
tional and educational links or rapid re-engagement in community activities."

Number of sessions: 18 sessions over 6 months planned; mean number of sessions at 6 months:
11.0 (SD = 4.7, range: 5-17; median: 11)

Sessions frequency and duration: NA

Therapist: clinical psychologist

Therapist experience: experts

Supervision: yes

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

75

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Jolley 2003  (Continued)

Modality: individual

Delivery: face-to-face

Cochrane Database of Systematic Reviews

Treatment manualised: yes (details in treatment manual by Fowler 1995)

2. Control (Treatment as usual). N = 9

Description of treatment: "Treatment as usual (TAU) was predominantly medical and social and
varied from reasonably intensive community follow-up from a team, including home visits, family
contact and individual meetings to outpatient follow-up only."

Number of sessions: NA

Sessions frequency and duration: NA

Therapist: NA

Therapist experience: NA

Supervision: NA

Modality: individual

Delivery: face-to-face

Treatment manualised: NA

Outcomes

Mental state - general - PANSS total endpoint (> 6 months)

Mental state - general - PANSS total change (< 6 months)

Mental state - specific - PANSS positive endpoint (< 6 months)

Mental state - specific - PANSS positive change (< 6 months)

Mental state - specific - PANSS negative endpoint (< 6 months)

Mental state - specific - PANSS negative change (< 6 months)

Mental state - specific - CDS endpoint (< 6 months)

Mental state - specific - CDS change (< 6 months)

Service use - admission to hospital (< 6 months)

Service use - number of days in hospital (< 6 months)

Leaving the study early - for any reason (dropout) (< 6 months)

Notes

We contacted the authors and obtained additional data.

Lecomte 2008 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: 13 w treatment, 39 w and 65 w follow-up

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

76

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lecomte 2008  (Continued)

Cochrane Database of Systematic Reviews

Number of study arms: 3

Type of blinding: rater blind

Type of data analysis for overall efficacy: ITT

Number of sites: 6

Number of countries: 1

Country: Canada

Sponsorship source: public

Trial registration ID: NCT00358709

Publication year: 2008

Researcher's allegiance: The authors developed the manual for both intervention and control.

Participants

Diagnosis: persistent or fluctuating psychotic symptoms; diagnostic criteria: NA

Current clinical state: stable

Definition of stability: considered “stabilised” by their psychiatrist

Inclusion criteria: "Potential participants were recruited from Early Psychosis Intervention pro-
grams and community mental health clinics in Quebec and British Columbia, Canada (...). Individ-
uals were eligible if aged between 18 and 35, ﬂuent (verbally as well as reading and writing skills)
in one of the ofﬁcial languages (English and French), currently presenting with persistent or ﬂuc-
tuating psychotic symptoms (deﬁned as delusions or hallucinations appearing occasionally, such
as in periods of stress), having consulted for the ﬁrst time a mental health professional for psychot-
ic symptoms in the past 2 years, and being followed by a psychiatrist (and therefore receiving an-
tipsychotic medication). Individuals were only recruited once they had been discharged from the
hospital and considered “stabilized” by their psychiatrist. Nonaffective psychosis was preferred but
individuals with unclear diagnoses at the time of the referral were also accepted."

Exclusion criteria: "Exclusion criteria included suffering from an organic disorder, having already
received one of the interventions, and not being able to give informed consent."

Setting: outpatient

Special subgroup: first episode, stable, positive symptoms

N: 129

Gender: 93 men, 36 women

Age: mean 24.76 years

CBT plus standard care arm: participants total: 48, participants male: 31, participants female: 17,
age: mean 24.92 years, age range: 18-35 years, duration of illness: 3.22 years, % taking antipsy-
chotics: 100, % diagnosis schizophrenia: 53.6, % mood disorder with psychotic features: 21.4, %
psychosis NOS: 25, baseline BPRS total M = 42.7, SD = 12.9, N = 48

Control arm (group social skills training): participants total: 54, participants male: 40, participants
female: 14, age: mean 25.44 years, age range: 18-35 years, duration of illness: 3.44 years, % taking
antipsychotics: 100, % diagnosis schizophrenia: 58.7, % mood disorder with psychotic features:
20.8, % psychosis NOS: 20.8, baseline BPRS total M = 41, SD = 14.65, N = 54

Waiting list: participants total: 27, participants male: 22, participants female: 5, age: mean 23.1
years, age range: 18-35 years, duration of illness: 1.4 years, % taking antipsychotics: 100, % diag-
nosis schizophrenia: 54.4, % mood disorder with psychotic features: 17.1, % psychosis NOS: 28.5,
baseline BPRS total M = 41.3, SD = 10.11, N = 27

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

77

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Lecomte 2008  (Continued)

Interventions

1. CBT plus standard care (group CBT). N = 48

Description of treatment: "The CBT manual was developed by 3 of the authors (...) and integrates
the principles and philosophy of individual CBT for psychosis, but adapted to a group format
and tailored for ﬁrst episodes. A detailed description of the intervention is described elsewhere
(Lecomte 2003). The manual is built in 4 parts: (1) stress: how it affects me; (2) testing hypotheses
and looking for alternatives, (3) drugs, alcohol, and how I feel; and (4) coping and competence. The
manual follows a positive approach (rather than problem based) with speciﬁc emphasis on reach-
ing personal goals, decreasing distress, and ﬁnding what works best for them; with the clients’ be-
ing the experts of their experience and the therapists acting as guides. The participants also learn
to understand and use CBT techniques such as normalization, the ABC’s of CBT (linking events to
thoughts and emotional and behavioral consequences), Socratic questioning, checking the facts,
ﬁnding alternatives, trying new coping strategies, and modifying attributions."

Number of sessions: 24

Sessions frequency and duration: 8 per month

Therapist: occupational therapists, nurse, psychologist, social worker

Therapist experience: average of six years of experience working with individuals with psychosis,
though none had previous training in CBT for psychosis. The therapists received two days of inten-
sive training.

Supervision: yes

Modality: group

Delivery: face-to-face

Treatment manualised: yes

2. Control (Group social skills training). N = 54

Description of treatment: "Social skills training is recognized as an evidence-based intervention
for acquiring skills necessary to live in the community (Kopelowicz 2006) and includes teaching
skills such as symptom management and relapse prevention. The manual used in this study was
the Symptom Management (SM) module developed by UCLA Psychiatric Rehabilitation Consul-
tants (Liberman 1988). The treatment aims at building 4 skill areas: (1) identifying warning signs of
relapse, (2) managing warning signs, (3) coping with persistent symptoms, and (4) avoiding alco-
hol and street drugs. Each section follows the exact same format: introduction to skill area, video-
tape questions and answers, roleplays, resource management, outcome problems (problem solv-
ing), in vivo exercises, and homework assignments. The intervention varies from the CBT interven-
tion in many ways, namely by its prescriptive approach to encouraging the appropriate behaviors
to diminish or cope with symptoms. The therapists are instructed to model appropriate interaction
styles and behaviors, and to teach clients how to effectively use the skills by using repetition and
encouragements. Though the manual was developed for more chronic clients, with one of the au-
thors (...), it was revised to eliminate any references to chronicity or diagnoses."

Number of sessions: 24

Sessions frequency and duration: 8 per month and NA duration

Therapist:occupational therapists, nurse, psychologist, social worker

Therapist experience: NA

Supervision: yes

Modality: group

Delivery: face-to-face

Treatment manualised: yes

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

78

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Lecomte 2008  (Continued)

3. Control (waiting list). N = 27

Description of the treatment: "Clients in the control group could receive 1 of the 2 treatments,
should they still wish to, after being in the study for a minimum of 9 months."

Outcomes

Mental state - general - BPRS endpoint (< 6 months, < 12 months)

Mental state - specific - number of participants with clinically important change in mental state (< 6
months, < 12 months)

Mental state - BPRS positive endpoint (< 6 months, < 12 months)

Mental state - BPRS negative endpoint (< 6 months, < 12 months)

Leaving the study early - for any reason (dropout) (< 6 months, < 12 months, > 1 year)

Notes

We contacted the authors and obtained additional information.

Lepage 2022 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: 13 weeks intervention phase, 26 weeks follow-up, 39 weeks follow-up

Number of study arms: 2

Type of blinding: rater blind

Type of data analysis for overall efficacy: ITT

Number of sites: 5

Number of countries: 1

Country: Canada

Sponsorship source: public

Trial registration ID: NCT02294409

Publication year: 2022

Researcher's allegiance: The authors developed the manual for both intervention and control.

Participants

Diagnosis: Psychotic disorder; diagnostic criteria: no information

Current clinical state: stable

Definition of stability: Exclusion criteria comprised: currently clinically unstable, defined as the
presence of positive symptoms that are moderate-to-severe on the SAPS rating scale

Inclusion criteria: "Participants within the first 2 years of treatment following the onset of a psy-
chotic disorder were recruited from these programs. Inclusion criteria were: a diagnosis of a psy-
chotic disorder; aged 18–35; ability to read and write English or French at an inter- mediate level
(Education > 8 years); scores above predetermined cut-offs on the three measures of SA [34 for the
Social Interaction Anxiety Scale (Mattick 1998), 20 for the Social Phobia Inventory (Connor 2000)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

79

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lepage 2022  (Continued)

Cochrane Database of Systematic Reviews

and 21 for the Brief Social Phobia Scale (Davidson 1991)]; and meet criteria for the diagnosis of SA
disorder as determined with the SCID social phobia module."

Exclusion criteria: "Exclusion criteria comprised: currently clinically unstable, defined as the pres-
ence of positive symptoms that are moderate to severe on the SAPS rating scale; IQ < 70; hospital-
ized at the time of recruitment; current diagnosis of substance dependence; lifetime history of a
neurological condition."

Setting: outpatient

Special subgroup: first episode, stable, social anxiety

N: 96

Gender: 63 men, 33 women

Age: mean 24.62 years

CBT plus standard care arm: participants total: 51, participants male: 31, participants female: 20,
age: mean 25.33 years (SD = 4.39), age range: 18-35 years, duration of illness: 1.56 years (SD = 1.46),
% taking antipsychotics: NA, % diagnosis schizophrenia: 19.6, % diagnosis schizophreniform disor-
der: 13.7, % diagnosis schizoaffective disorder: 5.9, % diagnosis delusional disorder: 2, % diagnosis
bipolar disorder: 13.7, % diagnosis affective disorder: 7.8

Control arm: participants total: 45, participants male: 32, participants female: 13, age: mean 23.82
years (SD = 4.36), age range: 18-35 years, duration of illness: 1.44 years (SD = 1.5), % taking antipsy-
chotics: NA, % diagnosis schizophrenia: 24.4, % diagnosis schizophreniform disorder: 15.5, % diag-
nosis schizoaffective disorder: 8.9, % diagnosis delusional disorder: 0, % diagnosis bipolar disor-
der: 11.1, % diagnosis affective disorder: 6.7

Interventions

1. CBT (group CBT for SA) plus standard care. N = 51

Description of treatment: "All CBT-SA sessions were conducted in either English or French by
trained clinicians with the aid of a group CBT-SA manual that is described in Montreuil 2016. This
intervention was delivered by a therapist (doctoral-level psychologist) and a co-therapist under the
supervision of an experienced CBT therapist (...). This intervention included the five following mod-
ules: (i) Psychoeducation on SA disorder, stress, psychosis and self- stigma; (ii) Cognitive restruc-
turing: identifying negative thoughts that occur before, during, or after anxiety-provoking situa-
tions; (iii) Social Skills training, which provided an opportunity to practice interpersonal skills; (iv)
Exposure component, which focused on the collection of information that would allow patients to
revise their judgments about the degree of risk to which they are exposed in feared situations, and
would challenge their dysfunctional beliefs; and (v) Relapse prevention and maintenance. Each of
the 13 group sessions consisted of 4–8 participants and lasted for 1.5 h each. One session per week
was provided for the 13-week period."

Number of sessions: 13

Sessions frequency and duration: 4 per month and 90 minutes

Therapist: doctoral level psychologist and co-therapist

Therapist experience: experts

Supervision: yes

Modality: group

Delivery: face-to-face

Treatment manualised: no information

2. Control (Computer-Assisted Cognitive Remediation Group Therapy (CR)). N = 45

Description of treatment: "This group intervention developed by Bowie 2012 devotes approximate-
ly 60% of the session to cognitive training activities on a computer, 20% to documenting and at-

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

80

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lepage 2022  (Continued)

Cochrane Database of Systematic Reviews

tempting new strategies for solving problems (‘strategic monitoring’), and 20% to doing ‘transfer
activities’, which consist of simulated real-world activities and discussion of how cognitive strate-
gies might be applied in everyday life and potential compensatory strategies for overcoming cogni-
tive challenges. This approach specifically targets processing speed, attention, memory, and exec-
utive function because they are domains that are commonly impaired in psychosis."

Number of sessions: 13

Sessions frequency and duration: 4 per month and 90 minutes

Therapist: therapist and co-therapist

Therapist experience: NA

Supervision: NA

Modality: group

Delivery: face-to-face

Treatment manualised: yes

Outcomes

Mental state - specific - SAPS endpoint (< 6 months, < 12 months)

Mental state - specific - SANS endpoint (< 6 months, < 12 months)

Mental state - specific - CDS (< 6 months, < 12 months)

Service use - admission to hospital (< 6 months)

Leaving the study early - for any reason (< 6 months)

Functioning - SOFAS endpoint (< 6 months, < 12 months)

Notes

We contacted the authors but received no reply.

Lewis 2002 (SOCRATES) 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: 5-week CBT programme plus community-based booster sessions (with an 18-
month follow-up)

Number of study arms: 3

Type of blinding: rater blind

Type of data analysis for overall efficacy: ITT

Number of sites: 11

Number of countries: 1

Country: England

Sponsorship source: public

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

81

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lewis 2002 (SOCRATES)  (Continued)

Trial registration ID: ISRCTN65818527

Publication year: 2022

Researcher's allegiance: NA

Cochrane Database of Systematic Reviews

Participants

Diagnosis: schizophrenia, schizophreniform disorder, schizoaffective disorder or delusional disor-
der; diagnostic criteria: DSM-IV

Current clinical state: NA

Definition of stability: NA

Inclusion criteria: "Inclusion criteria for subjects to enter the trial were: (a) either first or second ad-
mission (within 2 years of a first admission) to in-patient or day patient unit for treatment of psy-
chosis; (b) DSM–IV criteria for schizophrenia, schizophreniform disorder, schizoaffective disorder or
delusional disorder (APA 1994); (c) positive psychotic symptoms for 4 weeks or more; (d) score of 4
or more (moderate or severe) on the PANSS (Kay 1989) target item either for delusions (P1) or hallu-
cinations (P3)"

Exclusion criteria: "neither substance misuse nor organic disorder judged to be the major cause of
psychotic symptoms."

Setting: both inpatient and outpatient

Special subgroup: NA

N: 309

Gender: 216 men, 93 women

Age: median 24.4 years

CBT plus standard care arm: participants total: 101, participants male: 72, participants female: 29,
age: median 29.1 years, age range: 18-65 years, % taking antipsychotics: NA, % diagnosis schizo-
phrenia: 32.6, % diagnosis schizoaffective disorder: 16.8, % diagnosis schizophreniform: 37.6, % di-
agnosis delusional disorder: 10.9, % psychosis NOS: 2, baseline PANSS total M = 87.47, SD = 17.64, N
= 101

Control (supportive counselling + treatment-as-usual): participants total: 106, participants male:
75, participants female: 31, age: median 27.2 years, age range: 18-65 years, % taking antipsychotics:
NA, % diagnosis schizophrenia: 45, % diagnosis schizoaffective disorder: 7.5, % diagnosis schizo-
phreniform: 35.8, % diagnosis delusional disorder: 10.4, % psychosis NOS: 2, baseline PANSS total
M = 89.22, SD = 17.53, N = 106

Control (treatment-as-usual): participants total: 102, participants male: 69, participants female: 33,
age: median 27 years, age range: 18-65 years, % taking antipsychotics: NA, % diagnosis schizophre-
nia: 41.2, % diagnosis schizoaffective disorder: 13.7, % diagnosis schizophreniform: 32.4, % diagno-
sis delusional disorder: 6.9, % psychosis NOS: 5.9, baseline PANSS total M = 87.01, SD = 16.81, N =
102

Interventions

1. CBT plus standard care. N = 101

Description of treatment: "In summary, treatment was conducted in four stages. The first stage was
engagement and a detailed assessment of mental state and symptom dimensions (psychotic and
nonpsychotic) to allow a cognitive–behavioural analysis of how symptoms might relate to cogni-
tions, behaviour and coping strategies. Education about the nature and treatment of psychosis, us-
ing a stress vulnerability model to link biological and psychological mechanisms, was used to help
engagement. Second, a problem list was generated collaboratively with the patient. This was then
prioritised according to the degree of distress attached, feasibility and, where relevant, clinical risk
involved. Prioritised problems were assessed in detail and a formulation was agreed which includ-
ed such issues as trigger situations and cognitions. Third and fourth stages were intervention and
monitoring. Interventions particularly addressed positive psychotic symptoms of delusions and

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

82

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lewis 2002 (SOCRATES)  (Continued)

Cochrane Database of Systematic Reviews

hallucinations, generating alternative hypotheses for abnormal beliefs and hallucinations, identify-
ing precipitating and alleviating factors and reducing associated distress."

Number of sessions: 16.1

Sessions frequency and duration: 5-week treatment envelope (3-5 times per week up to 5 weeks),
total therapy time: mean 8.6 hours; planned: 180-240 min (15-20 hours within a 5-week treatment
envelope, plus "booster" sessions at a further 2 weeks and 1, 2 and 3 months)

Therapist: 5 therapists (3 clinical psychologists and 2 nurse therapists)

Therapist experience: experts

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: yes

2. Control (Supportive counselling + treatment as usual). N = 106

Description of treatment: "Supportive counselling was used as a comparison intervention to con-
trol for non-specific elements of therapist exposure. It was delivered in the same 5-week format
with three boosters, with the aim of matching the duration of total therapist contact time to that
in the CBT arm. The supportive counselling was also manual-based and supervised by an experi-
enced counsellor. The same five research therapists administered both CBT and supportive coun-
selling interventions, according to randomisation. Interventions were started within 3 days of ran-
domisation. Patients were seen in hospital settings, family practitioner surgeries and in their own
homes for treatment sessions. All treatment sessions, both for CBT and supportive counselling,
were audiotaped where consent was given. After the acute phase of the study was completed, a
random selection of 50 tapes were rated blindly by two independent raters, who were asked to
classify them as CBT or supportive counselling sessions and to rate the quality of therapy on the
Cognitive Therapy Scale for Psychosis (CTS–Psy; Haddock 2001)."

Number of sessions: mean 15.7

Sessions frequency and duration: 5-week with three boosters (3-5 times per week up to 5 weeks),
total therapy time: mean 7.1 hours; "It was delivered in the same 5-week format with three boost-
ers, with the aim of matching the duration of total therapist contact time to that in the CBT arm."

Therapist: 5 therapists (3 clinical psychologists and 2 nurse therapists)

Therapist experience: experts

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: yes

3. Control (treatment-as-usual). N = 102

Description of treatment: "Procedures to standardise routine clinical care, including drug treat-
ment, were not used". "This means that the content of "routine care" is not specifiable, except that
it always included day or in-patient treatment and included antipsychotic drugs."

Number of sessions: NA

Sessions frequency and duration: NA

Therapist: NA

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

83

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lewis 2002 (SOCRATES)  (Continued)

Therapist experience: NA

Supervision: NA

Modality: NA

Delivery: NA

Treatment manualised: NA

Cochrane Database of Systematic Reviews

Outcomes

Mental state - general - PANSS total endpoint (< 6 months, > 12 months)

Mental state - specific - PANSS positive endpoint (< 6 months, > 12 months)

Mental state - specific - PANSS negative endpoint (< 6 months, > 12 months)

Global state - number of participants that relapsed (> 1 year)

Service use - admission to hospital (> 1 year)

Leaving the study early - for any reason (dropout) (< 6 months, > 1 year)

Mortality - overall mortality (> 1 year)

Mortality - mortality due to natural causes (> 1 year)

Notes

Liu 2019 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: 10 weeks treatment phase, then data collection also at 36 m and 62 m follow-up

Number of study arms: 2

Type of blinding: rater blind

Type of data analysis for overall efficacy: ITT

Number of sites: 1

Number of countries: 1

Country: China

Sponsorship source: public

Trial registration ID: ChiCTR-TRC-13003929

Publication year: 2019

Researcher's allegiance: no

Participants

Diagnosis: schizophrenia; diagnostic criteria: DSM-IV

Current clinical state: first episode, with positive symptoms

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

84

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Liu 2019  (Continued)

Definition of stability: NA

Cochrane Database of Systematic Reviews

Inclusion criteria: "(1) A diagnosis of schizophrenia as assessed by experienced research psychia-
trists using the Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version; (2) Age
between 16–45 years; (3) The current illness episode was their ﬁrst episode of schizophrenia, and
any continuous treatment had been for less than 1 month or was inadequate treatment of less than
3 months veriﬁed through clinical interview and medical chart review; (4) Use of a single atypical
antipsychotic drug for at least two weeks; (5) A score of 4 or more on the delusion (P1) or hallucina-
tion (P3) symptom scales of the Positive and Negative Syndrome Scale (PANSS); (6) Their ﬁrst psy-
chotic symptoms had occurred less than 3 years ago."

Exclusion criteria: "(1) Co-morbid diagnosis of mental disability or primary substance dependence;
(2) Inability to communicate, or lack of spontaneity and ﬂow of conversation (5 or above on PANSS
in conceptual disorganization); (3) Electroconvulsive therapy within the 1 month prior to entry into
the study; (4) Serious or unstable physical health condition; (5) Currently receiving any other form
of systematic psychotherapy."

Setting: outpatient

Special subgroup: NA

N: 80

Gender: 46 men, 34 women

Age: mean 27.48 years

CBT plus standard care arm: participants total: 40, participants male: 26, participants female: 14,
age: mean 26.35 years, age range: 16-45 years, % taking antipsychotics: 100, % diagnosis schizo-
phrenia: 100, baseline PANSS total M = 68.48, SD = 15.67, N = 40

Control arm: participants total: 40, participants male: 20, participants female: 20, age: mean 28.6
years, age range: 16-45 years, % taking antipsychotics: 100, % diagnosis schizophrenia: 100, base-
line PANSS total M = 69.07, SD = 16.33, N = 40

Interventions

1. CBT plus standard care. N = 40

Description of treatment: "The main goals of this intervention were to apply the general principles
of CBT, such as case formulation, goal setting, homework and the cognitive process and behavior
experiment, with a focus on treatment of relapse prevention and primary positive symptoms. The
intervention can be divided into three stages. In the ﬁrst stage, therapists built a good rapport with
patients, assessed patients’ life experiences, and developed patients’ problem list. In the interme-
diate stage, patients primarily learnt how to manage positive symptoms (such as delusions, hallu-
cinations, thought disorder) via behavioural experiments, graded exposure, reattribution of symp-
toms and coping strategies. Emotional problems were also discussed. In the last stage, therapists
focused on stress management, problem solving and medication adherence, as well as relapse pre-
vention. Patients in stress management sessions discussed predisposing factors, stressors (e.g.
sleep deprivation, trauma and posttraumatic stress symptoms), protective factors (e.g. social skills,
social support and help seeking) and risk factors (e.g. social isolation, substance abuse). In relapse
prevention sessions, patients learned: 1) 6 stages of relapse (quiet period, stress period, hopeless
period, loss of control period, mental confusion and psychotic symptom occurrence); 2) the ear-
ly signs of relapse; 3) how to make their own list of signs of relapse with unique features; 4) how to
monitor their symptoms in daily life; 5) how to make emergency plans for early warning signs in-
cluding grading signs, prevention strategies and plans for seeking help. At the beginning of each
session, therapists reviewed patients’ homework to ensure patients had mastered the skills cov-
ered in previous sessions. In addition, all participants received treatment as usual; patients were
seen monthly by a psychiatrist across the duration of the trial."

Number of sessions: 10 planned, 7.4 (mean) actually done

Sessions frequency and duration: 4 sessions per month; 45 minute duration

Therapist: psychologist (delivered the CBT), psychiatrist (once a month)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

85

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Liu 2019  (Continued)

Cochrane Database of Systematic Reviews

Therapist experience: experts

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: yes

2. Control (Treatment as usual). N = 40

Description of treatment: "TAU included medication and case management (including some psy-
chological health education and social support). Psychiatrists evaluated all patients and formulat-
ed appropriate drug treatment, and saw patients and their family members in the outpatient unit
each month, in order to supervise and encourage medication adherence and provide guidance to
family members on managing adverse drug reactions. When patients presented with impulsive-
ness or serious adverse drug reactions, psychiatrists initiated an emergency response mechanism."
"In addition, all participants received treatment as usual; patients were seen monthly by a psychia-
trist across the duration of the trial."

Number of sessions: NA

Sessions frequency and duration: 1 per month

Therapist: psychiatrist

Therapist experience: NA

Supervision: no

Modality: individual and family

Delivery: face-to-face

Treatment manualised: no

Outcomes

Mental state - general - PANSS total endpoint (< 6 months, < 12 months, > 1 year)

Mental state - general - PSYRATS endpoint (< 6 months, < 12 months, > 1 year)

Mental state - specific - number of participants with clinically important change in mental state (> 1
year)

Mental state - specific - participants with change in positive symptoms (< 6 months, < 12 months, >
1 year)

Mental state - specific - PANSS positive endpoint (< 6 months, < 12 months, > 1 year)

Mental state - specific - PANSS negative endpoint (< 6 months, < 12 months, > 1 year)

Global state - number of participants that relapsed (< 6 months, < 12 months, > 1 year)

Service use - admission to hospital (< 6 months, < 12 months, > 1 year)

Leaving the study early - for any reason (dropout) (< 6 months, < 12 months, > 1 year)

Functioning - PSP endpoint (< 6 months, < 12 months, > 1 year)

Adverse events - non-compliance (< 6 months, < 12 months, > 1 year)

Notes

We contacted the authors but received no reply.

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

86

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Madigan 2013 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Cochrane Database of Systematic Reviews

Duration in weeks: 18 weeks (12 weeks plus a "booster" session 6 weeks later); reevaluation at 3
months and 1 year

Number of study arms: 2

Type of blinding: rater blind

Type of data analysis for overall efficacy: ITT

Number of sites: 3

Number of countries: 1

Country: Ireland

Sponsorship source: public

Trial registration ID: NA

Publication year: 2013

Researcher's allegiance: no

Participants

Diagnosis: diagnosis of psychosis with comorbid substance dependence; diagnostic criteria: DSM-
IV

Current clinical state: patients either experiencing their first psychotic episode or within 3 years fol-
lowing the onset of non-affective or affective psychosis

Definition of stability: NA

Inclusion criteria: "The subjects were 88 patients who were either experiencing their first psychot-
ic episode or within 3 years following the onset of non-affective or affective psychosis and who had
presented to (i) the DETECT first-episode psychosis service in South County Dublin/North Wick-
low (population 375,000), (ii) the National Drug Treatment Centre Board in Dublin city center, or
(iii) Cavan–Monaghan Mental Health Service (population 109,000); the study was approved by the
Provincial Ethics Committee of the St. John of God Hospitaller Services, the Research Ethics Com-
mittee for the National Drug Treatment Centre Board and the Research Ethics Committee of the
Health Service Executive Dublin North East Area, respectively. The recruitment procedure involved
a poster and media campaign, including appearance on a prime-time current affairs television pro-
gram, letters of information to referred patients prior to consent, and flexible appointments for as-
sessment at a time and venue of the patients choosing. Each patient's participation in assessment
was acknowledged with the allocation of a token voucher to cover any costs of attendance. Pa-
tients were also offered the opportunity to meet with a service user who had previously participat-
ed in the psychological intervention, to clarify any outstanding issues and help alleviate any anxi-
eties regarding involvement in the study. Once patients had given written, informed consent, pa-
tients who met inclusion criteria for the RCT were interviewed using the Structured Clinical Inter-
view (SCID-1) for DSM-1V (First 1995) to confirm a diagnosis of psychosis with comorbid substance
dependence. Both outpatients and inpatients aged between 16 and 65 years and without learning
disability or organic brain damage were included."

Exclusion criteria: "patients with learning disability or organic brain damage"

Setting: both inpatient and outpatient

Special subgroup: first-episode patients, drug abuse

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

87

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Madigan 2013  (Continued)

N: 88

Gender: 69 men, 19 women

Age: mean 27.8 years

Cochrane Database of Systematic Reviews

CBT plus standard care arm: participants total: 59, participants male: 46, participants female:
13, age: mean 27.6 years (SD = 8.4), age range: 16-65 years, duration of untreated psychosis: 14.4
months (SD = 28.1), % taking antipsychotics: NA, % diagnosis schizophrenia: 42.37, % diagnosis
schizophreniform disorder: 10.17, % diagnosis schizoaffective disorder: 1.69, % diagnosis bipolar
disorder: 16.95, % diagnosis major depressive disorder: 8.47, % diagnosis NOS: 6.78

Control arm: participants total: 29, participants male: 23, participants female: 6, age: mean 28.2
years (SD = 7.7), age range: 16-65 years, duration of untreated psychosis: 12.2 months (SD = 19.9), %
taking antipsychotics: NA, % diagnosis schizophrenia: 44.83, % diagnosis schizophreniform: 10.34,
% diagnosis schizoaffective disorder: 0, % diagnosis bipolar disorder: 13.79, % diagnosis major de-
pressive disorder: 3.44, % diagnosis NOS: 0

Interventions

1. CBT plus standard care. N = 59

Description of treatment: "This arm also continued to receive care from a multidisciplinary team
in their local service, similar to the TAU group. Ten patients in the GPI group had also availed of ad-
diction counseling, primarily for opiate use, in excess of one year prior to consenting to the present
trial. Group psychological intervention was provided by an experienced clinical psychologist; this
specialist in cognitive therapy is a ratified member of the British Association for Behavioral and
Cognitive Psychotherapies. Patients attended group sessions once per week for 12 weeks and were
then invited back 6 weeks later for a ‘booster’ session. The interventions were held in community
mental health centers and involved weekly sessions of anxiety management, motivational inter-
viewing and CBT techniques (Edwards 2006); they consisted of six phases based upon motivation-
al interviewing principles (Miller 1991; Edwards 2006), as per the Australian CAP trial, together with
cognitive behavioral therapy. 
1. Entry: engagement, gaining commitment to treatment and raising the issue of problem sub-
stance abuse (psychoeducation).
2. Commitment: building commitment to a goal of non-problematic
substance misuse (motivational interviewing; harm reduction).
3. Goal Setting: reinforcing commitment to change and development
of goal achievement strategies.
4. Challenges: withdrawal counseling and psychoeducation.
5. Relapse prevention and lifestyle: motivational interviewing and
psychoeducation.
6. Maintenance: coping skills and time management.
7. Exit: termination; provision of resources."

Number of sessions: 13 (12 sessions + 1 booster)

Sessions frequency and duration: 4 per month; duration NA

Therapist: psychologist

Therapist experience: experts

Supervision: NA

Modality: group

Delivery: face-to-face

Treatment manualised: no

2. Control (Treatment as usual). N = 29

Description of treatment: "This arm continued to receive care from a multidisciplinary team in their
local service; this included antipsychotic treatment and regular review."

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

88

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Madigan 2013  (Continued)

Cochrane Database of Systematic Reviews

Number of sessions: NA

Sessions frequency and duration: NA

Therapist: NA

Therapist experience: NA

Supervision: no

Modality: individual

Delivery: face-to-face

Treatment manualised: no

Outcomes

Mental state - specific - SAPS endpoint (< 6 months, < 12 months)

Mental state - specific - SANS endpoint (< 6 months, < 12 months)

Mental state - specific - CDS endpoint (< 6 months, < 12 months)

Leaving the study early - for any reason (dropout) (< 6 months, < 12 months)

Functioning - GAF endpoint (< 6 months, < 12 months)

Quality of life - WHOQoL-BREF (< 6 months, < 12 months)

Notes

We contacted the authors but received no reply.

Morrison 2018 (COMPARE) 

Study characteristics

Methods

Three-arm study (1. CBT + standard care, 2. standard care, 3. CBT alone); only arm 1 and 2 met
the inclusion criteria and were used for this systematic review

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: 26 treatment phase + 36 weeks follow-up

Number of study arms: 3

Type of blinding: rater blind

Type of data analysis for overall efficacy: ITT

Number of sites: 4

Number of countries: 1

Country: UK

Sponsorship source: public

Trial registration ID: ISRCTN06022197

Publication year: 2018

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

89

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Morrison 2018 (COMPARE)  (Continued)

Researcher's allegiance: The authors developed the manual for the intervention group.

Participants

Diagnosis: schizophrenia, schizoaffective disorder, or delusional disorder, or met the entry criteria
for an early intervention for psychosis service; diagnostic criteria: ICD-10

Current clinical state: NA

Definition of stability: NA

Inclusion criteria: "Eligible participants were aged 16 years or older; met ICD10 criteria for schizo-
phrenia, schizoaffective disorder, or 
delusional disorder, or met the entry criteria for an early intervention for psychosis service (opera-
tionally defined with the PANSS), because most individuals with first episode psychosis will receive
care from specialist teams, as recommended by National Institute for Health and Care Excellence
guidelines; were in contact with mental health services, under the care of a consultant psychiatrist;
scored at least 4 on the PANSS delusions or hallucinations items, or at least 5 on suspiciousness,
persecution, or grandiosity items; and had to have the 
capacity to consent and also had to be help seeking."

Exclusion criteria: "Exclusion criteria were receipt of antipsychotic 
medication or structured CBT with a qualified therapist within the past 3 months, moderate-to-se-
vere learning disabilities, organic impairment, a score of 5 or more on the PANSS conceptual disor-
ganisation item, and a primary diagnosis of alcohol or substance dependence; patients who were
an immediate risk to themselves or others, and those who did not speak English were also exclud-
ed."

Setting: both inpatient and outpatient

Special subgroup: first-episode patients, positive symptoms

N: 75

Gender: 43 men, 32 women

Age: mean 23.61 years

CBT plus standard care arm: participants total: 25, participants male: 14, participants female: 11,
age: mean 24.44 years, age range > 16 years, duration of untreated psychosis: 39.43 weeks, % tak-
ing antipsychotics during the study: 72, baseline PANSS total M = 70.76, SD = 8.46, N = 25

Standard care arm: participants total: 24, participants male: 13, participants female: 11, age: mean
23.21 years, age range > 16 years, duration of untreated psychosis: 37.33 weeks, % taking antipsy-
chotics during the study: 66.66, baseline PANSS total M = 70.13, SD = 10.11, N = 24

CBT only arm: participants total: 26, participants male: 16, participants female: 10, age: mean 23.19
years, age range > 16 years, duration of untreated psychosis: 44.48 weeks, % taking antipsychotics
during the study: 30.7, baseline PANSS total M = 70.35, SD = 8.03, N = 26

Interventions

1. CBT plus standard care. N = 25

Description of treatment: "26 sessions of therapy based on a specific cognitive model (Morrison
2001) during a 6-month treatment window. Up to four optional booster sessions were available
during the subsequent 6 months. Therapy was individualised and problem focused. Permissible
interventions were described in the manualised treatment protocol (Morrison 2017). Therapy ses-
sions were usually offered weekly and delivered by appropriately qualified psychological thera-
pists. Fidelity to protocol was ensured by weekly supervision and regular rating of recorded ses-
sions with the Cognitive Therapy Scale–Revised (Blackburn 2001)."

Number of sessions: 26 (14.39 received mean)

Sessions frequency and duration: 4 sessions per month with 60 min per session

Therapist: appropriately qualified psychological therapist and psychiatrist

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

90

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Morrison 2018 (COMPARE)  (Continued)

Cochrane Database of Systematic Reviews

Therapist experience: experts

Supervision: weekly

Modality: individual

Delivery: face-to-face

Treatment manualised: yes

2. Standard care. N = 24

Description of treatment: "Participants allocated to antipsychotics were prescribed medication by
their responsible psychiatrist. 
Treatment was begun as soon as possible after randomisation. Prescribing mirrored standard clin-
ical practice, and thus there were no restrictions on the antipsychotics that could be selected or
their doses. Clinicians could switch antipsychotics and adjust doses as clinically indicated, but
were encouraged to continue antipsychotic treatment for a minimum of 12 weeks, and preferably
for at least 26 weeks."

Number of sessions: NA

Sessions frequency and duration: NA

Therapist: psychiatrist

Therapist experience: NA

Supervision: NA

Modality: NA

Delivery: NA

Treatment manualised: NA

3. CBT only. N = 26

Description of treatment: "26 sessions of therapy based on a specific cognitive model (Morrison
2001) during a 6-month treatment window. Up to four optional booster sessions were available
during the subsequent 6 months. Therapy was individualised and problem focused. Permissible
interventions were described in the manualised treatment protocol (Morrison 2017). Therapy ses-
sions were usually offered weekly and delivered by appropriately qualified psychological thera-
pists. Fidelity to protocol was ensured by weekly supervision and regular rating of recorded ses-
sions with the Cognitive Therapy Scale–Revised (Blackburn 2001)."

Number of sessions: 26 (14.39 received mean)

Sessions frequency and duration: 4 sessions per month with 60 min per session

Therapist: appropriately qualified psychological therapist and psychiatrist

Therapist experience: experts

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: yes

Outcomes

Mental state - general - PANSS total endpoint (< 6 months, < 12 months)

Mental state - general - number of participants with clinically important change in mental state (< 6
months, < 12 months)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

91

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Morrison 2018 (COMPARE)  (Continued)

Cochrane Database of Systematic Reviews

Mental state - specific - PANSS positive endpoint (< 6 months, < 12 months)

Mental state - specific - PANSS negative endpoint (< 6 months, < 12 months)

Mental state - specific - HADS Depression (< 6 months, < 12 months)

Global state - number of participants that relapsed (< 6 months, < 12 months)

Global state - CGI-S endpoint (< 6 months, < 12 months)

Global state - CGI-I change (< 6 months, < 12 months)

Service use - admission to hospital (< 12 months)

Service use - number of days in hospital (< 12 months)

Leaving the study early - for any reason (< 6 months, < 12 months)

Functioning - PSP endpoint (< 6 months, < 12 months)

Quality of life - WHOQoL-BREF endpoint (< 6 months, < 12 months)

Behaviour - occurrence of violent incidents (< 12 months)

Behaviour - participants with self-injury (< 12 months)

Adverse events - deterioration of symptoms (< 6 months, < 12 months)

Notes

We contacted the authors and obtained additional information.

Morrison 2020 (MAPS) 

Study characteristics

Methods

Three-arm study (1. CBT + standard care, 2. standard care, 3. CBT alone); only arm 1 and 2 met
the inclusion criteria and were used for this systematic review

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: 26 weeks treatment phase + 26 weeks follow-up

Number of study arms: 3

Type of blinding: rater blind

Type of data analysis for overall efficacy: ITT

Number of sites: 7

Number of countries: 1

Country: UK

Sponsorship source: public

Trial registration ID: ISRCTN80567433

Publication year: 2020

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

92

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Morrison 2020 (MAPS)  (Continued)

Researcher's allegiance: The authors developed the manual for the intervention group.

Participants

Diagnosis: schizophrenia; diagnostic criteria: ICD-10

Current clinical state: first-episode

Definition of stability: NA

Inclusion criteria: "Eligible participants were aged 14–18 years; help-seeking; presented with first-
episode psychosis (defined as being within 1 year of presentation to mental health services with
psychosis symptoms); under the care of a psychiatrist within an Early Intervention in Psychosis
(EIP) service or Child and Adolescent Mental Health Service (CAMHS); symptomatic at the time
of randomisation (baseline), defined by a score of 4 or higher on the PANSS delusions or hallu-
cinations subscales for at least 7 consecutive days; and met either the ICD-10 criteria for schizo-
phrenia, schizoaffective disorder, or delusional disorder, or the entry criteria for an EIP service for
first-episode psychosis at baseline. All participants had to have the capacity to provide informed,
written consent to enter the trial. Participants aged 14–15 years also needed to have a parent or
guardian willing to provide initial written consent for the research team to contact their child."

Exclusion criteria: "Individuals who met any of the following criteria were excluded: receipt of an-
tipsychotics or structured psychological intervention within the past 3 months; non-English speak-
ing; scored 5 or higher on the PANSS conceptual disorganisation item (to maximise the likelihood
that those allocated to talking therapies would be able to engage in conversation with the thera-
pist); were deemed an immediate risk to themselves or others by their psychiatrist or care coordi-
nator; diagnoses of moderate-to-severe learning disabilities, ICD-10 organic psychosis, or primary
alcohol or substance dependence."

Setting: NA

Special subgroup: children or adolescents aged 14-18 years with an early onset psychosis, positive
symptoms

N: 61

Gender: 30 male, 29 female, 2 non-binary

Age: mean 16.3 years

CBT plus standard care arm: participants total: 21, participants male: 10, participants female: 10,
age: mean 16.2 years (SD = 1.3), age range 14-18 years, duration of untreated psychosis: 8 months,
% taking antipsychotics: 57.1, baseline PANSS total M = 75.9, SD = 14.8, N = 21

Standard care arm: participants total: 22, participants male: 12, participants female: 9, age: mean
16.4 years (SD = 1.3), age range 14-18 years, duration of untreated psychosis: 9 months, % taking
antipsychotics: 72.7, baseline PANSS total M = 74.8, SD = 12.2, N = 22

CBT only arm: participants total: 18, participants male: 8, participants female: 10, age: mean 16.3
years (SD = 1.4), age range 14-18 years, duration of untreated psychosis: 12 months, % taking an-
tipsychotics: 33, baseline PANSS total M = 72.9, SD = 9.7, N = 18

Interventions

1. CBT plusstandard care. N = 21

Description of treatment: "Participants allocated to receive antipsychotics plus psychological in-
tervention were offered all treatments as described for the monotherapy groups. All participants in
the trial were able to receive any other concomitant therapies throughout the trial including men-
tal health medications (this could include antipsychotics in the psychological intervention group),
and psychological therapies (this could include CBT or family intervention in the antipsychotics
group)."

Number of sessions: 26 CBT + 6 family (optional) + 4 CBT (booster); 15 median actually received

Sessions frequency and duration: 4 individual sessions and 1 family session per month

Therapist: appropriately trained therapist

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

93

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Morrison 2020 (MAPS)  (Continued)

Cochrane Database of Systematic Reviews

Therapist experience: experts

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: yes

2. Standard care. N = 22

Description of treatment: "For participants allocated to receive drug intervention, antipsychotics
were prescribed by the treating psychiatrist in their care team. Psychiatrists were asked to pre-
scribe in line with NICE guideline CG155. They were encouraged to commence treatment as soon as
possible following randomisation and to maintain treatment for at least 3 months, but preferably
for 6 months or longer. Psychiatrists made decisions about the type and dose of antipsychotic con-
sistent with their usual practice, and could change antipsychotic and dose as clinically required in
response to monitoring of efficacy and adverse effects. The psychiatrists within the MAPS team (...)
were available by phone or email to discuss antipsychotic prescribing with the participant’s psychi-
atrist."

Number of sessions: NA

Sessions frequency and duration: NA

Therapist: psychiatrist

Therapist experience: NA

Supervision: NA

Modality: individual

Delivery: face-to-face

Treatment manualised: NA

3. CBT only. N = 18

Description of treatment: "Participants allocated to receive psychological intervention were of-
fered up to 26 h of individual CBT and up to six optional sessions of family intervention (plus reg-
ular communication with family members following CBT sessions for individuals who consented
to the sharing of information) by appropriately trained therapists over a 6-month treatment peri-
od, and up to 4 booster sessions of CBT following the treatment period. CBT sessions were typically
once a week and family intervention once a month, and were generally delivered by the same ther-
apist. Both interventions were informed by an integrative cognitive model. In the initial phase of
CBT, patients and therapists collaboratively identified problems and agreed on goals to work on in
CBT and an individualised maintenance formulation was developed. Subsequent phases focused
on change strategies with interventions described in a published manual (Morrison 2017), histori-
cal formulations (ie, factors leading to the development of first-episode psychosis), and a final con-
solidation phase focusing on relapse prevention. Family intervention was based on the behavioural
family therapy approach (Fadden 2004). After an initial session involving assessment, formulation
sharing, and agreeing goals and problems to be worked on, family intervention involved aspects
such as psychoeducational work, provision of normalising information and recovery-oriented in-
formation, problem solving, and relapse prevention planning."

Number of sessions: 26 CBT + 6 family (optional) + 4 CBT (booster); 14 median actually received

Sessions frequency and duration: 4 individual sessions and 1 family session per month

Therapist: appropriately trained therapist

Therapist experience: experts

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

94

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Morrison 2020 (MAPS)  (Continued)

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: yes

Cochrane Database of Systematic Reviews

Outcomes

Mental state - general - PANSS total endpoint (< 6 months, < 12 months)

Mental state - specific - number of participants with clinically important change in mental state (< 6
months, < 12 months)

Mental state - specific - PANSS positive endpoint (< 6 months, < 12 months)

Mental state - specific - PANSS negative endpoint (< 6 months, < 12 months)

Mental state - specific - HADS Depression endpoint (< 6 months, < 12 months)

Global state - number of participants that relapsed (< 6 months, < 12 months)

Service use - admission to hospital (< 6 months)

Leaving the study early - for any reason (dropout) (< 6 months, < 12 months)

Functioning - FESFS endpoint (< 6 months, < 12 months)

Quality of life - EQ-5D-5L endpoint (< 6 months, < 12 months)

Behaviour - occurrence of violent incidents (< 12 months)

Behaviour - self-injury (< 12 months)

Behaviour - suicide attempts (< 12 months)

Adverse events - at least one adverse event (< 12 months)

Adverse events - deterioration of symptoms (< 12 months)

Notes

We contacted the authors and obtained additional information.

Müller 2020 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: 39

Number of study arms: 2

Type of blinding: rater blind

Type of data analysis for overall efficacy: ITT

Number of sites: 3

Number of countries: 1

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

95

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Müller 2020  (Continued)

Country:

Sponsorship source: public

Trial registration ID: NCT00465920

Publication year: 2020

Cochrane Database of Systematic Reviews

Researcher's allegiance: The authors developed the manual for the intervention group.

Participants

Diagnosis: current diagnosis of schizophrenia, schizophreniform, schizoaffective (DSM IV 295.1-0.9)
or delusional disorder (DSM IV 297.1) according to the SCID-P

Diagnostic criteria: DSM-IV

Current clinical state: moderate-to-severe psychotic symptoms

Definition of stability: moderate-to-severe psychotic symptoms

Inclusion criteria: "Eligibility criteria for participants were: (1) current diagnosis of schizophrenia,
schizophreniform, schizoaffective (DSM IV 295.1-0.9) or delusional disorder (DSM IV 297.1) accord-
ing to the SCID-P; (2) moderate to severe positive symptoms as evidenced by a score of 4 or high-
er in at least one of the three items P1 (delusions), P3 (hallucinatory behavior), and G9 (unusual
thought content) of the Positive and Negative Syndrome Scale (PANSS) (Kay 1987); (3) persistence
of positive symptoms for at least three months; (4) age 14–20 years (it is a feature of the German
health care system that young people can be treated in child and youth psychiatry up to the age of
20 years. Therefore, we have set the upper bound of our inclusion criteria to 20 years. Patients 19
years and older only are only included if they are still being treated in a youth setting); (5) sufficient
fluency of the German language; and (6) ability to give informed consent."

Exclusion criteria: "Exclusion criteria were defined as (1) organic disorder, (2) primary substance
use disorder in the past 3 months, (3) verbal IQ below 70, (4) travel time to the study center of more
than 1 hour, and (5) specific psychotherapy other than the study intervention during the study peri-
od."

Setting: both inpatient and outpatient

Special subgroup: children and adolescents with an early onset psychosis (EOP)

N: 25

Gender: 14 male, 11 female

Age: 17.28 years

CBT plus standard care arm: participants total: 13, participants male: 7, participants female: 6, age:
mean 17.46 years (SD = 1.51), age range 14-20 years, duration of illness: 6.38 years, % taking an-
tipsychotics: 100, baseline PANSS total M = 59.5, SD = 12.69, N = 13

Control arm: participants total: 12, participants male: 7, participants female: 5, age: mean 17.08
years (SD = 1.38), age range 14-20 years, duration of illness: 3.66 years, % taking antipsychotics:
100, baseline PANSS total M = 68.1, SD = 13.48, N = 12

Interventions

1. CBT plus standard care. N = 13

Description of treatment: "CBT consisted of 20 individual sessions over a period of 9 months. The
first four sessions were provided every week, followed by 16 sessions on a fortnightly basis. How-
ever, the timing could be adapted flexibly to specific needs of clients. After the initial assessment
and engagement phase, the manual provided modules addressing a range of symptom areas (delu-
sions, hallucinations, negative symptoms, and/or comorbid symptoms). Towards the end of treat-
ment, strategies for stabilization and relapse prevention were offered. If parents or caregivers were
available, five sessions were provided on an optional basis, with the last session addressing both
parents/caregivers and the index patient. While the first three of these sessions focused on psy-
choeducation and were meant to take place in the early stages of the individual therapy, the last

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

96

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Müller 2020  (Continued)

Cochrane Database of Systematic Reviews

two of these sessions focused on relapse prevention and were to take place near the end of the in-
dividual therapy."

Number of sessions: 20

Sessions frequency and duration: first four sessions were provided every week; the following 16
sessions on a fortnightly basis; "Participants of the study group attended a mean of 16.54 sessions
(SD = 3.71, range 9–20), and 76.9% (n = 10) of CBT participants were considered to be completers
(participated in a minimum of 15 sessions)."

Therapist: four clinical psychologists

Therapist experience: experts

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: yes

2. Control (Treatment as usual). N = 12

Description of treatment: "Patients assigned to the control group received standard outpatient
care within the German health care system. TAU included antipsychotic medication as well as sup-
portive counseling, i.e., regular appointments with the psychiatrist in charge. Patients may have
received additional interventions such as occupational therapy or art therapy but specific psy-
chotherapy sessions were not allowed."

Number of sessions: NA

Sessions frequency and duration: NA

Therapist: NA

Therapist experience: NA

Supervision: NA

Modality: individual

Delivery: face-to-face

Treatment manualised: no

Outcomes

Mental state - general - PANSS total endpoint (< 12 months, > 1 year)

Mental state - specific - PANSS positive endpoint (< 12 months, > 1 year)

Mental state - specific - PANSS positive change (< 12 months, > 1 year)

Mental state - specific - PANSS negative endpoint (< 12 months, > 1 year)

Mental state - specific - PANSS negative change (< 12 months, > 1 year)

Mental state - specific - CDS endpoint (< 12 months, > 1 year)

Mental state - specific - CDS change (< 12 months, > 1 year)

Global state -number of participants with remission (< 12 months, > 1 year)

Service use - admission to hospital (< 12 months, > 1 year)

Leaving the study early - for any reason (dropout) (< 12 months, > 1 year)

Functioning - GAF endpoint (< 12 months, > 1 year)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

97

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Müller 2020  (Continued)

Cochrane Database of Systematic Reviews

Functioning - GAF change (< 12 months, > 1 year)

Quality of Life - MSQoL endpoint (< 12 months, > 1 year)

Quality of Life - MSQoL change (< 12 months, > 1 year)

Behaviour - suicide attempts (< 12 months, > 1 year)

Adverse events - deterioration of symptoms (< 12 months, > 1 year)

Notes

We contacted the authors and obtained additional information.

Palma-Sevillano 2019 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: 12 months intervention, 18 months and 5 years follow-up

Number of study arms: 2

Type of blinding: rater blind

Type of data analysis for overall efficacy: probably ITT

Number of sites: 1

Number of countries: 1

Country: Spain

Sponsorship source: public

Trial registration ID: NA

Publication year: 2019

Researcher's allegiance: The authors developed the manual for the intervention group.

Participants

Diagnosis: initial phase of schizophrenia; diagnostic criteria: DSM-IV

Current clinical state: initial phase of schizophrenia

Definition of stability: NA

Inclusion criteria: "(a) patients had to be in the initial phase of schizophrenia (<3 years from the first
episode) and must not have been diagnosed with schizoaffective disorder, intellectual disabilities
or language difficulties; (b) they had to be users of the Mataró Mental Health Service (Barcelona).
Diagnoses were established by two experienced professionals based on the Structured Clinical In-
terview for DSM-IV Axis I Disorders (SCID) (APA 2000) and a review of the clinical history."

Exclusion criteria: "the diagnosis of schizoaffective disorder, severe mental retardation and lan-
guage difficulties were not included in the trial".

Setting: both inpatient and outpatient

Special subgroup: NA

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

98

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Palma-Sevillano 2019  (Continued)

N: 62

Gender: 46 male, 16 female

Age: mean 25.5 years

Cochrane Database of Systematic Reviews

CBT plus standard care arm: participants total: 35, participants male: 24, participants female: 11,
age: mean 25.5 years (SD = 4.8), age range NA years, duration of untreated psychosis: 39.7 years
(SD = 53.9), % taking antipsychotics: NA, % diagnosis schizophrenia: 100, baseline PANSS total M =
105.2, SD = 35.63, N = 35

Control arm: participants total: 27, participants male: 22, participants female: 5, age: mean 25.6
years (SD = 4.9), age range NA years, duration of untreated psychosis: 64.7 years (SD = 86.9), % tak-
ing antipsychotics: NA, % diagnosis schizophrenia: 100, baseline PANSS total M = 102.8, SD = 30.43,
N = 27

Interventions

1. CBT plus standard care. N = 35

Description of treatment: "The intervention program lasted for 12 months, with a total of 34 (week-
ly) sessions (of 45 min each), carried out at the Mental Health Centre. The PIPE early intervention
program consists of three different therapeutic components: psychoeducation and cognitive-mo-
tivational therapy conducted with both the individual and the family. The PIPE program has been
described elsewhere (Palma 2015). Motivational techniques were used to increase patients’ moti-
vation to change, help them overcome their ambivalence about treatment, promote their adher-
ence to both pharmacological and psychological treatment, change substance use habits (in the
case of patients who used drugs), increase daily life activities, maintain hygiene habits (in the case
of patients with difficulties in this area), treatment compliance, and increase their desire to start to
engage in occupational activities. These techniques were combined with cognitive therapy (e.g.,
cognitive restructuration, exposure, coping strategies for delusions and/or hallucinations). The
techniques of the IM promote change processes to generate an intrinsic motivation in its different
phases (pre-contemplative, contemplative, active phase, maintenance and relapse) (Palma 2005).
Individual CBT was used to treat delusional ideas and beliefs, hallucinations, neurotic cognitive bi-
ases, and obsessive and co-morbid symptoms (depression and anxiety) (Birchwood 1995). Fami-
ly intervention was aimed at fostering attitudes conducive to communication (reduce expressed
emotion) and at promoting improved adaptation to the illness within the family. As in individual
therapy, the goal of the work with the family was to promote healthy and functional changes, in ac-
cordance with MI."

Number of sessions: 34

Sessions frequency and duration: 4 sessions per month, 45 minutes each

Therapist: psychologist

Therapist experience: experts

Supervision: yes

Modality: individual and family

Delivery: face-to-face

Treatment manualised: yes

2. Control (Treatment as usual). N = 27

Description of treatment: "The patients received the usual treatment for the initial phase of schizo-
phrenia offered by the Spanish Mental Health Care system, namely pharmacological treatment pre-
scribed by a regular psychiatrist. Nursing care and monthly interventions by social workers were al-
so included. The intervention consisted of quarterly psychiatric visits for the purposes of pharma-
cological follow-up. The nursing visits were carried out monthly to improve patients’ health, diet
and treatment compliance. Issues related to the increase of occupational activity were treated by
social workers on a quarterly basis. Psychologists participated only where specific assessments or
interventions were necessary."

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

99

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Palma-Sevillano 2019  (Continued)

Cochrane Database of Systematic Reviews

Number of sessions: NA

Sessions frequency and duration: NA

Therapist: psychiatrist, nurse, social workers

Therapist experience: NA

Supervision: NA

Modality: individual

Delivery: face-to-face

Treatment manualised: no

Outcomes

Mental state - general - PANSS total endpoint (< 6 months, < 12 months, > 1 year)

Mental state - specific - PANSS positive endpoint (< 6 months, < 12 months, > 1 year)

Mental state - specific - PANSS negative endpoint (< 6 months, < 12 months, > 1 year)

Global state - CGI endpoint (< 6 months, < 12 months, > 1 year)

Service use - number of days in hospital (< 6 months, < 12 months, > 1 year)

Leaving the study early - for any reason (dropout) (< 6 months, < 12 months, > 1 year)

Functioning - GAF endpoint (< 6 months, < 12 months, > 1 year)

Adverse events - deterioration of symptoms (> 1 year)

Notes

We contacted the authors but received no reply.

Pos 2019 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: maximum of 3 months and 6 months post-treatment follow-up

Number of study arms: 2

Type of blinding: rater blind

Type of data analysis for overall efficacy: ITT

Number of sites: 5

Number of countries: 1

Country: Netherlands

Sponsorship source: public

Trial registration ID: NCT03217955

Publication year: 2019

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

100

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Pos 2019  (Continued)

Participants

Researcher's allegiance: The authors developed the manual for the intervention group.

Diagnosis: schizophrenia or a related disorder with onset of their first psychotic episode < 4 years
prior to inclusion; diagnostic criteria: DSM-IV-TR

Current clinical state: participants with a recent-onset psychotic disorder

Definition of stability: NA

Inclusion criteria: "To be eligible to participate in the study, participants had to be between 18 and
36 years old and diagnosed with DSM–IV–TR (APA 2000) schizophrenia or a related disorder with
onset of their first psychotic episode < 4 years prior to inclusion. Diagnosis was confirmed with the
Structured Clinical Interview for DSM Disorders (First 2002). Only participants with at least a mild
level of social withdrawal behavior, defined as a score of 3 on apathy/social withdrawal as mea-
sured with the negative scale of the Positive and Negative Syndrome Scale (PANSS; Kay 1988), or 2
on the social isolation items of the Brief Negative Symptom Scale (BNSS; Kirkpatrick 2011) were in-
cluded."

Exclusion criteria: "Patients with a comorbid diagnosis of bipolar disorder or autism spectrum dis-
order were not included in this study. The experience of positive symptoms was not an exclusion
criterion. However, individuals were not eligible when negative symptoms were primarily the result
of hallucinations or delusions (e.g., withdrawal due to paranoid delusions)."

Setting: both inpatient and outpatient

Special subgroup: primary negative symptoms, first-episode patients

N: 99

Gender: 80 men, 19 women

Age: mean 25.43 years

CBT plus standard care arm: participants total: 49, participants male: 37, participants female: 12,
age: mean 25.14 years (SD = 4.47), age range 18-36 years, % taking antipsychotics: 85.4, % diagno-
sis schizophrenia: 59.2, % diagnosis schizoaffective disorder: 14.3, % diagnosis psychotic disorder
NOS: 20.4, % diagnosis other psychotic diagnosis: 8.2, baseline PANSS total M = 57.95, SD = 9.08, N
= 49

Control arm: participants total: 50, participants male: 43, participants female: 7, age: mean 25.72
years (SD = 4.44), age range 18-36 years, % taking antipsychotics: 98.0, % diagnosis schizophrenia:
68.0, % diagnosis schizoaffective disorder: 6.0, % diagnosis psychotic disorder NOS: 18.0, % diag-
nosis other psychotic diagnosis: 8.0, baseline PANSS total M = 55.85, SD = 8.79, N = 50

Interventions

1. CBT plus standard care. N = 49

Description of treatment: "The overall aim of the treatment was to modify dysfunctional beliefs
and to increase engagement in constructive social activity in individuals with prominent negative
symptoms."
"During the first session of the group therapy, psychoeducation with a focus on negative symptoms
(e.g., anhedonia, lack of energy, cognitive deficits, problem in social interaction and social with-
drawal) was provided. Patients were asked to share their experiences and to define their individual
social goals (e.g., [re] connect with friends, [re] engage in team sport) aimed to increase social in-
teraction. To promote peer support as one of the major components of the group-based interven-
tion part, buddy couples were formed. These couples worked together during sessions and were
encouraged to support each other between sessions in completing their homework (e.g., by send-
ing reminders). At the start of the second session, goals with the highest personal value were se-
lected and divided into smaller steps necessary to reach these goals. Participants were asked to
rate which obstacles in reaching their goals they anticipated. Emphasis was placed on dysfunction-
al beliefs regarding one’s own cognitive functioning, skills, or the expected (lack of) pleasure or so-
cial devaluation (e.g., “I cannot enjoy things anymore,” “I am unable to concentrate and memo-
rize anything and will not be able to have an interesting conversation”). Psychoeducation during
this session was specifically focused on the cognitive model of negative symptoms, emphasizing

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

101

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Pos 2019  (Continued)

Cochrane Database of Systematic Reviews

the role of dysfunctional beliefs, avoidance behavior, and demoralization. Subsequent sessions
focused on challenging anticipated and experienced obstacles using standardized material such
as cognitive restructuring worksheets, role-plays, and on-site behavioral experiments. Specific ac-
tions to reach one’s personal goal were planned in detail during the sessions, and the participant
was asked to carry out that step before the next planned session as a homework assignment. At
the start of each following session, homework assignments were discussed. To maximize a sense of
personal efficacy, each failure of the patient to execute a new behavior was interpreted as the ther-
apist’s fault (e.g., due to insufficient preparation or setting goals too high). The underlying idea is
that small successes are prerequisite to the experience of hope and personal efficacy. To facilitate
engagement and generalization of learned skills to daily functioning, participants were encouraged
to actively participate in discussions, role-plays and behavior experiments."

" Individual therapy sessions were aimed at the continuation of social activation and achievement
of personal goals through a personalized focus on the person’s main dysfunctional beliefs and as-
sociated behaviors, and countering obstacles to these goals. Rather than providing a session-by-
session protocol, the treatment manual provided material for psychoeducation and interventions
that could be used if needed. Intervention tools were based on different elements of demoraliza-
tion (e.g., cognitive techniques used to investigate dysfunctional beliefs and behavior, such as
Socratic dialogue, behavioral and cognitive experiments; dimensional evaluation of negative or
stereotype self-image etc.; cognitive imagery techniques (imagining the steps needed to achieve
new goals); and behavioral techniques (activity scheduling, exposure to new situations that trig-
ger anxiety etc.). The choice for a particular combination of the above-mentioned techniques was
based on the individual needs and goals."

Number of sessions: 22

Sessions frequency and duration: 8 group sessions of 1 hour/twice a week followed by six weekly
individual sessions of 45 min

Therapist: MSc level psychologists provided the group and individual CBT sessions.

Therapist experience: experts

Supervision: yes

Modality: individual and group

Delivery: face-to-face

Treatment manualised: yes

2. Control (Treatment as usual). N = 50

Description of treatment: "Every participant in the TAU condition received either inpatient treat-
ment, day-treatment or outpatient treatment at one of the collaborating (local community) men-
tal health centers. Across sites, TAU consisted of early intervention programs where patient’s symp-
toms, functioning and medication use are monitored for 3 years. At minimum, treatment as usual
consisted of antipsychotic medication and supportive therapy. In addition, TAU could involve psy-
cho-education, family support, physical health care, psychomotor therapy and vocational therapy.
The latter includes individual placement and support (IPS), intended to support patients in their ef-
forts to achieve employment and reintegration."

Number of sessions: NA

Sessions frequency and duration: NA

Therapist: psychiatrists, psychologists, psychiatric nurses and social workers

Therapist experience: NA

Supervision: no

Modality: individual and group

Delivery: face-to-face

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

102

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Pos 2019  (Continued)

Treatment manualised: no

Cochrane Database of Systematic Reviews

Outcomes

Mental state - general - PANSS total endpoint (< 6 months, < 12 months)

Mental state - specific - PANSS positive endpoint (< 6 months, < 12 months)

Mental state - specific - PANSS negative endpoint (< 6 months, < 12 months)

Mental state - specific - BNSS endpoint (< 6 months, < 12 months)

Global state - number of participants with clinically important change in global state (< 6 months, <
12 months)

Leaving the study early - for any reason (dropout) (< 6 months, < 12 months)

Functioning - GAF endpoint (< 6 months, < 12 months)

Quality of life - EQ-5D (WHO) (< 6 months, < 12 months)

Notes

We contacted the authors and obtained additional data.

Puig-Navarro 2020 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: 15 weeks

Number of study arms: 2

Type of blinding: NA

Type of data analysis for overall efficacy: ITT

Number of sites: NA

Number of countries: 1

Country: Spain

Sponsorship source: Hospital Clinic of Barcelona

Trial registration ID: NCT03261557

Publication year: 2020

Researcher's allegiance: NA

Participants

Diagnosis: schizophrenia spectrum disorder (schizophrenia, schizoaffective disorder, psychotic dis-
order not otherwise specified); diagnostic criteria: DSM-V

Current clinical state: clinically stabilised

Definition of stability: "in non-acute treatment"

Inclusion criteria: "schizophrenia spectrum disorder (schizophrenia, schizoaffective disorder, psy-
chotic disorder not otherwise specified), diagnosed before 18; being clinically stabilized (outpa-
tients)"

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

103

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Puig-Navarro 2020  (Continued)

Cochrane Database of Systematic Reviews

Exclusion criteria: "IQ < 70; having a substance dependence disorder; having a neurological disor-
der"

Setting: outpatient

Special subgroup: onset of a psychotic disorder before age 18 (EOP)

N: 30

Gender: NA

Age: NA

CBT plus standard care arm: participants total: 16, age range 12-22 years

Control arm: participants total: 14, age range 12-22 years

Interventions

1. CBT plus standard care (CBSST-Adol). N = 16

Description of treatment: "The Cognitive-Behvioral Social Skills Training (CBSST) is an evi-
dence-based psychological intervention for patients with schizophrenia." "The CBSST-Adol version
included 3 original modules (cognitive abilities, social skills, problem-solving skills). It will consist
of 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: cogni-
tive skills module, which includes the basic principles of CBT for psychosis; social skills module,
which includes the usual strategies in HHSS training; and problem solving module."

Number of sessions: 16 (1 individual session + 15 weekly group sessions)

Sessions frequency and duration: weekly group sessions

Therapist: NA

Therapist experience: NA

Supervision: NA

Modality: individual and group sessions

Delivery: face-to-face

Treatment manualised: NA

2. Control (PSYCHOED-Adol). N = 14

Description of treatment: "The active control intervention, PSYCHOED-Adol, included 3 modules
(psychoeducation, relapse prevention, healthy life style)."

Number of sessions: 16 (1 individual session + 15 weekly group sessions)

Sessions frequency and duration: weekly group sessions

Therapist: NA

Therapist experience: NA

Supervision: NA

Modality: individual and group sessions

Delivery: face-to-face

Treatment manualised: NA

Outcomes

Leaving the study early - for any reason (dropout) (< 6 months)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

104

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Puig-Navarro 2020  (Continued)

Notes

We contacted the authors and obtained additional information.

Santos 2008 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: The intervention was for a 12-month period. Assessments on the primary out-
come measures were undertaken at baseline, 6-month, 12 months and 18-month follow-up.

Number of study arms: 2

Type of blinding: NA

Type of data analysis for overall efficacy: NA

Number of sites: 9

Number of countries: NA

Country: Portugal

Publication year: 2008

Researcher's allegiance: NA

Participants

Current clinical state: first-episode schizophrenia

N: 57

Gender: 39 men, 18 women

Age: mean 28 years

Interventions

1. CBT plus standard care.

Description of treatment: "Manualised cognitive-behavioural treatment delivered within a thera-
peutic case management framework (CBCM) for young people with first-episode schizophrenia and
related psychotic disorders."

Treatment manualised: yes

2. Control (Treatment as usual)

Description of treatment: NA

Outcomes

Notes

No outcome data available for this study

We contacted the authors but received no reply.

Supereden3 

Study characteristics

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

105

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Supereden3  (Continued)

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: 39 intervention phase and 65, 104 follow-up

Number of study arms: 2

Type of blinding: rater blind

Type of data analysis for overall efficacy: ITT

Number of sites: 4

Number of countries: 1

Country: UK

Sponsorship source: public

Trial registration ID: ISRCTN61621571

Publication year: 2018

Researcher's allegiance: The authors developed the manual for the intervention group.

Participants

Diagnosis: non-affective psychosis; diagnostic criteria: no information

Current clinical state: "early non-affective psychosis"

Definition of stability: NA

Inclusion criteria: "Eligible patients were aged 16–35 years; had non-affective psychosis; were
clients of early intervention services in Birmingham, Lancashire, Norfolk, and Sussex (for entry into
early intervention services in the UK, individuals are required to have psychotic symptoms with a
Positive and Negative Syndrome Scale [PANSS] score of ≥ 4); had been clients of early intervention
services for 12–30 months; and had low levels of structured activity after at least 1 year of treat-
ment in early intervention services (defined as ≤ 30 h/week on the Time Use Survey (Hodgekins
2015))."

Exclusion criteria: "We excluded patients if they were part of the original National EDEN cohort
(Birchwood 2014), did not speak adequate English to engage in the intervention, and were deemed
too unwell to engage with the intervention."

Setting: NA

Special subgroup: low levels of structured activity

N: 155

Gender: 116 men, 38 women

Age: mean 24.78 years

CBT plus standard care arm: participants total: 76, participants male: 56, participants female: 19,
age: mean 24.87 years (SD = 6.28), age range 16-35 years, duration of illness: 2.04 years, duration of
untreated psychosis: 19.14 weeks, % taking antipsychotics: NA, baseline PANSS total M = 58.33, SD
= 24.94, N = 75

Control arm: participants total: 79, participants male: 60, participants female: 19, age: mean 24.7
years (SD = 4.24), age range 16-35 years, duration of illness: 2.33 years, duration of untreated psy-
chosis: 19.14 weeks, % taking antipsychotics: NA, baseline PANSS total M = 63.3, SD = 20.38, N = 79

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

106

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Supereden3  (Continued)

Interventions

1. CBT plus standard care. N = 76

Description of treatment: "In the intervention group, early intervention services were augment-
ed by social recovery therapy delivered by a therapist who was trained and supervised by the tri-
al team." "In brief, social recovery therapy is delivered in three stages. Stage one involves engage-
ment and development of a formulation, which comprises establishment of a working therapeutic
relationship to facilitate engagement and identify a problem list. Alongside this approach is a de-
tailed assessment of personal motivation and pre-morbid hopes, expectations, and goals, which
might have changed with respect to the effect of illness. Specific behavioural assessment is done
in vivo to assess how symptoms affect activity. Links are identified between personally meaningful
values and goals and achievable day-to-day activity targets. Stage two involves preparing for new
activities, whereby the client and therapist work together to identify pathways to meaningful new
activities. This strategy includes referral to relevant vocational agencies, education providers, and
community providers of social or sports activities. Cognitive work at this stage involves promoting
a sense of agency and addressing hopelessness, feelings of stigma, and negative beliefs about self
and others. Behavioural experiments start focusing on managing symptoms while engaging in ac-
tivity. Stage three involves engagement in new activities, which involves the active promotion of
social activity using behavioural experiments, and fostering feelings of mastery and agency. The
behavioural experiments are progressively shaped to address specific problems presented by indi-
viduals. Therapists adopt an assertive outreach style of contact, most frequently visiting people at
home or in community settings. Therapists are also encouraged to work systematically with family
members, employers, and educational providers to discuss and overcome potential problems that
could impede social recovery."

Number of sessions: 16.49 mean

Sessions frequency and duration: NA

Therapist: therapists were either qualified clinical psychologists or cognitive behavioural thera-
pists.

Therapist experience: experts

Supervision: yes

Modality: individual and group

Delivery: face-to-face

Treatment manualised: yes (Fowler 2013)

2. Control (Treatment as usual). N = 79

Description of treatment: "These interventions include intensive and assertive recovery-oriented
case management, supported employment, peer support, group interventions, family work and
CBT for psychosis, and psychiatric medications and medical and psychiatric monitoring. All partici-
pants had an early intervention services case manager who provided oversight of their care and re-
mained in contact with the participant throughout the trial."

Number of sessions: NA

Sessions frequency and duration: NA

Therapist: NA

Therapist experience: experts

Supervision: NA

Modality: individual and group

Delivery: face-to-face

Treatment manualised: NA

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

107

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Supereden3  (Continued)

Cochrane Database of Systematic Reviews

Outcomes

Mental state - general - PANSS total endpoint (< 12 months, > 1 year)

Mental state - specific - SANS endpoint (< 12 months, > 1 year)

Mental state - specific - BDI endpoint (< 12 months, > 1 year)

Leaving the study early - for any reason (dropout) (< 12 months, > 1 year)

Mortality - overall mortality (< 12 months)

Notes

We contacted the authors and they provided information.

Sönmez 2020 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: 65 weeks: 6 months (end of therapy) + 15 months (follow-up)

Number of study arms: 2

Type of blinding: rater blind

Type of data analysis for overall efficacy: NA

Number of sites: 4

Number of countries: 1

Country: Norway

Sponsorship source: ExtraStiftelsen

Trial registration ID: NCT01511406

Publication year: 2020

Researcher's allegiance: no

Participants

Diagnosis: primary diagnosis of psychosis spectrum disorder; diagnostic criteria: DSM-IV

Current clinical state: NA

Definition of stability: NA

Inclusion criteria: "All participants had a primary diagnosis of psychosis spectrum disorder accord-
ing to the Diagnostic and Structural Manual of Mental Disorders, fourth edition (DSM-IV), were aged
18–65, and had a maximum of two illness episodes or two years of adequate treatment for psy-
chosis (not five years as registered in ClinicalTrials.gov). Furthermore, the patients must have had a
diagnosable depressive episode within the past year or have a score of five or higher on the Calgary
Depression Scale for Schizophrenia (CDSS)."

Exclusion criteria: "Exclusion criteria were a history of severe head injury or of neurological or de-
velopmental disorders."

Setting: NA

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

108

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Sönmez 2020  (Continued)

Cochrane Database of Systematic Reviews

Special subgroup: first episode, diagnosable depressive episode within the past year or have a
score of five or higher on the Calgary Depression Scale for Schizophrenia (CDSS)

N: 63

Gender: 37 men, 26 women

Age: mean 27.9 years

CBT plus standard care arm: participants total: 32, participants male: 17, participants female: 15,
age: mean 28.6 years, age range 19-51 years, duration of untreated psychosis: median 17 weeks, %
taking antipsychotics: 84.4, % diagnosis schizophrenia: 44.0, % diagnosis schizoaffective disorder:
21.9, % diagnosis delusional disorder: 6.3, % diagnosis other psychosis: 28.1

Control arm: participants total: 31, participants male: 20, participants female: 11, age: mean 27.1
years, age range 18-43 years, duration of untreated psychosis: median 20 weeks, % taking antipsy-
chotics: 90.3, % diagnosis schizophrenia: 52.0, % diagnosis schizoaffective disorder: 9.7, % diagno-
sis delusional disorder: 9.7, % diagnosis other psychosis: 29.0

Interventions

1. CBT plus standard care. N = 32

Description of treatment: "The present study applied a CBT manual based on Kingdon and Turking-
ton's CBT for psychosis (Kingdon 2005), and Fennel's CBT approach to overcoming low self-esteem
(Fennell 2007). The CBT intervention was designed with weekly individual sessions of 45–60 min,
delivered over a six-month period (maximum 26 sessions). The CBT treatment protocol was divid-
ed into three treatment stages. Stage 1 (sessions 1–5) focused on engagement and aimed to pre-
pare the patient for CBT. During this stage the therapist informed the patient about the basic princi-
ples of CBT and explained how psychotic symptoms often develop based on the stress-vulnerabil-
ity model (Zubin 1977). Early sessions emphasized the importance of active participation and col-
laboration and the significance of homework and developing a list of problems and goals for the
forthcoming sessions. A particular effort was made to clarify patients' expectations regarding ther-
apy. Stage 2 (sessions 6–20) targeted depressive symptoms and low self-esteem, which were the
study's main focus. However, a problem list was prepared for each patient to address the patient's
everyday psychological challenges and tailor therapy to patients' individual needs. The case for-
mulation developed by Morrison was applied for each patient at this stage, developed in collabo-
ration with the patients. The case formulation was updated and modified throughout the therapy
period. Stage 3 (sessions 20–26) was dedicated to the termination of the therapy and relapse pre-
vention. Specific attention was given to summarize the therapy and ensure that the patient had be-
come “their own cognitive therapist.”."

Number of sessions: maximum 26 sessions; mean number of 19.5 CBT sessions (median: 22 ses-
sions)

Sessions frequency and duration: 4 per month, duration 45-60 min per session

Therapist: clinical psychologists, psychiatrists, occupational therapist

Therapist experience: trained

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: yes

2. Control (Treatment as usual). N = 31

Description of treatment: "All patients continued to receive their ongoing usual treatment from
their therapists/case managers in various psychiatric units in Oslo, Norway. The core components
of TAU entailed ongoing medication, regular psychiatric review, and regular follow-ups by their
case managers. Some of these patients had access to wider multidisciplinary community mental
health services. The TAU patients most often received regular psychotherapy pertaining to differ-

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

109

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Sönmez 2020  (Continued)

Cochrane Database of Systematic Reviews

ent treatment methods, including some options of cognitive therapy. Treatment as usual specifica-
tions in terms of specific therapeutic interventions or number of sessions were not available to the
research team."

Number of sessions: NA

Sessions frequency and duration: NA

Therapist: therapists/case managers

Therapist experience: NA

Supervision: no

Modality: individual

Delivery: face-to-face

Treatment manualised: no information

Outcomes

Mental state - specific - PANSS positive endpoint (< 6 months, > 1 year)

Mental state - specific - PANSS negative endpoint (<6 months, > 1 year)

Mental state - specific - CDS endpoint (< 6 months, > 1 year)

Mental state - specific - BDI II endpoint (< 6 months, > 1 year)

Leaving the study early - for any reason (dropout) (< 6 months, > 1 year)

Functioning - GAF endpoint (< 6 months, > 1 year)

Notes

We contacted the authors and obtained additional information.

Uzenoff 2008 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: 26 weeks

Number of study arms: 2

Type of blinding: rater blind

Type of data analysis for overall efficacy: ITT

Number of sites: NA

Number of countries: 1

Country: USA

Sponsorship source: other

Trial registration ID: NA

Publication year: 2008

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

110

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Uzenoff 2008  (Continued)

Researcher's allegiance: The authors developed the manual for the intervention group.

Participants

Diagnosis: schizophrenia, schizoaffective disorder, schizophreniform disorder; diagnostic criteria:
DSM-IV

Current clinical state: clinical stable

Definition of stability: after hospital discharge and clinical stabilisation

Inclusion criteria: "Participants needed to be 16 years of age or older, meet DSM-IV (APA 2000) diag-
nostic criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder, and have
been in treatment for a first episode of psychosis for less than 12 months."

Exclusion criteria: no information

Setting: in and outpatient

Special subgroup: no information

N: 19

Gender: 12 men, 7 women

Age: mean 22.69 years

CBT plus standard care arm: participants total: 10, participants male: 6, participants female: 4, age:
mean 25.30 years (SD = 5.95), age range 16 years or older, % taking antipsychotics: NA, baseline
PANSS total M = 67.3, SD = 12.66, N = 10

Control arm: participants total: 11, participants male: 6, participants female: 3, age: mean 19.78
years (SD = 3.53), age range 16 years or older, % taking antipsychotics: NA, baseline PANSS total M =
54.44, SD = 11.43, N = 9

Interventions

1. CBT plus standard care. N = 10

Description of treatment: "ACE is a manual-based psychotherapy consisting of 4 phases: (1) estab-
lishing therapeutic alliance; (2) promoting treatment adherence; (3) developing a plan for main-
tenance treatment; and (4) rehabilitation. In ACE Therapy, the therapist assumes an active role
consistent with traditional cognitive-behavioral therapies, and the therapeutic stance emphasizes
empathy for the patient’s point of view. ACE Therapy draws upon the Health Belief Model (Becker
1975), a theoretical framework developed in preventative healthcare. This model posits that an in-
dividual’s decision to adhere to treatment is a dynamic process wherein patients weigh advantages
and disadvantages of treatment, and that beliefs about advantages and disadvantages change
over time (i.e., in response to education, or as symptom severity or treatment side effects change).
Key therapeutic techniques used include motivational interviewing (e.g., linking taking medica-
tions or not to the client’s ability to reach important goals), inductive questioning, reframing, using
normalizing rationales, selective validation of the patient’s beliefs and attitudes, and graded analy-
sis of evidence to address beliefs about illness and treatment."

Number of sessions: 14 therapy sessions planned; 13.8 sessions received

Sessions frequency and duration: 6 weekly sessions followed by 8 biweekly sessions; 30-45 minutes

Therapist: clinicians with at least a Master's degree and working experience with individuals with
first-episode psychosis

Therapist experience: trained

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: yes

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

111

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Uzenoff 2008  (Continued)

2. Control (Supportive therapy plus treatment as usual). N = 11

Description of treatment: "ST was intended to control for the nonspecific aspects of therapy, such
as therapeutic relationship and regular contact with a therapist. ST has 2 phases, which are: (1) es-
tablishing a therapeutic alliance, and (2) providing emotional support and discussing non-illness
issues or topics. ST therapists were instructed not to bring up or discuss issues related to medica-
tion or medication adherence. If patients brought up these issues in ST, the therapist was to listen
with an empathic therapeutic stance, and advise the patient to discuss these issues with his or her
treating physician."

Number of sessions: 14 therapy sessions planned; 13.44 sessions received

Sessions frequency and duration: 6 weekly sessions followed by 8 biweekly sessions

Therapist: clinicians with at least a Master's degree and working experience with individuals with
first-episode psychosis

Therapist experience: trained

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: NA

Outcomes

Mental state - general - PANSS total endpoint (< 6 months)

Mental state - specific - participants with change in positive symptoms (< 6 months)

Mental state - specific - PANSS positive endpoint (< 6 months)

Mental state - specific - PANSS negative endpoint (< 6 months)

Mental state - specific - CDS (< 6 months)

Leaving the study early - for any reason (dropout) (< 6 months)

Quality of life - QLS endpoint (< 6 months)

Notes

We contacted the authors but received no reply.

Weiden 2019 

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel group

Antipsychotic medication allowed: yes

Duration in weeks: NA

Number of study arms: 2

Type of blinding: NA

Type of data analysis for overall efficacy: NA

Number of sites: NA

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

112

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Weiden 2019  (Continued)

Number of countries: NA

Country: NA

Sponsorship source: NA

Trial registration ID: NA

Publication year: 2019

Researcher's allegiance: NA

Cochrane Database of Systematic Reviews

Participants

Diagnosis: schizophrenia; diagnostic criteria:

Current clinical state: first psychotic symptoms <= 5 years

Definition of stability: NA

Inclusion criteria: "Subjects meeting diagnostic criteria of schizophrenia with 1st psychotic symp-
tom ≤ 5 years with interest in receiving individual psychotherapy were enrolled from the UIC Psy-
chosis Program."

Exclusion criteria: NA

Setting: NA

Special subgroup: NA

N: 34

Gender: 23 men, 11 women

Age: mean 24 years

CBT plus standard care arm: NA

Control arm: NA

Interventions

1. CBT plus standard care (Health Dialogue Intervention). N = 16

Description of treatment: "The CBT Intervention was called Health Dialogue Intervention (HDI) and
was based on the CBT Insight Model with an added section on medication adherence. "

Number of sessions: 17.6 sessions

Sessions frequency and duration: up to 5 sessions over 6 months to a maximum of 22 over a year

Therapist: yes (not further described)

Therapist experience: trained

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: yes

2. Control (Psychoeducation). N = 18

Description of treatment:

Number of sessions: 9.2 sessions

Sessions frequency and duration: up to 5 sessions over 6 months to a maximum of 22 over a year

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

113

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Weiden 2019  (Continued)

Cochrane Database of Systematic Reviews

Therapist: yes (not further described)

Therapist experience: trained

Supervision: yes

Modality: individual

Delivery: face-to-face

Treatment manualised: yes

Outcomes

Notes

No outcome data available for this study.

We contacted the authors but received no reply.

ACE = Adherence-coping-education
ACT = Acceptance and Committment Therapy
BDI = Beck depression inventory
BNSS = Brief Negative Symptom Scale
BPRS = Brief Psychiatric Rating Scale
BPRS-E = Brief Psychiatric Rating Scale-Expanded
BPRS-P = BPRS total psychotic subscore
BPRS-PS = BPRS positive symptom subscale
CAMHS = Child and Adolescent Mental Health Services
CAP = community-acquired pneumonia
CBCM = Cognitive Behavioural Case Management
CBSST = Cognitive-Behvioral Social Skills Training
CBSST-Adol = Adolescent version of CBSST
CBT = Cognitive behavioural therapy
CDS = Calgary Depression Scale
CDSS = Calgary Depression Scale for Schizophrenia
CESD-R = Centre for Epidemiologic Studies Depression scale - Revised
CGI = Clinical Global Impression
CGI-I = Clinical Gloabal Impression of Improvement
CGI-S = Clinical Global Impression of Severity
CLZ = Clozapine
CM = case management
CMHC = community mental health center
CMHS = community mental health service
CR = cognitive remediation
CRI = Cognitive therapy based recovery intervention
CT = Cognitive therapy
CTS-Psy = Cognitive Therapy Scale for Psychosis
DHI = Digital health intervention
DSM = Diagnostic and Statistical Manual of Mental Disorders
DVD = digital video disc
ECT = electro-convulsive therapy
EIP = Early Intervention in Psychosis
EIS = Early intervention services
EOP = early onset psychosis
EPPIC = Early Psychosis Prevention and Intervention Centre
EQ-5D = EuroQol-5D
EQ-5D-5L = EuroQol-5D-5L
FAST = Functioning Assessment Short Test
FEP = First-episode psychosis
FESFS = First Episode Social Functioning Scale
FIp = psychosis-focused family intervention
GAF = Global Assessment of Functioning
GPI = group-based psychological in-
tervention

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

114

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

HADS = Hospital Anxiety and Depression Scale
HDI = Health Dialogue Intervention
HHSS = "Habilidades
sociales" (social skills)
ICD-10 = International Classification of Diseases, Tenth Revision
IM = motivational interviews
IPS = individual placement and support
IQ = intelligence quotient
ITT = Intention-to-treat analysis
MADRS = Montgomery-Åsberg Depression Rating Scale
MANSA = Manchester Short Assessment of Quality of Life
MAPS = Managing Adolescent first episode Psychosis
MDE = major depressive episode
MI = Motivational interviews
MI-CBT = Motivational interviewing and cognitive behavioural therapy
MSQoL = Modular System for Quality of Life
NA = not available
NOS = not otherwise specified
OYH = Orygen Youth Health
PANSS = Positive and Negative Syndrome Scale
PE = Psychoeducation
PIPE = cognitive-motivational therapy program
PSP = Personal and Social Performance Scale
PSYCHOED-Adol = Psychoeducation for Adolescents
PSYRATS = The Psychotic Symptoms Rating Scales
QLS = Quality of life scale
RCT = Randomised controlled study
RPT = Relapse prevention therapy
SA = social anxiety
SANS = Scale for the assessment of negative symptoms
SAPS = Scale for the assessment of positive Symptoms
SCID-P = Structured Clinical Interview for DSM disorders - Patients
SD = standard deviation
SM = Symptom Management
SOFAS =Social and Occupational Functioning Assessment Scale
ST = supportive therapy
STOPP = systematic treatment of persistent psychosis
TAU = Treatment-as-usual
TDZ = Thioridazine
WHOQoL-BREF = World Health Organization Quality of Life abbreviated form
WoL-bref = World Health Organization Quality of Life abbreviated form

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Amann 2005

Design: randomised

Participants: first episode

Intervention: no CBT

Browning 2013

Design: not randomised

Drury 1996

Design: randomised

Participants: no first episode

Edwards 2008

Design: not randomised

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

115

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Reason for exclusion

Fowler 2002

Design: randomised

Participants: no first episode

Fowler 2009 (Isrep)

Design: randomised

Participants: no first episode

Gaebel 2005

Design: randomised

Participants: first episode

Intervention: no CBT

Gleeson 2012

Design: randomised

Participants: first episode

Intervention: no CBT

Griffiths 2019

Design: randomised

Participants: first episode

Intervention: no CBT

Gumley 2003

Design: randomised

Participants: no first episode

Haddock 2018

Design: randomised

Participants: no first episode

Jackson 2005

Design: not randomised

Kemp 2007

Design: randomised

Population: substance-induced psychosis (communication with the author)

Kidd 2020

Design: randomised

Participants: first episode

Intervention: no CBT

Lally 2019

Design: not randomised

Lecomte 2020

Design: randomised

Participants: no first episode

Lysaker 2007

Design: randomised

Participants: no first episode

McGorry 1998

Design: randomised

Participants: no first episode

McGorry 2000

Design: randomised

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

116

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Reason for exclusion

Participants: no first episode

Morrison 2014 (ACTION)

Design: randomised

Participants: unclear

Intervention: no CBT plus standard care

Morrison 2016

Design: randomised

Participants: no first episode

Morrison 2018 (FOCUS)

Design: randomised

Participants: no first episode

NCT00722163

Study has been cancelled.

Newton 2005

Design: not randomised

Ostergaard Christensen 2014

Design: randomised

Participants: first episode

Intervention: no CBT

Tarrier 2014

Design: randomised

Participants: no first episode

Van der Gaag 2011

Design: randomised

Participants: no first episode

Vohs 2018

Design: randomised

Participants: first episode

Intervention: no CBT

Weller 2018 (EBIRT)

Design: randomised

Participants: first episode

Intervention: no CBT

Wölwer 2022

Design: randomised

Participants: no first episode

CBT: cognitive behaviour therapy

Characteristics of studies awaiting classification [ordered by study ID]

Gonzalez-Ortega 2022 

Methods

Study design: randomised controlled trial

Trial registration ID: NCT02319746

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

117

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gonzalez-Ortega 2022  (Continued)

Participants

Inclusion criteria:

Cochrane Database of Systematic Reviews

- Diagnosed as FEP according to the revised fourth edition of the Diagnostic and Statistical Manu-
al of Mental Disorders, Fourth Edition, Text Revision (DSM- IV-TR) (APA 2000) (i.e. schizophreniform
disorder, schizoaffective disorder, delusional disorder, bipolar disorder with psychotic symptoms,
atypical psychosis, brief psychotic disorder, non-specified psychotic disorder, or major depressive
disorder with psychotic symptoms)

- Meeting dependence or abuse of cannabis criteria according to the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) (APA 2000) and the scores of
the European Addiction (Europ-ASI) (Kokkevi 1995) (scores of 4 to 7: abuse; scores of 8 to 9: depen-
dence)

- Aged between 15 and 40 years. In the case of minors (under 18 years of age), written informed
consent was requested from their parents or guardians

Exclusion criteria:

- Organic brain pathology and/or mental disability according to DSM-IV-TR (APA 2000) criteria

Interventions

1. CBT (Specific cognitive behavioural therapy (CBT) for cannabis cessation (CBT-CC)) plus standard
care. N = 34

2. Control (treatment-as-usual). N = 31

Outcomes

- Mental state - Positive and Negative Syndrome Scale (PANSS positive, negative, total)

- Depression - Hamilton Depression Rating Scale (HDRS)

- Anxiety - Hamilton Anxiety Scale (HAM-A)

- Manic symptoms - Young Mania Rating Scale (YMRS)

- Illness awareness - Scale to assess Unawareness in Mental Disorders (SUMD)

- Functioning - Functioning Assessment Short Test (FAST)

Notes

Asked the authors for some more information about the diagnoses of the included participants

We contacted the authors but received no reply.

Lewis 2000 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: "recent onset schizophrenia sufferers with substance misuse problems"

Exclusion criteria: NA

Interventions

1. CBT plus standard care

Outcomes

Notes

2. Control

- Relapse rate

Asked the authors to provide some more information about the population included in the study,
especially referring to first-episode and recent-onset patients

We contacted the authors but received no reply.

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

118

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT02653729 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria:

- Patients diagnosed with psychosis by psychiatrist of the recruiting unit

- Patients with duration of illness till 3 years

- Patients with the minimum of 5 years of education

- Patients within the age range of 18 to 35 years

- Competent and willing to give informed consent

- Patients living in the study catchment area.

Exclusion criteria:

- Patients with drug-induced psychosis

- Patients with severe psychopathology, unable to give informed consent

- Patients suffering from organic or neurological disorder

- Patients suffering from chronic physical condition

Age: 18 to 35 years

Interventions

1. CBT plus standard care (Espidone, Olepra, Donu)

2. Control (Espidone, Olepra, Donu)

N = 50

Outcomes

- Mental state - Positive and Negative Symptom Scale (PANSS)

- Mental state - The PsychoSocial Remission Scale (PSRS)

- Insight - Schedule for Assessment of Insight (SAI)

Notes

We attempted to contact the authors, but it was not possible to retrieve a valid contact.

NCT04889911 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: "Inclusion criteria for the RCT phase will be assessed by an initial screening and
the baseline interview. We will use relatively broad inclusion criteria to maximise the generalisabil-
ity of the findings for the population of persons with FEP. Inclusion criteria will be: 1) meets criteria
for FEP youth based on the following definition: age 15-24, onset of psychotic symptoms within the
last 5 years, and an absence of a primary substance use or mood disorder that could be causing the
psychotic symptoms (confirmed by programme eligibility); 2) meets criteria for moderate (defined
as a mean score of 1-1.5 on the 0-3 scale of the Internalized Stigma of Mental lllness Scale [ISMI]) or
elevated (defined as a mean score of 1.5-3 on the 0-3 scale of the ISMI) self-stigma; 3) speaks Eng-
lish well enough to complete assessments and participate in groups; 4) is able to provide informed
consent to participate."

Exclusion criteria: "Does not meet any of the above inclusion criteria."

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

119

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT04889911  (Continued)

Interventions

1. Narrative Enhancement and Cognitive Therapy- Young Adult, combined with Co-ordinated Spe-
cialty Care

2. Control (Co-ordinated Specialty Care).

N = 40

Outcomes

Primary outcome measures:

- Service use - treatment engagement

- Therapeutic alliance - Working Alliance Inventory Short Form-Client Version (WAI-SF)

- Coping strategies - Coping with Symptoms Checklist

Secondary outcomes measures:

- Self-esteem - Rosenberg Self Esteem Scale

- Hopelessness - Beck Hopelessness Scale

- Social functioning - Quality of Life Scale

Notes

It was not clear whether the intervention met our inclusion criteria.

We attempted to contact the authors, but it was not possible to retrieve a valid contact.

Renton 2004 

Methods

Unclear

Participants

Inclusion criteria: NA

Exclusion criteria: NA

Interventions

1. CBT plus standard care (cognitive therapy)

Outcomes

Notes

Suri 2001 

Methods

2. Control (waiting-list/treatment-as-usual)

- Mental state - Positive and Negative Syndrome Scale (PANSS)

Asked the authors to provide some more information about the population included in the study,
especially referring to first-episode and recent-onset patients. Furthermore, we asked whether the
intervention also had a behavioural component.

We contacted the authors but received no reply.

Study design: randomised controlled trial

Participants

Inclusion criteria: "patients with early onset or acute schizophrenia"

Exclusion criteria: NA

Interventions

1. CBT plus standard care

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

120

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Suri 2001  (Continued)

Outcomes

Notes

2. Control

NA

We attempted to contact the authors, but it was not possible to retrieve a valid contact (no email
address available, we contacted the hospital where the authors were affiliated, but they do not
work there any more).

Wood 2022 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria:

- aged 18 and above

- meet criteria for schizophrenia-spectrum diagnoses (schizophrenia, schizophreniform disorder,
schizoaffective disorder, delusional disorder or psychotic disorder not otherwise specified; ICD-10),
or meet criteria for an early intervention service (EIS) for treatment of psychosis to allow for diag-
nostic uncertainty

- able to give informed consent and have the capacity to consent to participation in the study

- currently receiving care from an acute psychiatric inpatient team

- able to complete the research in English

Exclusion criteria:

- non-English speakers (due to translation costs and difficulty of producing valid translations of the
research instruments and intervention)

- an acquired brain injury or substance misuse judged to be the acute cause of the psychotic experi-
ences

- already undertaking a structured psychological intervention delivered by a psychologist or
trained therapist at the time of the study

Interventions

1. CBT (crisis-focused Cognitive Behavioural Therapy for psychosis) plus standard care

2. Control (treatment-as-usual)

N = 60 (target number)

Outcomes

- Mental state - Positive and Negative Syndrome Scale (PANSS)

- Depression - Beck Depression Inventory (BDI-7)

- Hopelessness - Beck Hopelessness Scale (BHS-9)

- Anxiety - Generalised Anxiety Disorder Measure (GAD-7)

- Personal recovery - Process of Recovery Questionnaire (QPR)

- Subjective experiences of crisis - Crisis Scale in Psychosis (CRISP)

- Quality of life - Recovering Quality of Life (REQOL-10)

- Service use - Client Service Receipt Inventory (CSRI)

- Functioning - Global Assessment of Functioning (GAF)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

121

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Wood 2022  (Continued)

- Mental state - Threshold Assessment Grid (TAG)

- Relapse

- Hospitalisation

- Adverse events

Notes

Asked the authors to provide some more information about the population included in the study,
especially referring to first-episode and recent-onset patients

We contacted the authors but received no reply.

BDI-7 = Beck Depression Inventory
BHS-9 = Beck Hopelessness Scale
BPRS = Brief Psychiatric Rating Scale
CBT(-CC) = Specific cognitive behavioural therapy for cannabis cessation
CRISP = Crisis Scale in Psychosis
CSRI = Client Service Receipt Inventory
DSM-IV-TR = Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision
EIS = Early intervention service
Europ-AST = European Addiction
FAST = Functioning Assessment Short Test
GAD-7 = Generalised Anxiety Disorder Measure
GAF = Global Assessment of Functioning
HAM-A = Hamilton Anxiety Scale
HDRS = Hamilton Depression Rating Scale
ICD-10 = International Classification of Diseases,Tenth Revision
ISMI = Internalized Stigma of Mental Illness Scale
FEP = First-episode psychosis
NA = not available
PANSS = Positive and Negative Syndrome Scale
PSRS = PsychoSocial Remission Scale
QPR = Process of Recovery Questionnaire
RCT = Randomised controlled trial
REQOL-10 = Recovering Quality of Life Questionnaire
SAI = Schedule for Assessment of Insight
SUMD = Scale to assess Unawareness in Mental Disorders
TAG = Threshold Assessment Grid
WAI-SF = Working Alliance Inventory Short Form-Client Version
YMRS = Young Mania Rating Scale

Characteristics of ongoing studies [ordered by study ID]

Barrowclough 2001 

Study name

Methods

Participants

Barrowclough 2001

NA

Inclusion criteria: NA

Exclusion criteria: NA

Interventions

1. CBT plus standard care

Outcomes

2. Control

NA

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

122

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Barrowclough 2001  (Continued)

Starting date

Contact information

Notes

Haddock 2000 

Study name

Methods

Participants

Haddock 2000

Study design: randomised controlled trial

Inclusion criteria: "an ICD10 diagnosis of schizophrenia, schizoaffective disorder or delusional dis-
order, have less than five years since onset and have associated alcohol or drug abuse."

Exclusion criteria: NA

Interventions

1. CBT plus standard care

Description of the treatment: "The individual cognitive-behaviour therapy will take place over 18
weekly sessions, followed by 6 fortnightly sessions. The individual intervention will include stan-
dardised assessment followed by techniques designed to reduce the severity and distress of persis-
tent symptoms, such as distraction and coping skills, self-monitoring, reality testing, monitoring of
prodromal signs, techniques to enhance self-esteem and interventions to improve knowledge re-
garding illness and medication."

2. Control

N = 70

Outcomes

- Patient and carer functioning

- Number of days of substance use

- Satisfaction

- Severity of substance use

- Use of services

- Engagement with services

Starting date

Contact information

Notes

ISRCTN60855021 

Study name

Methods

ISRCTN60855021

Study design: randomised controlled trial

Participants

Inclusion criteria:

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

123

 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

ISRCTN60855021  (Continued)

- Score above 30 on the Social Interaction Anxiety Scale (SIAS)

- Early Intervention Service user

- Aged 14 years and above, either sex

Exclusion criteria:

- Current acute psychotic episode

Interventions

1. CBT plus standard care

Description: "Cognitive behavioural intervention provided by graduate mental health workers. Fol-
low-up length: 6 months"

2. Control

N = 48 (planned)

Outcomes

Primary outcome measure:

- Anxiety - Social Anxiety Interaction Scale

Secondary outcome measures:

- Paranoia - Paranoia Scale

- Schemata - Brief Core Schema Scale

Starting date

Contact information

Notes

ISRCTN65536352 

Study name

Methods

ISRCTN65536352

Study design: randomised controlled trial

Participants

Inclusion criteria: "12-15 patients with first-episode"

Exclusion criteria: "Presence of organic mental disorder, mental retardation, or inadequate com-
mand of language."

Interventions

1. CBT (Cognitive Behavioural Case Management (CBCM)) plus standard care

2. Control (treatment-as-usual)

Outcomes

Primary outcome measures:

- Quality of Life Survey

Secondary outcomes measures:

- Brief Psychiatric rating scale (expanded version)

- Montgomery-Asberg Depression Rating Scale

- World Health Organization Quality of Life-BREF (WHOQOL-BREF)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

124

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

ISRCTN65536352  (Continued)

- Social and Occupational Functioning Assessment Scale

- Addiction Severity Scale

- Illness Duration Interview

- Pathways to care item

- Premorbid Adjustment Scale

- Verona Service Satisfaction Scale

- An engagement measure

- Sociodemographic & Service Receipt Inventory

- Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)-III-R (APA 1987) Patients
(SCID-P)

- Operational Criteria Checklist for Psychotic Disorders (OPCRIT)

Starting date

Contact information

Notes

NCT00161408 

Study name

NCT00161408

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria:

- diagnosis of schizophrenic disorder according to ICD10: F20

- first episode

- age between 18 and 55

- willingness to give informed consent also to a double-blind pharmacological treatment study

Exclusion criteria:

- residence outside the catchment area

- insufficient knowledge of the German language

- substance abuse or addiction as primary clinical problem

- serious physical illness

- organic brain disease

- pregnancy

- contraindications to neuroleptic treatment

Age: 18 to 55 years

Interventions

1. CBT plus standard care

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

125

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT00161408  (Continued)

Cochrane Database of Systematic Reviews

Description of treatment: "CBT includes 8 sessions of psychoeducation, 8 sessions of comput-
er-based cognitive training, 8 sessions with relatives and 20 sessions of focusing on stress manage-
ment, relapse prevention and coping with persistent symptoms."

2. Control (psychoeducation)

Description of treatment: "a short "information-centred psychoeducation" (ICP) of 8 sessions"

N = 106 (enrolment)

Outcomes

Primary outcome measure:

- Relapse

Secondary outcome measures:

- Quantitative measures of symptoms

- Social functioning

- Cognitive functioning

- Quality of life

Starting date

Contact information

Notes

NCT03491852 

Study name

Methods

Participants

NCT03491852

Study design: randomised controlled trial

Inclusion criteria: "Involvement in an early psychosis clinic for a period of less than 3 years, due to
the focus of this study being on the treatment of early psychosis. Participants must be between the
ages of 16 and 65 years. Participants 16 years of age who are incapable to consent without a par-
ent or guardian will be excluded. Participants must be fluent in English, as determined by referring
clinicians or researchers (in the case of advertisement-referred participants) in order to meaning-
fully participate in the BOOST intervention and complete the assessment tools."

Exclusion criteria: "Potential participants who are unable to provide informed consent, as deter-
mined by the treatment team, will not be able to meaningfully participate in the BOOST interven-
tion and will, therefore, be unable to participate in the research study. Individuals with a presence
of intellectual disability or history of traumatic brain injury will also be excluded."

Age: 16 to 65 years

Interventions

1. CBT (Be Outspoken and Overcome Stigmatizing Thoughts (BOOST)) plus standard care

Description of treatment: "The BOOST intervention consists of 8 group-based, weekly one-hour
sessions. While every BOOST session is different, in general they will focus on helping participants
fight back against stigmatizing thoughts and develop a sense of self-worth and empowerment.
BOOST sessions are group-based and facilitated by trained clinicians, with the aid of a peer support
worker to provide unique insights on living with and overcoming self-stigma. Content of sessions
involve group discussions, exercises conducted in session, and between-session "missions" (i.e.
home practice activities)."

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

126

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT03491852  (Continued)

2. Control (waiting-list control)

Description of treatment: "Participants on the waitlist will still receive treatment as usual, which
includes medical, psychosocial, and occupational interventions to help maximize patients' inte-
gration within the community and support recovery from a first episode of psychosis. Frequency
of contact largely depends on the individual needs of patients. Waitlist controls will be offered the
BOOST intervention 3 months post-enrollment."

N = 40 (estimated enrolment)

Outcomes

Primary outcome measure:

- Change in self-stigma - Internalized Stigma of Mental Illness Scale (ISMI)

Secondary outcome measures:

- Change in self-Esteem - Rosenberg Self-Esteem Scale (RSES)

- Change in quality of Life - Satisfaction with Life Safe (SWLS)

- Change in stigma stress - Cognitive Appraisal of Stigma Stress (CogApp)

- Change in depression - Beck Depression Inventory-II (BDI)

- Change in social anxiety - Social Interaction Anxiety Scale (SIAS)

- Change in personal recovery - Questionnaire about the Process of Recovery (QPR)

- Change in functioning - Sheehan Disability Scale (SDS)

Starting date

Contact information

Notes

We contacted the authors and obtained additional information.

NCT04180709 

Study name

NCT04180709

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria:

- Experiencing or having experienced a First Episode of Psychosis (FEP) within the past 5 years

- Currently participating in CAMEO Early Intervention services (north or south) and intending to
continue TAU with CAMEO for at least the next 4 months

- Mental capacity for consent

- Currently experiencing threshold level (score ≤ 16 on SCI-8) of disrupted sleep

- Adults 18 years or older

- Ability to understand and follow therapeutic instructions necessary for experiment and respond
to online questionnaires

- Illness duration less than or equal to 5 years. Onset of illness was defined as first contact with psy-
chiatric services for psychotic symptoms.

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

127

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT04180709  (Continued)

- Access to the internet

Exclusion criteria:

Cochrane Database of Systematic Reviews

- Too unwell to viably participate in study

- A diagnosis of drug-induced psychosis or bipolar disorder

- Psychotic disorder due to a medical or physical disease (i.e. considered to have an organic basis)

- Current drug or alcohol dependency

- Currently taking prescribed sleep medication or intending to do so during study

- Currently doing shift work

- Travel over 2 time zones during or within two weeks prior to assessment period

Age: 18 years and older

Interventions

1. CBT (web-based CBT Intervention (Sleepio)) plus standard care

2. Control (treatment-as-usual)

N = 44 (enrolment)

Outcomes

Primary outcome measure:

- Change from baseline Work and Social Adjustment Scale (WSAS) score at week 9

Secondary outcome measures:

- Social recovery - Time Use Survey - Structured Hours (TUS-SH)

- Depression - Patient Health Questionnaire (PHQ-9)

- Sustained attention - Rapid Visual Information Processing (RVP)

- Visual episodic memory - Paired Associates Learning (PAL)

- Working memory and strategy - Spatial Working Memory (SWM)

- Emotional recognition - Emotion Recognition Task (ERT)

- Functioning - Global Assessment of Functioning (GAF)

- Change from baseline Work and Social Adjustment Scale (WSAS) score at week 5, 13 and 17

Starting date

Contact information

Notes

NCT04916626 

Study name

NCT04916626

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria:

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

128

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT04916626  (Continued)

Cochrane Database of Systematic Reviews

"1. Between 12 and 17 years of age (both inclusive) at trial inclusion. 2. First-episode psychosis
within F2 spectrum (F20 schizophrenia, F21 Schizotypal disorder, F22 delusional disorder, F23
acute and transient psychotic disorders, F25 schizoaffective disorders, F28/29 other or un-speci-
fied non-organic psychosis) or depression with psychotic symptoms (F32.3, F33.3) or substance-in-
duced psychosis (F1X.5) according to the International Statistical Classification of Diseases and
Related Health Problems (ICD-10). 3. Maximum 12 months since first prescription of antipsychotic
treatment on the indication psychosis. 4. Speak and understand Danish. 5. Written informed con-
sent from parents or legal caretakers. Participants who reach age 18 years during the trial will be
asked to give personal written informed consent to continue their study participation."

Exclusion criteria:

"1. A diagnosis of mental retardation of at least moderate severity defined as an intelligence quo-
tient (IQ) of 49 or below (F71, F72, F73 according to the International Statistical Classification of
Diseases and Related Health Problems (ICD-10). 2. Currently compulsory admission and/or treat-
ment according to Danish legislation"

Age: 12 to 17 years

Interventions

1. CBT (OPUS YOUNG) plus standard care

Description of treatment: "OPUS YOUNG is a two-year out-patient specialized early intervention
service for children and adolescents with a first episode psychosis. The OPUS YOUNG treatment
consists of the following elements: modified assertive community treatment, low patients to case
manager ratio, cognitive-behavioural case management (CBCM), psychoeducational family treat-
ment including multiple family groups (MFG) and psychoeducational siblings groups, Social Cog-
nition and Interaction Training (SCIT), possible individual Cognitive Behavioural Therapy (CBT) in
addition to CBCM, and manual based psychopharmacologic treatment. Additional, special transi-
tion support, individual school/employment support, and prevention and treatment of substance
abuse."

2. Control (treatment-as-usual)

Description of treatment: "The patients allocated to TAU will be offered non-manualized treatment
following national Danish guidelines and local guidelines. Treatment is provided by a multidiscipli-
nary team and consists of case-management (no defined upper case load), family support and psy-
choeducation, in addition to psychopharmacological treatment. In some cases, social skills train-
ing and CBT may be offered. In general, office visits take place in outpatient clinics."

N = 284 (estimated enrolment)

Outcomes

Primary outcome measure:

- Functioning - Personal and Social Performance Scale (PSP)

Secondary outcome measures:

- Mental state - Scale for Assessing Psychotic Symptoms in Schizophrenia (SAPS)

- Mental state - Scale for Assessing Negative Symptoms in Schizophrenia (SANS)

- Satisfaction - Client Satisfaction Questionnaire (CSQ)

- Quality of life - Health Related Quality of Life Questionnaire for Children and Young People and
their Parents (KIDSCREEN-10)

Starting date

Contact information

Notes

We contacted the authors and obtained additional information.

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

129

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

BDI = Beck depression inventory
BOOST = Be Outspoken and Overcome Stigmatizing Thoughts
CAMEO = Cambridgeshire and Peterborough Assessing, Managing and Enhancing Outcomes
CBCM = Cognitive Behavioural Case Management
CBT = Cognitive behavioural therapy
CogApp = Cognitive Appraisal of Stigma Stress
CSQ = Client Satisfaction Questionnaire
DSM(-III-R) = Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised
ERT = Emotion Recognition Task
FEP = First-episode psychosis
GAF = Global Assessment of Functioning
ICD-10 = International Classification of Diseases, Tenth Revision
ICP = information-centred psychoeducation
ISMI = Internalized Stigma of Mental Illness Scale
IQ = intelligence quotient
KIDSCREEN-10 = Health Related Quality of Life Questionnaire for Children and Young People and their Parents
MFG = multiple family groups
NA = not available
OPCRIT = Operational Criteria Checklist for Psychotic Disorders
PAL = Paired Associates Learning
PHQ-9 = Patient Health Questionnaire
PSP = Personal and Social Performance Scale
QPR = Questionnaire about the Process of Recovery
RSES = Rosenberg Self-Esteem Scale
RVP = Rapid Visual Information Processing
SANS = Scale for the assessment of negative symptoms
SAPS = Scale for the assessment of positive Symptoms
SCI(-8) = Sleep Condition Indicator
SCID(-P) = Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)-III-R Patients
SCIT = Social Cognition and Interaction Training
SDS = Sheehan Disability Scale
SIAS = Social Interaction Anxiety Scale
Sleepio = fully automated digital sleep improvement program based on Cognitive Behavioral Therapy (CBT)
SWLS = Satisfaction with Life Safe
SWM = Spatial Working Memory
TAU = treatment-as-usual
TUS-SH = Time Use Survey - Structured Hours
WSAS = Work and Social Adjustment Scale
WHOQoL-BREF = World Health Organization Quality of Life abbreviated form

R I S K   O F   B I A S

Legend:   

  Low risk of bias    

  High risk of bias    

  Some concerns   

Risk of bias for analysis 1.5 Mental state - general: mean endpoint overall symptom scales (high = poor) (combined time points)

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Bias

Barrowclough
2014

Bucci 2018 (Actis-
sist)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

130

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Bias

Edwards 2006

GetUp

Gleeson 2009
(EPISODE II)

Gonzalez-Ortega
2021

Haddock 1999

Hjorthoj 2013
(CapOpus)

Jackson 2008
(ACE)

Jolley 2003

Lecomte 2008

Lecomte 2008

Lewis 2002
(SOCRATES)

Lewis 2002
(SOCRATES)

Liu 2019

Morrison 2018
(COMPARE)

Morrison 2020
(MAPS)

Müller 2020

Palma-Sevillano
2019

Pos 2019

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

131

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Supereden3

Uzenoff 2008

Risk of bias for analysis 1.34 Global state - number of participants with relapse/exacerbations of psychosis (combined time
points)

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Barrowclough
2014

Gleeson 2009
(EPISODE II)

Haddock 1999

Lewis 2002
(SOCRATES)

Lewis 2002
(SOCRATES)

Liu 2019

Morrison 2018
(COMPARE)

Morrison 2020
(MAPS)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

132

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Risk of bias for analysis 1.48 Leaving the study early - for any reason - overall acceptability (combined time points)

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Barrowclough
2014

Bucci 2018 (Actis-
sist)

Edwards 2006

GetUp

Gleeson 2009
(EPISODE II)

Gonzalez-Ortega
2021

Haddock 1999

Hjorthoj 2013
(CapOpus)

Jackson 2008
(ACE)

Jackson 2009

Jolley 2003

Lecomte 2008

Lecomte 2008

Lepage 2022

Lewis 2002
(SOCRATES)

Lewis 2002
(SOCRATES)

Liu 2019

Madigan 2013

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

133

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Morrison 2018
(COMPARE)

Morrison 2020
(MAPS)

Müller 2020

Palma-Sevillano
2019

Pos 2019

Puig-Navarro 2020

Supereden3

Sönmez 2020

Uzenoff 2008

Risk of bias for analysis 1.56 Functioning - mean endpoint functioning scale (high = good) (combined time points)

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Barrowclough
2014

Bucci 2018 (Actis-
sist)

Edwards 2006

Edwards 2011

GetUp

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

134

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Bias

Gleeson 2009
(EPISODE II)

Gonzalez-Ortega
2021

Hjorthoj 2013
(CapOpus)

Jackson 2008
(ACE)

Lepage 2022

Liu 2019

Madigan 2013

Morrison 2018
(COMPARE)

Morrison 2020
(MAPS)

Müller 2020

Palma-Sevillano
2019

Pos 2019

Sönmez 2020

Risk of bias for analysis 1.69 Adverse events - participants with at least one adverse event

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Morrison 2020
(MAPS)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

135

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Risk of bias for analysis 1.76 Sensitivity analysis - Blinding of outcome assessor

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Barrowclough
2014

Bucci 2018 (Actis-
sist)

Edwards 2006

Gleeson 2009
(EPISODE II)

Gonzalez-Ortega
2021

Haddock 1999

Hjorthoj 2013
(CapOpus)

Jackson 2008
(ACE)

Jolley 2003

Lecomte 2008

Lecomte 2008

Lewis 2002
(SOCRATES)

Lewis 2002
(SOCRATES)

Liu 2019

Morrison 2018
(COMPARE)

Morrison 2020
(MAPS)

Müller 2020

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

136

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Bias

Palma-Sevillano
2019

Pos 2019

Supereden3

Uzenoff 2008

Risk of bias for analysis 1.77 Sensitivity analysis - Assumptions for missing data

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Barrowclough
2014

Edwards 2006

GetUp

Gleeson 2009
(EPISODE II)

Hjorthoj 2013
(CapOpus)

Lecomte 2008

Lecomte 2008

Lewis 2002
(SOCRATES)

Lewis 2002
(SOCRATES)

Liu 2019

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

137

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Bias

Morrison 2018
(COMPARE)

Morrison 2020
(MAPS)

Müller 2020

Palma-Sevillano
2019

Pos 2019

Supereden3

Uzenoff 2008

Risk of bias for analysis 1.78 Sensitivity analysis - Risk of Bias

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Barrowclough
2014

Bucci 2018 (Actis-
sist)

Edwards 2006

Gleeson 2009
(EPISODE II)

Gonzalez-Ortega
2021

Haddock 1999

Hjorthoj 2013
(CapOpus)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

138

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Jackson 2008
(ACE)

Lewis 2002
(SOCRATES)

Lewis 2002
(SOCRATES)

Liu 2019

Morrison 2018
(COMPARE)

Müller 2020

Palma-Sevillano
2019

Pos 2019

Uzenoff 2008

Risk of bias for analysis 1.79 Sensitivity analysis - Imputed values

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Barrowclough
2014

Bucci 2018 (Actis-
sist)

Edwards 2006

Gleeson 2009
(EPISODE II)

Gonzalez-Ortega
2021

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

139

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Haddock 1999

Hjorthoj 2013
(CapOpus)

Jackson 2008
(ACE)

Lecomte 2008

Lecomte 2008

Lewis 2002
(SOCRATES)

Lewis 2002
(SOCRATES)

Liu 2019

Morrison 2018
(COMPARE)

Morrison 2020
(MAPS)

Müller 2020

Palma-Sevillano
2019

Pos 2019

Supereden3

Uzenoff 2008

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

140

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Risk of bias for analysis 1.80 Sensitivity analysis - Fixed-effect

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Barrowclough
2014

Bucci 2018 (Actis-
sist)

Edwards 2006

GetUp

Gleeson 2009
(EPISODE II)

Gonzalez-Ortega
2021

Haddock 1999

Hjorthoj 2013
(CapOpus)

Jackson 2008
(ACE)

Jolley 2003

Lecomte 2008

Lecomte 2008

Lewis 2002
(SOCRATES)

Lewis 2002
(SOCRATES)

Liu 2019

Morrison 2018
(COMPARE)

Morrison 2020
(MAPS)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

141

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Bias

Müller 2020

Palma-Sevillano
2019

Pos 2019

Supereden3

Uzenoff 2008

Risk of bias for analysis 1.81 Sensitivity analysis excluding outliers

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Barrowclough
2014

Bucci 2018 (Actis-
sist)

Edwards 2006

GetUp

Gleeson 2009
(EPISODE II)

Gonzalez-Ortega
2021

Haddock 1999

Hjorthoj 2013
(CapOpus)

Jackson 2008
(ACE)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

142

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Jolley 2003

Lecomte 2008

Lecomte 2008

Lewis 2002
(SOCRATES)

Lewis 2002
(SOCRATES)

Liu 2019

Morrison 2018
(COMPARE)

Morrison 2020
(MAPS)

Müller 2020

Pos 2019

Supereden3

Uzenoff 2008

Risk of bias for analysis 1.82 Subgroup analysis - Different types of CBT

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Subgroup 1.82.1 CBT

Gonzalez-Ortega
2021

Haddock 1999

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

143

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Jackson 2008
(ACE)

Jolley 2003

Lecomte 2008

Lecomte 2008

Lewis 2002
(SOCRATES)

Lewis 2002
(SOCRATES)

Liu 2019

Morrison 2018
(COMPARE)

Morrison 2020
(MAPS)

Müller 2020

Pos 2019

Subgroup 1.82.2 CBT integrated with other psychosocial interventions

Bucci 2018 (Actis-
sist)

GetUp

Palma-Sevillano
2019

Supereden3

Subgroup 1.82.3 CBT and Motivational Interviewing for cannabis use cessation

Barrowclough
2014

Edwards 2006

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

144

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Hjorthoj 2013
(CapOpus)

Subgroup 1.82.4 Special types of CBT

Gleeson 2009
(EPISODE II)

Uzenoff 2008

Risk of bias for analysis 1.83 Subgroup analysis - Modality of treatment

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Subgroup 1.83.1 Individual CBT

Barrowclough
2014

Bucci 2018 (Actis-
sist)

Edwards 2006

GetUp

Gleeson 2009
(EPISODE II)

Gonzalez-Ortega
2021

Haddock 1999

Hjorthoj 2013
(CapOpus)

Jackson 2008
(ACE)

Jolley 2003

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

145

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Lewis 2002
(SOCRATES)

Lewis 2002
(SOCRATES)

Liu 2019

Morrison 2018
(COMPARE)

Morrison 2020
(MAPS)

Müller 2020

Palma-Sevillano
2019

Uzenoff 2008

Subgroup 1.83.2 Group CBT

Lecomte 2008

Lecomte 2008

Pos 2019

Supereden3

Risk of bias for analysis 1.84 Subgroup analysis - Method of delivery

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Subgroup 1.84.1 Face to face

Barrowclough
2014

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

146

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Bias

Edwards 2006

GetUp

Gleeson 2009
(EPISODE II)

Gonzalez-Ortega
2021

Haddock 1999

Hjorthoj 2013
(CapOpus)

Jackson 2008
(ACE)

Jolley 2003

Lecomte 2008

Lecomte 2008

Lewis 2002
(SOCRATES)

Lewis 2002
(SOCRATES)

Liu 2019

Morrison 2018
(COMPARE)

Morrison 2020
(MAPS)

Müller 2020

Palma-Sevillano
2019

Pos 2019

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

147

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bias

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Study

Supereden3

Uzenoff 2008

Subgroup 1.84.2 Smartphone app

Bucci 2018 (Actis-
sist)

Risk of bias for analysis 1.85 Subgroup analysis - Control group

Bias

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Subgroup 1.85.1 CBT compared to TAU

Barrowclough
2014

GetUp

Gleeson 2009
(EPISODE II)

Gonzalez-Ortega
2021

Hjorthoj 2013
(CapOpus)

Jolley 2003

Lecomte 2008

Lewis 2002
(SOCRATES)

Liu 2019

Morrison 2018
(COMPARE)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

148

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Randomisation
process

Deviations
from intended
interventions

Missing
outcome data

Measurement
of the outcome

Selection of
the reported
results

Overall

Bias

Morrison 2020
(MAPS)

Müller 2020

Palma-Sevillano
2019

Pos 2019

Supereden3

Subgroup 1.85.2 CBT compared to other psychosocial interventions

Bucci 2018 (Actis-
sist)

Edwards 2006

Haddock 1999

Jackson 2008
(ACE)

Lecomte 2008

Lewis 2002
(SOCRATES)

Uzenoff 2008

D A T A   A N D   A N A L Y S E S

Comparison 1.   CBT plus standard care versus control

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.1 Mental state - general: mean
endpoint PANSS total (high = poor)

15

Mean Difference (IV, Random,
95% CI)

Subtotals only

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

149

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.1.1 < 6 months

1.1.2 < 12 months

1.1.3 > 1 year

1.2 Mental state - general: mean
change PANSS total (high = poor)

1.2.1 < 6 months

1.2.2 < 12 months

1.2.3 > 1 year

1.3 Mental state - general: mean
endpoint PSYRATS (high = poor)

1.3.1 < 6 months

1.3.2 < 12 months

1.3.3 > 1 year

1.4 Mental state - general: mean
endpoint BPRS total (high = poor)

1.4.1 < 6 months

1.4.2 < 12 months

1.4.3 > 1 year

1.5 Mental state - general: mean
endpoint overall symptom scales
(high = poor) (combined time
points)

1.6 Mental state - general: mean
endpoint overall symptom scales
(high = poor) (separated time
points)

12

10

6

2

1

1

1

1

1

1

1

5

4

3

1

20

20

857

808

555

15

25

22

240

80

80

80

214

179

81

1508

Mean Difference (IV, Random,
95% CI)

-7.48 [-12.79,
-2.17]

Mean Difference (IV, Random,
95% CI)

-6.66 [-13.36, 0.05]

Mean Difference (IV, Random,
95% CI)

-10.81 [-21.23,
-0.39]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-1.40 [-12.59, 9.79]

Mean Difference (IV, Random,
95% CI)

10.90 [-0.28, 22.08]

Mean Difference (IV, Random,
95% CI)

8.00 [-2.30, 18.30]

Mean Difference (IV, Random,
95% CI)

-7.44 [-9.65, -5.22]

Mean Difference (IV, Random,
95% CI)

-5.75 [-9.66, -1.84]

Mean Difference (IV, Random,
95% CI)

-8.00 [-11.66,
-4.34]

Mean Difference (IV, Random,
95% CI)

-8.50 [-12.45,
-4.55]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-1.05 [-4.39, 2.29]

Mean Difference (IV, Random,
95% CI)

-1.99 [-4.96, 0.97]

Mean Difference (IV, Random,
95% CI)

1.60 [0.95, 2.25]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.27 [-0.47, -0.08]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

150

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.6.1 < 6 months

1.6.2 < 12 months

1.6.3 > 1 year

1.7 Mental state - general: number
of participants with clinically impor-
tant change in general mental state
(combined time points)

1.8 Mental state - general: number
of participants with clinically impor-
tant change in general mental state
(separated time points)

1.8.1 < 6 months

1.8.2 < 12 months

1.8.3 > 1 year

1.9 Mental state - specific: number
of participants with clinically impor-
tant change in positive symptoms
(combined time points)

1.10 Mental state - specific: number
of participants with clinically impor-
tant change in positive symptoms
(separated time points)

1.10.1 > 6 months

1.10.2 > 12 months

1.10.3 > 1 year

1.11 Mental state - specific: mean
endpoint PANSS positive (high =
poor)

1.11.1 < 6 months

16

13

7

4

4

3

3

1

2

2

2

1

1

15

13

1071

987

636

301

221

221

80

99

99

80

80

913

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.33 [-0.57, -0.09]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.32 [-0.60, -0.03]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.42 [-1.03, 0.20]

Risk Ratio (IV, Random, 95%
CI)

1.50 [0.95, 2.39]

Risk Ratio (IV, Random, 95%
CI)

Subtotals only

Risk Ratio (IV, Random, 95%
CI)

1.89 [1.26, 2.85]

Risk Ratio (IV, Random, 95%
CI)

1.42 [0.78, 2.59]

Risk Ratio (IV, Random, 95%
CI)

1.90 [1.01, 3.56]

Risk Ratio (IV, Random, 95%
CI)

1.38 [0.98, 1.93]

Risk Ratio (IV, Random, 95%
CI)

Subtotals only

Risk Ratio (IV, Random, 95%
CI)

1.78 [1.11, 2.83]

Risk Ratio (IV, Random, 95%
CI)

1.33 [0.93, 1.91]

Risk Ratio (IV, Random, 95%
CI)

1.31 [1.01, 1.70]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-1.76 [-3.09, -0.43]

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

151

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.11.2 < 12 months

1.11.3 > 1 year

1.12 Mental state - specific: mean
change PANSS positive (high = poor)

1.12.1 < 6 months

1.12.2 < 12 months

1.12.3 > 1 year

1.13 Mental state - specific: mean
endpoint BPRS positive (high =
poor)

1.13.1 < 6 months

1.13.2 < 12 months

1.13.3 > 1 year

1.14 Mental state - specific: mean
endpoint SAPS (high = poor)

1.14.1 < 6 months

1.14.2 < 12 months

1.15 Mental state - specific: mean
endpoint positive symptoms scales
(high = poor) (combined time
points)

1.16 Mental state - specific: mean
endpoint positive symptoms scales
(high = poor) (separated time
points)

1.16.1 < 6 months

1.16.2 < 12 months

9

6

2

1

1

1

5

4

2

2

2

2

2

22

22

19

13

684

502

15

25

22

253

98

143

105

86

1565

1271

868

Mean Difference (IV, Random,
95% CI)

-2.03 [-4.18, 0.11]

Mean Difference (IV, Random,
95% CI)

-2.83 [-5.44, -0.22]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

0.80 [-3.94, 5.54]

Mean Difference (IV, Random,
95% CI)

-1.90 [-4.39, 0.59]

Mean Difference (IV, Random,
95% CI)

2.60 [-2.67, 7.87]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-0.85 [-1.78, 0.08]

Mean Difference (IV, Random,
95% CI)

0.25 [-1.62, 2.12]

Mean Difference (IV, Random,
95% CI)

-0.20 [-0.40, -0.01]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-0.13 [-2.06, 1.81]

Mean Difference (IV, Random,
95% CI)

-0.12 [-2.40, 2.16]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.22 [-0.38, -0.06]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.26 [-0.43, -0.10]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.19 [-0.44, 0.06]

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

152

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.16.3 > 1 year

1.17 Mental state - specific: mean
endpoint PANSS negative (high =
poor)

1.17.1 < 6 months

1.17.2 < 12 months

1.17.3 > 1 year

1.18 Mental state - specific: mean
change PANSS negative (high =
poor)

1.18.1 < 6 months

1.18.2 < 12 months

1.18.3 > 1 year

1.19 Mental state - specific: mean
endpoint BPRS negative (high =
poor)

1.19.1 < 6 months

1.19.2 < 12 months

1.20 Mental state - specific: mean
endpoint SANS (high = poor)

1.20.1 < 6 months

1.20.2 < 12 months

1.20.3 > 1 year

1.21 Mental state - specific: mean
endpoint BNSS (high = poor)

8

15

12

9

6

2

1

1

1

1

1

1

6

4

4

2

1

645

706

682

501

15

25

22

98

65

196

272

166

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.40 [-0.76, -0.04]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-0.91 [-1.70, -0.13]

Mean Difference (IV, Random,
95% CI)

-0.94 [-1.81, -0.08]

Mean Difference (IV, Random,
95% CI)

-2.54 [-4.04, -1.04]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-1.30 [-6.53, 3.93]

Mean Difference (IV, Random,
95% CI)

0.70 [-2.72, 4.12]

Mean Difference (IV, Random,
95% CI)

-0.50 [-5.37, 4.37]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

0.50 [-1.26, 2.26]

Mean Difference (IV, Random,
95% CI)

-0.21 [-1.80, 1.38]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-3.28 [-6.36, -0.20]

Mean Difference (IV, Random,
95% CI)

-2.34 [-6.18, 1.51]

Mean Difference (IV, Random,
95% CI)

-2.60 [-7.38, 2.18]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

153

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.21.1 < 6 months

1.21.2 < 12 months

1.22 Mental state - specific: mean
endpoint negative symptoms
scale (high = poor) (combined time
points)

1.23 Mental state - specific: mean
endpoint negative symptoms
scale (high = poor) (separated time
points)

1.23.1 < 6 months

1.23.2 < 12 months

1.23.3 > 1 year

1.24 Mental state - specific: mean
endpoint BDI short form (high =
poor)

1.24.1 < 6 months

1.24.2 < 12 months

1.25 Mental state - specific: mean
endpoint BDI-II (high = poor)

1.25.1 < 6 months

1.25.2 < 12 months

1.25.3 > 1 year

1.26 Mental state - specific: mean
endpoint HADS Depression (high =
poor)

1.26.1 < 6 months

1

1

22

22

17

14

8

2

2

1

2

1

1

2

2

2

79

74

1651

1000

1019

667

93

33

56

117

146

59

Mean Difference (IV, Random,
95% CI)

-2.60 [-7.25, 2.05]

Mean Difference (IV, Random,
95% CI)

0.50 [-4.32, 5.32]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.20 [-0.30, -0.11]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.20 [-0.32, -0.07]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.19 [-0.32, -0.06]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.42 [-0.65, -0.18]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-0.95 [-3.58, 1.68]

Mean Difference (IV, Random,
95% CI)

1.20 [-3.41, 5.81]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-1.70 [-7.31, 3.91]

Mean Difference (IV, Random,
95% CI)

-1.66 [-6.77, 3.45]

Mean Difference (IV, Random,
95% CI)

-0.69 [-4.61, 3.22]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-2.95 [-5.70, -0.20]

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

154

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.26.2 < 12 months

1.27 Mental state - specific: mean
endpoint CDS (high = poor)

1.27.1 < 6 months

1.27.2 < 12 months

1.27.3 > 1 year

1.28 Mental state - specific: mean
change CDS (high = poor)

1.28.1 > 6 months

1.28.2 < 12 months

1.28.3 > 1 year

1.29 Mental state - specific: mean
endpoint MADRS (high = poor)

1.29.1 < 12 months

1.29.2 > 1 year

1.30 Mental state - specific: mean
endpoint Hamilton Depression (high
= poor)

1.30.1 < 6 months

1.30.2 < 12 months

1.31 Mental state - specific: mean
endpoint CESD-R (high = poor)

1.31.1 < 6 months

2

9

8

5

3

2

1

1

1

1

1

1

2

1

1

1

1

53

337

215

134

15

25

22

162

81

81

467

177

290

48

48

Mean Difference (IV, Random,
95% CI)

-0.15 [-2.94, 2.64]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

0.28 [-0.70, 1.26]

Mean Difference (IV, Random,
95% CI)

-0.22 [-1.37, 0.92]

Mean Difference (IV, Random,
95% CI)

0.71 [-0.81, 2.24]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

0.30 [-3.58, 4.18]

Mean Difference (IV, Random,
95% CI)

2.20 [-1.37, 5.77]

Mean Difference (IV, Random,
95% CI)

2.10 [-1.88, 6.08]

Mean Difference (IV, Random,
95% CI)

-0.20 [-2.07, 1.68]

Mean Difference (IV, Random,
95% CI)

-2.50 [-7.00, 2.00]

Mean Difference (IV, Random,
95% CI)

0.20 [-0.54, 0.94]

Mean Difference (IV, Random,
95% CI)

-1.55 [-2.81, -0.30]

Mean Difference (IV, Random,
95% CI)

-1.41 [-2.97, 0.15]

Mean Difference (IV, Random,
95% CI)

-1.81 [-3.93, 0.31]

Mean Difference (IV, Random,
95% CI)

-3.94 [-13.24, 5.36]

Mean Difference (IV, Random,
95% CI)

-3.94 [-13.24, 5.36]

1.32 Mental state - specific: mean
endpoint depressive symptoms

18

1182

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.13 [-0.24, -0.01]

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

155

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

(high = poor) (combined time
points)

1.33 Mental state - specific: mean
endpoint depressive symptoms
(high = poor) (separated time
points)

1.33.1 < 6 months

1.33.2 < 12 months

1.33.3 > 1 year

1.34 Global state - number of partici-
pants with relapse/exacerbations of
psychosis (combined time points)

1.35 Global state - number of partici-
pants with relapse/exacerbations of
psychosis (separated time points)

1.35.1 < 6 months

1.35.2 < 12 months

1.35.3 > 1 year

1.36 Global state - number of par-
ticipants with remission (combined
time points)

1.37 Global state - number of par-
ticipants with remission (separated
time points)

1.37.1 < 6 months

1.37.2 < 12 months

1.37.3 > 1 year

1.38 Global state - number of par-
ticipants with clinically important
change in global state

18

14

11

5

7

7

3

5

5

2

2

1

1

1

1

714

789

313

693

172

363

601

73

48

25

25

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.11 [-0.27, 0.06]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.13 [-0.27, 0.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.13 [-0.10, 0.35]

Risk Ratio (IV, Random, 95%
CI)

0.82 [0.57, 1.18]

Risk Ratio (IV, Random, 95%
CI)

Subtotals only

Risk Ratio (IV, Random, 95%
CI)

0.43 [0.09, 2.07]

Risk Ratio (IV, Random, 95%
CI)

0.54 [0.22, 1.32]

Risk Ratio (IV, Random, 95%
CI)

0.86 [0.62, 1.19]

Risk Ratio (IV, Random, 95%
CI)

1.16 [0.70, 1.91]

Risk Ratio (IV, Random, 95%
CI)

Subtotals only

Risk Ratio (IV, Random, 95%
CI)

0.99 [0.52, 1.88]

Risk Ratio (IV, Random, 95%
CI)

1.48 [0.67, 3.27]

Risk Ratio (IV, Random, 95%
CI)

1.11 [0.45, 2.70]

Risk Ratio (IV, Random, 95%
CI)

Subtotals only

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

156

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.38.1 < 6 months

1.38.2 < 12 months

1.39 Global state - mean endpoint
CGI (high = poor) (separated time
points)

1.39.1 < 6 months

1.39.2 < 12 months

1.39.3 > 1 year

1.40 Global state - mean end-
point/change CGI-S (high = poor)
(separated time points)

1.40.1 < 6 months

1.40.2 < 12 months

1.41 Global state - mean endpoint
CGI-I (high = poor) (separated time
points)

1.41.1 < 6 months

1.41.2 < 12 months

1.42 Global state - mean end-
point/change global state scales
(high = poor) (combined time
points)

1.43 Global state - mean end-
point/change global state scales
(high = poor) (separated time
points)

1.43.1 < 6 months

1.43.2 < 12 months

1

1

1

1

1

1

3

3

1

2

2

1

4

4

4

2

99

99

62

62

62

268

42

220

42

329

330

104

Risk Ratio (IV, Random, 95%
CI)

1.58 [0.82, 3.01]

Risk Ratio (IV, Random, 95%
CI)

1.53 [0.83, 2.83]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-1.00 [-1.37, -0.63]

Mean Difference (IV, Random,
95% CI)

-0.80 [-1.25, -0.35]

Mean Difference (IV, Random,
95% CI)

-1.30 [-1.85, -0.75]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-0.30 [-0.65, 0.05]

Mean Difference (IV, Random,
95% CI)

-0.23 [-0.89, 0.43]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-0.29 [-1.78, 1.20]

Mean Difference (IV, Random,
95% CI)

-0.20 [-0.86, 0.46]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.34 [-0.67, -0.01]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.51 [-1.02, 0.01]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.55 [-1.19, 0.09]

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

157

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.43.3 > 1 year

1.44 Service use - admission to hos-
pital (combined time points)

1.45 Service use - admission to hos-
pital (separated time points)

1.45.1 < 6 months

1.45.2 < 12 months

1.45.3 > 1 year

1.46 Service use - number of days in
hospital (combined time points)

1.47 Service use - number of days in
hospital (separated time points)

1.47.1 < 6 months

1.47.2 < 12 months

1.47.3 > 1 year

1.48 Leaving the study early - for any
reason - overall acceptability (com-
bined time points)

1.49 Leaving the study early - for any
reason - overall acceptability (sepa-
rated time points)

1.49.1 < 6 months

1.49.2 < 12 months

1.49.3 > 1 year

1.50 Functioning - mean endpoint
GAF (high = good)

1.50.1 < 6 months

1

10

10

4

5

5

7

7

3

4

4

25

25

21

15

10

10

8

62

1121

240

590

586

571

98

488

199

2242

1655

1396

1076

570

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.12 [-1.66, -0.58]

Risk Ratio (IV, Random, 95%
CI)

1.00 [0.80, 1.25]

Risk Ratio (IV, Random, 95%
CI)

Subtotals only

Risk Ratio (IV, Random, 95%
CI)

1.36 [0.42, 4.41]

Risk Ratio (IV, Random, 95%
CI)

0.90 [0.56, 1.45]

Risk Ratio (IV, Random, 95%
CI)

0.92 [0.68, 1.23]

Mean Difference (IV, Random,
95% CI)

-8.18 [-24.74, 8.38]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-21.56 [-60.13,
17.02]

Mean Difference (IV, Random,
95% CI)

2.95 [-9.42, 15.33]

Mean Difference (IV, Random,
95% CI)

-12.39 [-36.62,
11.84]

Risk Ratio (IV, Random, 95%
CI)

0.87 [0.72, 1.05]

Risk Ratio (IV, Random, 95%
CI)

Subtotals only

Risk Ratio (IV, Random, 95%
CI)

0.87 [0.70, 1.07]

Risk Ratio (IV, Random, 95%
CI)

0.86 [0.66, 1.13]

Risk Ratio (IV, Random, 95%
CI)

0.81 [0.69, 0.96]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-4.62 [-9.35, 0.10]

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

158

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.50.2 < 12 months

1.50.3 > 1 year

1.51 Functioning - mean change GAF
(high = good)

1.51.1 < 12 months

1.51.2 > 1 year

1.52 Functioning - mean endpoint
SOFAS (high = good)

1.52.1 < 6 months

1.52.2 < 12 months

1.52.3 > 1 year

1.53 Functioning - mean endpoint
PSP (high = good)

1.53.1 < 6 months

1.53.2 < 12 months

1.53.3 > 1 year

1.54 Functioning - mean endpoint
FAST (high = poor)

1.54.1 < 6 months

1.55 Functioning - mean endpoint
FESFS (high = good)

1.55.1 < 6 months

1.55.2 < 12 months

7

4

1

1

1

5

4

3

2

3

3

2

1

1

1

1

1

1

592

196

25

22

196

151

143

153

122

80

177

9

3

Mean Difference (IV, Random,
95% CI)

-2.91 [-8.15, 2.33]

Mean Difference (IV, Random,
95% CI)

-9.63 [-18.70,
-0.56]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-0.30 [-8.18, 7.58]

Mean Difference (IV, Random,
95% CI)

-0.40 [-11.39,
10.59]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-2.78 [-6.13, 0.57]

Mean Difference (IV, Random,
95% CI)

0.02 [-4.82, 4.87]

Mean Difference (IV, Random,
95% CI)

4.51 [-5.39, 14.41]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-4.59 [-9.73, 0.54]

Mean Difference (IV, Random,
95% CI)

-4.80 [-9.66, 0.07]

Mean Difference (IV, Random,
95% CI)

-7.88 [-13.85,
-1.91]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-4.90 [-9.57, -0.23]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-1.15 [-4.91, 2.61]

Mean Difference (IV, Random,
95% CI)

0.27 [-7.22, 7.76]

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

159

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Outcome or subgroup title

No. of studies

1.56 Functioning - mean endpoint
functioning scale (high = good)
(combined time points)

1.57 Functioning - mean endpoint
functioning scale (high = good) (sep-
arated time points)

1.57.1 < 6 months

1.57.2 < 12 months

1.57.3 > 1 year

1.58 Quality of life - mean endpoint
WHO QoL-bref (high = good)

1.58.1 < 6 months

1.58.2 < 12 months

1.59 Quality of life - mean endpoint
EQ5d (WHO) (high = good)

1.59.1 < 6 months

1.59.2 < 12 months

1.60 Quality of life - mean endpoint
QLS (high = good)

1.60.1 < 6 months

1.61 Quality of life - mean endpoint
MSQoL (high = good)

1.61.1 < 12 months

1.61.2 > 1 year

1.62 Quality of life - mean change
MSQoL (high = good)

1.62.1 < 12 months

18

18

15

13

7

3

2

3

3

3

2

2

2

1

1

1

1

1

Cochrane Database of Systematic Reviews

No. of partici-
pants

1241

Statistical method

Effect size

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.23 [-0.42, -0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.32 [-0.54, -0.10]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.18 [-0.43, 0.07]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.15 [-1.16, 0.87]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-3.15 [-10.79, 4.49]

Mean Difference (IV, Random,
95% CI)

-0.24 [-1.06, 0.57]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.38 [-0.66, -0.10]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.50 [-0.86, -0.13]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.21 [-0.64, 0.22]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

1.63 [-6.44, 9.69]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-5.80 [-18.30, 6.70]

Mean Difference (IV, Random,
95% CI)

-7.50 [-24.63, 9.63]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

-3.70 [-15.01, 7.61]

898

868

419

87

166

209

125

84

67

22

16

25

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

160

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.62.2 > 1 year

1.63 Quality of life - MANSA (high =
good)

1.63.1 < 6 months

1.63.2 < 12 months

1.64 Quality of life - mean endpoint
quality of life scale (high = good)
(combined time points)

1.65 Quality of life - mean endpoint
quality of life scale (high = good)
(separated time points)

1.65.1 < 6 months

1.65.2 < 12 months

1.65.3 > 1 year

1.66 Behaviour - occurence of vio-
lent incidents

1.66.1 < 12 months

1.67 Behaviour - participants with
self-injury

1.67.1 < 12 months

1.68 Behaviour - participants with
suicide attempts

1.68.1 < 12 months

1.68.2 > 1 year

1.69 Adverse events - participants
with at least one adverse event

1.70 Adverse events - specific: Non
Compliance

1

1

1

1

9

9

7

7

1

2

2

2

2

2

2

1

1

2

22

36

36

386

296

308

16

92

92

68

25

Mean Difference (IV, Random,
95% CI)

-4.30 [-14.09, 5.49]

Mean Difference (IV, Random,
95% CI)

Subtotals only

Mean Difference (IV, Random,
95% CI)

2.90 [-2.95, 8.75]

Mean Difference (IV, Random,
95% CI)

-0.20 [-7.72, 7.32]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.13 [-0.33, 0.07]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.24 [-0.51, 0.02]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.16 [-0.39, 0.07]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.40 [-1.40, 0.60]

Risk Ratio (IV, Random, 95%
CI)

Subtotals only

Risk Ratio (IV, Random, 95%
CI)

0.96 [0.15, 6.20]

Risk Ratio (IV, Random, 95%
CI)

Subtotals only

Risk Ratio (IV, Random, 95%
CI)

1.89 [0.95, 3.80]

Risk Ratio (IV, Random, 95%
CI)

Subtotals only

Risk Ratio (IV, Random, 95%
CI)

0.97 [0.10, 9.41]

Risk Ratio (IV, Random, 95%
CI)

0.31 [0.01, 6.94]

Risk Ratio (IV, Random, 95%
CI)

Subtotals only

Risk Ratio (IV, Random, 95%
CI)

Subtotals only

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

161

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.70.1 < 6 months

1.70.2 < 12 months

1.70.3 > 1 year

1.71 Adverse events - specific: Dete-
rioration of symptoms

1.71.1 < 6 months

1.71.2 < 12 months

1.71.3 > 1 year

1.72 Mortality - overall mortality
(combined time points)

1.73 Mortality - overall mortality
(separated time points)

1.73.1 < 12 months

1.73.2 > 1 year

1.74 Mortality - due to natural caus-
es

1.74.1 < 12 months

1.74.2 > 1 year

1.75 Mortality - due to suicide

1.75.1 < 12 months

1.75.2 > 1 year

2

1

1

4

2

3

2

4

4

2

2

2

1

1

2

1

1

190

80

80

92

117

87

900

481

419

635

326

309

388

326

62

Risk Ratio (IV, Random, 95%
CI)

1.06 [0.47, 2.37]

Risk Ratio (IV, Random, 95%
CI)

0.33 [0.04, 3.07]

Risk Ratio (IV, Random, 95%
CI)

0.33 [0.04, 3.07]

Risk Ratio (IV, Random, 95%
CI)

Subtotals only

Risk Ratio (IV, Random, 95%
CI)

1.08 [0.17, 7.03]

Risk Ratio (IV, Random, 95%
CI)

0.58 [0.12, 2.79]

Risk Ratio (IV, Random, 95%
CI)

0.53 [0.27, 1.02]

Risk Ratio (IV, Random, 95%
CI)

1.22 [0.41, 3.66]

Risk Ratio (IV, Random, 95%
CI)

Subtotals only

Risk Ratio (IV, Random, 95%
CI)

0.97 [0.18, 5.13]

Risk Ratio (IV, Random, 95%
CI)

1.38 [0.20, 9.60]

Risk Ratio (IV, Random, 95%
CI)

2.00 [0.22, 17.99]

Risk Ratio (IV, Random, 95%
CI)

0.21 [0.01, 5.13]

Risk Ratio (IV, Random, 95%
CI)

6.12 [0.64, 58.07]

Risk Ratio (IV, Random, 95%
CI)

1.08 [0.05, 24.00]

Risk Ratio (IV, Random, 95%
CI)

0.21 [0.01, 5.13]

Risk Ratio (IV, Random, 95%
CI)

5.00 [0.25, 100.08]

1.76 Sensitivity analysis - Blinding of
outcome assessor

19

1229

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.28 [-0.50, -0.06]

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

162

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.77 Sensitivity analysis - Assump-
tions for missing data

1.78 Sensitivity analysis - Risk of
Bias

1.79 Sensitivity analysis - Imputed
values

1.80 Sensitivity analysis - Fixed-ef-
fect

1.81 Sensitivity analysis excluding
outliers

1.82 Subgroup analysis - Different
types of CBT

1.82.1 CBT

1.82.2 CBT integrated with other
psychosocial interventions

1.82.3 CBT and Motivational Inter-
viewing for cannabis use cessation

1.82.4 Special types of CBT

1.83 Subgroup analysis - Modality of
treatment

1.83.1 Individual CBT

1.83.2 Group CBT

1.84 Subgroup analysis - Method of
delivery

1.84.1 Face to face

1.84.2 Smartphone app

1.85 Subgroup analysis - Control
group

1.85.1 CBT compared to TAU

15

15

18

20

19

20

11

4

3

2

20

17

3

20

19

1

20

15

1215

1006

1214

1508

1446

1508

775

494

139

100

1508

1246

262

1508

1478

30

1508

1211

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.29 [-0.52, -0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.29 [-0.56, -0.01]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.28 [-0.50, -0.05]

Std. Mean Difference (IV, Fixed,
95% CI)

-0.25 [-0.35, -0.14]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.19 [-0.30, -0.09]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.27 [-0.47, -0.08]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.19 [-0.35, -0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.87 [-1.73, -0.01]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.04 [-0.38, 0.30]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.26 [-0.82, 0.31]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.27 [-0.47, -0.08]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.29 [-0.53, -0.05]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.18 [-0.42, 0.07]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.27 [-0.47, -0.08]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.26 [-0.47, -0.06]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.60 [-1.39, 0.20]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.27 [-0.47, -0.08]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.34 [-0.59, -0.09]

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

163

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

1.85.2 CBT compared to other psy-
chosocial interventions

7

No. of partici-
pants

297

Statistical method

Effect size

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.08 [-0.32, 0.17]

Analysis 1.1.   Comparison 1: CBT plus standard care versus control,
Outcome 1: Mental state - general: mean endpoint PANSS total (high = poor)

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.1.1 < 6 months
Barrowclough 2014
Bucci 2018 (Actissist)
Gonzalez-Ortega 2021
Hjorthoj 2013 (CapOpus)
Jolley 2003
Lewis 2002 (SOCRATES) (1)
Lewis 2002 (SOCRATES) (2)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Palma-Sevillano 2019
Pos 2019
Uzenoff 2008
Subtotal (95% CI)
Heterogeneity: Tau² = 75.41; Chi² = 90.58, df = 12 (P < 0.00001); I² = 87%
Test for overall effect: Z = 2.76 (P = 0.006)

10.445665
17.4
10.03
15.2
13.87
19.69
19.69
11.22
12.54
15.9
20.7
12.76863
6.72

59.75
52.9
40.37
59.4
49.2
61.73
61.73
51.65
53.77
62
56.6
51.4103
48.4

48
21
86
18
7
39
39
40
22
17
35
39
10
421

58.9
63.6
45.11
63.8
54.7
64.38
59.96
55.05
61.06
68.6
116.2
51.8718
55.67

1.1.2 < 12 months
Barrowclough 2014
GetUp
Hjorthoj 2013 (CapOpus)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Palma-Sevillano 2019
Pos 2019
Supereden3
Subtotal (95% CI)
Heterogeneity: Tau² = 100.87; Chi² = 100.92, df = 9 (P < 0.00001); I² = 91%
Test for overall effect: Z = 1.95 (P = 0.05)

59.419149
50.1
57.2
44.88
57.4
56.2
51.3
52.1
52.2051
55.33

9.639697
14.73
21.5
8.06
13.58
12.3
8.65
19.3
13.7385
25.77

47
170
18
40
20
11
12
35
39
66
458

59.4
53.4
61.9
49.6
56.77
55.4
52
110
52.3714
58.67

11.6
17.54
9.89
16.9
14.94
16.79
16.39
9.56
14.44
17.3
26.42
11.68485
12.22

11.3
14.39
23.4
10.47
14.1
7
7.02
23.5
11.52768
21.2

1.1.3 > 1 year
Barrowclough 2014
Lewis 2002 (SOCRATES) (1)
Lewis 2002 (SOCRATES) (2)
Liu 2019
Müller 2020
Palma-Sevillano 2019
Supereden3
Subtotal (95% CI)
Heterogeneity: Tau² = 184.09; Chi² = 107.45, df = 6 (P < 0.00001); I² = 94%
Test for overall effect: Z = 2.03 (P = 0.04)

10.375331
12.69
12.69
7.89
10.84
18.14
21.3

61.8
58.83
58.83
43.2
49.1
48.6
51.33

49
38
37
40
9
35
57
265

59.5
66.37
61.44
52
53.7
103.2
53.67

11.9
15.99
16.09
13.92
9.93
20.05
19.1

24
9
91
18
8
60
71
40
22
18
27
39
9
436

23
109
18
40
22
9
10
27
35
57
350

21
70
79
40
7
27
46
290

8.8%
5.9%
9.4%
7.0%
5.6%
8.1%
8.2%
9.1%
8.0%
6.9%
6.5%
8.8%
7.6%
100.0%

10.8%
11.2%
7.5%
11.1%
9.8%
9.7%
10.4%
8.9%
10.7%
9.8%
100.0%

0.85 [-4.65 , 6.35]
-10.70 [-24.36 , 2.96]
-4.74 [-7.68 , -1.80]
-4.40 [-14.90 , 6.10]
-5.50 [-20.09 , 9.09]
-2.65 [-10.15 , 4.85]
1.77 [-5.49 , 9.03]
-3.40 [-7.97 , 1.17]
-7.29 [-15.28 , 0.70]
-6.60 [-17.60 , 4.40]
-59.60 [-71.70 , -47.50]
-0.46 [-5.89 , 4.97]
-7.27 [-16.27 , 1.73]
-7.48 [-12.79 , -2.17]

0.02 [-5.36 , 5.40]
-3.30 [-6.79 , 0.19]
-4.70 [-19.38 , 9.98]
-4.72 [-8.81 , -0.63]
0.63 [-7.74 , 9.00]
0.80 [-7.79 , 9.39]
-0.70 [-7.25 , 5.85]
-57.90 [-68.83 , -46.97]
-0.17 [-5.93 , 5.59]
-3.34 [-11.64 , 4.96]
-6.66 [-13.36 , 0.05]

14.6%
14.7%
14.7%
14.8%
13.4%
13.6%
14.1%
100.0%

2.30 [-3.56 , 8.16]
-7.54 [-13.05 , -2.03]
-2.61 [-8.02 , 2.80]
-8.80 [-13.76 , -3.84]
-4.60 [-14.81 , 5.61]
-54.60 [-64.26 , -44.94]
-2.34 [-10.15 , 5.47]
-10.81 [-21.23 , -0.39]

Test for subgroup differences: Chi² = 0.44, df = 2 (P = 0.80), I² = 0%

Footnotes
(1) comparator treatment-as-usual (TAU)
(2) comparator supportive counselling + TAU

-50

-25
CBT + TAU

0

50

25
Control

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

164

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.2.   Comparison 1: CBT plus standard care versus control,
Outcome 2: Mental state - general: mean change PANSS total (high = poor)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.2.1 < 6 months
Jolley 2003
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.25 (P = 0.81)

-6.8

13.03

1.2.2 < 12 months
Müller 2020
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.91 (P = 0.06)

-8.2

10.09

1.2.3 > 1 year
Müller 2020
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.52 (P = 0.13)

-6.5

8.56

7
7

13
13

12
12

-5.4

8.18

8
8

100.0%
100.0%

-1.40 [-12.59 , 9.79]
-1.40 [-12.59 , 9.79]

-19.1

17.22

12
12

100.0%
100.0%

10.90 [-0.28 , 22.08]
10.90 [-0.28 , 22.08]

-14.5

14.67

10
10

100.0%
100.0%

8.00 [-2.30 , 18.30]
8.00 [-2.30 , 18.30]

Test for subgroup differences: Chi² = 2.56, df = 2 (P = 0.28), I² = 21.9%

-20

-10
CBT + TAU

0

20

10
Control

Analysis 1.3.   Comparison 1: CBT plus standard care versus control,
Outcome 3: Mental state - general: mean endpoint PSYRATS (high = poor)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.3.1 < 6 months
Liu 2019
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.88 (P = 0.004)

15

9.04

1.3.2 < 12 months
Liu 2019
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 4.28 (P < 0.0001)

7.5

5.1

1.3.3 > 1 year
Liu 2019
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 4.21 (P < 0.0001)

7.75

5.8

40
40

40
40

40
40

20.75

8.81

40
40

32.1%
32.1%

-5.75 [-9.66 , -1.84]
-5.75 [-9.66 , -1.84]

15.5

10.67

40
40

36.5%
36.5%

-8.00 [-11.66 , -4.34]
-8.00 [-11.66 , -4.34]

16.25

11.36

40
40

31.4%
31.4%

-8.50 [-12.45 , -4.55]
-8.50 [-12.45 , -4.55]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.08, df = 2 (P = 0.58); I² = 0%
Test for overall effect: Z = 6.58 (P < 0.00001)
Test for subgroup differences: Chi² = 1.08, df = 2 (P = 0.58), I² = 0%

120

120

100.0%

-7.44 [-9.65 , -5.22]

-20

-10
CBT + TAU

0

10
Control

20

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

165

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.4.   Comparison 1: CBT plus standard care versus control,
Outcome 4: Mental state - general: mean endpoint BPRS total (high = poor)

Study or Subgroup

CBT + TAU
SD

Mean

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.4.1 < 6 months
Edwards 2006
Haddock 1999
Jackson 2008 (ACE)
Lecomte 2008 (1)
Lecomte 2008 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.73, df = 4 (P = 0.60); I² = 0%
Test for overall effect: Z = 0.61 (P = 0.54)

13.8
8.75
13.634
9.14
9.14

44.1
46.8
37.25
35.9
35.9

22
8
28
21
21
100

1.4.2 < 12 months
Edwards 2006
Gleeson 2009 (EPISODE II)
Lecomte 2008 (1)
Lecomte 2008 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.18, df = 3 (P = 0.54); I² = 0%
Test for overall effect: Z = 1.32 (P = 0.19)

45.6
34.3
33.4
33.4

13.5
8.4
8.29
8.29

16
41
18
17
92

47.7
38.3
38.51
38.4
37

18.2
17.4
12.028
15.03
11.7

23
10
25
23
33
114

12.6%
7.3%
23.4%
21.0%
35.7%
100.0%

-3.60 [-13.01 , 5.81]
8.50 [-3.87 , 20.87]
-1.26 [-8.17 , 5.65]
-2.50 [-9.78 , 4.78]
-1.10 [-6.69 , 4.49]
-1.05 [-4.39 , 2.29]

44.8
35
39.3
36.5

15.4
9.8
9.68
14.1

17
40
13
17
87

9.0%
55.6%
20.8%
14.6%
100.0%

0.80 [-9.07 , 10.67]
-0.70 [-4.68 , 3.28]
-5.90 [-12.41 , 0.61]
-3.10 [-10.88 , 4.68]
-1.99 [-4.96 , 0.97]

1.4.3 > 1 year
Gleeson 2009 (EPISODE II)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 4.80 (P < 0.00001)

33.8

1.5

41
41

32.2

1.5

40
40

100.0%
100.0%

1.60 [0.95 , 2.25]
1.60 [0.95 , 2.25]

Test for subgroup differences: Chi² = 7.42, df = 2 (P = 0.02), I² = 73.1%

Footnotes
(1) comparator waiting list (WL)
(2) comparator skills training for symptom management (SST)

-20

-10
CBT + TAU

0

20

10
Control

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

166

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.5.   Comparison 1: CBT plus standard care versus control, Outcome 5: Mental
state - general: mean endpoint overall symptom scales (high = poor) (combined time points)

Risk of Bias
E
B

D

C

+
?
+
+
+
?
?
+
?
?
+
+
+
+
+
+
+
+
?
+
+
+

?
+
?
+
+
+
+
?
+
−
−
−
?
?
+
+
−
+
+
?
−

?

+
+
+
?
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

?
+
?
+
?
+
?
+
?
?
+
+
+
+
+
+
+
?
?
+
+
?

F

?
?
?
−
?
?
?
?
?
−
−
−
?
?
+
+
−
?
?
?
−

?

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Barrowclough 2014
Bucci 2018 (Actissist)
Edwards 2006
GetUp
Gleeson 2009 (EPISODE II)
Gonzalez-Ortega 2021
Haddock 1999
Hjorthoj 2013 (CapOpus)
Jackson 2008 (ACE)
Jolley 2003
Lecomte 2008 (1)
Lecomte 2008 (2)
Lewis 2002 (SOCRATES) (3)
Lewis 2002 (SOCRATES) (4)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Palma-Sevillano 2019
Pos 2019
Supereden3
Uzenoff 2008

59.419149
52.9
45.6
50.1
34.3
40.37
46.8
57.2
37.25
49.2
33.4
33.4
61.73
61.73
44.88
57.4
56.2
51.3
52.1
52.2051
55.33
48.4

9.639697
17.4
13.5
14.73
8.4
10.03
8.75
21.5
13.634
13.87
8.29
8.29
19.69
19.69
8.06
13.58
12.3
8.65
19.3
13.7385
25.77
6.72

47
21
16
170
41
86
8
18
28
7
18
17
39
39
40
20
11
12
35
39
66
10

59.4
63.6
44.8
53.4
35
45.11
38.3
61.9
38.51
54.7
39.3
36.5
59.96
64.38
49.6
56.77
55.4
52
110
52.3714
58.67
55.67

11.3
17.54
15.4
14.39
9.8
9.89
17.4
23.4
12.028
14.94
9.68
14.1
16.39
16.79
10.47
14.1
7
7.02
23.5
11.52768
21.2
12.22

Total (95% CI)
Heterogeneity: Tau² = 0.13; Chi² = 64.70, df = 21 (P < 0.00001); I² = 68%
Test for overall effect: Z = 2.70 (P = 0.007)
Test for subgroup differences: Not applicable

788

23
9
17
109
40
91
10
18
25
8
13
17
71
60
40
22
9
10
27
35
57
9

5.2%
3.4%
4.0%
6.9%
5.6%
6.5%
2.8%
4.2%
4.9%
2.5%
3.7%
4.1%
5.9%
5.8%
5.5%
4.5%
3.1%
3.2%
3.9%
5.4%
6.1%
2.8%

0.00 [-0.50 , 0.50]
-0.60 [-1.39 , 0.20]
0.05 [-0.63 , 0.74]
-0.23 [-0.47 , 0.02]
-0.08 [-0.51 , 0.36]
-0.47 [-0.77 , -0.17]
0.57 [-0.39 , 1.52]
-0.20 [-0.86 , 0.45]
-0.10 [-0.64 , 0.44]
-0.36 [-1.38 , 0.67]
-0.65 [-1.38 , 0.09]
-0.26 [-0.94 , 0.41]
0.10 [-0.29 , 0.49]
-0.15 [-0.55 , 0.26]
-0.50 [-0.95 , -0.05]
0.04 [-0.56 , 0.65]
0.07 [-0.81 , 0.96]
-0.08 [-0.92 , 0.76]
-2.69 [-3.40 , -1.99]
-0.01 [-0.47 , 0.44]
-0.14 [-0.49 , 0.22]
-0.72 [-1.65 , 0.22]

720

100.0%

-0.27 [-0.47 , -0.08]

-4

-2
CBT + TAU

0

2
Control

4

A

+
+
+
−
+
+
+
+
+
+
?
?
+
+
+
+
+
+
+
+
+
?

Footnotes
(1) comparator waiting list (WL)
(2) comparator skills training for symptom management (SST)
(3) comparator supportive counselling + TAU
(4) comparator treatment-as-usual (TAU)

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

167

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.6.   Comparison 1: CBT plus standard care versus control, Outcome 6: Mental
state - general: mean endpoint overall symptom scales (high = poor) (separated time points)

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.6.1 < 6 months
Barrowclough 2014
Bucci 2018 (Actissist)
Edwards 2006
Gonzalez-Ortega 2021
Haddock 1999
Hjorthoj 2013 (CapOpus)
Jackson 2008 (ACE)
Jolley 2003
Lecomte 2008 (1)
Lecomte 2008 (2)
Lewis 2002 (SOCRATES) (3)
Lewis 2002 (SOCRATES) (4)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Palma-Sevillano 2019
Pos 2019
Uzenoff 2008
Subtotal (95% CI)
Heterogeneity: Tau² = 0.17; Chi² = 56.82, df = 17 (P < 0.00001); I² = 70%
Test for overall effect: Z = 2.69 (P = 0.007)

10.445665
17.4
13.8
10.03
8.75
15.2
13.634
13.87
9.14
9.14
19.69
19.69
11.22
12.54
15.9
20.7
12.76863
6.72

59.75
52.9
44.1
40.37
46.8
59.4
37.25
49.2
35.9
35.9
61.73
61.73
51.65
53.77
62
56.6
51.4103
48.4

48
21
22
86
8
18
28
7
21
21
39
39
40
22
17
35
39
10
521

1.6.2 < 12 months
Barrowclough 2014
Edwards 2006
GetUp
Gleeson 2009 (EPISODE II)
Hjorthoj 2013 (CapOpus)
Lecomte 2008 (2)
Lecomte 2008 (5)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Palma-Sevillano 2019
Pos 2019
Supereden3
Subtotal (95% CI)
Heterogeneity: Tau² = 0.21; Chi² = 54.35, df = 13 (P < 0.00001); I² = 76%
Test for overall effect: Z = 2.17 (P = 0.03)

59.419149
45.6
50.1
34.3
57.2
33.4
33.4
44.88
57.4
56.2
51.3
52.1
52.2051
55.33

9.639697
13.5
14.73
8.4
21.5
8.29
8.29
8.06
13.58
12.3
8.65
19.3
13.7385
25.77

47
16
170
41
18
18
17
40
20
11
12
35
39
66
550

1.6.3 > 1 year
Barrowclough 2014
Gleeson 2009 (EPISODE II)
Lewis 2002 (SOCRATES) (3)
Lewis 2002 (SOCRATES) (4)
Liu 2019
Müller 2020
Palma-Sevillano 2019
Supereden3
Subtotal (95% CI)
Heterogeneity: Tau² = 0.72; Chi² = 90.14, df = 7 (P < 0.00001); I² = 92%
Test for overall effect: Z = 1.32 (P = 0.19)

10.375331
1.5
12.69
12.69
7.89
10.84
18.14
21.3

61.8
33.8
58.83
58.83
43.2
49.1
48.6
51.33

49
41
37
38
40
9
35
57
306

58.9
63.6
47.7
45.11
38.3
63.8
38.51
54.7
37
38.4
59.96
64.38
55.05
61.06
68.6
116.2
51.8718
55.67

59.4
44.8
53.4
35
61.9
39.3
36.5
49.6
56.77
55.4
52
110
52.3714
58.67

11.6
17.54
18.2
9.89
17.4
16.9
12.028
14.94
11.7
15.03
16.39
16.79
9.56
14.44
17.3
26.42
11.68485
12.22

11.3
15.4
14.39
9.8
23.4
9.68
14.1
10.47
14.1
7
7.02
23.5
11.52768
21.2

59.5
32.2
61.44
66.37
52
53.7
103.2
53.67

11.9
1.5
16.09
15.99
13.92
9.93
20.05
19.1

24
9
23
91
10
18
25
8
33
23
71
60
40
22
18
27
39
9
550

23
17
109
40
18
13
17
40
22
9
10
27
35
57
437

21
40
79
70
40
7
27
46
330

6.3%
4.4%
5.6%
7.6%
3.6%
5.2%
6.0%
3.3%
5.9%
5.6%
7.0%
6.9%
6.6%
5.5%
5.1%
5.1%
6.6%
3.7%
100.0%

7.8%
6.4%
9.5%
8.2%
6.6%
6.1%
6.5%
8.2%
7.0%
5.2%
5.4%
6.3%
8.1%
8.8%
100.0%

12.7%
12.9%
13.2%
13.2%
12.9%
10.2%
11.7%
13.2%
100.0%

0.08 [-0.41 , 0.57]
-0.60 [-1.39 , 0.20]
-0.22 [-0.80 , 0.37]
-0.47 [-0.77 , -0.17]
0.57 [-0.39 , 1.52]
-0.27 [-0.92 , 0.39]
-0.10 [-0.64 , 0.44]
-0.36 [-1.38 , 0.67]
-0.10 [-0.65 , 0.45]
-0.20 [-0.79 , 0.40]
0.10 [-0.29 , 0.49]
-0.15 [-0.55 , 0.26]
-0.32 [-0.76 , 0.12]
-0.53 [-1.13 , 0.07]
-0.39 [-1.06 , 0.28]
-2.52 [-3.20 , -1.84]
-0.04 [-0.48 , 0.41]
-0.72 [-1.65 , 0.22]
-0.33 [-0.57 , -0.09]

0.00 [-0.50 , 0.50]
0.05 [-0.63 , 0.74]
-0.23 [-0.47 , 0.02]
-0.08 [-0.51 , 0.36]
-0.20 [-0.86 , 0.45]
-0.65 [-1.38 , 0.09]
-0.26 [-0.94 , 0.41]
-0.50 [-0.95 , -0.05]
0.04 [-0.56 , 0.65]
0.07 [-0.81 , 0.96]
-0.08 [-0.92 , 0.76]
-2.69 [-3.40 , -1.99]
-0.01 [-0.47 , 0.44]
-0.14 [-0.49 , 0.22]
-0.32 [-0.60 , -0.03]

0.21 [-0.30 , 0.72]
1.06 [0.59 , 1.52]
-0.17 [-0.56 , 0.22]
-0.50 [-0.90 , -0.10]
-0.77 [-1.23 , -0.32]
-0.42 [-1.42 , 0.59]
-2.84 [-3.56 , -2.12]
-0.11 [-0.50 , 0.27]
-0.42 [-1.03 , 0.20]

Test for subgroup differences: Chi² = 0.08, df = 2 (P = 0.96), I² = 0%

Footnotes
(1) comparator skills training for symptom management (SST)
(2) comparator waiting list (WL)
(3) comparator supportive counselling + TAU
(4) comparator treatment-as-usual (TAU)
(5) comparator Skills Training for Symptom Mangement (SST)

-4

-2
CBT + TAU

0

2
Control

4

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

168

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.7.   Comparison 1: CBT plus standard care versus control, Outcome 7: Mental state - general:
number of participants with clinically important change in general mental state (combined time points)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Lecomte 2008 (1)
Lecomte 2008 (2)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)

8
7
19
13
8

24
24
40
25
21

0
9
10
13
6

27
54
40
24
22

2.6%
19.0%
27.5%
32.3%
18.7%

19.04 [1.16 , 313.33]
1.75 [0.74 , 4.15]
1.90 [1.01 , 3.56]
0.96 [0.57 , 1.63]
1.40 [0.58 , 3.35]

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.10; Chi² = 6.47, df = 4 (P = 0.17); I² = 38%
Test for overall effect: Z = 1.73 (P = 0.08)
Test for subgroup differences: Not applicable

134

55

38

167

100.0%

1.50 [0.95 , 2.39]

0.005

0.1
Control

1

10

200

CBT + TAU

Footnotes
(1) comparator waiting list (WL)
(2) comparator skills training for symptom management (SST)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

169

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.8.   Comparison 1: CBT plus standard care versus control, Outcome 8: Mental state - general:
number of participants with clinically important change in general mental state (separated time points)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

1.8.1 < 6 months
Lecomte 2008 (1)
Lecomte 2008 (2)
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 1.87, df = 3 (P = 0.60); I² = 0%
Test for overall effect: Z = 3.05 (P = 0.002)

24
24
25
21
94

6
6
18
11

12
3
8
5

28

41

1.8.2 < 12 months
Lecomte 2008 (2)
Lecomte 2008 (1)
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.15; Chi² = 5.24, df = 3 (P = 0.15); I² = 43%
Test for overall effect: Z = 1.14 (P = 0.25)

24
24
25
21
94

8
7
13
8

0
9
13
6

28

36

54
27
24
22
127

23.1%
10.4%
44.3%
22.2%
100.0%

1.13 [0.48 , 2.64]
2.25 [0.63 , 8.03]
2.16 [1.17 , 4.00]
2.30 [0.96 , 5.51]
1.89 [1.26 , 2.85]

27
54
24
22
127

4.3%
27.2%
41.8%
26.8%
100.0%

19.04 [1.16 , 313.33]
1.75 [0.74 , 4.15]
0.96 [0.57 , 1.63]
1.40 [0.58 , 3.35]
1.42 [0.78 , 2.59]

1.8.3 > 1 year
Liu 2019
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 2.00 (P = 0.05)

19

19

40
40

10

10

40
40

100.0%
100.0%

1.90 [1.01 , 3.56]
1.90 [1.01 , 3.56]

Test for subgroup differences: Chi² = 0.66, df = 2 (P = 0.72), I² = 0%

Footnotes
(1) comparator skills training for symptom management (SST)
(2) comparator waiting list (WL)

0.005

0.1
Control

1

10

200

CBT + TAU

Analysis 1.9.   Comparison 1: CBT plus standard care versus control, Outcome 9: Mental state - specific:
number of participants with clinically important change in positive symptoms (combined time points)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Liu 2019
Uzenoff 2008

28
6

40
10

21
3

40
9

89.7%
10.3%

1.33 [0.93 , 1.91]
1.80 [0.63 , 5.16]

Total (95% CI)
34
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.28, df = 1 (P = 0.60); I² = 0%
Test for overall effect: Z = 1.84 (P = 0.07)
Test for subgroup differences: Not applicable

50

24

49

100.0%

1.38 [0.98 , 1.93]

0.2

0.5
Control

1

2

5
CBT + TAU

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

170

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.10.   Comparison 1: CBT plus standard care versus control, Outcome 10: Mental state - specific:
number of participants with clinically important change in positive symptoms (separated time points)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

1.10.1 > 6 months
Liu 2019
Uzenoff 2008
Subtotal (95% CI)
29
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.98); I² = 0%
Test for overall effect: Z = 2.41 (P = 0.02)

40
10
50

13
3

23
6

16

40
9
49

80.4%
19.6%
100.0%

1.77 [1.05 , 2.98]
1.80 [0.63 , 5.16]
1.78 [1.11 , 2.83]

1.10.2 > 12 months
Liu 2019
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.58 (P = 0.12)

28

28

1.10.3 > 1 year
Liu 2019
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 2.01 (P = 0.04)

34

34

40
40

40
40

21

21

26

26

40
40

100.0%
100.0%

1.33 [0.93 , 1.91]
1.33 [0.93 , 1.91]

40
40

100.0%
100.0%

1.31 [1.01 , 1.70]
1.31 [1.01 , 1.70]

Test for subgroup differences: Chi² = 1.32, df = 2 (P = 0.52), I² = 0%

0.2

0.5
Control

1

2

5
CBT + TAU

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

171

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.11.   Comparison 1: CBT plus standard care versus control, Outcome
11: Mental state - specific: mean endpoint PANSS positive (high = poor)

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.11.1 < 6 months
Barrowclough 2014
Bucci 2018 (Actissist)
Gonzalez-Ortega 2021
Hjorthoj 2013 (CapOpus)
Jolley 2003
Lewis 2002 (SOCRATES) (1)
Lewis 2002 (SOCRATES) (2)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Palma-Sevillano 2019
Pos 2019
Sönmez 2020
Uzenoff 2008
Subtotal (95% CI)
Heterogeneity: Tau² = 3.92; Chi² = 48.10, df = 13 (P < 0.00001); I² = 73%
Test for overall effect: Z = 2.60 (P = 0.009)

14.008333
13.2
8.47
13
13.6
13.03
13.03
11.92
15.23
15.3
17.6
10.75
7.7
9.4

3.922105
4.6
3.22
4.5
5.05
5.06
5.06
4.1
5.31
5.9
12.8
4.16179
4.3
2.68

48
21
86
18
7
39
39
40
22
17
35
40
29
10
451

14.2
16.2
10.39
16.2
13.9
13.67
12.58
13.17
17.81
18
41.6
11.1282
7.4
12.11

5.2
5.4
4.9
5.2
6.93
5.33
4.8
3.17
6.85
19.2
16.2
4.18757
2.9
4.57

1.11.2 < 12 months
Barrowclough 2014
GetUp
Hjorthoj 2013 (CapOpus)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Palma-Sevillano 2019
Pos 2019
Subtotal (95% CI)
Heterogeneity: Tau² = 7.87; Chi² = 51.20, df = 8 (P < 0.00001); I² = 84%
Test for overall effect: Z = 1.86 (P = 0.06)

13.357447
10.22
13.9
9.97
16.8
13.4
12.1
16.1
10.9744

3.922025
5.77
6.1
2.48
6.05
7
5.2
11.6
3.78005

47
169
18
40
20
11
12
35
39
391

14.6
10.64
14.9
10.85
18.18
14
11.9
39
10.2857

5.1
6.01
6.6
3.29
6.52
5.7
3.5
13.1
4.25352

1.11.3 > 1 year
Barrowclough 2014
Lewis 2002 (SOCRATES) (1)
Lewis 2002 (SOCRATES) (2)
Liu 2019
Müller 2020
Palma-Sevillano 2019
Sönmez 2020
Subtotal (95% CI)
Heterogeneity: Tau² = 10.28; Chi² = 58.69, df = 6 (P < 0.00001); I² = 90%
Test for overall effect: Z = 2.12 (P = 0.03)

4.344598
3.72
3.72
2.62
5.1
10.9
3.9

13.624
12.45
12.45
9.42
12.2
14.8
7.9

50
38
37
40
9
35
28
237

12.7
15.25
13.38
12.03
12.1
35.9
7.5

5.1
5.93
4.75
3.99
4.4
11.5
2.8

24
9
91
18
8
60
71
40
21
18
27
39
27
9
462

23
109
18
40
22
9
10
27
35
293

21
71
79
40
7
27
20
265

8.6%
5.6%
10.7%
7.0%
3.4%
9.1%
9.4%
10.0%
6.2%
1.7%
2.5%
9.6%
9.5%
6.6%
100.0%

12.9%
14.3%
9.7%
14.5%
10.3%
7.5%
10.6%
6.6%
13.7%
100.0%

-0.19 [-2.55 , 2.17]
-3.00 [-7.04 , 1.04]
-1.92 [-3.14 , -0.70]
-3.20 [-6.38 , -0.02]
-0.30 [-6.39 , 5.79]
-0.64 [-2.72 , 1.44]
0.45 [-1.49 , 2.39]
-1.25 [-2.86 , 0.36]
-2.58 [-6.26 , 1.10]
-2.70 [-12.00 , 6.60]
-24.00 [-31.44 , -16.56]
-0.38 [-2.22 , 1.46]
0.30 [-1.61 , 2.21]
-2.71 [-6.13 , 0.71]
-1.76 [-3.09 , -0.43]

-1.24 [-3.61 , 1.12]
-0.42 [-1.84 , 1.00]
-1.00 [-5.15 , 3.15]
-0.88 [-2.16 , 0.40]
-1.38 [-5.18 , 2.42]
-0.60 [-6.17 , 4.97]
0.20 [-3.46 , 3.86]
-22.90 [-29.16 , -16.64]
0.69 [-1.15 , 2.53]
-2.03 [-4.18 , 0.11]

14.9%
15.9%
16.2%
16.4%
11.1%
9.6%
15.8%
100.0%

0.92 [-1.57 , 3.42]
-2.80 [-4.62 , -0.98]
-0.93 [-2.52 , 0.66]
-2.61 [-4.09 , -1.13]
0.10 [-4.56 , 4.76]
-21.10 [-26.74 , -15.46]
0.40 [-1.50 , 2.30]
-2.83 [-5.44 , -0.22]

Test for subgroup differences: Chi² = 0.51, df = 2 (P = 0.78), I² = 0%

Footnotes
(1) comparator treatment-as-usual (TAU)
(2) comparator supportive counselling + TAU

-20 -10 0

CBT + TAU

10 20
Control

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

172

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.12.   Comparison 1: CBT plus standard care versus control, Outcome
12: Mental state - specific: mean change PANSS positive (high = poor)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.12.1 < 6 months
Jolley 2003
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.33 (P = 0.74)

-1

1.12.2 < 12 months
Müller 2020
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.50 (P = 0.13)

-2.7

1.12.3 > 1 year
Müller 2020
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.97 (P = 0.33)

-2.6

4.9

4.5

6

7
7

13
13

12
12

-1.8

4.4

8
8

100.0%
100.0%

0.80 [-3.94 , 5.54]
0.80 [-3.94 , 5.54]

-0.8

0.8

12
12

100.0%
100.0%

-1.90 [-4.39 , 0.59]
-1.90 [-4.39 , 0.59]

-5.2

6.5

10
10

100.0%
100.0%

2.60 [-2.67 , 7.87]
2.60 [-2.67 , 7.87]

Test for subgroup differences: Chi² = 2.78, df = 2 (P = 0.25), I² = 28.2%

-10

-5
CBT + TAU

0

5
Control

10

Analysis 1.13.   Comparison 1: CBT plus standard care versus control, Outcome
13: Mental state - specific: mean endpoint BPRS positive (high = poor)

Study or Subgroup

CBT + TAU
SD

Mean

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.13.1 < 6 months
22
Edwards 2006
23
Edwards 2011
31
Jackson 2008 (ACE)
21
Lecomte 2008 (1)
21
Lecomte 2008 (2)
118
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.48, df = 4 (P = 0.65); I² = 0%
Test for overall effect: Z = 1.78 (P = 0.07)

4.8
3.066599
4.05
3.97
3.97

8.9
7.169565
7.45
10.2
10.2

1.13.2 < 12 months
Edwards 2006
Lecomte 2008 (2)
Lecomte 2008 (1)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.11, df = 2 (P = 0.58); I² = 0%
Test for overall effect: Z = 0.27 (P = 0.79)

9.4
10.2
10.2

4.6
4.6
4.6

16
18
17
51

1.13.3 > 1 year
41
Gleeson 2009 (EPISODE II)
31
Jackson 2008 (ACE)
72
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.02, df = 1 (P = 0.89); I² = 0%
Test for overall effect: Z = 2.01 (P = 0.04)

0.5
4.08

5.4
7.2

9.5
9.008
7.65
10.8
10.2

5.4
2.472923
4.03
3.97
3.97

23
25
31
33
23
135

9.8%
34.6%
21.5%
18.4%
15.7%
100.0%

-0.60 [-3.58 , 2.38]
-1.84 [-3.42 , -0.25]
-0.20 [-2.21 , 1.81]
-0.60 [-2.77 , 1.57]
0.00 [-2.35 , 2.35]
-0.85 [-1.78 , 0.08]

8.8
11.4
9

4.8
4.8
4.8

17
13
17
47

34.0%
30.9%
35.1%
100.0%

0.60 [-2.61 , 3.81]
-1.20 [-4.57 , 2.17]
1.20 [-1.96 , 4.36]
0.25 [-1.62 , 2.12]

5.6
7.55

0.4
4.76

40
31
71

99.2%
0.8%
100.0%

-0.20 [-0.40 , -0.00]
-0.35 [-2.56 , 1.86]
-0.20 [-0.40 , -0.01]

Test for subgroup differences: Chi² = 2.03, df = 2 (P = 0.36), I² = 1.2%

Footnotes
(1) comparator skills training for symptom management (SST)
(2) comparator waiting list (WL)

-4
-2
CBT + TAU

0

2
4
Control

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

173

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.14.   Comparison 1: CBT plus standard care versus control,
Outcome 14: Mental state - specific: mean endpoint SAPS (high = poor)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.14.1 < 6 months
Lepage 2022
Madigan 2013
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.27, df = 1 (P = 0.61); I² = 0%
Test for overall effect: Z = 0.13 (P = 0.90)

10.64
4.8

25
42
67

8.8
3.7

9.26
5.1

1.14.2 < 12 months
Lepage 2022
Madigan 2013
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.03, df = 1 (P = 0.85); I² = 0%
Test for overall effect: Z = 0.10 (P = 0.92)

7.57
4.9

9.43
4

22
32
54

7.1
5.1

10.09
4.1

16
22
38

10.3%
89.7%
100.0%

1.38 [-4.65 , 7.41]
-0.30 [-2.35 , 1.75]
-0.13 [-2.06 , 1.81]

10.48
4.2

15
17
32

11.9%
88.1%
100.0%

0.47 [-6.14 , 7.08]
-0.20 [-2.63 , 2.23]
-0.12 [-2.40 , 2.16]

Test for subgroup differences: Chi² = 0.00, df = 1 (P = 1.00), I² = 0%

-10

-5
CBT + TAU

0

5
Control

10

Analysis 1.15.   Comparison 1: CBT plus standard care versus control, Outcome 15: Mental
state - specific: mean endpoint positive symptoms scales (high = poor) (combined time points)

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Barrowclough 2014
Bucci 2018 (Actissist)
Edwards 2006
Edwards 2011
GetUp
Gleeson 2009 (EPISODE II)
Gonzalez-Ortega 2021
Hjorthoj 2013 (CapOpus)
Jackson 2008 (ACE)
Jolley 2003
Lecomte 2008 (1)
Lecomte 2008 (2)
Lepage 2022
Lewis 2002 (SOCRATES) (3)
Lewis 2002 (SOCRATES) (4)
Liu 2019
Madigan 2013
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Palma-Sevillano 2019
Pos 2019
Sönmez 2020
Uzenoff 2008

13.357447
13.2
9.4
7.169565
10.22
5.4
8.47
13.9
7.45
13.6
10.2
10.2
7.57
13.03
13.03
9.97
4.9
16.8
13.4
12.1
16.1
10.9744
7.7
9.4

3.922025
4.6
4.6
3.066599
5.77
0.5
3.22
6.1
4.05
5.05
4.6
4.6
9.43
5.06
5.06
2.48
4
6.05
7
5.2
11.6
3.78005
4.3
2.68

47
21
16
23
169
41
86
18
31
7
18
17
22
39
39
40
32
20
11
12
35
39
29
10

14.6
16.2
8.8
9.008
10.64
5.6
10.39
14.9
7.65
13.9
11.4
9
7.1
13.67
12.58
10.85
5.1
18.18
14
11.9
39
10.2857
7.4
12.11

5.1
5.4
4.8
2.472923
6.01
0.4
4.9
6.6
4.03
6.93
4.8
4.8
10.48
5.33
4.8
3.29
4.2
6.52
5.7
3.5
13.1
4.25352
2.9
4.57

Total (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 48.32, df = 23 (P = 0.002); I² = 52%
Test for overall effect: Z = 2.73 (P = 0.006)
Test for subgroup differences: Not applicable

822

Footnotes
(1) comparator waiting list (WL)
(2) comparator skills training for symptom management (SST)
(3) comparator treatment-as-usual (TAU)
(4) comparator supportive counselling + TAU

23
9
17
25
109
40
91
18
31
8
13
17
15
60
71
40
17
22
9
10
27
35
27
9

4.7%
2.7%
3.4%
4.1%
7.4%
5.3%
6.8%
3.5%
4.8%
1.9%
3.2%
3.4%
3.5%
5.7%
5.8%
5.3%
4.0%
3.9%
2.4%
2.6%
3.9%
5.1%
4.5%
2.2%

-0.28 [-0.78 , 0.22]
-0.60 [-1.40 , 0.20]
0.12 [-0.56 , 0.81]
-0.65 [-1.23 , -0.07]
-0.07 [-0.31 , 0.17]
-0.44 [-0.88 , 0.00]
-0.46 [-0.76 , -0.16]
-0.15 [-0.81 , 0.50]
-0.05 [-0.55 , 0.45]
-0.05 [-1.06 , 0.97]
-0.25 [-0.97 , 0.47]
0.25 [-0.43 , 0.92]
0.05 [-0.61 , 0.70]
-0.12 [-0.53 , 0.28]
0.09 [-0.30 , 0.48]
-0.30 [-0.74 , 0.14]
-0.05 [-0.64 , 0.54]
-0.21 [-0.82 , 0.39]
-0.09 [-0.97 , 0.79]
0.04 [-0.80 , 0.88]
-1.84 [-2.45 , -1.24]
0.17 [-0.29 , 0.63]
0.08 [-0.44 , 0.60]
-0.70 [-1.64 , 0.23]

743

100.0%

-0.22 [-0.38 , -0.06]

-2

-1

0

CBT + TAU

1
Control

2

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

174

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.16.   Comparison 1: CBT plus standard care versus control, Outcome 16: Mental state - specific: mean
endpoint positive symptoms scales (high = poor) (separated time points)

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.16.1 < 6 months
Barrowclough 2014
Bucci 2018 (Actissist)
Edwards 2006
Edwards 2011
Gonzalez-Ortega 2021
Hjorthoj 2013 (CapOpus)
Jackson 2008 (ACE)
Jolley 2003
Lecomte 2008 (1)
Lecomte 2008 (2)
Lepage 2022
Lewis 2002 (SOCRATES) (3)
Lewis 2002 (SOCRATES) (4)
Liu 2019
Madigan 2013
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Palma-Sevillano 2019
Pos 2019
Sönmez 2020
Uzenoff 2008
Subtotal (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 38.90, df = 20 (P = 0.007); I² = 49%
Test for overall effect: Z = 3.14 (P = 0.002)

14.008333
13.2
8.9
7.169565
8.47
13
7.45
13.6
10.2
10.2
10.64
13.03
13.03
11.92
4.8
15.23
15.3
17.6
10.75
7.7
9.4

3.922105
4.6
4.8
3.066599
3.22
4.5
4.05
5.05
3.97
3.97
8.8
5.06
5.06
4.1
3.7
5.31
5.9
12.8
4.16179
4.3
2.68

48
21
22
23
86
18
31
7
21
21
25
39
39
40
42
22
17
35
40
29
10
636

1.16.2 < 12 months
Barrowclough 2014
Edwards 2006
GetUp
Hjorthoj 2013 (CapOpus)
Lecomte 2008 (1)
Lecomte 2008 (2)
Lepage 2022
Liu 2019
Madigan 2013
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Palma-Sevillano 2019
Pos 2019
Subtotal (95% CI)
Heterogeneity: Tau² = 0.13; Chi² = 35.91, df = 13 (P = 0.0006); I² = 64%
Test for overall effect: Z = 1.52 (P = 0.13)

13.357447
9.4
10.22
13.9
10.2
10.2
7.57
9.97
4.9
16.8
13.4
12.1
16.1
10.9744

3.922025
4.6
5.77
6.1
4.6
4.6
9.43
2.48
4
6.05
7
5.2
11.6
3.78005

47
16
169
18
18
17
22
40
32
20
11
12
35
39
496

1.16.3 > 1 year
Barrowclough 2014
Gleeson 2009 (EPISODE II)
Jackson 2008 (ACE)
Lewis 2002 (SOCRATES) (3)
Lewis 2002 (SOCRATES) (4)
Liu 2019
Müller 2020
Palma-Sevillano 2019
Sönmez 2020
Subtotal (95% CI)
Heterogeneity: Tau² = 0.23; Chi² = 36.97, df = 8 (P < 0.0001); I² = 78%
Test for overall effect: Z = 2.18 (P = 0.03)

4.344598
0.5
4.08
3.72
3.72
2.62
5.1
10.9
3.9

13.624
5.4
7.2
12.45
12.45
9.42
12.2
14.8
7.9

50
41
31
38
37
40
9
35
28
309

14.2
16.2
9.5
9.008
10.39
16.2
7.65
13.9
10.2
10.8
9.26
13.67
12.58
13.17
5.1
17.81
18
41.6
11.1282
7.4
12.11

14.6
8.8
10.64
14.9
11.4
9
7.1
10.85
5.1
18.18
14
11.9
39
10.2857

12.7
5.6
7.55
15.25
13.38
12.03
12.1
35.9
7.5

5.2
5.4
5.4
2.472923
4.9
5.2
4.03
6.93
3.97
3.97
10.09
5.33
4.8
3.17
4.1
6.85
19.2
16.2
4.18757
2.9
4.57

5.1
4.8
6.01
6.6
4.8
4.8
10.48
3.29
4.2
6.52
5.7
3.5
13.1
4.25352

5.1
0.4
4.76
5.93
4.75
3.99
4.4
11.5
2.8

24
9
23
25
91
18
31
8
23
33
16
60
71
40
22
21
18
27
39
27
9
635

23
17
109
18
13
17
15
40
17
22
9
10
27
35
372

21
40
31
71
79
40
7
27
20
336

5.4%
3.0%
4.5%
4.5%
7.8%
3.8%
5.3%
2.1%
4.4%
4.8%
4.1%
6.4%
6.6%
6.0%
5.1%
4.3%
3.9%
4.5%
6.0%
5.1%
2.4%
100.0%

8.2%
6.4%
11.0%
6.6%
6.1%
6.4%
6.6%
8.8%
7.3%
7.1%
4.8%
5.1%
7.1%
8.6%
100.0%

11.4%
12.1%
11.5%
12.5%
12.5%
11.9%
7.0%
10.4%
10.7%
100.0%

-0.04 [-0.53 , 0.45]
-0.60 [-1.40 , 0.20]
-0.12 [-0.70 , 0.47]
-0.65 [-1.23 , -0.07]
-0.46 [-0.76 , -0.16]
-0.64 [-1.32 , 0.03]
-0.05 [-0.55 , 0.45]
-0.05 [-1.06 , 0.97]
0.00 [-0.59 , 0.59]
-0.15 [-0.70 , 0.40]
0.15 [-0.48 , 0.77]
-0.12 [-0.53 , 0.28]
0.09 [-0.30 , 0.48]
-0.34 [-0.78 , 0.10]
-0.08 [-0.59 , 0.44]
-0.41 [-1.02 , 0.19]
-0.18 [-0.85 , 0.48]
-1.65 [-2.23 , -1.06]
-0.09 [-0.53 , 0.35]
0.08 [-0.44 , 0.60]
-0.70 [-1.64 , 0.23]
-0.26 [-0.43 , -0.10]

-0.28 [-0.78 , 0.22]
0.12 [-0.56 , 0.81]
-0.07 [-0.31 , 0.17]
-0.15 [-0.81 , 0.50]
-0.25 [-0.97 , 0.47]
0.25 [-0.43 , 0.92]
0.05 [-0.61 , 0.70]
-0.30 [-0.74 , 0.14]
-0.05 [-0.64 , 0.54]
-0.21 [-0.82 , 0.39]
-0.09 [-0.97 , 0.79]
0.04 [-0.80 , 0.88]
-1.84 [-2.45 , -1.24]
0.17 [-0.29 , 0.63]
-0.19 [-0.44 , 0.06]

0.20 [-0.31 , 0.71]
-0.44 [-0.88 , 0.00]
-0.08 [-0.58 , 0.42]
-0.53 [-0.93 , -0.13]
-0.21 [-0.60 , 0.18]
-0.77 [-1.22 , -0.31]
0.02 [-0.97 , 1.01]
-1.87 [-2.47 , -1.26]
0.11 [-0.46 , 0.69]
-0.40 [-0.76 , -0.04]

Test for subgroup differences: Chi² = 0.88, df = 2 (P = 0.64), I² = 0%

Footnotes
(1) comparator waiting list (WL)
(2) comparator skills training for symptom management (SST)
(3) comparator treatment-as-usual (TAU)

-2

-1

0

CBT + TAU

1
Control

2

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

175

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 1.16.   (Continued)
(1) comparator waiting list (WL)
(2) comparator skills training for symptom management (SST)
(3) comparator treatment-as-usual (TAU)
(4) comparator supportive counselling + TAU

Cochrane Database of Systematic Reviews

Analysis 1.17.   Comparison 1: CBT plus standard care versus control, Outcome
17: Mental state - specific: mean endpoint PANSS negative (high = poor)

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.17.1 < 6 months
48
Barrowclough 2014
21
Bucci 2018 (Actissist)
86
Gonzalez-Ortega 2021
18
Hjorthoj 2013 (CapOpus)
7
Jolley 2003
40
Liu 2019
22
Morrison 2018 (COMPARE)
18
Morrison 2020 (MAPS)
35
Palma-Sevillano 2019
40
Pos 2019
29
Sönmez 2020
10
Uzenoff 2008
374
Subtotal (95% CI)
Heterogeneity: Tau² = 0.16; Chi² = 11.95, df = 11 (P = 0.37); I² = 8%
Test for overall effect: Z = 2.28 (P = 0.02)

13.933333
13.8
10.55
14.5
10
13.25
12.41
16.8
20.4
14.55
8.6
14.3

4.941997
4.9
5.71
5.8
5.44
3.01
4.6
7.4
11.1
4.79824
2.7
4.92

1.17.2 < 12 months
Barrowclough 2014
GetUp
Hjorthoj 2013 (CapOpus)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Palma-Sevillano 2019
Pos 2019
Subtotal (95% CI)
Heterogeneity: Tau² = 0.26; Chi² = 9.39, df = 8 (P = 0.31); I² = 15%
Test for overall effect: Z = 2.13 (P = 0.03)

13.470213
13.09
14
12
12.8
14.5
11.9
18.3
15.2051

4.413981
5.36
6.1
2.78
3.68
5.7
3.9
9.9
6.3709

47
169
18
40
20
11
12
35
39
391

1.17.3 > 1 year
49
Barrowclough 2014
38
Lewis 2002 (SOCRATES) (1)
37
Lewis 2002 (SOCRATES) (2)
40
Liu 2019
9
Müller 2020
35
Palma-Sevillano 2019
28
Sönmez 2020
236
Subtotal (95% CI)
Heterogeneity: Tau² = 2.09; Chi² = 13.76, df = 6 (P = 0.03); I² = 56%
Test for overall effect: Z = 3.32 (P = 0.0009)

14.018367
14.34
14.34
10.5
11
17.1
8.6

4.140787
4.54
4.54
4.17
4.2
9.1
3

12.7
13.8
11.39
15.7
14.4
13.75
14.14
17.8
29.7
15.3077
10.7
16

12.7
14.07
15.7
13.75
12.73
15.1
13.4
26.5
15.4571

15.2
15.99
14.66
14
13.8
25
13

5
4.21
5.43
6.3
6.26
3.01
5.47
5.3
16
5.7361
5
7.38

4.4
6.03
6.5
3.48
4.58
4.8
4.1
15.3
5.101

6.5
5.63
4.58
4.41
5.5
12.8
5.1

24
9
91
18
8
40
22
18
27
39
27
9
332

23
107
18
40
22
9
10
27
35
291

21
71
79
40
7
27
20
265

9.4%
4.9%
18.7%
3.8%
1.7%
26.4%
6.5%
3.4%
1.2%
10.2%
12.0%
1.9%
100.0%

13.0%
25.6%
4.2%
26.1%
10.4%
3.4%
6.1%
1.7%
9.6%
100.0%

1.23 [-1.21 , 3.67]
0.00 [-3.46 , 3.46]
-0.84 [-2.48 , 0.80]
-1.20 [-5.16 , 2.76]
-4.40 [-10.32 , 1.52]
-0.50 [-1.82 , 0.82]
-1.73 [-4.72 , 1.26]
-1.00 [-5.20 , 3.20]
-9.30 [-16.37 , -2.23]
-0.76 [-3.09 , 1.58]
-2.10 [-4.23 , 0.03]
-1.70 [-7.40 , 4.00]
-0.91 [-1.70 , -0.13]

0.77 [-1.43 , 2.97]
-0.98 [-2.38 , 0.42]
-1.70 [-5.82 , 2.42]
-1.75 [-3.13 , -0.37]
0.07 [-2.43 , 2.57]
-0.60 [-5.20 , 4.00]
-1.50 [-4.87 , 1.87]
-8.20 [-14.84 , -1.56]
-0.25 [-2.87 , 2.37]
-0.94 [-1.81 , -0.08]

13.1%
19.0%
20.1%
19.4%
7.0%
5.6%
15.8%
100.0%

-1.18 [-4.19 , 1.83]
-1.65 [-3.60 , 0.30]
-0.32 [-2.10 , 1.46]
-3.50 [-5.38 , -1.62]
-2.80 [-7.71 , 2.11]
-7.90 [-13.59 , -2.21]
-4.40 [-6.90 , -1.90]
-2.54 [-4.04 , -1.04]

Test for subgroup differences: Chi² = 3.87, df = 2 (P = 0.14), I² = 48.3%

Footnotes
(1) comparator treatment-as-usual (TAU)
(2) comparator supportive counselling + TAU

-20

-10
CBT + TAU

0

10
Control

20

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

176

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.18.   Comparison 1: CBT plus standard care versus control, Outcome
18: Mental state - specific: mean change PANSS negative (high = poor)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.18.1 < 6 months
Jolley 2003
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.49 (P = 0.63)

0.6

1.18.2 < 12 months
Müller 2020
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.40 (P = 0.69)

-1.6

1.18.3 > 1 year
Müller 2020
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.20 (P = 0.84)

-2.5

6.3

4.2

5.8

7
7

13
13

12
12

1.9

3.4

8
8

100.0%
100.0%

-1.30 [-6.53 , 3.93]
-1.30 [-6.53 , 3.93]

-2.3

4.5

12
12

100.0%
100.0%

0.70 [-2.72 , 4.12]
0.70 [-2.72 , 4.12]

-2

5.8

10
10

100.0%
100.0%

-0.50 [-5.37 , 4.37]
-0.50 [-5.37 , 4.37]

Test for subgroup differences: Chi² = 0.44, df = 2 (P = 0.80), I² = 0%

-10

-5
CBT + TAU

0

5
Control

10

Analysis 1.19.   Comparison 1: CBT plus standard care versus control, Outcome
19: Mental state - specific: mean endpoint BPRS negative (high = poor)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.19.1 < 6 months
Lecomte 2008 (1)
Lecomte 2008 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 0.56 (P = 0.58)

21
21
42

4.8
4.8

8
8

7.5
7.5

1.19.2 < 12 months
Lecomte 2008 (2)
Lecomte 2008 (1)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.09, df = 1 (P = 0.76); I² = 0%
Test for overall effect: Z = 0.26 (P = 0.80)

3.65
3.65

17
18
35

7
7

7
7.5

2.85
4.9

2.45
3.3

23
33
56

55.7%
44.3%
100.0%

0.50 [-1.86 , 2.86]
0.50 [-2.15 , 3.15]
0.50 [-1.26 , 2.26]

17
13
30

58.1%
41.9%
100.0%

0.00 [-2.09 , 2.09]
-0.50 [-2.96 , 1.96]
-0.21 [-1.80 , 1.38]

Test for subgroup differences: Chi² = 0.34, df = 1 (P = 0.56), I² = 0%

Footnotes
(1) comparator waiting list (WL)
(2) comparator skills training for symptom management (SST)

-2

-4
CBT + TAU

0

2
Control

4

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

177

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.20.   Comparison 1: CBT plus standard care versus control,
Outcome 20: Mental state - specific: mean endpoint SANS (high = poor)

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.20.1 < 6 months
Edwards 2006
Edwards 2011
Jackson 2008 (ACE)
Lepage 2022
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.18, df = 3 (P = 0.54); I² = 0%
Test for overall effect: Z = 2.09 (P = 0.04)

14.9
10.721959
10.19
9

21.8
25.421739
17.67
20.14

23.5
25.908
22.88
25.78

14
7.811046
12.87
10.3

22
23
31
25
101

23
25
31
16
95

13.3%
33.2%
28.4%
25.0%
100.0%

-1.70 [-10.16 , 6.76]
-0.49 [-5.83 , 4.86]
-5.21 [-10.99 , 0.57]
-5.64 [-11.80 , 0.52]
-3.28 [-6.36 , -0.20]

1.20.2 < 12 months
Edwards 2006
Gleeson 2009 (EPISODE II)
Lepage 2022
Supereden3
Subtotal (95% CI)
Heterogeneity: Tau² = 4.47; Chi² = 4.23, df = 3 (P = 0.24); I² = 29%
Test for overall effect: Z = 1.19 (P = 0.23)

23.7
14
18.86
16.6

17.2
12.3
9.64
11.38

16
41
22
64
143

19.4
13.8
25.07
21

13.5
12.1
10.66
17.49

17
40
15
57
129

11.4%
32.5%
23.6%
32.4%
100.0%

4.30 [-6.29 , 14.89]
0.20 [-5.11 , 5.51]
-6.21 [-12.94 , 0.52]
-4.40 [-9.73 , 0.93]
-2.34 [-6.18 , 1.51]

1.20.3 > 1 year
Jackson 2008 (ACE)
Supereden3
Subtotal (95% CI)
Heterogeneity: Tau² = 0.32; Chi² = 1.03, df = 1 (P = 0.31); I² = 3%
Test for overall effect: Z = 1.07 (P = 0.29)

14.66
20

10.9
19.8

19.55
20

14.79
16.1

31
57
88

31
47
78

53.1%
46.9%
100.0%

-4.89 [-11.36 , 1.58]
0.00 [-6.90 , 6.90]
-2.60 [-7.38 , 2.18]

Test for subgroup differences: Chi² = 0.15, df = 2 (P = 0.93), I² = 0%

-10

-5

CBT + TAU

0

10

5
Control

Analysis 1.21.   Comparison 1: CBT plus standard care versus control,
Outcome 21: Mental state - specific: mean endpoint BNSS (high = poor)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.21.1 < 6 months
Pos 2019
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.10 (P = 0.27)

22

10.62

1.21.2 < 12 months
Pos 2019
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.20 (P = 0.84)

23.2

10.63

40
40

39
39

24.6

10.48

39
39

100.0%
100.0%

-2.60 [-7.25 , 2.05]
-2.60 [-7.25 , 2.05]

22.7

10.51

35
35

100.0%
100.0%

0.50 [-4.32 , 5.32]
0.50 [-4.32 , 5.32]

Test for subgroup differences: Chi² = 0.82, df = 1 (P = 0.36), I² = 0%

-10

-5
CBT + TAU

0

5
Control

10

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

178

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.22.   Comparison 1: CBT plus standard care versus control, Outcome 22: Mental
state - specific: mean endpoint negative symptoms scale (high = poor) (combined time points)

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Barrowclough 2014
Bucci 2018 (Actissist)
Edwards 2006
Edwards 2011
GetUp
Gleeson 2009 (EPISODE II)
Gonzalez-Ortega 2021
Hjorthoj 2013 (CapOpus)
Jackson 2008 (ACE)
Jolley 2003
Lecomte 2008 (1)
Lecomte 2008 (2)
Lepage 2022
Lewis 2002 (SOCRATES) (3)
Lewis 2002 (SOCRATES) (4)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Palma-Sevillano 2019
Pos 2019
Sönmez 2020
Supereden3
Uzenoff 2008

13.470213
13.8
23.7
25.421739
13.09
14
10.55
14
17.67
10
7
7
18.86
14.34
14.34
12
12.8
14.5
11.9
18.3
15.2051
8.6
16.6
14.3

4.413981
4.9
17.2
10.721959
5.36
12.3
5.71
6.1
10.19
5.44
3.65
3.65
9.64
4.54
4.54
2.78
3.68
5.7
3.9
9.9
6.3709
2.7
11.38
4.92

47
21
16
23
169
41
86
18
31
7
18
17
22
37
38
40
20
11
12
35
39
29
64
10

12.7
13.8
19.4
25.908
14.07
13.8
11.39
15.7
22.88
14.4
7.5
7
25.07
14.66
15.99
13.75
12.73
15.1
13.4
26.5
15.4571
10.7
21
16

4.4
4.21
13.5
7.811046
6.03
12.1
5.43
6.5
12.87
6.26
3.3
2.45
10.66
4.58
5.63
3.48
4.58
4.8
4.1
15.3
5.101
5
17.49
7.38

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 17.92, df = 23 (P = 0.76); I² = 0%
Test for overall effect: Z = 4.06 (P < 0.0001)
Test for subgroup differences: Not applicable

851

Footnotes
(1) comparator waiting list (WL)
(2) comparator skills training for symptom management (SST)
(3) comparator supportive counselling + TAU
(4) comparator treatment-as-usual (TAU)

23
9
17
25
107
40
91
18
31
8
13
17
15
79
71
40
22
9
10
27
35
27
57
9

3.9%
1.6%
2.1%
3.0%
16.6%
5.1%
11.2%
2.3%
3.8%
0.9%
1.9%
2.2%
2.2%
6.4%
6.2%
4.9%
2.7%
1.3%
1.4%
3.7%
4.7%
3.4%
7.6%
1.2%

0.17 [-0.33 , 0.67]
0.00 [-0.78 , 0.78]
0.27 [-0.41 , 0.96]
-0.05 [-0.62 , 0.52]
-0.17 [-0.42 , 0.07]
0.02 [-0.42 , 0.45]
-0.15 [-0.45 , 0.14]
-0.26 [-0.92 , 0.39]
-0.44 [-0.95 , 0.06]
-0.70 [-1.76 , 0.35]
-0.14 [-0.85 , 0.58]
0.00 [-0.67 , 0.67]
-0.60 [-1.28 , 0.07]
-0.07 [-0.46 , 0.32]
-0.31 [-0.71 , 0.09]
-0.55 [-1.00 , -0.10]
0.02 [-0.59 , 0.62]
-0.11 [-0.99 , 0.77]
-0.36 [-1.21 , 0.49]
-0.65 [-1.16 , -0.13]
-0.04 [-0.50 , 0.41]
-0.52 [-1.05 , 0.01]
-0.30 [-0.66 , 0.06]
-0.26 [-1.17 , 0.64]

800

100.0%

-0.20 [-0.30 , -0.11]

-2

-1
CBT + TAU

0

1
Control

2

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

179

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.23.   Comparison 1: CBT plus standard care versus control, Outcome 23: Mental
state - specific: mean endpoint negative symptoms scale (high = poor) (separated time points)

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.23.1 < 6 months
Barrowclough 2014
Bucci 2018 (Actissist)
Edwards 2006
Edwards 2011
Gonzalez-Ortega 2021
Hjorthoj 2013 (CapOpus)
Jackson 2008 (ACE)
Jolley 2003
Lecomte 2008 (1)
Lecomte 2008 (2)
Lepage 2022
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Palma-Sevillano 2019
Pos 2019
Sönmez 2020
Uzenoff 2008
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 14.38, df = 17 (P = 0.64); I² = 0%
Test for overall effect: Z = 3.04 (P = 0.002)

4.941997
4.9
14.9
10.721959
5.71
5.8
10.19
5.44
4.8
4.8
9
3.01
4.6
7.4
11.1
4.79824
2.7
4.92

13.933333
13.8
21.8
25.421739
10.55
14.5
17.67
10
8
8
20.14
13.25
12.41
16.8
20.4
14.55
8.6
14.3

48
21
22
23
86
18
31
7
21
21
25
40
22
18
35
40
29
10
517

1.23.2 < 12 months
Barrowclough 2014
Edwards 2006
GetUp
Gleeson 2009 (EPISODE II)
Hjorthoj 2013 (CapOpus)
Lecomte 2008 (1)
Lecomte 2008 (2)
Lepage 2022
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Palma-Sevillano 2019
Pos 2019
Supereden3
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 13.38, df = 14 (P = 0.50); I² = 0%
Test for overall effect: Z = 2.98 (P = 0.003)

13.470213
23.7
13.09
14
14
7
7
18.86
12
12.8
14.5
11.9
18.3
15.2051
16.6

4.413981
17.2
5.36
12.3
6.1
3.65
3.65
9.64
2.78
3.68
5.7
3.9
9.9
6.3709
11.38

47
16
169
41
18
18
17
22
40
20
11
12
35
39
64
569

1.23.3 > 1 year
Barrowclough 2014
Jackson 2008 (ACE)
Lewis 2002 (SOCRATES) (3)
Lewis 2002 (SOCRATES) (4)
Liu 2019
Müller 2020
Palma-Sevillano 2019
Sönmez 2020
Supereden3
Subtotal (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 16.64, df = 8 (P = 0.03); I² = 52%
Test for overall effect: Z = 3.44 (P = 0.0006)

14.018367
14.66
14.34
14.34
10.5
11
17.1
8.6
20

4.140787
10.9
4.54
4.54
4.17
4.2
9.1
3
19.8

49
31
38
37
40
9
35
28
57
324

12.7
13.8
23.5
25.908
11.39
15.7
22.88
14.4
7.5
7.5
25.78
13.75
14.14
17.8
29.7
15.3077
10.7
16

12.7
19.4
14.07
13.8
15.7
7.5
7
25.07
13.75
12.73
15.1
13.4
26.5
15.4571
21

15.2
19.55
15.99
14.66
14
13.8
25
13
20

5
4.21
14
7.811046
5.43
6.3
12.87
6.26
2.85
4.9
10.3
3.01
5.47
5.3
16
5.7361
5
7.38

4.4
13.5
6.03
12.1
6.5
3.3
2.45
10.66
3.48
4.58
4.8
4.1
15.3
5.101
17.49

6.5
14.79
5.63
4.58
4.41
5.5
12.8
5.1
16.1

24
9
23
25
91
18
31
8
23
33
16
40
22
18
27
39
27
9
483

23
17
107
40
18
13
17
15
40
22
9
10
27
35
57
450

21
31
71
79
40
7
27
20
47
343

6.6%
2.6%
4.6%
4.9%
18.2%
3.7%
6.2%
1.4%
4.5%
5.3%
3.9%
8.2%
4.5%
3.7%
5.9%
8.1%
5.6%
1.9%
100.0%

6.3%
3.3%
26.6%
8.3%
3.6%
3.1%
3.5%
3.5%
7.8%
4.3%
2.0%
2.2%
5.9%
7.5%
12.2%
100.0%

10.9%
11.1%
13.7%
13.9%
12.2%
4.4%
10.8%
8.9%
14.0%
100.0%

0.25 [-0.25 , 0.74]
0.00 [-0.78 , 0.78]
-0.12 [-0.70 , 0.47]
-0.05 [-0.62 , 0.52]
-0.15 [-0.45 , 0.14]
-0.19 [-0.85 , 0.46]
-0.44 [-0.95 , 0.06]
-0.70 [-1.76 , 0.35]
0.13 [-0.47 , 0.72]
0.10 [-0.45 , 0.65]
-0.58 [-1.22 , 0.06]
-0.16 [-0.60 , 0.27]
-0.34 [-0.93 , 0.26]
-0.15 [-0.81 , 0.50]
-0.68 [-1.20 , -0.17]
-0.14 [-0.58 , 0.30]
-0.52 [-1.05 , 0.01]
-0.26 [-1.17 , 0.64]
-0.20 [-0.32 , -0.07]

0.17 [-0.33 , 0.67]
0.27 [-0.41 , 0.96]
-0.17 [-0.42 , 0.07]
0.02 [-0.42 , 0.45]
-0.26 [-0.92 , 0.39]
-0.14 [-0.85 , 0.58]
0.00 [-0.67 , 0.67]
-0.60 [-1.28 , 0.07]
-0.55 [-1.00 , -0.10]
0.02 [-0.59 , 0.62]
-0.11 [-0.99 , 0.77]
-0.36 [-1.21 , 0.49]
-0.65 [-1.16 , -0.13]
-0.04 [-0.50 , 0.41]
-0.30 [-0.66 , 0.06]
-0.19 [-0.32 , -0.06]

-0.24 [-0.75 , 0.28]
-0.37 [-0.87 , 0.13]
-0.31 [-0.71 , 0.09]
-0.07 [-0.46 , 0.32]
-0.81 [-1.26 , -0.35]
-0.55 [-1.56 , 0.46]
-0.72 [-1.24 , -0.20]
-1.08 [-1.70 , -0.46]
0.00 [-0.39 , 0.39]
-0.42 [-0.65 , -0.18]

Test for subgroup differences: Chi² = 2.99, df = 2 (P = 0.22), I² = 33.1%

Footnotes
(1) comparator waiting list (WL)
(2) comparator skills training for symptom management (SST)
(3) comparator treatment-as-usual (TAU)
(4) comparator supportive counselling + TAU

-2

-1
CBT + TAU

0

1
Control

2

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

180

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.24.   Comparison 1: CBT plus standard care versus control, Outcome
24: Mental state - specific: mean endpoint BDI short form (high = poor)

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.24.1 < 6 months
Edwards 2006
Edwards 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.16, df = 1 (P = 0.69); I² = 0%
Test for overall effect: Z = 0.71 (P = 0.48)

6.2
19.678261

5.9
6.149424

22
23
45

7.8
20.184

8.1
5.91912

23
25
48

40.7%
59.3%
100.0%

-1.60 [-5.73 , 2.53]
-0.51 [-3.93 , 2.91]
-0.95 [-3.58 , 1.68]

1.24.2 < 12 months
Edwards 2006
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.51 (P = 0.61)

7.5

6.3

16
16

6.3

7.2

17
17

100.0%
100.0%

1.20 [-3.41 , 5.81]
1.20 [-3.41 , 5.81]

Test for subgroup differences: Chi² = 0.63, df = 1 (P = 0.43), I² = 0%

-10

-5
CBT + TAU

0

5
Control

10

Analysis 1.25.   Comparison 1: CBT plus standard care versus control,
Outcome 25: Mental state - specific: mean endpoint BDI-II (high = poor)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.25.1 < 6 months
Sönmez 2020
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.59 (P = 0.55)

12.6

9.5

1.25.2 < 12 months
Supereden3
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.64 (P = 0.52)

13.67

15.94

29
29

62
62

14.3

11.7

27
27

100.0%
100.0%

-1.70 [-7.31 , 3.91]
-1.70 [-7.31 , 3.91]

15.33

12.18

55
55

100.0%
100.0%

-1.66 [-6.77 , 3.45]
-1.66 [-6.77 , 3.45]

1.25.3 > 1 year
Sönmez 2020
Supereden3
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.98, df = 1 (P = 0.32); I² = 0%
Test for overall effect: Z = 0.35 (P = 0.73)

12.5
11.67

7.9
13.7

28
55
83

15.5
10.67

12
12.3

20
43
63

42.4%
57.6%
100.0%

-3.00 [-9.02 , 3.02]
1.00 [-4.16 , 6.16]
-0.69 [-4.61 , 3.22]

Test for subgroup differences: Chi² = 0.13, df = 2 (P = 0.94), I² = 0%

-10

-5
CBT + TAU

0

5
Control

10

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

181

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.26.   Comparison 1: CBT plus standard care versus control, Outcome
26: Mental state - specific: mean endpoint HADS Depression (high = poor)

Study or Subgroup

CBT + TAU
SD

Mean

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.26.1 < 6 months
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.93); I² = 0%
Test for overall effect: Z = 2.10 (P = 0.04)

13.42
7.3

5.83
3.4

19
10
29

1.26.2 < 12 months
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.03, df = 1 (P = 0.86); I² = 0%
Test for overall effect: Z = 0.11 (P = 0.92)

14.94
5.1

5.36
4.2

17
7
24

16.27
10.4

5.84
5.4

22
8
30

59.0%
41.0%
100.0%

-2.85 [-6.43 , 0.73]
-3.10 [-7.39 , 1.19]
-2.95 [-5.70 , -0.20]

14.91
5.6

5.52
4.9

22
7
29

65.9%
34.1%
100.0%

0.03 [-3.41 , 3.47]
-0.50 [-5.28 , 4.28]
-0.15 [-2.94 , 2.64]

Test for subgroup differences: Chi² = 1.96, df = 1 (P = 0.16), I² = 49.1%

-10

-5
CBT + TAU

0

5
Control

10

Analysis 1.27.   Comparison 1: CBT plus standard care versus control,
Outcome 27: Mental state - specific: mean endpoint CDS (high = poor)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.27.1 < 6 months
Barrowclough 2014
Bucci 2018 (Actissist)
Jackson 2009
Jolley 2003
Lepage 2022
Madigan 2013
Sönmez 2020
Uzenoff 2008
Subtotal (95% CI)
Heterogeneity: Tau² = 0.30; Chi² = 8.25, df = 7 (P = 0.31); I² = 15%
Test for overall effect: Z = 0.56 (P = 0.57)

6.366667
6
3.9
4.2
4.73
4.4
4.69
10.2

4.313084
4.9
3.5
3.89
3.96
4.3
4.41
1.87

48
21
22
7
25
40
29
10
202

4.8
7.3
4.9
2.7
4.53
4.6
2.74
11.67

1.27.2 < 12 months
Barrowclough 2014
Jackson 2009
Lepage 2022
Madigan 2013
Müller 2020
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.47, df = 4 (P = 0.98); I² = 0%
Test for overall effect: Z = 0.38 (P = 0.70)

4.338913
3.9
4.24
4.4
3.5

48
19
22
33
12
134

6
3.7
3.99
4.3
3.9

6.1
3.9
3.65
4.3
4.8

4
4.82
3.4
4.15
4.68
4.8
3.44
3.94

5.3
3.3
4.74
4.2
2.3

23
9
24
8
15
20
27
9
135

18.0%
6.2%
18.6%
5.4%
10.5%
13.0%
17.7%
10.5%
100.0%

1.57 [-0.47 , 3.61]
-1.30 [-5.08 , 2.48]
-1.00 [-3.00 , 1.00]
1.50 [-2.57 , 5.57]
0.20 [-2.63 , 3.03]
-0.20 [-2.69 , 2.29]
1.95 [-0.11 , 4.01]
-1.47 [-4.29 , 1.35]
0.28 [-0.70 , 1.26]

23
22
15
11
10
81

21.2%
26.4%
14.8%
15.6%
22.1%
100.0%

-0.10 [-2.59 , 2.39]
-0.20 [-2.43 , 2.03]
0.34 [-2.64 , 3.32]
0.00 [-2.90 , 2.90]
-0.90 [-3.34 , 1.54]
-0.22 [-1.37 , 0.92]

1.27.3 > 1 year
Barrowclough 2014
Müller 2020
Sönmez 2020
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.02, df = 2 (P = 0.60); I² = 0%
Test for overall effect: Z = 0.92 (P = 0.36)

7.091837
3.5
4.29

5.456603
4.1
3.54

49
9
28
86

5.9
4.5
3.3

5
3.4
3.99

21
7
20
48

33.8%
17.3%
48.9%
100.0%

1.19 [-1.44 , 3.82]
-1.00 [-4.68 , 2.68]
0.99 [-1.20 , 3.18]
0.71 [-0.81 , 2.24]

Test for subgroup differences: Chi² = 0.98, df = 2 (P = 0.61), I² = 0%

-4
-2
CBT + TAU

0

2
4
Control

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

182

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.28.   Comparison 1: CBT plus standard care versus control,
Outcome 28: Mental state - specific: mean change CDS (high = poor)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.28.1 > 6 months
Jolley 2003
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.15 (P = 0.88)

-1.6

1.28.2 < 12 months
Müller 2020
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.21 (P = 0.23)

-1

1.28.3 > 1 year
Müller 2020
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.03 (P = 0.30)

-1.5

4.3

3.4

4.8

7
7

13
13

12
12

-1.9

3.2

8
8

100.0%
100.0%

0.30 [-3.58 , 4.18]
0.30 [-3.58 , 4.18]

-3.2

5.4

12
12

100.0%
100.0%

2.20 [-1.37 , 5.77]
2.20 [-1.37 , 5.77]

-3.6

4.7

10
10

100.0%
100.0%

2.10 [-1.88 , 6.08]
2.10 [-1.88 , 6.08]

Test for subgroup differences: Chi² = 0.60, df = 2 (P = 0.74), I² = 0%

-10

-5
CBT + TAU

0

5
Control

10

Analysis 1.29.   Comparison 1: CBT plus standard care versus control,
Outcome 29: Mental state - specific: mean endpoint MADRS (high = poor)

Study or Subgroup

CBT + TAU
SD

Mean

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.29.1 < 12 months
Gleeson 2009 (EPISODE II)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.09 (P = 0.28)

8.3

1.29.2 > 1 year
Gleeson 2009 (EPISODE II)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.53 (P = 0.60)

7.6

9

1.7

41
41

41
41

10.8

11.5

40
40

14.8%
14.8%

-2.50 [-7.00 , 2.00]
-2.50 [-7.00 , 2.00]

7.4

1.7

40
40

85.2%
85.2%

0.20 [-0.54 , 0.94]
0.20 [-0.54 , 0.94]

Total (95% CI)
Heterogeneity: Tau² = 0.93; Chi² = 1.34, df = 1 (P = 0.25); I² = 26%
Test for overall effect: Z = 0.21 (P = 0.84)
Test for subgroup differences: Chi² = 1.34, df = 1 (P = 0.25), I² = 25.6%

82

80

100.0%

-0.20 [-2.07 , 1.68]

-10

-5
CBT + TAU

0

5
Control

10

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

183

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.30.   Comparison 1: CBT plus standard care versus control, Outcome
30: Mental state - specific: mean endpoint Hamilton Depression (high = poor)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.30.1 < 6 months
Gonzalez-Ortega 2021
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.77 (P = 0.08)

5.24

1.30.2 < 12 months
GetUp
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.68 (P = 0.09)

8.81

5.58

86
86

6.65

4.96

91
91

64.8%
64.8%

-1.41 [-2.97 , 0.15]
-1.41 [-2.97 , 0.15]

6.58

178
178

10.62

10.17

112
112

35.2%
35.2%

-1.81 [-3.93 , 0.31]
-1.81 [-3.93 , 0.31]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.09, df = 1 (P = 0.77); I² = 0%
Test for overall effect: Z = 2.42 (P = 0.02)
Test for subgroup differences: Chi² = 0.09, df = 1 (P = 0.77), I² = 0%

264

203

100.0%

-1.55 [-2.81 , -0.30]

-2

-4
CBT + TAU

0

2
Control

4

Analysis 1.31.   Comparison 1: CBT plus standard care versus control,
Outcome 31: Mental state - specific: mean endpoint CESD-R (high = poor)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.31.1 < 6 months
Jackson 2008 (ACE)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.83 (P = 0.41)

15.92

13.359

Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable

26
26

26

19.86

18.566

22
22

100.0%
100.0%

-3.94 [-13.24 , 5.36]
-3.94 [-13.24 , 5.36]

22

100.0%

-3.94 [-13.24 , 5.36]

-20

-10
CBT + TAU

0

10
Control

20

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

184

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.32.   Comparison 1: CBT plus standard care versus control, Outcome 32: Mental
state - specific: mean endpoint depressive symptoms (high = poor) (combined time points)

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Barrowclough 2014
Bucci 2018 (Actissist)
Edwards 2006
Edwards 2011
GetUp
Gleeson 2009 (EPISODE II)
Gonzalez-Ortega 2021
Jackson 2008 (ACE)
Jackson 2009
Jolley 2003
Lepage 2022
Madigan 2013
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Sönmez 2020
Supereden3
Uzenoff 2008

6
6
7.5
19.678261
8.81
8.3
5.24
15.92
3.7
4.2
3.99
4.3
14.94
5.1
3.9
4.69
13.67
10.2

4.338913
4.9
6.3
6.149424
6.58
9
5.58
13.359
3.9
3.89
4.24
4.4
5.36
4.2
3.5
4.41
15.94
1.87

48
21
16
23
178
41
86
26
19
7
22
33
17
7
12
29
62
10

6.1
7.3
6.3
20.184
10.62
10.8
6.65
19.86
3.9
2.7
3.65
4.3
14.91
5.6
4.8
2.74
15.33
11.67

5.3
4.82
7.2
5.91912
10.17
11.5
4.96
18.566
3.3
4.15
4.74
4.2
5.52
4.9
2.3
3.44
12.18
3.94

23
9
17
25
112
40
91
22
22
8
15
11
22
7
10
27
55
9

5.5%
2.2%
2.9%
4.2%
24.2%
7.1%
15.5%
4.2%
3.6%
1.3%
3.2%
2.9%
3.4%
1.2%
1.9%
4.8%
10.3%
1.6%

-0.02 [-0.52 , 0.48]
-0.26 [-1.04 , 0.52]
0.17 [-0.51 , 0.86]
-0.08 [-0.65 , 0.48]
-0.22 [-0.46 , 0.02]
-0.24 [-0.68 , 0.20]
-0.27 [-0.56 , 0.03]
-0.24 [-0.81 , 0.33]
-0.05 [-0.67 , 0.56]
0.35 [-0.67 , 1.37]
0.07 [-0.58 , 0.73]
0.00 [-0.68 , 0.68]
0.01 [-0.63 , 0.64]
-0.10 [-1.15 , 0.95]
-0.29 [-1.13 , 0.56]
0.48 [-0.05 , 1.02]
-0.12 [-0.48 , 0.25]
-0.46 [-1.38 , 0.45]

657
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 10.20, df = 17 (P = 0.90); I² = 0%
Test for overall effect: Z = 2.11 (P = 0.04)
Test for subgroup differences: Not applicable

525

100.0%

-0.13 [-0.24 , -0.01]

-2

-1
CBT + TAU

0

1
Control

2

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

185

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.33.   Comparison 1: CBT plus standard care versus control, Outcome 33: Mental
state - specific: mean endpoint depressive symptoms (high = poor) (separated time points)

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.33.1 < 6 months
48
Barrowclough 2014
21
Bucci 2018 (Actissist)
22
Edwards 2006
23
Edwards 2011
86
Gonzalez-Ortega 2021
26
Jackson 2008 (ACE)
22
Jackson 2009
7
Jolley 2003
25
Lepage 2022
40
Madigan 2013
19
Morrison 2018 (COMPARE)
10
Morrison 2020 (MAPS)
29
Sönmez 2020
10
Uzenoff 2008
388
Subtotal (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 14.48, df = 13 (P = 0.34); I² = 10%
Test for overall effect: Z = 1.29 (P = 0.20)

6.366667
6
6.2
19.678261
5.24
15.92
3.9
4.2
4.73
4.4
13.42
7.3
4.69
10.2

4.313084
4.9
5.9
6.149424
5.58
13.359
3.5
3.89
3.96
4.3
5.83
3.4
4.41
1.87

1.33.2 < 12 months
Barrowclough 2014
Edwards 2006
GetUp
Gleeson 2009 (EPISODE II)
Jackson 2009
Lepage 2022
Madigan 2013
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Supereden3
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.64, df = 10 (P = 0.99); I² = 0%
Test for overall effect: Z = 1.75 (P = 0.08)

4.338913
6.3
6.58
9
3.9
4.24
4.4
5.36
4.2
3.5
15.94

6
7.5
8.81
8.3
3.7
3.99
4.3
14.94
5.1
3.9
13.67

48
16
178
41
19
22
33
17
7
12
62
455

1.33.3 > 1 year
Barrowclough 2014
Gleeson 2009 (EPISODE II)
Müller 2020
Sönmez 2020
Supereden3
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.95, df = 4 (P = 0.92); I² = 0%
Test for overall effect: Z = 1.10 (P = 0.27)

7.091837
7.6
3.5
4.29
11.67

5.456603
1.7
4.1
3.54
13.7

49
41
9
28
55
182

4.8
7.3
7.8
20.184
6.65
19.86
4.9
2.7
4.53
4.6
16.27
10.4
2.74
11.67

4
4.82
8.1
5.91912
4.96
18.566
3.4
4.15
4.68
4.8
5.84
5.4
3.44
3.94

6.1
6.3
10.62
10.8
3.9
3.65
4.3
14.91
5.6
4.8
15.33

5.9
7.4
4.5
3.3
10.67

5.3
7.2
10.17
11.5
3.3
4.74
4.2
5.52
4.9
2.3
12.18

5
1.7
3.4
3.99
12.3

23
9
23
25
91
22
24
8
15
20
22
8
27
9
326

23
17
112
40
22
15
11
22
7
10
55
334

9.2%
4.1%
7.0%
7.4%
21.2%
7.3%
7.1%
2.4%
5.9%
8.1%
6.2%
2.8%
8.3%
3.0%
100.0%

8.3%
4.4%
36.5%
10.7%
5.4%
4.8%
4.4%
5.1%
1.9%
2.9%
15.5%
100.0%

0.37 [-0.13 , 0.87]
-0.26 [-1.04 , 0.52]
-0.22 [-0.81 , 0.37]
-0.08 [-0.65 , 0.48]
-0.27 [-0.56 , 0.03]
-0.24 [-0.81 , 0.33]
-0.29 [-0.87 , 0.30]
0.35 [-0.67 , 1.37]
0.05 [-0.59 , 0.69]
-0.04 [-0.58 , 0.49]
-0.48 [-1.10 , 0.14]
-0.67 [-1.64 , 0.29]
0.48 [-0.05 , 1.02]
-0.46 [-1.38 , 0.45]
-0.11 [-0.27 , 0.06]

-0.02 [-0.52 , 0.48]
0.17 [-0.51 , 0.86]
-0.22 [-0.46 , 0.02]
-0.24 [-0.68 , 0.20]
-0.05 [-0.67 , 0.56]
0.07 [-0.58 , 0.73]
0.00 [-0.68 , 0.68]
0.01 [-0.63 , 0.64]
-0.10 [-1.15 , 0.95]
-0.29 [-1.13 , 0.56]
-0.12 [-0.48 , 0.25]
-0.13 [-0.27 , 0.02]

21
40
7
20
43
131

19.6%
27.2%
5.2%
15.5%
32.4%
100.0%

0.22 [-0.29 , 0.73]
0.12 [-0.32 , 0.55]
-0.25 [-1.24 , 0.74]
0.26 [-0.32 , 0.84]
0.08 [-0.32 , 0.47]
0.13 [-0.10 , 0.35]

Test for subgroup differences: Chi² = 3.72, df = 2 (P = 0.16), I² = 46.2%

-2

-1
CBT + TAU

0

1
Control

2

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

186

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.34.   Comparison 1: CBT plus standard care versus control, Outcome 34: Global state
- number of participants with relapse/exacerbations of psychosis (combined time points)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Barrowclough 2014
Gleeson 2009 (EPISODE II)
Haddock 1999
Lewis 2002 (SOCRATES) (1)
Lewis 2002 (SOCRATES) (2)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)

19
4
4
26
27
3
0
0

75
41
10
50
51
40
25
21

8
11
8
50
47
10
2
0

14.8%
8.8%
12.2%
27.8%
27.8%
7.1%
1.4%

35
40
11
106
102
40
24
22

1.11 [0.54 , 2.28]
0.35 [0.12 , 1.02]
0.55 [0.24 , 1.28]
1.10 [0.79 , 1.54]
1.15 [0.82 , 1.60]
0.30 [0.09 , 1.01]
0.19 [0.01 , 3.81]
Not estimable

A

+
+
+
+
+
+
+
+

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.09; Chi² = 11.62, df = 6 (P = 0.07); I² = 48%
Test for overall effect: Z = 1.05 (P = 0.30)
Test for subgroup differences: Not applicable

136

313

83

380

100.0%

0.82 [0.57 , 1.18]

0.01

0.1
CBT + TAU

1

10
Control

100

Risk of Bias
E
B

C

D

+
+
?
+
+
+
+
+

+
?
+
+
+
+
+
−

+
+
?
+
+
+
+
+

?
+
?
+
+
+
+
+

F

?
?
?
+
+
+
+
−

Footnotes
(1) comparator supportive counselling + TAU
(2) comparator treatment-as-usual (TAU)

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

187

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.35.   Comparison 1: CBT plus standard care versus control, Outcome 35: Global state
- number of participants with relapse/exacerbations of psychosis (separated time points)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

1.35.1 < 6 months
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.07; Chi² = 2.07, df = 2 (P = 0.35); I² = 4%
Test for overall effect: Z = 1.05 (P = 0.30)

40
25
21
86

1
0
1

5
1
0

2

6

1.35.2 < 12 months
Barrowclough 2014
Gleeson 2009 (EPISODE II)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.37; Chi² = 4.91, df = 2 (P = 0.09); I² = 59%
Test for overall effect: Z = 1.35 (P = 0.18)

75
41
40
25
21
202

8
11
10
0
0

19
4
3
0
0

26

29

1.35.3 > 1 year
Barrowclough 2014
Gleeson 2009 (EPISODE II)
Haddock 1999
Lewis 2002 (SOCRATES) (1)
Lewis 2002 (SOCRATES) (2)
Liu 2019
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.07; Chi² = 9.01, df = 5 (P = 0.11); I² = 45%
Test for overall effect: Z = 0.91 (P = 0.36)

75
41
10
51
50
40
267

10
9
4
27
26
4

5
13
8
47
50
13

136

80

40
24
22
86

52.0%
23.9%
24.0%
100.0%

0.20 [0.02 , 1.64]
0.32 [0.01 , 7.50]
3.14 [0.13 , 72.96]
0.43 [0.09 , 2.07]

35
40
40
24
22
161

41.1%
31.4%
27.5%

100.0%

1.11 [0.54 , 2.28]
0.35 [0.12 , 1.02]
0.30 [0.09 , 1.01]
Not estimable
Not estimable
0.54 [0.22 , 1.32]

35
40
11
102
106
40
334

8.6%
13.6%
11.1%
29.3%
29.3%
8.1%
100.0%

0.93 [0.34 , 2.53]
0.68 [0.33 , 1.40]
0.55 [0.24 , 1.28]
1.15 [0.82 , 1.60]
1.10 [0.79 , 1.54]
0.31 [0.11 , 0.86]
0.86 [0.62 , 1.19]

Test for subgroup differences: Chi² = 1.51, df = 2 (P = 0.47), I² = 0%

Footnotes
(1) comparator treatment-as-usual (TAU)
(2) comparator supportive counselling + TAU

0.01

0.1
CBT + TAU

1

10
Control

100

Analysis 1.36.   Comparison 1: CBT plus standard care versus control, Outcome
36: Global state - number of participants with remission (combined time points)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Edwards 2011
Müller 2020

10
8

23
13

11
5

25
12

60.5%
39.5%

0.99 [0.52 , 1.88]
1.48 [0.67 , 3.27]

Total (95% CI)
18
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.59, df = 1 (P = 0.44); I² = 0%
Test for overall effect: Z = 0.58 (P = 0.57)
Test for subgroup differences: Not applicable

16

36

37

100.0%

1.16 [0.70 , 1.91]

0.2

0.5
Control

1

2

5

CBT + TAU

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

188

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.37.   Comparison 1: CBT plus standard care versus control, Outcome
37: Global state - number of participants with remission (separated time points)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

1.37.1 < 6 months
Edwards 2011
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.04 (P = 0.97)

10

10

1.37.2 < 12 months
Müller 2020
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.96 (P = 0.34)

8

8

1.37.3 > 1 year
Müller 2020
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.23 (P = 0.82)

6

6

23
23

13
13

13
13

11

11

5

5

5

5

25
25

100.0%
100.0%

0.99 [0.52 , 1.88]
0.99 [0.52 , 1.88]

12
12

100.0%
100.0%

1.48 [0.67 , 3.27]
1.48 [0.67 , 3.27]

12
12

100.0%
100.0%

1.11 [0.45 , 2.70]
1.11 [0.45 , 2.70]

Test for subgroup differences: Chi² = 0.60, df = 2 (P = 0.74), I² = 0%

0.2

0.5
Control

1

2

5

CBT + TAU

Analysis 1.38.   Comparison 1: CBT plus standard care versus control, Outcome 38:
Global state - number of participants with clinically important change in global state

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

1.38.1 < 6 months
Pos 2019
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.38 (P = 0.17)

17

17

1.38.2 < 12 months
Pos 2019
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.36 (P = 0.17)

18

18

49
49

49
49

11

11

12

12

50
50

100.0%
100.0%

1.58 [0.82 , 3.01]
1.58 [0.82 , 3.01]

50
50

100.0%
100.0%

1.53 [0.83 , 2.83]
1.53 [0.83 , 2.83]

Test for subgroup differences: Chi² = 0.00, df = 1 (P = 0.95), I² = 0%

0.2

0.5
Control

1

2

5

CBT + TAU

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

189

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.39.   Comparison 1: CBT plus standard care versus control, Outcome
39: Global state - mean endpoint CGI (high = poor) (separated time points)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.39.1 < 6 months
Palma-Sevillano 2019
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 5.24 (P < 0.00001)

3.6

0.8

1.39.2 < 12 months
Palma-Sevillano 2019
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.50 (P = 0.0005)

3.3

1

1.39.3 > 1 year
Palma-Sevillano 2019
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 4.65 (P < 0.00001)

2.8

1.3

35
35

35
35

35
35

4.6

0.7

27
27

100.0%
100.0%

-1.00 [-1.37 , -0.63]
-1.00 [-1.37 , -0.63]

4.1

0.8

27
27

100.0%
100.0%

-0.80 [-1.25 , -0.35]
-0.80 [-1.25 , -0.35]

4.1

0.9

27
27

100.0%
100.0%

-1.30 [-1.85 , -0.75]
-1.30 [-1.85 , -0.75]

Test for subgroup differences: Chi² = 1.91, df = 2 (P = 0.38), I² = 0%

-2

-1

0

CBT + TAU

1
Control

2

Analysis 1.40.   Comparison 1: CBT plus standard care versus control, Outcome 40:
Global state - mean endpoint/change CGI-S (high = poor) (separated time points)

Study or Subgroup

CBT + TAU
SD

Mean

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.40.1 < 6 months
23
Edwards 2011
86
Gonzalez-Ortega 2021
21
Morrison 2018 (COMPARE)
130
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.78, df = 2 (P = 0.68); I² = 0%
Test for overall effect: Z = 1.67 (P = 0.10)

0.693633
6.61
1.06

3.23913
6.09
2.86

3.444
6.99
3.32

0.784793
6.68
1.17

25
91
22
138

69.5%
3.2%
27.3%
100.0%

-0.20 [-0.62 , 0.21]
-0.90 [-2.86 , 1.06]
-0.46 [-1.13 , 0.21]
-0.30 [-0.65 , 0.05]

1.40.2 < 12 months
Morrison 2018 (COMPARE)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.68 (P = 0.50)

3

1.08

3.23

1.11

20
20

22
22

100.0%
100.0%

-0.23 [-0.89 , 0.43]
-0.23 [-0.89 , 0.43]

Test for subgroup differences: Chi² = 0.03, df = 1 (P = 0.86), I² = 0%

-2

-4
CBT + TAU

0

2
Control

4

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

190

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.41.   Comparison 1: CBT plus standard care versus control, Outcome
41: Global state - mean endpoint CGI-I (high = poor) (separated time points)

Study or Subgroup

CBT + TAU
SD

Mean

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.41.1 < 6 months
Gonzalez-Ortega 2021
Morrison 2018 (COMPARE)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.74; Chi² = 2.25, df = 1 (P = 0.13); I² = 56%
Test for overall effect: Z = 0.38 (P = 0.70)

86
21
107

7.57
0.91

7.07
2.14

6.25
2.95

6.09
1.21

91
22
113

31.8%
68.2%
100.0%

0.82 [-1.21 , 2.85]
-0.81 [-1.45 , -0.17]
-0.29 [-1.78 , 1.20]

1.41.2 < 12 months
Morrison 2018 (COMPARE)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.59 (P = 0.55)

2.25

1.12

20
20

2.45

1.06

22
22

100.0%
100.0%

-0.20 [-0.86 , 0.46]
-0.20 [-0.86 , 0.46]

Test for subgroup differences: Chi² = 0.01, df = 1 (P = 0.91), I² = 0%

-4

-2
CBT + TAU

0

2
Control

4

Analysis 1.42.   Comparison 1: CBT plus standard care versus control, Outcome 42: Global
state - mean endpoint/change global state scales (high = poor) (combined time points)

Study or Subgroup

CBT + TAU
SD

Mean

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Edwards 2011
Gonzalez-Ortega 2021
Morrison 2018 (COMPARE)
Palma-Sevillano 2019

3.23913
6.09
3
3.3

0.693633
6.61
1.08
1

23
86
20
35

3.444
6.99
3.23
4.1

0.784793
6.68
1.11
0.8

25
91
22
27

20.7%
37.6%
19.0%
22.7%

-0.27 [-0.84 , 0.30]
-0.13 [-0.43 , 0.16]
-0.21 [-0.81 , 0.40]
-0.86 [-1.39 , -0.33]

164
Total (95% CI)
Heterogeneity: Tau² = 0.05; Chi² = 5.65, df = 3 (P = 0.13); I² = 47%
Test for overall effect: Z = 2.03 (P = 0.04)
Test for subgroup differences: Not applicable

165

100.0%

-0.34 [-0.67 , -0.01]

-2

-1
CBT + TAU

0

1
Control

2

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

191

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.43.   Comparison 1: CBT plus standard care versus control, Outcome 43: Global
state - mean endpoint/change global state scales (high = poor) (separated time points)

Study or Subgroup

CBT + TAU
SD

Mean

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.43.1 < 6 months
Edwards 2011
Gonzalez-Ortega 2021
Morrison 2018 (COMPARE)
Palma-Sevillano 2019
Subtotal (95% CI)
Heterogeneity: Tau² = 0.21; Chi² = 13.40, df = 3 (P = 0.004); I² = 78%
Test for overall effect: Z = 1.92 (P = 0.05)

0.693633
6.61
1.06
0.8

3.23913
6.09
2.86
3.6

23
86
21
35
165

1.43.2 < 12 months
20
Morrison 2018 (COMPARE)
35
Palma-Sevillano 2019
55
Subtotal (95% CI)
Heterogeneity: Tau² = 0.13; Chi² = 2.55, df = 1 (P = 0.11); I² = 61%
Test for overall effect: Z = 1.69 (P = 0.09)

1.08
1

3
3.3

3.444
6.99
3.32
4.6

0.784793
6.68
1.17
0.7

25
91
22
27
165

23.6%
29.8%
22.7%
23.9%
100.0%

-0.27 [-0.84 , 0.30]
-0.13 [-0.43 , 0.16]
-0.40 [-1.01 , 0.20]
-1.30 [-1.86 , -0.75]
-0.51 [-1.02 , 0.01]

3.23
4.1

1.11
0.8

22
27
49

47.2%
52.8%
100.0%

-0.21 [-0.81 , 0.40]
-0.86 [-1.39 , -0.33]
-0.55 [-1.19 , 0.09]

1.43.3 > 1 year
Palma-Sevillano 2019
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 4.06 (P < 0.0001)

2.8

1.3

35
35

4.1

0.9

27
27

100.0%
100.0%

-1.12 [-1.66 , -0.58]
-1.12 [-1.66 , -0.58]

Test for subgroup differences: Chi² = 3.02, df = 2 (P = 0.22), I² = 33.8%

-2

-1

0

CBT + TAU

1
Control

2

Analysis 1.44.   Comparison 1: CBT plus standard care versus control,
Outcome 44: Service use - admission to hospital (combined time points)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Barrowclough 2014
GetUp
Jackson 2008 (ACE)
Jolley 2003
Lepage 2022
Lewis 2002 (SOCRATES) (1)
Lewis 2002 (SOCRATES) (2)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020

8
45
12
3
2
16
17
3
3
1
5

75
200
31
12
51
50
51
40
25
21
13

5
26
8
2
0
31
37
8
0
0
8

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 9.16, df = 10 (P = 0.52); I² = 0%
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Not applicable

569

125

115

35
126
31
9
45
106
102
40
24
22
12

4.7%
27.6%
9.2%
2.1%
0.6%
20.2%
23.4%
3.2%
0.6%
0.5%
8.0%

0.75 [0.26 , 2.12]
1.09 [0.71 , 1.67]
1.50 [0.71 , 3.15]
1.13 [0.23 , 5.39]
4.42 [0.22 , 89.76]
1.09 [0.66 , 1.81]
0.92 [0.58 , 1.46]
0.38 [0.11 , 1.31]
6.73 [0.37 , 123.79]
3.14 [0.13 , 72.96]
0.58 [0.26 , 1.28]

552

100.0%

1.00 [0.80 , 1.25]

0.005

0.1

1

CBT + TAU

10
Control

200

Footnotes
(1) comparator supportive counselling + TAU
(2) comparator treatment-as-usual (TAU)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

192

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.45.   Comparison 1: CBT plus standard care versus control,
Outcome 45: Service use - admission to hospital (separated time points)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

1.45.1 < 6 months
Jolley 2003
Lepage 2022
Liu 2019
Morrison 2020 (MAPS)
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 1.67, df = 3 (P = 0.64); I² = 0%
Test for overall effect: Z = 0.50 (P = 0.61)

12
51
40
21
124

2
0
1
0

3
2
0
1

6

3

1.45.2 < 12 months
Barrowclough 2014
GetUp
Liu 2019
Morrison 2018 (COMPARE)
Müller 2020
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.05; Chi² = 4.58, df = 4 (P = 0.33); I² = 13%
Test for overall effect: Z = 0.43 (P = 0.67)

75
200
40
25
13
353

5
26
4
0
5

8
45
2
3
2

40

60

1.45.3 > 1 year
Barrowclough 2014
Jackson 2008 (ACE)
Lewis 2002 (SOCRATES) (1)
Lewis 2002 (SOCRATES) (2)
Liu 2019
Müller 2020
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.01; Chi² = 5.57, df = 5 (P = 0.35); I² = 10%
Test for overall effect: Z = 0.58 (P = 0.56)

75
31
51
50
40
13
260

8
12
17
16
3
5

5
8
37
31
8
8

97

61

9
45
40
22
116

56.7%
15.4%
13.8%
14.1%
100.0%

1.13 [0.23 , 5.39]
4.42 [0.22 , 89.76]
0.33 [0.01 , 7.95]
3.14 [0.13 , 72.96]
1.36 [0.42 , 4.41]

35
126
40
24
12
237

17.8%
61.6%
7.9%
2.6%
10.1%
100.0%

0.75 [0.26 , 2.12]
1.09 [0.71 , 1.67]
0.50 [0.10 , 2.58]
6.73 [0.37 , 123.79]
0.37 [0.09 , 1.56]
0.90 [0.56 , 1.45]

35
31
102
106
40
12
326

7.6%
14.3%
31.9%
28.3%
5.3%
12.6%
100.0%

0.75 [0.26 , 2.12]
1.50 [0.71 , 3.15]
0.92 [0.58 , 1.46]
1.09 [0.66 , 1.81]
0.38 [0.11 , 1.31]
0.58 [0.26 , 1.28]
0.92 [0.68 , 1.23]

Test for subgroup differences: Chi² = 0.42, df = 2 (P = 0.81), I² = 0%

Footnotes
(1) comparator treatment-as-usual (TAU)
(2) comparator supportive counselling + TAU

0.005

0.1

1

CBT + TAU

10
Control

200

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

193

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.46.   Comparison 1: CBT plus standard care versus control,
Outcome 46: Service use - number of days in hospital (combined time points)

Study or Subgroup

GetUp
Gleeson 2009 (EPISODE II)
Haddock 1999
Jackson 2008 (ACE)
Jolley 2003
Morrison 2018 (COMPARE)
Palma-Sevillano 2019

CBT + TAU
SD

Mean

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

4.6
10.5
78.5
32
25.3
42.5
21.2

15.2
16.3
65.6
24.02
20.8
27.77
30.3

194
30
9
30
8
21
35

5.4
8.4
119.25
18.25
76
0
70

20.2
13
81.3
10.27
8.5
36
42.3

120
30
11
27
8
21
27

17.5%
17.1%
4.8%
16.7%
15.3%
14.2%
14.4%

-0.80 [-5.00 , 3.40]
2.10 [-5.36 , 9.56]
-40.75 [-105.13 , 23.63]
13.75 [4.32 , 23.18]
-50.70 [-66.27 , -35.13]
42.50 [23.05 , 61.95]
-48.80 [-67.65 , -29.95]

Total (95% CI)
Heterogeneity: Tau² = 403.69; Chi² = 94.60, df = 6 (P < 0.00001); I² = 94%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable

327

244

100.0%

-8.18 [-24.74 , 8.38]

-100 -50
CBT + TAU

0

100

50
Control

Analysis 1.47.   Comparison 1: CBT plus standard care versus control,
Outcome 47: Service use - number of days in hospital (separated time points)

Study or Subgroup

CBT + TAU
SD

Mean

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.47.1 < 6 months
Haddock 1999
Jolley 2003
Palma-Sevillano 2019
Subtotal (95% CI)
Heterogeneity: Tau² = 1062.33; Chi² = 33.52, df = 2 (P < 0.00001); I² = 94%
Test for overall effect: Z = 1.10 (P = 0.27)

55.09
76
28.2

37.89
25.3
31.1

17.12
20.8
19.2

9
8
35
52

1.47.2 < 12 months
GetUp
Gleeson 2009 (EPISODE II)
Morrison 2018 (COMPARE)
Palma-Sevillano 2019
Subtotal (95% CI)
Heterogeneity: Tau² = 107.00; Chi² = 30.68, df = 3 (P < 0.00001); I² = 90%
Test for overall effect: Z = 0.47 (P = 0.64)

15.2
9.8
27.77
58.3

194
34
21
35
284

4.6
3.3
42.5
22

5.4
1.5
0
86.3

1.47.3 > 1 year
Gleeson 2009 (EPISODE II)
Haddock 1999
Jackson 2008 (ACE)
Palma-Sevillano 2019
Subtotal (95% CI)
Heterogeneity: Tau² = 467.62; Chi² = 35.52, df = 3 (P < 0.00001); I² = 92%
Test for overall effect: Z = 1.00 (P = 0.32)

8.4
119.25
18.25
70

16.3
65.6
24.02
30.3

30
9
30
35
104

10.5
78.5
32
21.2

47
8.5
18.3

20.2
5.8
36
82

11
8
27
46

29.9%
34.4%
35.7%
100.0%

-17.20 [-47.14 , 12.74]
-50.70 [-66.27 , -35.13]
2.90 [-6.49 , 12.29]
-21.56 [-60.13 , 17.02]

120
36
21
27
204

35.8%
36.0%
19.4%
8.8%
100.0%

-0.80 [-5.00 , 3.40]
1.80 [-2.00 , 5.60]
42.50 [23.05 , 61.95]
-64.30 [-100.77 , -27.83]
2.95 [-9.42 , 15.33]

13
81.3
10.27
42.3

30
11
27
27
95

31.7%
9.9%
31.1%
27.3%
100.0%

2.10 [-5.36 , 9.56]
-40.75 [-105.13 , 23.63]
13.75 [4.32 , 23.18]
-48.80 [-67.65 , -29.95]
-12.39 [-36.62 , 11.84]

Test for subgroup differences: Chi² = 2.31, df = 2 (P = 0.32), I² = 13.4%

-100 -50
CBT + TAU

0

100

50
Control

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

194

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.48.   Comparison 1: CBT plus standard care versus control, Outcome 48:
Leaving the study early - for any reason - overall acceptability (combined time points)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Barrowclough 2014
Bucci 2018 (Actissist)
Edwards 2006
GetUp
Gleeson 2009 (EPISODE II)
Gonzalez-Ortega 2021
Haddock 1999
Hjorthoj 2013 (CapOpus)
Jackson 2008 (ACE)
Jackson 2009
Jolley 2003
Lecomte 2008 (1)
Lecomte 2008 (2)
Lepage 2022
Lewis 2002 (SOCRATES) (3)
Lewis 2002 (SOCRATES) (4)
Liu 2019
Madigan 2013
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Palma-Sevillano 2019
Pos 2019
Puig-Navarro 2020
Sönmez 2020
Supereden3
Uzenoff 2008

20
3
7
33
7
6
1
5
3
17
5
6
7
21
9
8
4
27
2
1
1
0
10
5
3
3
2

75
24
23
200
41
92
10
18
31
36
12
24
24
51
51
50
40
59
25
21
13
35
49
16
32
76
13

11
3
7
19
4
1
0
7
6
8
1
37
14
25
21
18
7
10
1
0
2
0
15
4
4
9
2

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.03; Chi² = 28.26, df = 25 (P = 0.30); I² = 12%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable

1141

236

216

35
12
24
126
40
92
11
18
31
30
9
54
27
45
102
106
40
29
24
22
12
27
50
14
31
79
11

7.3%
1.6%
4.1%
9.6%
2.5%
0.8%
0.4%
3.6%
2.0%
6.2%
0.9%
5.8%
5.7%
12.8%
5.9%
5.2%
2.5%
8.2%
0.6%
0.4%
0.7%

6.0%
2.7%
1.7%
2.1%
1.1%

0.85 [0.46 , 1.57]
0.50 [0.12 , 2.12]
1.04 [0.43 , 2.51]
1.09 [0.65 , 1.84]
1.71 [0.54 , 5.38]
6.00 [0.74 , 48.86]
3.27 [0.15 , 72.23]
0.71 [0.28 , 1.84]
0.50 [0.14 , 1.82]
1.77 [0.89 , 3.52]
3.75 [0.53 , 26.77]
0.36 [0.18 , 0.75]
0.56 [0.27 , 1.16]
0.74 [0.49 , 1.13]
0.86 [0.42 , 1.73]
0.94 [0.44 , 2.02]
0.57 [0.18 , 1.80]
1.33 [0.75 , 2.35]
1.92 [0.19 , 19.82]
3.14 [0.13 , 72.96]
0.46 [0.05 , 4.46]
Not estimable
0.68 [0.34 , 1.37]
1.09 [0.36 , 3.29]
0.73 [0.18 , 2.99]
0.35 [0.10 , 1.23]
0.85 [0.14 , 5.06]

1101

100.0%

0.87 [0.72 , 1.05]

0.01

0.1
CBT + TAU

1

10
Control

100

A

+
+
+
−

+
+
+
+
+
+
+
?
?
+
+
+
+
+
+
+
+
+
+
?
+
+
?

Risk of Bias
E
B

D

C

+
?
+
+
+
?
?
+
?
+
?
+
+
+
+
+
+
+
+
+
+
?
+
+
?
+
+

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

F

+
?
+
−

+
?
?
+
?
+
?
?
?
+
+
+
+
+
+
+
+
?
+
?
?
+
?

Footnotes
(1) comparator skills training for symptom management (SST)
(2) comparator waiting list (WL)
(3) comparator treatment-as-usual (TAU)
(4) comparator supportive counselling + TAU

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

195

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.49.   Comparison 1: CBT plus standard care versus control, Outcome 49: Leaving the study early - for any
reason - overall acceptability (separated time points)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

1.49.1 < 6 months
Barrowclough 2014
Bucci 2018 (Actissist)
Edwards 2006
Gonzalez-Ortega 2021
Haddock 1999
Hjorthoj 2013 (CapOpus)
Jackson 2008 (ACE)
Jackson 2009
Jolley 2003
Lecomte 2008 (1)
Lecomte 2008 (2)
Lepage 2022
Lewis 2002 (SOCRATES) (3)
Lewis 2002 (SOCRATES) (4)
Liu 2019
Madigan 2013
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Palma-Sevillano 2019
Pos 2019
Puig-Navarro 2020
Sönmez 2020
Uzenoff 2008
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 17.52, df = 21 (P = 0.68); I² = 0%
Test for overall effect: Z = 1.35 (P = 0.18)

75
24
23
92
10
18
31
36
12
24
24
51
51
50
40
59
25
21
35
49
16
32
13
811

11
3
1
1
0
7
6
6
1
21
4
25
21
18
3
7
1
0
0
11
4
4
2

16
3
1
6
1
5
3
14
5
3
3
21
9
8
2
17
2
1
0
9
5
3
2

139

157

1.49.2 < 12 months
Barrowclough 2014
Edwards 2006
GetUp
Gleeson 2009 (EPISODE II)
Hjorthoj 2013 (CapOpus)
Jackson 2009
Lecomte 2008 (1)
Lecomte 2008 (2)
Liu 2019
Madigan 2013
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Palma-Sevillano 2019
Pos 2019
Supereden3
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.08; Chi² = 20.05, df = 14 (P = 0.13); I² = 30%
Test for overall effect: Z = 1.08 (P = 0.28)

75
23
200
41
18
36
24
24
40
59
25
21
13
35
49
76
759

11
7
19
4
7
8
37
14
7
10
1
0
2
0
15
9

20
7
33
7
5
17
6
7
4
27
2
1
1
0
10
3

150

151

35
12
24
92
11
18
31
30
9
54
27
45
102
106
40
29
24
22
27
50
14
31
11
844

35
24
126
40
18
30
54
27
40
29
24
22
12
27
50
79
637

10.1%
2.1%
0.6%
1.0%
0.5%
4.9%
2.6%
6.4%
1.1%
3.5%
2.2%
24.6%
8.7%
7.5%
1.4%
7.5%
0.8%
0.4%

7.0%
3.6%
2.2%
1.4%
100.0%

10.6%
6.8%
12.7%
4.5%
6.1%
9.4%
8.9%
8.8%
4.5%
11.5%
1.3%
0.7%
1.3%

9.2%
3.8%
100.0%

0.68 [0.35 , 1.31]
0.50 [0.12 , 2.12]
1.04 [0.07 , 15.72]
6.00 [0.74 , 48.86]
3.27 [0.15 , 72.23]
0.71 [0.28 , 1.84]
0.50 [0.14 , 1.82]
1.94 [0.85 , 4.43]
3.75 [0.53 , 26.77]
0.32 [0.11 , 0.98]
0.84 [0.21 , 3.40]
0.74 [0.49 , 1.13]
0.86 [0.42 , 1.73]
0.94 [0.44 , 2.02]
0.67 [0.12 , 3.78]
1.19 [0.56 , 2.55]
1.92 [0.19 , 19.82]
3.14 [0.13 , 72.96]
Not estimable
0.83 [0.38 , 1.84]
1.09 [0.36 , 3.29]
0.73 [0.18 , 2.99]
0.85 [0.14 , 5.06]
0.87 [0.70 , 1.07]

0.85 [0.46 , 1.57]
1.04 [0.43 , 2.51]
1.09 [0.65 , 1.84]
1.71 [0.54 , 5.38]
0.71 [0.28 , 1.84]
1.77 [0.89 , 3.52]
0.36 [0.18 , 0.75]
0.56 [0.27 , 1.16]
0.57 [0.18 , 1.80]
1.33 [0.75 , 2.35]
1.92 [0.19 , 19.82]
3.14 [0.13 , 72.96]
0.46 [0.05 , 4.46]
Not estimable
0.68 [0.34 , 1.37]
0.35 [0.10 , 1.23]
0.86 [0.66 , 1.13]

1.49.3 > 1 year
Barrowclough 2014
Gleeson 2009 (EPISODE II)
Jackson 2008 (ACE)

21
11
3

75
41
31

13
10
4

35
40
31

8.3%
4.8%
1.3%

0.75 [0.43 , 1.32]
1.07 [0.51 , 2.24]
0.75 [0.18 , 3.08]

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

196

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 1.49.   (Continued)

Cochrane Database of Systematic Reviews

21
11
3
17
17
13
13
5
4
0
4
5

Barrowclough 2014
Gleeson 2009 (EPISODE II)
Jackson 2008 (ACE)
Lecomte 2008 (2)
Lecomte 2008 (1)
Lewis 2002 (SOCRATES) (3)
Lewis 2002 (SOCRATES) (4)
Liu 2019
Müller 2020
Palma-Sevillano 2019
Sönmez 2020
Supereden3
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 6.90, df = 10 (P = 0.73); I² = 0%
Test for overall effect: Z = 2.52 (P = 0.01)

75
41
31
24
24
51
50
40
13
35
32
76
492

13
10
4
20
49
31
27
11
5
0
11
10

191

113

35
40
31
27
54
102
106
40
12
27
31
79
584

8.3%
4.8%
1.3%
22.7%
36.0%
8.6%
8.1%
2.8%
2.4%

2.5%
2.5%
100.0%

0.75 [0.43 , 1.32]
1.07 [0.51 , 2.24]
0.75 [0.18 , 3.08]
0.96 [0.68 , 1.34]
0.78 [0.60 , 1.02]
0.84 [0.48 , 1.46]
1.02 [0.58 , 1.80]
0.45 [0.17 , 1.19]
0.74 [0.26 , 2.12]
Not estimable
0.35 [0.13 , 0.99]
0.52 [0.19 , 1.45]
0.81 [0.69 , 0.96]

Test for subgroup differences: Chi² = 0.28, df = 2 (P = 0.87), I² = 0%

Footnotes
(1) comparator skills training for symptom management (SST)
(2) comparator waiting list (WL)
(3) comparator treatment-as-usual (TAU)
(4) comparator supportive counselling + TAU

0.01

0.1
CBT + TAU

1

10
Control

100

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

197

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.50.   Comparison 1: CBT plus standard care versus control,
Outcome 50: Functioning - mean endpoint GAF (high = good)

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.50.1 < 6 months
Barrowclough 2014 (1)
Bucci 2018 (Actissist) (1)
Gonzalez-Ortega 2021 (1)
Hjorthoj 2013 (CapOpus) (1)
Madigan 2013 (1)
Palma-Sevillano 2019 (1)
Pos 2019 (1)
Sönmez 2020 (1)
Subtotal (95% CI)
Heterogeneity: Tau² = 36.48; Chi² = 39.46, df = 7 (P < 0.00001); I² = 82%
Test for overall effect: Z = 1.92 (P = 0.06)

8.903824
16.2
13.6
11
8
10.9
10.92
12.3

-39.025
-52
-76.03
-53.1
-37.4
-65.2
-49
-59.6

48
21
86
18
39
35
40
29
316

-39.7
-48.2
-69.58
-51.5
-36.6
-47.6
-48.8
-53.3

1.50.2 < 12 months
Barrowclough 2014 (1)
GetUp (1)
Hjorthoj 2013 (CapOpus) (1)
Madigan 2013 (1)
Müller 2020 (1)
Palma-Sevillano 2019 (1)
Pos 2019 (1)
Subtotal (95% CI)
Heterogeneity: Tau² = 38.41; Chi² = 30.79, df = 6 (P < 0.0001); I² = 81%
Test for overall effect: Z = 1.09 (P = 0.28)

10.816673
16.94
16.6
8.34
11.9
10.2
10.94

-39.9
-63.15
-53.1
-37.6
-62.1
-67.8
-50.8

48
171
18
31
12
35
39
354

-41.4
-60.11
-58
-37.2
-57.9
-51.4
-51.3

11.2
14.7
13.91
12.3
9.6
8.3
10.63
13.2

16.5
16.63
16.9
11.5
6.1
10.6
10.79

24
9
91
18
19
27
39
27
254

23
109
18
16
10
27
35
238

13.4%
8.0%
14.3%
11.3%
13.5%
13.7%
13.7%
12.1%
100.0%

0.68 [-4.47 , 5.82]
-3.80 [-15.64 , 8.04]
-6.45 [-10.50 , -2.40]
-1.60 [-9.22 , 6.02]
-0.80 [-5.79 , 4.19]
-17.60 [-22.38 , -12.82]
-0.20 [-4.95 , 4.55]
-6.30 [-13.00 , 0.40]
-4.62 [-9.35 , 0.10]

13.6%
16.7%
10.3%
14.6%
13.2%
15.7%
15.9%
100.0%

1.50 [-5.91 , 8.91]
-3.04 [-7.06 , 0.98]
4.90 [-6.04 , 15.84]
-0.40 [-6.75 , 5.95]
-4.20 [-11.92 , 3.52]
-16.40 [-21.63 , -11.17]
0.50 [-4.46 , 5.46]
-2.91 [-8.15 , 2.33]

1.50.3 > 1 year
Barrowclough 2014 (1)
Müller 2020 (1)
Palma-Sevillano 2019 (1)
Sönmez 2020 (1)
Subtotal (95% CI)
Heterogeneity: Tau² = 68.24; Chi² = 16.97, df = 3 (P = 0.0007); I² = 82%
Test for overall effect: Z = 2.08 (P = 0.04)

14.668021
13.5
8.9
11.8

-41.97551
-66
-70.22
-61.1

49
9
35
28
121

-41.9
-61.7
-50.9
-48.8

16.5
11.4
11.7
12

21
7
27
20
75

25.0%
20.0%
28.3%
26.6%
100.0%

-0.08 [-8.24 , 8.09]
-4.30 [-16.51 , 7.91]
-19.32 [-24.63 , -14.01]
-12.30 [-19.14 , -5.46]
-9.63 [-18.70 , -0.56]

Test for subgroup differences: Chi² = 1.58, df = 2 (P = 0.45), I² = 0%

Footnotes
(1) Scores were reversed so that the area to the left of the line of no effect indicates a favourable outcome for CBT.

-20

-10
CBT + TAU

0

20

10
Control

Analysis 1.51.   Comparison 1: CBT plus standard care versus
control, Outcome 51: Functioning - mean change GAF (high = good)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.51.1 < 12 months
Müller 2020 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.07 (P = 0.94)

-12.3

10.6

1.51.2 > 1 year
Müller 2020 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.07 (P = 0.94)

-16.2

12.2

13
13

12
12

-12

9.5

12
12

100.0%
100.0%

-0.30 [-8.18 , 7.58]
-0.30 [-8.18 , 7.58]

-15.8

13.8

10
10

100.0%
100.0%

-0.40 [-11.39 , 10.59]
-0.40 [-11.39 , 10.59]

Test for subgroup differences: Chi² = 0.00, df = 1 (P = 0.99), I² = 0%

Footnotes
(1) Scores were reversed so that the area to the left of the line of no effect indicates a favourable outcome for CBT.

-10

-5

CBT + TAU

0

10

5
Control

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

198

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.52.   Comparison 1: CBT plus standard care versus control,
Outcome 52: Functioning - mean endpoint SOFAS (high = good)

Study or Subgroup

CBT + TAU
SD

Mean

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.52.1 < 6 months
22
Edwards 2006 (1)
23
Edwards 2011 (1)
31
Jackson 2008 (ACE) (1)
25
Lepage 2022 (1)
101
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.94, df = 3 (P = 0.59); I² = 0%
Test for overall effect: Z = 1.63 (P = 0.10)

17
8.181298
13.81
10.88

-50.5
-55.4
-62.69
-58.75

1.52.2 < 12 months
16
Edwards 2006 (1)
41
Gleeson 2009 (EPISODE II) (1)
22
Lepage 2022 (1)
79
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.43, df = 2 (P = 0.49); I² = 0%
Test for overall effect: Z = 0.01 (P = 0.99)

-51.7
-63.8
-60.29

18.3
15.7
11.67

-51.3
-54.416
-57.6
-53.48

14.9
10.749988
11.37
12.47

23
25
31
16
95

12.8%
38.7%
28.3%
20.2%
100.0%

0.80 [-8.56 , 10.16]
-0.98 [-6.36 , 4.40]
-5.09 [-11.39 , 1.21]
-5.27 [-12.72 , 2.18]
-2.78 [-6.13 , 0.57]

-56.4
-64.8
-56.72

15.9
16.5
12.96

17
40
15
72

17.1%
47.7%
35.2%
100.0%

4.70 [-7.03 , 16.43]
1.00 [-6.02 , 8.02]
-3.57 [-11.74 , 4.60]
0.02 [-4.82 , 4.87]

1.52.3 > 1 year
Gleeson 2009 (EPISODE II) (1)
Jackson 2008 (ACE) (1)
Subtotal (95% CI)
Heterogeneity: Tau² = 44.35; Chi² = 6.78, df = 1 (P = 0.009); I² = 85%
Test for overall effect: Z = 0.89 (P = 0.37)

-63.2
-64.21

3.1
15.18

41
31
72

-72.1
-62.91

3.1
15.18

40
31
71

56.9%
43.1%
100.0%

8.90 [7.55 , 10.25]
-1.30 [-8.86 , 6.26]
4.51 [-5.39 , 14.41]

Test for subgroup differences: Chi² = 2.35, df = 2 (P = 0.31), I² = 15.0%

Footnotes
(1) Scores were reversed so that the area to the left of the line of no effect indicates a favourable outcome for CBT.

-20

-10
CBT + TAU

0

10
Control

20

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

199

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.53.   Comparison 1: CBT plus standard care versus control,
Outcome 53: Functioning - mean endpoint PSP (high = good)

Study or Subgroup

CBT + TAU
SD

Mean

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.53.1 < 6 months
Bucci 2018 (Actissist) (1)
Liu 2019 (1)
Morrison 2018 (COMPARE) (1)
Subtotal (95% CI)
Heterogeneity: Tau² = 1.22; Chi² = 2.11, df = 2 (P = 0.35); I² = 5%
Test for overall effect: Z = 1.75 (P = 0.08)

-56.9
-66.42
-62.48

14.2
11.86
17.47

21
40
21
82

1.53.2 < 12 months
Liu 2019 (1)
Morrison 2018 (COMPARE) (1)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.84, df = 1 (P = 0.36); I² = 0%
Test for overall effect: Z = 1.93 (P = 0.05)

-74.75
-61

10.14
16.47

40
20
60

-54.3
-59
-63.95

15.5
16.42
18.53

9
40
22
71

18.3%
59.8%
21.9%
100.0%

-2.60 [-14.41 , 9.21]
-7.42 [-13.70 , -1.14]
1.47 [-9.29 , 12.23]
-4.59 [-9.73 , 0.54]

-68.74
-60.45

14.62
17.61

40
22
62

77.8%
22.2%
100.0%

-6.01 [-11.52 , -0.50]
-0.55 [-10.86 , 9.76]
-4.80 [-9.66 , 0.07]

1.53.3 > 1 year
Liu 2019 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.59 (P = 0.010)

-75.73

11.88

40
40

-67.85

15.18

40
40

100.0%
100.0%

-7.88 [-13.85 , -1.91]
-7.88 [-13.85 , -1.91]

Test for subgroup differences: Chi² = 0.81, df = 2 (P = 0.67), I² = 0%

Footnotes
(1) Scores were reversed so that the area to the left of the line of no effect indicates a favourable outcome for CBT.

-20

-10
CBT + TAU

0

10
Control

20

Analysis 1.54.   Comparison 1: CBT plus standard care versus control,
Outcome 54: Functioning - mean endpoint FAST (high = poor)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.54.1 < 6 months
Gonzalez-Ortega 2021
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.06 (P = 0.04)

15.15

16.43

86
86

20.05

15.22

91
91

100.0%
100.0%

-4.90 [-9.57 , -0.23]
-4.90 [-9.57 , -0.23]

Test for subgroup differences: Not applicable

-10

-5
CBT + TAU

0

5
Control

10

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

200

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.55.   Comparison 1: CBT plus standard care versus control,
Outcome 55: Functioning - mean endpoint FESFS (high = good)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.55.1 < 6 months
Morrison 2020 (MAPS) (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.60 (P = 0.55)

-10.72

1.55.2 < 12 months
Morrison 2020 (MAPS) (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.07 (P = 0.94)

-10.77

2.77

3.36

3
3

2
2

-9.57

2.6

6
6

100.0%
100.0%

-1.15 [-4.91 , 2.61]
-1.15 [-4.91 , 2.61]

-11.04

2.99

1
1

100.0%
100.0%

0.27 [-7.22 , 7.76]
0.27 [-7.22 , 7.76]

Test for subgroup differences: Chi² = 0.11, df = 1 (P = 0.74), I² = 0%

Footnotes
(1) Scores were reversed so that the area to the left of the line of no effect indicates a favourable outcome for CBT.

-10

-5
CBT + TAU

0

5
Control

10

Analysis 1.56.   Comparison 1: CBT plus standard care versus control, Outcome 56:
Functioning - mean endpoint functioning scale (high = good) (combined time points)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Barrowclough 2014 (1)
Bucci 2018 (Actissist) (1)
Edwards 2006 (1)
Edwards 2011 (1)
GetUp (1)
Gleeson 2009 (EPISODE II) (1)
Gonzalez-Ortega 2021 (1)
Hjorthoj 2013 (CapOpus) (1)
Jackson 2008 (ACE) (1)
Lepage 2022 (1)
Liu 2019 (1)
Madigan 2013 (1)
Morrison 2018 (COMPARE) (1)
Morrison 2020 (MAPS) (1)
Müller 2020 (1)
Palma-Sevillano 2019 (1)
Pos 2019 (1)
Sönmez 2020 (1)

-39.9
-52
-51.7
-55.4
-63.15
-63.8
-76.03
-53.1
-62.69
-60.29
-74.75
-37.6
-61
-10.77
-62.1
-67.8
-50.8
-59.6

10.816673
16.2
18.3
8.181298
16.94
15.7
13.6
16.6
13.81
11.67
10.14
8.34
16.47
3.36
11.9
10.2
10.94
12.3

48
21
16
23
171
41
86
18
31
22
40
31
20
2
12
35
39
29

-41.4
-48.2
-56.4
-54.416
-60.11
-64.8
-69.58
-58
-57.6
-56.72
-68.74
-37.2
-60.45
-11.04
-57.9
-51.4
-51.3
-53.3

16.5
14.7
15.9
10.749988
16.63
16.5
13.91
16.9
11.37
12.96
14.62
11.5
17.61
2.99
6.1
10.6
10.79
13.2

Total (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 36.05, df = 17 (P = 0.005); I² = 53%
Test for overall effect: Z = 2.54 (P = 0.01)
Test for subgroup differences: Not applicable

685

23
9
17
25
109
40
91
18
31
15
40
16
22
1
10
27
35
27

6.3%
3.7%
4.4%
5.5%
9.8%
7.0%
9.0%
4.6%
6.2%
4.6%
6.9%
5.1%
5.1%
0.5%
3.3%
5.4%
6.8%
5.9%

0.11 [-0.38 , 0.61]
-0.23 [-1.02 , 0.55]
0.27 [-0.42 , 0.95]
-0.10 [-0.67 , 0.47]
-0.18 [-0.42 , 0.06]
0.06 [-0.37 , 0.50]
-0.47 [-0.77 , -0.17]
0.29 [-0.37 , 0.94]
-0.40 [-0.90 , 0.11]
-0.29 [-0.95 , 0.37]
-0.47 [-0.92 , -0.03]
-0.04 [-0.64 , 0.56]
-0.03 [-0.64 , 0.57]
0.00 [-2.40 , 2.40]
-0.42 [-1.27 , 0.43]
-1.56 [-2.14 , -0.98]
0.05 [-0.41 , 0.50]
-0.49 [-1.02 , 0.04]

556

100.0%

-0.23 [-0.42 , -0.05]

Footnotes
(1) Scores were reversed so that the area to the left of the line of no effect indicates a favourable outcome for CBT.

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

-2

-1

0

CBT + TAU

1
Control

2

A

+
+
+
?
−

+
+
+
+
+
+
+
+
+
+
+
+
+

Risk of Bias
E
B

D

C

+
?
+
+
+
+
?
+
+
+
+
+
+
+
+
?
+
?

?
+
?
+
+
+
+
?
+
?
+
?
+
−

+
+
?
+

+
+
+
+
?
+
+
+
+
+
+
+
+
+
+
+
+
+

?
+
?
?
+
?
+
?
?
+
+
?
+
+
?
?
+
?

F

?
?
?
?
−

?
?
?
?
?
+
?
+
−

?
?
?
?

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

201

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.57.   Comparison 1: CBT plus standard care versus control, Outcome 57:
Functioning - mean endpoint functioning scale (high = good) (separated time points)

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.57.1 < 6 months
48
Barrowclough 2014 (1)
21
Bucci 2018 (Actissist) (1)
22
Edwards 2006 (1)
23
Edwards 2011 (1)
86
Gonzalez-Ortega 2021 (1)
18
Hjorthoj 2013 (CapOpus) (1)
31
Jackson 2008 (ACE) (1)
25
Lepage 2022 (1)
40
Liu 2019 (1)
39
Madigan 2013 (1)
21
Morrison 2018 (COMPARE) (1)
3
Morrison 2020 (MAPS) (1)
35
Palma-Sevillano 2019 (1)
40
Pos 2019 (1)
29
Sönmez 2020 (1)
481
Subtotal (95% CI)
Heterogeneity: Tau² = 0.10; Chi² = 33.86, df = 14 (P = 0.002); I² = 59%
Test for overall effect: Z = 2.85 (P = 0.004)

8.903824
16.2
17
8.181298
13.6
11
13.81
10.88
11.86
8
17.47
2.77
10.9
10.92
12.3

-39.025
-52
-50.5
-55.4
-76.03
-53.1
-62.69
-58.75
-66.42
-37.4
-62.48
-10.72
-65.2
-49
-59.6

-39.7
-48.2
-51.3
-54.416
-69.58
-51.5
-57.6
-53.48
-59
-36.6
-63.95
-9.57
-47.6
-48.8
-53.3

11.2
14.7
14.9
10.749988
13.91
12.3
11.37
12.47
16.42
9.6
18.53
2.6
8.3
10.63
13.2

1.57.2 < 12 months
48
Barrowclough 2014 (1)
16
Edwards 2006 (1)
171
GetUp (1)
41
Gleeson 2009 (EPISODE II) (1)
18
Hjorthoj 2013 (CapOpus) (1)
22
Lepage 2022 (1)
40
Liu 2019 (1)
31
Madigan 2013 (1)
20
Morrison 2018 (COMPARE) (1)
2
Morrison 2020 (MAPS) (1)
12
Müller 2020 (1)
35
Palma-Sevillano 2019 (1)
39
Pos 2019 (1)
495
Subtotal (95% CI)
Heterogeneity: Tau² = 0.11; Chi² = 31.58, df = 12 (P = 0.002); I² = 62%
Test for overall effect: Z = 1.43 (P = 0.15)

10.816673
18.3
16.94
15.7
16.6
11.67
10.14
8.34
16.47
3.36
11.9
10.2
10.94

-39.9
-51.7
-63.15
-63.8
-53.1
-60.29
-74.75
-37.6
-61
-10.77
-62.1
-67.8
-50.8

1.57.3 > 1 year
Barrowclough 2014 (1)
Gleeson 2009 (EPISODE II) (1)
Jackson 2008 (ACE) (1)
Liu 2019 (1)
Müller 2020 (1)
Palma-Sevillano 2019 (1)
Sönmez 2020 (1)
Subtotal (95% CI)
Heterogeneity: Tau² = 1.78; Chi² = 130.39, df = 6 (P < 0.00001); I² = 95%
Test for overall effect: Z = 0.28 (P = 0.78)

14.668021
3.1
15.18
11.88
13.5
8.9
11.8

-41.97551
-63.2
-64.21
-75.73
-66
-70.22
-61.1

49
41
31
40
9
35
28
233

-41.4
-56.4
-60.11
-64.8
-58
-56.72
-68.74
-37.2
-60.45
-11.04
-57.9
-51.4
-51.3

-41.9
-72.1
-62.91
-67.85
-61.7
-50.9
-48.8

16.5
15.9
16.63
16.5
16.9
12.96
14.62
11.5
17.61
2.99
6.1
10.6
10.79

16.5
3.1
15.18
15.18
11.4
11.7
12

24
9
23
25
91
18
31
16
40
19
22
6
27
39
27
417

23
17
109
40
18
15
40
16
22
1
10
27
35
373

21
40
31
40
7
27
20
186

7.6%
4.8%
6.5%
6.7%
9.9%
5.9%
7.4%
6.0%
8.1%
6.9%
6.4%
2.0%
6.4%
8.2%
7.1%
100.0%

8.9%
6.7%
12.3%
9.7%
7.0%
7.0%
9.6%
7.6%
7.6%
1.0%
5.2%
7.9%
9.4%
100.0%

14.6%
14.3%
14.6%
14.7%
13.2%
14.3%
14.3%
100.0%

0.07 [-0.42 , 0.56]
-0.23 [-1.02 , 0.55]
0.05 [-0.54 , 0.63]
-0.10 [-0.67 , 0.47]
-0.47 [-0.77 , -0.17]
-0.13 [-0.79 , 0.52]
-0.40 [-0.90 , 0.11]
-0.45 [-1.08 , 0.19]
-0.51 [-0.96 , -0.07]
-0.09 [-0.64 , 0.46]
0.08 [-0.52 , 0.68]
-0.39 [-1.79 , 1.02]
-1.76 [-2.36 , -1.17]
-0.02 [-0.46 , 0.42]
-0.49 [-1.02 , 0.04]
-0.32 [-0.54 , -0.10]

0.11 [-0.38 , 0.61]
0.27 [-0.42 , 0.95]
-0.18 [-0.42 , 0.06]
0.06 [-0.37 , 0.50]
0.29 [-0.37 , 0.94]
-0.29 [-0.95 , 0.37]
-0.47 [-0.92 , -0.03]
-0.04 [-0.64 , 0.56]
-0.03 [-0.64 , 0.57]
0.00 [-2.40 , 2.40]
-0.42 [-1.27 , 0.43]
-1.56 [-2.14 , -0.98]
0.05 [-0.41 , 0.50]
-0.18 [-0.43 , 0.07]

-0.00 [-0.52 , 0.51]
2.84 [2.22 , 3.47]
-0.08 [-0.58 , 0.41]
-0.57 [-1.02 , -0.12]
-0.32 [-1.32 , 0.67]
-1.87 [-2.48 , -1.26]
-1.02 [-1.63 , -0.41]
-0.15 [-1.16 , 0.87]

Test for subgroup differences: Chi² = 0.74, df = 2 (P = 0.69), I² = 0%

Footnotes
(1) Scores were reversed so that the area to the left of the line of no effect indicates a favourable outcome for CBT.

-4

-2
CBT + TAU

0

2
Control

4

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

202

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.58.   Comparison 1: CBT plus standard care versus control,
Outcome 58: Quality of life - mean endpoint WHO QoL-bref (high = good)

Study or Subgroup

CBT + TAU
SD

Mean

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.58.1 < 6 months
Madigan 2013 (1)
Morrison 2018 (COMPARE) (1)
Subtotal (95% CI)
Heterogeneity: Tau² = 19.18; Chi² = 1.90, df = 1 (P = 0.17); I² = 47%
Test for overall effect: Z = 0.81 (P = 0.42)

-13.5
-89.06

3.3
18.87

34
18
52

1.58.2 < 12 months
Gleeson 2009 (EPISODE II) (1)
Madigan 2013 (1)
Morrison 2018 (COMPARE) (1)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.16; Chi² = 2.33, df = 2 (P = 0.31); I² = 14%
Test for overall effect: Z = 0.58 (P = 0.56)

-3.6
-12.6
-82.93

0.8
3.4
19.17

41
34
15
90

-12.6
-79.15

3.4
20.95

15
20
35

75.0%
25.0%
100.0%

-0.90 [-2.95 , 1.15]
-9.91 [-22.57 , 2.75]
-3.15 [-10.79 , 4.49]

-3.6
-11.1
-81.36

1.1
2.9
20.02

40
14
22
76

83.9%
15.7%
0.4%
100.0%

0.00 [-0.42 , 0.42]
-1.50 [-3.40 , 0.40]
-1.57 [-14.38 , 11.24]
-0.24 [-1.06 , 0.57]

Test for subgroup differences: Chi² = 0.55, df = 1 (P = 0.46), I² = 0%

Footnotes
(1) Scores were reversed so that the area to the left of the line of no effect indicates a favourable outcome for CBT.

-20

-10
CBT + TAU

0

20

10
Control

Analysis 1.59.   Comparison 1: CBT plus standard care versus control,
Outcome 59: Quality of life - mean endpoint EQ5d (WHO) (high = good)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.59.1 < 6 months
Bucci 2018 (Actissist) (1)
Morrison 2020 (MAPS) (2)
Pos 2019 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.35, df = 2 (P = 0.84); I² = 0%
Test for overall effect: Z = 2.68 (P = 0.007)

-63.1
-0.868
-0.82

21.2
0.058
0.14

21
7
40
68

-56.9
-0.763
-0.71

1.59.2 < 12 months
Morrison 2020 (MAPS) (2)
Pos 2019 (2)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.07, df = 1 (P = 0.79); I² = 0%
Test for overall effect: Z = 0.96 (P = 0.34)

-0.815
-0.83

0.25
0.17

6
39
45

-0.804
-0.79

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.42, df = 4 (P = 0.84); I² = 0%
Test for overall effect: Z = 2.67 (P = 0.008)
Test for subgroup differences: Chi² = 1.00, df = 1 (P = 0.32), I² = 0%

113

18
0.203
0.25

9
9
39
57

12.6%
7.4%
38.3%
58.3%

-0.30 [-1.08 , 0.49]
-0.63 [-1.65 , 0.39]
-0.54 [-0.99 , -0.09]
-0.50 [-0.86 , -0.13]

0.133
0.17

4
35
39

4.8%
36.9%
41.7%

-0.05 [-1.31 , 1.22]
-0.23 [-0.69 , 0.23]
-0.21 [-0.64 , 0.22]

96

100.0%

-0.38 [-0.66 , -0.10]

-2

-1

0

CBT + TAU

1
Control

2

Footnotes
(1) EQ-5D scale scores given as 0-100
(2) Scores were reversed so that the area to the left of the line of no effect indicates a favourable outcome for CBT.

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

203

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.60.   Comparison 1: CBT plus standard care versus control,
Outcome 60: Quality of life - mean endpoint QLS (high = good)

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.60.1 < 6 months
Edwards 2011 (1)
Uzenoff 2008
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.02, df = 1 (P = 0.88); I² = 0%
Test for overall effect: Z = 0.40 (P = 0.69)

-54.847826
75.7

16.495161
19.1

23
10
33

-56.744
75.63

14.154213
26.63

25
9
34

85.3%
14.7%
100.0%

1.90 [-6.83 , 10.63]
0.07 [-20.97 , 21.11]
1.63 [-6.44 , 9.69]

Test for subgroup differences: Not applicable

Footnotes
(1) Scores were reversed so that the area to the left of the line of no effect indicates a favourable outcome for CBT.

-20

-10
CBT + TAU

0

20

10
Control

Analysis 1.61.   Comparison 1: CBT plus standard care versus control,
Outcome 61: Quality of life - mean endpoint MSQoL (high = good)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.61.1 < 12 months
Müller 2020 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.91 (P = 0.36)

-67.4

14.4

1.61.2 > 1 year
Müller 2020 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.86 (P = 0.39)

-67.1

18.6

12
12

9
9

-61.6

15.3

10
10

100.0%
100.0%

-5.80 [-18.30 , 6.70]
-5.80 [-18.30 , 6.70]

-59.6

16.3

7
7

100.0%
100.0%

-7.50 [-24.63 , 9.63]
-7.50 [-24.63 , 9.63]

Test for subgroup differences: Chi² = 0.02, df = 1 (P = 0.88), I² = 0%

Footnotes
(1) Scores were reversed so that the area to the left of the line of no effect indicates a favourable outcome for CBT.

-20 -10 0

CBT + TAU

10 20
Control

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

204

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.62.   Comparison 1: CBT plus standard care versus control,
Outcome 62: Quality of life - mean change MSQoL (high = good)

Study or Subgroup

Mean

CBT + TAU
SD

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.62.1 < 12 months
Müller 2020 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.64 (P = 0.52)

-11.2

17.3

1.62.2 > 1 year
Müller 2020 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.86 (P = 0.39)

-10.9

13.9

13
13

12
12

-7.5

11.1

12
12

100.0%
100.0%

-3.70 [-15.01 , 7.61]
-3.70 [-15.01 , 7.61]

-6.6

9.4

10
10

100.0%
100.0%

-4.30 [-14.09 , 5.49]
-4.30 [-14.09 , 5.49]

Test for subgroup differences: Chi² = 0.01, df = 1 (P = 0.94), I² = 0%

-20

-10
CBT + TAU

0

10
Control

20

Footnotes
(1) Scores were reversed so that the area to the left of the line of no effect indicates a favourable outcome for CBT.

Analysis 1.63.   Comparison 1: CBT plus standard care versus
control, Outcome 63: Quality of life - MANSA (high = good)

Study or Subgroup

CBT + TAU
SD

Mean

Total

Mean

Control
SD

Total

Weight

Mean Difference
IV, Random, 95% CI

Mean Difference
IV, Random, 95% CI

1.63.1 < 6 months
Hjorthoj 2013 (CapOpus) (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.97 (P = 0.33)

-54

1.63.2 < 12 months
Hjorthoj 2013 (CapOpus) (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.05 (P = 0.96)

-55.4

8.5

11

18
18

18
18

-56.9

9.4

18
18

100.0%
100.0%

2.90 [-2.95 , 8.75]
2.90 [-2.95 , 8.75]

-55.2

12

18
18

100.0%
100.0%

-0.20 [-7.72 , 7.32]
-0.20 [-7.72 , 7.32]

Test for subgroup differences: Chi² = 0.41, df = 1 (P = 0.52), I² = 0%

Footnotes
(1) Scores were reversed so that the area to the left of the line of no effect indicates a favourable outcome for CBT.

-10

-5
CBT + TAU

0

5
Control

10

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

205

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.64.   Comparison 1: CBT plus standard care versus control, Outcome 64:
Quality of life - mean endpoint quality of life scale (high = good) (combined time points)

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Bucci 2018 (Actissist) (1)
Edwards 2011 (1)
Gleeson 2009 (EPISODE II) (1)
Hjorthoj 2013 (CapOpus) (1)
Madigan 2013 (1)
Morrison 2018 (COMPARE) (1)
Morrison 2020 (MAPS) (1)
Müller 2020 (1)
Pos 2019 (1)

-63.1
-54.847826
-3.6
-55.4
-12.6
-82.93
-0.815
-67.4
-0.83

21.2
16.495161
0.8
11
3.4
19.17
0.25
14.4
0.17

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.95, df = 8 (P = 0.94); I² = 0%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable

-56.9
-56.744
-3.6
-55.2
-11.1
-81.36
-0.804
-61.6
-0.79

18
14.154213
1.1
12
2.9
20.02
0.133
15.3
0.17

21
23
41
18
34
15
6
12
39

209

9
25
40
18
14
22
4
10
35

6.8%
13.0%
22.0%
9.8%
10.5%
9.7%
2.6%
5.8%
19.9%

-0.30 [-1.08 , 0.49]
0.12 [-0.45 , 0.69]
0.00 [-0.44 , 0.44]
-0.02 [-0.67 , 0.64]
-0.45 [-1.08 , 0.18]
-0.08 [-0.73 , 0.58]
-0.05 [-1.31 , 1.22]
-0.38 [-1.22 , 0.47]
-0.23 [-0.69 , 0.23]

177

100.0%

-0.13 [-0.33 , 0.07]

Footnotes
(1) Scores were reversed so that the area to the left of the line of no effect indicates a favourable outcome for CBT.

-2

-1
CBT + TAU

0

1
Control

2

Analysis 1.65.   Comparison 1: CBT plus standard care versus control, Outcome 65:
Quality of life - mean endpoint quality of life scale (high = good) (separated time points)

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.65.1 < 6 months
Bucci 2018 (Actissist) (1)
Edwards 2011 (1)
Hjorthoj 2013 (CapOpus) (1)
Madigan 2013 (1)
Morrison 2018 (COMPARE) (1)
Morrison 2020 (MAPS) (1)
Pos 2019 (1)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 7.15, df = 6 (P = 0.31); I² = 16%
Test for overall effect: Z = 1.83 (P = 0.07)

-63.1
-54.847826
-54
-13.5
-89.06
-0.868
-0.82

21.2
16.495161
8.5
3.3
18.87
0.058
0.14

1.65.2 < 12 months
Gleeson 2009 (EPISODE II) (1)
Hjorthoj 2013 (CapOpus) (1)
Madigan 2013 (1)
Morrison 2018 (COMPARE) (1)
Morrison 2020 (MAPS) (1)
Müller 2020 (1)
Pos 2019 (1)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.97, df = 6 (P = 0.92); I² = 0%
Test for overall effect: Z = 1.35 (P = 0.18)

-3.6
-55.4
-12.6
-82.93
-0.815
-67.4
-0.83

0.8
11
3.4
19.17
0.25
14.4
0.17

1.65.3 > 1 year
Müller 2020 (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.79 (P = 0.43)

-67.1

18.6

21
23
18
34
18
7
40
161

41
18
34
15
6
12
39
165

9
9

-56.9
-56.744
-56.9
-12.6
-79.15
-0.763
-0.71

18
14.154213
9.4
3.4
20.95
0.203
0.25

-3.6
-55.2
-11.1
-81.36
-0.804
-61.6
-0.79

1.1
12
2.9
20.02
0.133
15.3
0.17

9
25
18
15
20
9
39
135

40
18
14
22
4
10
35
143

9.9%
17.1%
13.4%
15.2%
13.8%
6.1%
24.5%
100.0%

27.4%
12.2%
13.1%
12.1%
3.2%
7.2%
24.8%
100.0%

-0.30 [-1.08 , 0.49]
0.12 [-0.45 , 0.69]
0.32 [-0.34 , 0.97]
-0.27 [-0.88 , 0.34]
-0.49 [-1.13 , 0.16]
-0.63 [-1.65 , 0.39]
-0.54 [-0.99 , -0.09]
-0.24 [-0.51 , 0.02]

0.00 [-0.44 , 0.44]
-0.02 [-0.67 , 0.64]
-0.45 [-1.08 , 0.18]
-0.08 [-0.73 , 0.58]
-0.05 [-1.31 , 1.22]
-0.38 [-1.22 , 0.47]
-0.23 [-0.69 , 0.23]
-0.16 [-0.39 , 0.07]

-59.6

16.3

7
7

100.0%
100.0%

-0.40 [-1.40 , 0.60]
-0.40 [-1.40 , 0.60]

Test for subgroup differences: Chi² = 0.40, df = 2 (P = 0.82), I² = 0%

Footnotes
(1) Scores were reversed so that the area to the left of the line of no effect indicates a favourable outcome for CBT.

-2

-1

0

CBT + TAU

1
Control

2

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

206

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.66.   Comparison 1: CBT plus standard care versus
control, Outcome 66: Behaviour - occurence of violent incidents

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

1.66.1 < 12 months
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.73, df = 1 (P = 0.39); I² = 0%
Test for overall effect: Z = 0.05 (P = 0.96)

25
21
46

0
2

1
1

2

2

24
22
46

35.2%
64.8%
100.0%

2.88 [0.12 , 67.53]
0.52 [0.05 , 5.36]
0.96 [0.15 , 6.20]

Test for subgroup differences: Not applicable

0.01

0.1
CBT + TAU

1

10
Control

100

Analysis 1.67.   Comparison 1: CBT plus standard care versus
control, Outcome 67: Behaviour - participants with self-injury

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

1.67.1 < 12 months
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.40, df = 1 (P = 0.53); I² = 0%
Test for overall effect: Z = 1.80 (P = 0.07)

25
21
46

2
12

0
7

14

7

24
22
46

5.4%
94.6%
100.0%

4.81 [0.24 , 95.25]
1.80 [0.88 , 3.67]
1.89 [0.95 , 3.80]

Test for subgroup differences: Not applicable

0.01

0.1
CBT + TAU

1

10
Control

100

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

207

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.68.   Comparison 1: CBT plus standard care versus
control, Outcome 68: Behaviour - participants with suicide attempts

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

1.68.1 < 12 months
Morrison 2020 (MAPS)
Müller 2020
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.13; Chi² = 1.05, df = 1 (P = 0.30); I² = 5%
Test for overall effect: Z = 0.02 (P = 0.98)

21
13
34

1
0

0
1

1

1

22
12
34

49.4%
50.6%
100.0%

3.14 [0.13 , 72.96]
0.31 [0.01 , 6.94]
0.97 [0.10 , 9.41]

1.68.2 > 1 year
Müller 2020
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.74 (P = 0.46)

0

0

13
13

1

1

12
12

100.0%
100.0%

0.31 [0.01 , 6.94]
0.31 [0.01 , 6.94]

Test for subgroup differences: Chi² = 0.34, df = 1 (P = 0.56), I² = 0%

0.01

0.1
CBT + TAU

1

10
Control

100

Analysis 1.69.   Comparison 1: CBT plus standard care versus control,
Outcome 69: Adverse events - participants with at least one adverse event

Study or Subgroup

Events

Total

Events

Total

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

A

Risk of Bias
E
B

C

D

F

Morrison 2020 (MAPS)

16

21

13

22

1.29 [0.85 , 1.97]

+

+

+

?

+

?

Test for subgroup differences: Not applicable

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

0.5

0.7
CBT + TAU

1

2

1.5
Control

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

208

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.70.   Comparison 1: CBT plus standard care versus
control, Outcome 70: Adverse events - specific: Non Compliance

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

1.70.1 < 6 months
Barrowclough 2014
Liu 2019
Subtotal (95% CI)
16
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.44, df = 1 (P = 0.51); I² = 0%
Test for overall effect: Z = 0.13 (P = 0.89)

75
40
115

15
1

6
2

8

35
40
75

88.3%
11.7%
100.0%

1.17 [0.49 , 2.75]
0.50 [0.05 , 5.30]
1.06 [0.47 , 2.37]

1.70.2 < 12 months
Liu 2019
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.97 (P = 0.33)

1

1

1.70.3 > 1 year
Liu 2019
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.97 (P = 0.33)

1

1

40
40

40
40

3

3

3

3

40
40

100.0%
100.0%

0.33 [0.04 , 3.07]
0.33 [0.04 , 3.07]

40
40

100.0%
100.0%

0.33 [0.04 , 3.07]
0.33 [0.04 , 3.07]

Test for subgroup differences: Chi² = 1.64, df = 2 (P = 0.44), I² = 0%

0.01

0.1
CBT + TAU

1

10
Control

100

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

209

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.71.   Comparison 1: CBT plus standard care versus control,
Outcome 71: Adverse events - specific: Deterioration of symptoms

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

1.71.1 < 6 months
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.88, df = 1 (P = 0.35); I² = 0%
Test for overall effect: Z = 0.08 (P = 0.93)

25
21
46

1
1

0
2

2

2

1.71.2 < 12 months
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 1.67, df = 2 (P = 0.43); I² = 0%
Test for overall effect: Z = 0.67 (P = 0.50)

25
21
13
59

2
0
2

0
1
1

4

2

1.71.3 > 1 year
Müller 2020
Palma-Sevillano 2019
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.90); I² = 0%
Test for overall effect: Z = 1.91 (P = 0.06)

13
35
48

2
13

1
9

15

10

24
22
46

35.2%
64.8%
100.0%

0.32 [0.01 , 7.50]
2.10 [0.20 , 21.42]
1.08 [0.17 , 7.03]

24
22
12
58

27.5%
24.8%
47.7%
100.0%

0.19 [0.01 , 3.81]
3.14 [0.13 , 72.96]
0.46 [0.05 , 4.46]
0.58 [0.12 , 2.79]

12
27
39

8.4%
91.6%
100.0%

0.46 [0.05 , 4.46]
0.53 [0.27 , 1.06]
0.53 [0.27 , 1.02]

Test for subgroup differences: Chi² = 0.50, df = 2 (P = 0.78), I² = 0%

0.01

0.1
CBT + TAU

1

10
Control

100

Analysis 1.72.   Comparison 1: CBT plus standard care versus control,
Outcome 72: Mortality - overall mortality (combined time points)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

Barrowclough 2014
GetUp
Lewis 2002 (SOCRATES) (1)
Lewis 2002 (SOCRATES) (2)
Supereden3

0
2
2
2
1

75
200
50
51
76

1
2
3
0
0

35
126
106
102
79

11.6%
29.1%
35.0%
12.8%
11.5%

0.16 [0.01 , 3.78]
0.63 [0.09 , 4.42]
1.41 [0.24 , 8.19]
9.90 [0.48 , 202.54]
3.12 [0.13 , 75.35]

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.10; Chi² = 4.24, df = 4 (P = 0.37); I² = 6%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable

452

6

7

448

100.0%

1.22 [0.41 , 3.66]

0.005

0.1

1

CBT + TAU

10
Control

200

Footnotes
(1) comparator supportive counselling + TAU
(2) comparator treatment-as-usual (TAU)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

210

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.73.   Comparison 1: CBT plus standard care versus control,
Outcome 73: Mortality - overall mortality (separated time points)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

1.73.1 < 12 months
GetUp
Supereden3
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.70, df = 1 (P = 0.40); I² = 0%
Test for overall effect: Z = 0.03 (P = 0.97)

200
76
276

2
0

2
1

2

3

1.73.2 > 1 year
Barrowclough 2014
Lewis 2002 (SOCRATES) (1)
Lewis 2002 (SOCRATES) (2)
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 1.26; Chi² = 3.43, df = 2 (P = 0.18); I² = 42%
Test for overall effect: Z = 0.32 (P = 0.75)

75
51
50
176

1
0
3

0
2
2

4

4

126
79
205

72.8%
27.2%
100.0%

0.63 [0.09 , 4.42]
3.12 [0.13 , 75.35]
0.97 [0.18 , 5.13]

35
102
106
243

25.3%
27.1%
47.6%
100.0%

0.16 [0.01 , 3.78]
9.90 [0.48 , 202.54]
1.41 [0.24 , 8.19]
1.38 [0.20 , 9.60]

Test for subgroup differences: Chi² = 0.07, df = 1 (P = 0.79), I² = 0%

0.005

0.1

1

CBT + TAU

10
Control

200

Footnotes
(1) comparator treatment-as-usual (TAU)
(2) comparator supportive counselling + TAU

Analysis 1.74.   Comparison 1: CBT plus standard care versus control, Outcome 74: Mortality - due to natural causes

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

1.74.1 < 12 months
GetUp
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.96 (P = 0.34)

0

0

200
200

1

1

126
126

33.2%
33.2%

0.21 [0.01 , 5.13]
0.21 [0.01 , 5.13]

1.74.2 > 1 year
Lewis 2002 (SOCRATES) (1)
Lewis 2002 (SOCRATES) (2)
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.98); I² = 0%
Test for overall effect: Z = 1.58 (P = 0.11)

50
51
101

0
0

1
1

2

0

106
102
208

33.4%
33.4%
66.8%

6.29 [0.26 , 151.84]
5.94 [0.25 , 143.35]
6.12 [0.64 , 58.07]

Total (95% CI)
Total events:
Heterogeneity: Tau² = 1.13; Chi² = 2.86, df = 2 (P = 0.24); I² = 30%
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Chi² = 2.86, df = 1 (P = 0.09), I² = 65.0%

301

334

2

1

100.0%

2.00 [0.22 , 17.99]

0.005

0.1

1

CBT + TAU

10
Control

200

Footnotes
(1) comparator supportive counselling + TAU
(2) comparator treatment-as-usual (TAU)

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

211

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.75.   Comparison 1: CBT plus standard care versus control, Outcome 75: Mortality - due to suicide

Study or Subgroup

Events

Total

Events

Total

Weight

CBT + TAU

Control

Risk Ratio
IV, Random, 95% CI

Risk Ratio
IV, Random, 95% CI

1.75.1 < 12 months
GetUp
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.96 (P = 0.34)

0

0

1.75.2 > 1 year
Jackson 2008 (ACE)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.05 (P = 0.29)

2

2

200
200

31
31

1

1

0

0

126
126

48.4%
48.4%

0.21 [0.01 , 5.13]
0.21 [0.01 , 5.13]

31
31

51.6%
51.6%

5.00 [0.25 , 100.08]
5.00 [0.25 , 100.08]

231

Total (95% CI)
2
Total events:
Heterogeneity: Tau² = 2.52; Chi² = 2.01, df = 1 (P = 0.16); I² = 50%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi² = 2.01, df = 1 (P = 0.16), I² = 50.2%

157

1

100.0%

1.08 [0.05 , 24.00]

0.01

0.1
CBT + TAU

1

10
Control

100

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

212

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.76.   Comparison 1: CBT plus standard care versus control,
Outcome 76: Sensitivity analysis - Blinding of outcome assessor

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Barrowclough 2014
Bucci 2018 (Actissist)
Edwards 2006
Gleeson 2009 (EPISODE II)
Gonzalez-Ortega 2021
Haddock 1999
Hjorthoj 2013 (CapOpus)
Jackson 2008 (ACE)
Jolley 2003
Lecomte 2008 (1)
Lecomte 2008 (2)
Lewis 2002 (SOCRATES) (3)
Lewis 2002 (SOCRATES) (4)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Palma-Sevillano 2019
Pos 2019
Supereden3
Uzenoff 2008

59.419149
52.9
45.6
34.3
40.37
46.8
57.2
37.25
49.2
33.4
33.4
61.73
61.73
44.88
57.4
56.2
51.3
52.1
52.2051
55.33
48.4

9.639697
17.4
13.5
8.4
10.03
8.75
21.5
13.634
13.87
8.29
8.29
19.69
19.69
8.06
13.58
12.3
8.65
19.3
13.7385
25.77
6.72

47
21
16
41
86
8
18
28
7
18
17
39
39
40
20
11
12
35
39
66
10

59.4
63.6
44.8
35
45.11
38.3
61.9
38.51
54.7
39.3
36.5
59.96
64.38
49.6
56.77
55.4
52
110
52.3714
58.67
55.67

11.3
17.54
15.4
9.8
9.89
17.4
23.4
12.028
14.94
9.68
14.1
16.39
16.79
10.47
14.1
7
7.02
23.5
11.52768
21.2
12.22

Total (95% CI)
Heterogeneity: Tau² = 0.17; Chi² = 64.66, df = 20 (P < 0.00001); I² = 69%
Test for overall effect: Z = 2.49 (P = 0.01)
Test for subgroup differences: Not applicable

618

23
9
17
40
91
10
18
25
8
13
17
71
60
40
22
9
10
27
35
57
9

5.5%
3.8%
4.4%
5.9%
6.7%
3.1%
4.5%
5.2%
2.9%
4.1%
4.4%
6.1%
6.1%
5.8%
4.8%
3.4%
3.6%
4.3%
5.7%
6.3%
3.2%

0.00 [-0.50 , 0.50]
-0.60 [-1.39 , 0.20]
0.05 [-0.63 , 0.74]
-0.08 [-0.51 , 0.36]
-0.47 [-0.77 , -0.17]
0.57 [-0.39 , 1.52]
-0.20 [-0.86 , 0.45]
-0.10 [-0.64 , 0.44]
-0.36 [-1.38 , 0.67]
-0.65 [-1.38 , 0.09]
-0.26 [-0.94 , 0.41]
0.10 [-0.29 , 0.49]
-0.15 [-0.55 , 0.26]
-0.50 [-0.95 , -0.05]
0.04 [-0.56 , 0.65]
0.07 [-0.81 , 0.96]
-0.08 [-0.92 , 0.76]
-2.69 [-3.40 , -1.99]
-0.01 [-0.47 , 0.44]
-0.14 [-0.49 , 0.22]
-0.72 [-1.65 , 0.22]

611

100.0%

-0.28 [-0.50 , -0.06]

-4

-2
CBT + TAU

0

2
Control

4

A

+
+
+
+
+
+
+
+
+
?
?
+
+
+
+
+
+
+
+
+
?

Footnotes
(1) comparator waiting list (WL)
(2) comparator skills training for symptom management (SST)
(3) comparator supportive counselling + TAU
(4) comparator treatment-as-usual (TAU)

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Risk of Bias
E
B

D

C

+
?
+
+
?
?
+
?
?
+
+
+
+
+
+
+
+
?
+
+
+

?
+
?
+
+
+
?
+
−
−
−

?
?
+
+
−

+
+
?
−

?

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

?
+
?
?
+
?
+
?
?
+
+
+
+
+
+
+
?
?
+
+
?

F

?
?
?
?
?
?
?
?
−
−
−

?
?
+
+
−

?
?
?
−

?

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

213

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.77.   Comparison 1: CBT plus standard care versus control,
Outcome 77: Sensitivity analysis - Assumptions for missing data

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Barrowclough 2014
Edwards 2006
GetUp
Gleeson 2009 (EPISODE II)
Hjorthoj 2013 (CapOpus)
Lecomte 2008 (1)
Lecomte 2008 (2)
Lewis 2002 (SOCRATES) (3)
Lewis 2002 (SOCRATES) (4)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Palma-Sevillano 2019
Pos 2019
Supereden3
Uzenoff 2008

59.419149
45.6
50.1
34.3
57.2
33.4
33.4
61.73
61.73
44.88
57.4
56.2
51.3
52.1
52.2051
55.33
48.4

9.639697
13.5
14.73
8.4
21.5
8.29
8.29
19.69
19.69
8.06
13.58
12.3
8.65
19.3
13.7385
25.77
6.72

47
16
170
41
18
17
18
39
39
40
20
11
12
35
39
66
10

59.4
44.8
53.4
35
61.9
36.5
39.3
59.96
64.38
49.6
56.77
55.4
52
110
52.3714
58.67
55.67

11.3
15.4
14.39
9.8
23.4
14.1
9.68
16.39
16.79
10.47
14.1
7
7.02
23.5
11.52768
21.2
12.22

Total (95% CI)
Heterogeneity: Tau² = 0.17; Chi² = 58.43, df = 16 (P < 0.00001); I² = 73%
Test for overall effect: Z = 2.35 (P = 0.02)
Test for subgroup differences: Not applicable

638

23
17
109
40
18
17
13
71
60
40
22
9
10
27
35
57
9

6.4%
5.2%
8.2%
6.9%
5.3%
5.2%
4.8%
7.2%
7.1%
6.8%
5.7%
4.0%
4.2%
5.0%
6.7%
7.4%
3.8%

0.00 [-0.50 , 0.50]
0.05 [-0.63 , 0.74]
-0.23 [-0.47 , 0.02]
-0.08 [-0.51 , 0.36]
-0.20 [-0.86 , 0.45]
-0.26 [-0.94 , 0.41]
-0.65 [-1.38 , 0.09]
0.10 [-0.29 , 0.49]
-0.15 [-0.55 , 0.26]
-0.50 [-0.95 , -0.05]
0.04 [-0.56 , 0.65]
0.07 [-0.81 , 0.96]
-0.08 [-0.92 , 0.76]
-2.69 [-3.40 , -1.99]
-0.01 [-0.47 , 0.44]
-0.14 [-0.49 , 0.22]
-0.72 [-1.65 , 0.22]

577

100.0%

-0.29 [-0.52 , -0.05]

-4

-2
CBT + TAU

0

2
Control

4

A

+
+
−

+
+
?
?
+
+
+
+
+
+
+
+
+
?

Footnotes
(1) comparator skills training for symptom management (SST)
(2) comparator waiting list (WL)
(3) comparator supportive counselling + TAU
(4) comparator treatment-as-usual (TAU)

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Risk of Bias
E
B

D

C

+
+
+
+
+
+
+
+
+
+
+
+
+
?
+
+
+

?
?
+
+
?
−
−

?
?
+
+
−

+
+
?
−

?

+
+
?
+
+
+
+
+
+
+
+
+
+
+
+
+
+

?
?
+
?
+
+
+
+
+
+
+
+
?
?
+
+
?

F

?
?
−

?
?
−
−

?
?
+
+
−

?
?
?
−

?

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

214

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.78.   Comparison 1: CBT plus standard care versus control, Outcome 78: Sensitivity analysis - Risk of Bias

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Barrowclough 2014
Bucci 2018 (Actissist)
Edwards 2006
Gleeson 2009 (EPISODE II)
Gonzalez-Ortega 2021
Haddock 1999
Hjorthoj 2013 (CapOpus)
Jackson 2008 (ACE)
Lewis 2002 (SOCRATES) (1)
Lewis 2002 (SOCRATES) (2)
Liu 2019
Morrison 2018 (COMPARE)
Müller 2020
Palma-Sevillano 2019
Pos 2019
Uzenoff 2008

59.419149
52.9
45.6
34.3
40.37
46.8
57.2
37.25
61.73
61.73
44.88
57.4
51.3
52.1
52.2051
48.4

9.639697
17.4
13.5
8.4
10.03
8.75
21.5
13.634
19.69
19.69
8.06
13.58
8.65
19.3
13.7385
6.72

47
21
16
41
86
8
18
28
39
39
40
20
12
35
39
10

59.4
63.6
44.8
35
45.11
38.3
61.9
38.51
59.96
64.38
49.6
56.77
52
110
52.3714
55.67

11.3
17.54
15.4
9.8
9.89
17.4
23.4
12.028
16.39
16.79
10.47
14.1
7.02
23.5
11.52768
12.22

Total (95% CI)
Heterogeneity: Tau² = 0.22; Chi² = 62.58, df = 15 (P < 0.00001); I² = 76%
Test for overall effect: Z = 2.05 (P = 0.04)
Test for subgroup differences: Not applicable

499

23
9
17
40
91
10
18
25
71
60
40
22
10
27
35
9

6.9%
5.1%
5.7%
7.2%
8.0%
4.3%
5.9%
6.6%
7.5%
7.4%
7.2%
6.2%
4.9%
5.6%
7.1%
4.4%

0.00 [-0.50 , 0.50]
-0.60 [-1.39 , 0.20]
0.05 [-0.63 , 0.74]
-0.08 [-0.51 , 0.36]
-0.47 [-0.77 , -0.17]
0.57 [-0.39 , 1.52]
-0.20 [-0.86 , 0.45]
-0.10 [-0.64 , 0.44]
0.10 [-0.29 , 0.49]
-0.15 [-0.55 , 0.26]
-0.50 [-0.95 , -0.05]
0.04 [-0.56 , 0.65]
-0.08 [-0.92 , 0.76]
-2.69 [-3.40 , -1.99]
-0.01 [-0.47 , 0.44]
-0.72 [-1.65 , 0.22]

507

100.0%

-0.29 [-0.56 , -0.01]

-4

-2
CBT + TAU

0

2
Control

4

A

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
?

Footnotes
(1) comparator supportive counselling + TAU
(2) comparator treatment-as-usual (TAU)

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Risk of Bias
E
B

D

C

+
?
+
+
?
?
+
?
+
+
+
+
+
?
+
+

?
+
?
+
+
+
?
+
?
?
+
+
+
+
?
?

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

?
+
?
?
+
?
+
?
+
+
+
+
?
?
+
?

F

?
?
?
?
?
?
?
?
?
?
+
+
?
?
?
?

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

215

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.79.   Comparison 1: CBT plus standard care versus
control, Outcome 79: Sensitivity analysis - Imputed values

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Barrowclough 2014
Bucci 2018 (Actissist)
Edwards 2006
Gleeson 2009 (EPISODE II)
Gonzalez-Ortega 2021
Haddock 1999
Hjorthoj 2013 (CapOpus)
Jackson 2008 (ACE)
Lecomte 2008 (1)
Lecomte 2008 (2)
Lewis 2002 (SOCRATES) (3)
Lewis 2002 (SOCRATES) (4)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Palma-Sevillano 2019
Pos 2019
Supereden3
Uzenoff 2008

59.419149
52.9
45.6
34.3
40.37
46.8
57.2
37.25
33.4
33.4
61.73
61.73
44.88
57.4
56.2
51.3
52.1
52.2051
55.33
48.4

9.639697
17.4
13.5
8.4
10.03
8.75
21.5
13.634
8.29
8.29
19.69
19.69
8.06
13.58
12.3
8.65
19.3
13.7385
25.77
6.72

47
21
16
41
86
8
18
28
17
18
39
39
40
20
11
12
35
39
66
10

59.4
63.6
44.8
35
45.11
38.3
61.9
38.51
36.5
39.3
64.38
59.96
49.6
56.77
55.4
52
110
52.3714
58.67
55.67

11.3
17.54
15.4
9.8
9.89
17.4
23.4
12.028
14.1
9.68
16.79
16.39
10.47
14.1
7
7.02
23.5
11.52768
21.2
12.22

Total (95% CI)
Heterogeneity: Tau² = 0.17; Chi² = 64.62, df = 19 (P < 0.00001); I² = 71%
Test for overall effect: Z = 2.40 (P = 0.02)
Test for subgroup differences: Not applicable

611

23
9
17
40
91
10
18
25
17
13
60
71
40
22
9
10
27
35
57
9

5.6%
3.9%
4.5%
6.0%
6.8%
3.3%
4.7%
5.4%
4.6%
4.3%
6.2%
6.3%
6.0%
5.0%
3.6%
3.7%
4.4%
5.9%
6.5%
3.3%

0.00 [-0.50 , 0.50]
-0.60 [-1.39 , 0.20]
0.05 [-0.63 , 0.74]
-0.08 [-0.51 , 0.36]
-0.47 [-0.77 , -0.17]
0.57 [-0.39 , 1.52]
-0.20 [-0.86 , 0.45]
-0.10 [-0.64 , 0.44]
-0.26 [-0.94 , 0.41]
-0.65 [-1.38 , 0.09]
-0.15 [-0.55 , 0.26]
0.10 [-0.29 , 0.49]
-0.50 [-0.95 , -0.05]
0.04 [-0.56 , 0.65]
0.07 [-0.81 , 0.96]
-0.08 [-0.92 , 0.76]
-2.69 [-3.40 , -1.99]
-0.01 [-0.47 , 0.44]
-0.14 [-0.49 , 0.22]
-0.72 [-1.65 , 0.22]

603

100.0%

-0.28 [-0.50 , -0.05]

-4

-2
CBT + TAU

0

2
Control

4

A

+
+
+
+
+
+
+
+
?
?
+
+
+
+
+
+
+
+
+
?

Footnotes
(1) comparator skills training for symptom management (SST)
(2) comparator waiting list (WL)
(3) comparator treatment-as-usual (TAU)
(4) comparator supportive counselling + TAU

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Risk of Bias
E
B

C

D

+
?
+
+
?
?
+
?
+
+
+
+
+
+
+
+
?
+
+
+

?
+
?
+
+
+
?
+
−
−
?
?
+
+
−
+
+
?
−
?

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

?
+
?
?
+
?
+
?
+
+
+
+
+
+
+
?
?
+
+
?

F

?
?
?
?
?
?
?
?
−
−
?
?
+
+
−
?
?
?
−
?

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

216

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.80.   Comparison 1: CBT plus standard care versus control, Outcome 80: Sensitivity analysis - Fixed-effect

Risk of Bias
E
B

C

D

+
?
+
+
+
?
?
+
?
?
+
+
+
+
+
+
+
+
?
+
+
+

?
+
?
+
+
+
+
?
+
−
−
−
?
?
+
+
−
+
+
?
−

?

+
+
+
?
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

?
+
?
+
?
+
?
+
?
?
+
+
+
+
+
+
+
?
?
+
+
?

F

?
?
?
−
?
?
?
?
?
−
−
−
?
?
+
+
−
?
?
?
−

?

A

+
+
+
−
+
+
+
+
+
+
?
?
+
+
+
+
+
+
+
+
+
?

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Fixed, 95% CI

Std. Mean Difference
IV, Fixed, 95% CI

59.4
63.6
44.8
53.4
35
45.11
38.3
61.9
38.51
54.7
36.5
39.3
59.96
64.38
49.6
56.77
55.4
52
110
52.3714
58.67
55.67

11.3
17.54
15.4
14.39
9.8
9.89
17.4
23.4
12.028
14.94
14.1
9.68
16.39
16.79
10.47
14.1
7
7.02
23.5
11.52768
21.2
12.22

47
21
16
170
41
86
8
18
28
7
17
18
39
39
40
20
11
12
35
39
66
10

788

23
9
17
109
40
91
10
18
25
8
17
13
71
60
40
22
9
10
27
35
57
9

4.4%
1.7%
2.3%
18.6%
5.7%
12.1%
1.2%
2.5%
3.7%
1.0%
2.4%
2.0%
7.1%
6.6%
5.5%
3.0%
1.4%
1.5%
2.2%
5.2%
8.6%
1.2%

0.00 [-0.50 , 0.50]
-0.60 [-1.39 , 0.20]
0.05 [-0.63 , 0.74]
-0.23 [-0.47 , 0.02]
-0.08 [-0.51 , 0.36]
-0.47 [-0.77 , -0.17]
0.57 [-0.39 , 1.52]
-0.20 [-0.86 , 0.45]
-0.10 [-0.64 , 0.44]
-0.36 [-1.38 , 0.67]
-0.26 [-0.94 , 0.41]
-0.65 [-1.38 , 0.09]
0.10 [-0.29 , 0.49]
-0.15 [-0.55 , 0.26]
-0.50 [-0.95 , -0.05]
0.04 [-0.56 , 0.65]
0.07 [-0.81 , 0.96]
-0.08 [-0.92 , 0.76]
-2.69 [-3.40 , -1.99]
-0.01 [-0.47 , 0.44]
-0.14 [-0.49 , 0.22]
-0.72 [-1.65 , 0.22]

720

100.0%

-0.25 [-0.35 , -0.14]

-4

-2
CBT + TAU

0

2
Control

4

Barrowclough 2014
Bucci 2018 (Actissist)
Edwards 2006
GetUp
Gleeson 2009 (EPISODE II)
Gonzalez-Ortega 2021
Haddock 1999
Hjorthoj 2013 (CapOpus)
Jackson 2008 (ACE)
Jolley 2003
Lecomte 2008 (1)
Lecomte 2008 (2)
Lewis 2002 (SOCRATES) (3)
Lewis 2002 (SOCRATES) (4)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Palma-Sevillano 2019
Pos 2019
Supereden3
Uzenoff 2008

59.419149
52.9
45.6
50.1
34.3
40.37
46.8
57.2
37.25
49.2
33.4
33.4
61.73
61.73
44.88
57.4
56.2
51.3
52.1
52.2051
55.33
48.4

9.639697
17.4
13.5
14.73
8.4
10.03
8.75
21.5
13.634
13.87
8.29
8.29
19.69
19.69
8.06
13.58
12.3
8.65
19.3
13.7385
25.77
6.72

Total (95% CI)
Heterogeneity: Chi² = 64.70, df = 21 (P < 0.00001); I² = 68%
Test for overall effect: Z = 4.66 (P < 0.00001)
Test for subgroup differences: Not applicable

Footnotes
(1) comparator skills training for symptom management (SST)
(2) comparator waiting list (WL)
(3) comparator supportive counselling + TAU
(4) comparator treatment-as-usual (TAU)

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

217

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.81.   Comparison 1: CBT plus standard care versus
control, Outcome 81: Sensitivity analysis excluding outliers

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

23
9
17
109
40
91
10
18
25
8
13
17
60
71
40
22
9
10
35
57
9

4.5%
1.7%
2.4%
19.0%
5.8%
12.4%
1.2%
2.6%
3.8%
1.1%
2.1%
2.4%
6.8%
7.2%
5.6%
3.0%
1.4%
1.6%
5.3%
8.8%
1.3%

0.00 [-0.50 , 0.50]
-0.60 [-1.39 , 0.20]
0.05 [-0.63 , 0.74]
-0.23 [-0.47 , 0.02]
-0.08 [-0.51 , 0.36]
-0.47 [-0.77 , -0.17]
0.57 [-0.39 , 1.52]
-0.20 [-0.86 , 0.45]
-0.10 [-0.64 , 0.44]
-0.36 [-1.38 , 0.67]
-0.65 [-1.38 , 0.09]
-0.26 [-0.94 , 0.41]
-0.15 [-0.55 , 0.26]
0.10 [-0.29 , 0.49]
-0.50 [-0.95 , -0.05]
0.04 [-0.56 , 0.65]
0.07 [-0.81 , 0.96]
-0.08 [-0.92 , 0.76]
-0.01 [-0.47 , 0.44]
-0.14 [-0.49 , 0.22]
-0.72 [-1.65 , 0.22]

693

100.0%

-0.19 [-0.30 , -0.09]

Barrowclough 2014
Bucci 2018 (Actissist)
Edwards 2006
GetUp
Gleeson 2009 (EPISODE II)
Gonzalez-Ortega 2021
Haddock 1999
Hjorthoj 2013 (CapOpus)
Jackson 2008 (ACE)
Jolley 2003
Lecomte 2008 (1)
Lecomte 2008 (2)
Lewis 2002 (SOCRATES) (3)
Lewis 2002 (SOCRATES) (4)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Pos 2019
Supereden3
Uzenoff 2008

59.419149
52.9
45.6
50.1
34.3
40.37
46.8
57.2
37.25
49.2
33.4
33.4
61.73
61.73
44.88
57.4
56.2
51.3
52.2051
55.33
48.4

9.639697
17.4
13.5
14.73
8.4
10.03
8.75
21.5
13.634
13.87
8.29
8.29
19.69
19.69
8.06
13.58
12.3
8.65
13.7385
25.77
6.72

47
21
16
170
41
86
8
18
28
7
18
17
39
39
40
20
11
12
39
66
10

59.4
63.6
44.8
53.4
35
45.11
38.3
61.9
38.51
54.7
39.3
36.5
64.38
59.96
49.6
56.77
55.4
52
52.3714
58.67
55.67

11.3
17.54
15.4
14.39
9.8
9.89
17.4
23.4
12.028
14.94
9.68
14.1
16.79
16.39
10.47
14.1
7
7.02
11.52768
21.2
12.22

753
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 16.91, df = 20 (P = 0.66); I² = 0%
Test for overall effect: Z = 3.58 (P = 0.0003)
Test for subgroup differences: Not applicable

Footnotes
(1) comparator waiting list (WL)
(2) comparator skills training for symptom management (SST)
(3) comparator treatment-as-usual (TAU)
(4) comparator supportive counselling + TAU

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

-2

-1
CBT + TAU

0

1
Control

2

A

+
+
+
−

+
+
+
+
+
+
?
?
+
+
+
+
+
+
+
+
?

Risk of Bias
E
B

D

C

+
?
+
+
+
?
?
+
?
?
+
+
+
+
+
+
+
+
+
+
+

?
+
?
+
+
+
+
?
+
−
−
−

?
?
+
+
−

+
?
−

?

+
+
+
?
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

?
+
?
+
?
+
?
+
?
?
+
+
+
+
+
+
+
?
+
+
?

F

?
?
?
−

?
?
?
?
?
−
−
−

?
?
+
+
−

?
?
−

?

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

218

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.82.   Comparison 1: CBT plus standard care versus
control, Outcome 82: Subgroup analysis - Different types of CBT

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Risk of Bias
E
B

C

D

?
?
?
?
+
+
+
+
+
+
+
+
+

?
+
?
+

+
+
+
−
−
−
?
?
+
+
−
+
?

+
+
+
−

+
+
+
+
+
+
+
+
+
+
+
+
+

+
?
+
+

+
?
?
?
+
+
+
+
+
+
+
?
+

+
+
?
+

A

+
+
+
+
?
?
+
+
+
+
+
+
+

+
−

+
+

F

?
?
?
−
−
−
?
?
+
+
−
?
?

?
−

?
−

+
+
+

+
+
+

?
?
?

+
+
+

?
?
+

?
?
?

+
?

+
+

+
?

+
+

?
?

?
?

-4

-2
CBT + TAU

0

2
Control

4

91
10
25
8
17
13
71
60
40
22
9
10
35
411

9
109
27
57
202

23
17
18
58

40
9
49

6.5%
2.8%
4.9%
2.5%
4.1%
3.7%
5.9%
5.8%
5.5%
4.5%
3.1%
3.2%
5.4%
57.9%

3.4%
6.9%
3.9%
6.1%
20.3%

-0.47 [-0.77 , -0.17]
0.57 [-0.39 , 1.52]
-0.10 [-0.64 , 0.44]
-0.36 [-1.38 , 0.67]
-0.26 [-0.94 , 0.41]
-0.65 [-1.38 , 0.09]
0.10 [-0.29 , 0.49]
-0.15 [-0.55 , 0.26]
-0.50 [-0.95 , -0.05]
0.04 [-0.56 , 0.65]
0.07 [-0.81 , 0.96]
-0.08 [-0.92 , 0.76]
-0.01 [-0.47 , 0.44]
-0.19 [-0.35 , -0.04]

-0.60 [-1.39 , 0.20]
-0.23 [-0.47 , 0.02]
-2.69 [-3.40 , -1.99]
-0.14 [-0.49 , 0.22]
-0.87 [-1.73 , -0.01]

5.2%
4.0%
4.2%
13.3%

0.00 [-0.50 , 0.50]
0.05 [-0.63 , 0.74]
-0.20 [-0.86 , 0.45]
-0.04 [-0.38 , 0.30]

5.6%
2.8%
8.4%

-0.08 [-0.51 , 0.36]
-0.72 [-1.65 , 0.22]
-0.26 [-0.82 , 0.31]

720

100.0%

-0.27 [-0.47 , -0.08]

1.82.1 CBT
86
Gonzalez-Ortega 2021
8
Haddock 1999
28
Jackson 2008 (ACE)
7
Jolley 2003
17
Lecomte 2008 (1)
18
Lecomte 2008 (2)
39
Lewis 2002 (SOCRATES) (3)
39
Lewis 2002 (SOCRATES) (4)
40
Liu 2019
20
Morrison 2018 (COMPARE)
11
Morrison 2020 (MAPS)
12
Müller 2020
39
Pos 2019
364
Subtotal (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 13.19, df = 12 (P = 0.36); I² = 9%
Test for overall effect: Z = 2.46 (P = 0.01)

10.03
8.75
13.634
13.87
8.29
8.29
19.69
19.69
8.06
13.58
12.3
8.65
13.7385

40.37
46.8
37.25
49.2
33.4
33.4
61.73
61.73
44.88
57.4
56.2
51.3
52.2051

45.11
38.3
38.51
54.7
36.5
39.3
59.96
64.38
49.6
56.77
55.4
52
52.3714

9.89
17.4
12.028
14.94
14.1
9.68
16.39
16.79
10.47
14.1
7
7.02
11.52768

63.6
53.4
110
58.67

17.54
14.39
23.5
21.2

59.4
44.8
61.9

11.3
15.4
23.4

35
55.67

9.8
12.22

1.82.2 CBT integrated with other psychosocial interventions
Bucci 2018 (Actissist)
GetUp
Palma-Sevillano 2019
Supereden3
Subtotal (95% CI)
Heterogeneity: Tau² = 0.69; Chi² = 45.39, df = 3 (P < 0.00001); I² = 93%
Test for overall effect: Z = 1.98 (P = 0.05)

17.4
14.73
19.3
25.77

52.9
50.1
52.1
55.33

21
170
35
66
292

1.82.3 CBT and Motivational Interviewing for cannabis use cessation
Barrowclough 2014
Edwards 2006
Hjorthoj 2013 (CapOpus)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.34, df = 2 (P = 0.84); I² = 0%
Test for overall effect: Z = 0.24 (P = 0.81)

59.419149
45.6
57.2

9.639697
13.5
21.5

47
16
18
81

1.82.4 Special types of CBT
Gleeson 2009 (EPISODE II)
Uzenoff 2008
Subtotal (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 1.47, df = 1 (P = 0.22); I² = 32%
Test for overall effect: Z = 0.89 (P = 0.37)

8.4
6.72

34.3
48.4

41
10
51

Total (95% CI)
Heterogeneity: Tau² = 0.13; Chi² = 64.70, df = 21 (P < 0.00001); I² = 68%
Test for overall effect: Z = 2.70 (P = 0.007)
Test for subgroup differences: Chi² = 3.16, df = 3 (P = 0.37), I² = 5.0%

788

Footnotes
(1) comparator skills training for symptom management (SST)
(2) comparator waiting list (WL)
(3) comparator Supportive Counselling + TAU
(4) comparator Treatment as usual (TAU)

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

219

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.83.   Comparison 1: CBT plus standard care versus
control, Outcome 83: Subgroup analysis - Modality of treatment

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

23
9
17
109
40
91
10
18
25
8
71
60
40
22
9
10
27
9
598

17
13
35
57
122

5.2%
3.4%
4.0%
6.9%
5.6%
6.5%
2.8%
4.2%
4.9%
2.5%
5.9%
5.8%
5.5%
4.5%
3.1%
3.2%
3.9%
2.8%
80.6%

4.1%
3.7%
5.4%
6.1%
19.4%

0.00 [-0.50 , 0.50]
-0.60 [-1.39 , 0.20]
0.05 [-0.63 , 0.74]
-0.23 [-0.47 , 0.02]
-0.08 [-0.51 , 0.36]
-0.47 [-0.77 , -0.17]
0.57 [-0.39 , 1.52]
-0.20 [-0.86 , 0.45]
-0.10 [-0.64 , 0.44]
-0.36 [-1.38 , 0.67]
0.10 [-0.29 , 0.49]
-0.15 [-0.55 , 0.26]
-0.50 [-0.95 , -0.05]
0.04 [-0.56 , 0.65]
0.07 [-0.81 , 0.96]
-0.08 [-0.92 , 0.76]
-2.69 [-3.40 , -1.99]
-0.72 [-1.65 , 0.22]
-0.29 [-0.53 , -0.05]

-0.26 [-0.94 , 0.41]
-0.65 [-1.38 , 0.09]
-0.01 [-0.47 , 0.44]
-0.14 [-0.49 , 0.22]
-0.18 [-0.42 , 0.07]

720

100.0%

-0.27 [-0.47 , -0.08]

-4

-2
CBT + TAU

0

2
Control

4

1.83.1 Individual CBT
Barrowclough 2014
Bucci 2018 (Actissist)
Edwards 2006
GetUp
Gleeson 2009 (EPISODE II)
Gonzalez-Ortega 2021
Haddock 1999
Hjorthoj 2013 (CapOpus)
Jackson 2008 (ACE)
Jolley 2003
Lewis 2002 (SOCRATES) (1)
Lewis 2002 (SOCRATES) (2)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Palma-Sevillano 2019
Uzenoff 2008
Subtotal (95% CI)
Heterogeneity: Tau² = 0.17; Chi² = 62.12, df = 17 (P < 0.00001); I² = 73%
Test for overall effect: Z = 2.34 (P = 0.02)

59.419149
52.9
45.6
50.1
34.3
40.37
46.8
57.2
37.25
49.2
61.73
61.73
44.88
57.4
56.2
51.3
52.1
48.4

9.639697
17.4
13.5
14.73
8.4
10.03
8.75
21.5
13.634
13.87
19.69
19.69
8.06
13.58
12.3
8.65
19.3
6.72

47
21
16
170
41
86
8
18
28
7
39
39
40
20
11
12
35
10
648

59.4
63.6
44.8
53.4
35
45.11
38.3
61.9
38.51
54.7
59.96
64.38
49.6
56.77
55.4
52
110
55.67

11.3
17.54
15.4
14.39
9.8
9.89
17.4
23.4
12.028
14.94
16.39
16.79
10.47
14.1
7
7.02
23.5
12.22

1.83.2 Group CBT
Lecomte 2008 (3)
Lecomte 2008 (4)
Pos 2019
Supereden3
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.17, df = 3 (P = 0.54); I² = 0%
Test for overall effect: Z = 1.41 (P = 0.16)

33.4
33.4
52.2051
55.33

8.29
8.29
13.7385
25.77

17
18
39
66
140

36.5
39.3
52.3714
58.67

14.1
9.68
11.52768
21.2

Total (95% CI)
Heterogeneity: Tau² = 0.13; Chi² = 64.70, df = 21 (P < 0.00001); I² = 68%
Test for overall effect: Z = 2.70 (P = 0.007)
Test for subgroup differences: Chi² = 0.41, df = 1 (P = 0.52), I² = 0%

788

Footnotes
(1) comparator supportive counselling + TAU
(2) comparator treatment-as-usual (TAU)
(3) comparator skills training for symptom management (SST)
(4) comparator waiting list (WL)

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

A

+
+
+
−
+
+
+
+
+
+
+
+
+
+
+
+
+
?

?
?
+
+

Risk of Bias
E
B

D

C

+
?
+
+
+
?
?
+
?
?
+
+
+
+
+
+
?
+

+
+
+
+

?
+
?
+
+
+
+
?
+
−

?
?
+
+
−

+
+
?

−
−

?
−

+
+
+
?
+
+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
+
+

?
+
?
+
?
+
?
+
?
?
+
+
+
+
+
?
?
?

+
+
+
+

F

?
?
?
−
?
?
?
?
?
−

?
?
+
+
−

?
?
?

−
−

?
−

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

220

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.84.   Comparison 1: CBT plus standard care versus
control, Outcome 84: Subgroup analysis - Method of delivery

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.84.1 Face to face
Barrowclough 2014
Edwards 2006
GetUp
Gleeson 2009 (EPISODE II)
Gonzalez-Ortega 2021
Haddock 1999
Hjorthoj 2013 (CapOpus)
Jackson 2008 (ACE)
Jolley 2003
Lecomte 2008 (1)
Lecomte 2008 (2)
Lewis 2002 (SOCRATES) (3)
Lewis 2002 (SOCRATES) (4)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Palma-Sevillano 2019
Pos 2019
Supereden3
Uzenoff 2008
Subtotal (95% CI)
Heterogeneity: Tau² = 0.14; Chi² = 63.94, df = 20 (P < 0.00001); I² = 69%
Test for overall effect: Z = 2.52 (P = 0.01)

59.419149
45.6
50.1
34.3
40.37
46.8
57.2
37.25
49.2
33.4
33.4
61.73
61.73
44.88
57.4
56.2
51.3
52.1
52.2051
55.33
48.4

9.639697
13.5
14.73
8.4
10.03
8.75
21.5
13.634
13.87
8.29
8.29
19.69
19.69
8.06
13.58
12.3
8.65
19.3
13.7385
25.77
6.72

47
16
170
41
86
8
18
28
7
18
17
39
39
40
20
11
12
35
39
66
10
767

59.4
44.8
53.4
35
45.11
38.3
61.9
38.51
54.7
39.3
36.5
64.38
59.96
49.6
56.77
55.4
52
110
52.3714
58.67
55.67

11.3
15.4
14.39
9.8
9.89
17.4
23.4
12.028
14.94
9.68
14.1
16.79
16.39
10.47
14.1
7
7.02
23.5
11.52768
21.2
12.22

23
17
109
40
91
10
18
25
8
13
17
60
71
40
22
9
10
27
35
57
9
711

5.2%
4.0%
6.9%
5.6%
6.5%
2.8%
4.2%
4.9%
2.5%
3.7%
4.1%
5.8%
5.9%
5.5%
4.5%
3.1%
3.2%
3.9%
5.4%
6.1%
2.8%
96.6%

0.00 [-0.50 , 0.50]
0.05 [-0.63 , 0.74]
-0.23 [-0.47 , 0.02]
-0.08 [-0.51 , 0.36]
-0.47 [-0.77 , -0.17]
0.57 [-0.39 , 1.52]
-0.20 [-0.86 , 0.45]
-0.10 [-0.64 , 0.44]
-0.36 [-1.38 , 0.67]
-0.65 [-1.38 , 0.09]
-0.26 [-0.94 , 0.41]
-0.15 [-0.55 , 0.26]
0.10 [-0.29 , 0.49]
-0.50 [-0.95 , -0.05]
0.04 [-0.56 , 0.65]
0.07 [-0.81 , 0.96]
-0.08 [-0.92 , 0.76]
-2.69 [-3.40 , -1.99]
-0.01 [-0.47 , 0.44]
-0.14 [-0.49 , 0.22]
-0.72 [-1.65 , 0.22]
-0.26 [-0.47 , -0.06]

A

+
+
−
+
+
+
+
+
+
?
?
+
+
+
+
+
+
+
+
+
?

Risk of Bias
E
B

D

C

+
+
+
+
?
?
+
?
?
+
+
+
+
+
+
+
+
?
+
+
+

?
?
+
+
+
+
?
+
−
−
−

?
?
+
+
−
+
+
?
−
?

+
+
?
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

?
?
+
?
+
?
+
?
?
+
+
+
+
+
+
+
?
?
+
+
?

F

?
?
−
?
?
?
?
?
−
−
−

?
?
+
+
−
?
?
?
−
?

1.84.2 Smartphone app
Bucci 2018 (Actissist)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.47 (P = 0.14)

52.9

17.4

63.6

17.54

21
21

9
9

3.4%
3.4%

-0.60 [-1.39 , 0.20]
-0.60 [-1.39 , 0.20]

+

?

+

+

+

?

Total (95% CI)
Heterogeneity: Tau² = 0.13; Chi² = 64.70, df = 21 (P < 0.00001); I² = 68%
Test for overall effect: Z = 2.70 (P = 0.007)
Test for subgroup differences: Chi² = 0.63, df = 1 (P = 0.43), I² = 0%

788

720

100.0%

-0.27 [-0.47 , -0.08]

-4

-2
CBT + TAU

0

2
Control

4

Footnotes
(1) comparator waiting list (WL)
(2) comparator skills training for symptom management (SST)
(3) comparator treatment-as-usual (TAU)
(4) comparator supportive counselling + TAU

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

221

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.85.   Comparison 1: CBT plus standard care versus control, Outcome 85: Subgroup analysis - Control group

Risk of Bias
E
B

C

D

+
+
+
?
+
?
+
+
+
+
+
+
?
+
+

?
+
?
?
+
+
+

?
+
+
+
?
−
−
?
+
+
−

+
+
?
−

+
?
+
+
−

?
?

+
?
+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+

?
+
?
+
+
?
+
+
+
+
+
?
?
+
+

+
?
?
?
+
+
?

F

?
−

?
?
?
−
−
?
+
+
−

?
?
?
−

?
?
?
?
−

?
?

A

+
−

+
+
+
+
?
+
+
+
+
+
+
+
+

+
+
+
+
?
+
?

Study or Subgroup

Mean

SD

Total

Mean

CBT + TAU

Control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

23
109
40
91
18
8
13
60
40
22
9
10
27
35
57
562

9
17
10
25
17
71
9
158

5.2%
6.9%
5.6%
6.5%
4.2%
2.5%
3.7%
5.8%
5.5%
4.5%
3.1%
3.2%
3.9%
5.4%
6.1%
72.1%

3.4%
4.0%
2.8%
4.9%
4.1%
5.9%
2.8%
27.9%

0.00 [-0.50 , 0.50]
-0.23 [-0.47 , 0.02]
-0.08 [-0.51 , 0.36]
-0.47 [-0.77 , -0.17]
-0.20 [-0.86 , 0.45]
-0.36 [-1.38 , 0.67]
-0.65 [-1.38 , 0.09]
-0.15 [-0.55 , 0.26]
-0.50 [-0.95 , -0.05]
0.04 [-0.56 , 0.65]
0.07 [-0.81 , 0.96]
-0.08 [-0.92 , 0.76]
-2.69 [-3.40 , -1.99]
-0.01 [-0.47 , 0.44]
-0.14 [-0.49 , 0.22]
-0.34 [-0.59 , -0.09]

-0.60 [-1.39 , 0.20]
0.05 [-0.63 , 0.74]
0.57 [-0.39 , 1.52]
-0.10 [-0.64 , 0.44]
-0.26 [-0.94 , 0.41]
0.10 [-0.29 , 0.49]
-0.72 [-1.65 , 0.22]
-0.08 [-0.32 , 0.17]

720

100.0%

-0.27 [-0.47 , -0.08]

-4

-2
CBT + TAU

0

2
Control

4

1.85.1 CBT compared to TAU
Barrowclough 2014
GetUp
Gleeson 2009 (EPISODE II)
Gonzalez-Ortega 2021
Hjorthoj 2013 (CapOpus)
Jolley 2003
Lecomte 2008 (1)
Lewis 2002 (SOCRATES) (2)
Liu 2019
Morrison 2018 (COMPARE)
Morrison 2020 (MAPS)
Müller 2020
Palma-Sevillano 2019
Pos 2019
Supereden3
Subtotal (95% CI)
Heterogeneity: Tau² = 0.17; Chi² = 55.58, df = 14 (P < 0.00001); I² = 75%
Test for overall effect: Z = 2.64 (P = 0.008)

59.419149
50.1
34.3
40.37
57.2
49.2
33.4
61.73
44.88
57.4
56.2
51.3
52.1
52.2051
55.33

9.639697
14.73
8.4
10.03
21.5
13.87
8.29
19.69
8.06
13.58
12.3
8.65
19.3
13.7385
25.77

47
170
41
86
18
7
18
39
40
20
11
12
35
39
66
649

59.4
53.4
35
45.11
61.9
54.7
39.3
64.38
49.6
56.77
55.4
52
110
52.3714
58.67

11.3
14.39
9.8
9.89
23.4
14.94
9.68
16.79
10.47
14.1
7
7.02
23.5
11.52768
21.2

1.85.2 CBT compared to other psychosocial interventions
Bucci 2018 (Actissist)
Edwards 2006
Haddock 1999
Jackson 2008 (ACE)
Lecomte 2008 (3)
Lewis 2002 (SOCRATES) (4)
Uzenoff 2008
Subtotal (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 6.39, df = 6 (P = 0.38); I² = 6%
Test for overall effect: Z = 0.61 (P = 0.54)

17.4
13.5
8.75
13.634
8.29
19.69
6.72

52.9
45.6
46.8
37.25
33.4
61.73
48.4

21
16
8
28
17
39
10
139

63.6
44.8
38.3
38.51
36.5
59.96
55.67

17.54
15.4
17.4
12.028
14.1
16.39
12.22

Total (95% CI)
Heterogeneity: Tau² = 0.13; Chi² = 64.70, df = 21 (P < 0.00001); I² = 68%
Test for overall effect: Z = 2.70 (P = 0.007)
Test for subgroup differences: Chi² = 2.12, df = 1 (P = 0.14), I² = 52.9%

788

Footnotes
(1) comparator waiting list (WL)
(2) comparator treatment-as-usual (TAU)
(3) comparator skills training for symptom management (SST)
(4) comparator supportive counselling + TAU

Risk of bias legend
(A) Bias arising from the randomization process
(B) Bias due to deviations from intended interventions
(C) Bias due to missing outcome data
(D) Bias in measurement of the outcome
(E) Bias in selection of the reported result
(F) Overall bias

H I S T O R Y

Protocol first published: Issue 5, 2022

C O N T R I B U T I O N S   O F   A U T H O R S

• Susanna Franziska Mayer: search and selection of studies for inclusion in the review; collection of data for the review; assessment of

the risk of bias in the included studies; analysis of data; GRADE assessment; interpretation of data; writing of the review

• Ciaran Corcoran: search and selection of studies for inclusion in the review; collection of data for the review; assessment of the risk of

bias in the included studies; interpretation of data; writing of the review

• Liam Kennedy: collection of data for the review; assessment of the risk of bias in the included studies; interpretation of data; writing

of the review

• Stefan Leucht: conception of the review; design of the review; interpretation of data; writing of the review
• Irene Bighelli: conception of the review; design of the review; search and selection of studies for inclusion in the review; collection of
data for the review; assessment of the risk of bias in the included studies; analysis of data; GRADE assessment; interpretation of data;
writing of the review

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

222

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

D E C L A R A T I O N S   O F   I N T E R E S T

Susanna Mayer: none

Ciaran Corcoran: none

Liam Kennedy: none

Cochrane Database of Systematic Reviews

Stefan Leucht: In the last three years SL has received honoraria for advising/consulting and/or for lectures and/or for educational material
from  Angelini,  Boehringer  Ingelheim,  Eisai,  Ekademia,  GedeonRichter,  Janssen,  Karuna,  Kynexis,  Lundbeck,  Medichem,  Medscape,
Mitsubishi, Otsuka, NovoNordisk, Recordati, Rovi, Teva. SL is an editor of Cochrane Schizophrenia. He was not involved in the editorial
process of the present review (see Acknowledgements for details about editorial process).

Irene Bighelli: IB is the Deputy Co-ordinating editor of Cochrane Schizophrenia. She was not involved in the editorial process of the present
review (see Acknowledgements for details about editorial process).

S O U R C E S   O F   S U P P O R T

Internal sources

• Freistaat Bayern, Germany

Irene Bighelli and Stefan Leucht are employed by Freistaat Bayern.

• National Institute for Health and Care Research (NIHR), UK

Provided funding for Cochrane Schizophrenia Group

External sources

• Evidence Synthesis Ireland (ESI) Fellowship, Ireland

Ciaran Corcoran and Liam Kennedy were part supported by the Health Research Board (Ireland) and the HSC Public Health Agency
(Grant number CBES-2018-001) through Evidence Synthesis Ireland and Cochrane Ireland.

D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W

The title of the review was originally "Cognitive behavioural therapy plus standard care for first episode psychosis" and has been changed
to “Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis“.

In the protocol, we planned to include participants with a first episode of psychosis, as defined in the single studies. During the screening of
the studies, we realised that different and contradicting definitions were often used and, that strictly following the 'first episode' criterion
would have resulted in the exclusion of relevant studies, where the population also included patients in their first episode, but that just
used other definitions to describe this population. Therefore, we decided to also accept studies that included participants with a recent
onset of the condition, but we limited this to a period of five years, with the idea of capturing the first episodes. In order to be consistent,
we also decided to accept studies in which participants were recruited from centres focusing on early intervention for psychosis, because
these services also recruit patients within their first three to five years of the illness. We added a threshold for inclusion of studies including
participants with recent-onset psychosis with no further definition of this term; where this occurred, we accepted the study if it was clear
that at least 75% of the participants had a first-episode or recent-onset psychosis, as defined above.

We also accepted studies that included participants independently of their age (except for those aged more than 65 years), instead of a
minimum of 15 years as previously planned. This decision was made to take into account the variability in the age of onset of schizophrenia.

Moreover, in the protocol, we planned that, if we found a study including participants with other diagnoses, we would have included the
study if participants with a first episode of psychosis comprised at least 80% of the total. We altered this threshold to 50% in terms of
diagnosis, mainly to have some more flexibility with studies that reported participants with a diagnosis of psychosis NOS.

In the protocol, we planned to create GRADE tables for cognitive behavioural therapy plus standard care versus different control conditions
separately. However, a majority of the studies compared cognitive behavioural therapy plus standard care to standard care, so separate
summary of findings tables would split the information and be less informative. Instead, the role of different comparators is investigated
in a subgroup analysis.

The section on skewed data was adapted from the new template protocol of the Schizophrenia group.

We performed an additional post hoc sensitivity analysis excluding one strong outlier (Palma-Sevillano 2019).

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

223

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

I N D E X   T E R M S

Medical Subject Headings (MeSH)

Cochrane Database of Systematic Reviews

Antipsychotic Agents  [therapeutic use];  Bias;  *Cognitive Behavioral Therapy;  Combined Modality Therapy  [methods];  *Psychotic
Disorders  [therapy];  Quality of Life;  *Randomized Controlled Trials as Topic;  Recurrence;  Schizophrenia  [therapy]

MeSH check words

Adult; Humans; Young Adult

Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis (Review)
Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

224
